<SEC-DOCUMENT>0000950123-21-007570.txt : 20210628
<SEC-HEADER>0000950123-21-007570.hdr.sgml : 20210628
<ACCEPTANCE-DATETIME>20210604170256
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER: 0000950123-21-007570
CONFORMED SUBMISSION TYPE: DRS
PUBLIC DOCUMENT COUNT: 4
FILED AS OF DATE: 20210604
<PUBLIC-REL-DATE>20210628
DATE AS OF CHANGE: 20210604
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aligos Therapeutics, Inc.
CENTRAL INDEX KEY: 0001799448
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: DRS
SEC ACT: 1933 Act
SEC FILE NUMBER: 377-04970
FILM NUMBER: 21997233
BUSINESS ADDRESS:
STREET 1: ONE CORPORATE DR., 2ND FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: (800) 466-6059
MAIL ADDRESS:
STREET 1: ONE CORPORATE DR., 2ND FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>Draft Registration Statement</TITLE>
</HEAD>
<BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>Confidential draft submitted to the Securities and Exchange Commission on June 4, 2021.
This draft registration statement has not been filed publicly with the Securities and Exchange Commission and all information contained herein remains confidential. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT
STYLE="font-family:arial" SIZE="1"><B>Registration <FONT STYLE="white-space:nowrap">No. 333- </FONT> </B></FONT></P>
<P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px"> </P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px"> </P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000"> </P>
<P STYLE="margin-top:3px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="5"><B>UNITED STATES </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="5"><B>SECURITIES
AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><B>Washington, D.C. 20549 </B></FONT></P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%"> </P></center> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="5"><B><FONT
STYLE="white-space:nowrap">FORM S-1</FONT> </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="5"><B>REGISTRATION STATEMENT </B></FONT></P>
<P STYLE="margin-top:3px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Under </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><B><I>The
Securities Act of 1933 </I></B></FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px"> </P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%"> </P></center>
<P STYLE="margin-top:3px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="5"><B>Aligos Therapeutics, Inc. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>(Exact name of registrant as specified in its charter) </B></FONT></P>
<P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px"> </P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%"> </P></center>
<P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">
<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>Delaware</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:arial" SIZE="1"><B>(State or other jurisdiction of</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>incorporation or organization)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>2836</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:arial" SIZE="1"><B>(Primary Standard Industrial</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>Classification Code Number)</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>One Corporate Dr., 2nd Floor</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>South San Francisco, CA 94080</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>(800) <FONT STYLE="white-space:nowrap">466-6059</FONT></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B><FONT STYLE="white-space:nowrap">82-4724808</FONT></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>(I.R.S. Employer</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>Identification Number)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:3px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>(Address, including zip code, and telephone number, including area code, of Registrant’s principal executive
offices) </B></FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px"> </P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%"> </P></center>
<P STYLE="margin-top:3px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>Lawrence M. Blatt, Ph.D. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>Chief Executive Officer </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>Aligos Therapeutics, Inc. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>One Corporate Dr., 2nd Floor </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>South San Francisco, CA 94080 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>(800) <FONT STYLE="white-space:nowrap">466-6059</FONT> </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:arial" SIZE="1"><B>(Name, address, including zip code, and telephone number, including area code, of agent for service) </B></FONT></P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%"> </P></center> <P STYLE="margin-top:3px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>Copies to:
</B></FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">
<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>Mark V. Roeder</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:arial" SIZE="1"><B>John C. Williams</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>Latham & Watkins LLP</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>140 Scott Drive</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>Menlo Park,
California 94025</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B><FONT STYLE="white-space:nowrap">(650) 328-4600</FONT></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>Lucinda Quan, J.D.</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:arial" SIZE="1"><B>Executive Vice President, Chief Business</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>Officer and General Counsel</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>Aligos Therapeutics, Inc.</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>One Corporate Dr., 2nd Floor</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>South San Francisco, CA 94080</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B><FONT STYLE="white-space:nowrap">(800) 466-6059</FONT></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>Alan F. Denenberg</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:arial" SIZE="1"><B>Emily Roberts</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>Davis Polk & Wardwell LLP</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>1600 El Camino Real</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>Menlo
Park, California 94025</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>(650) <FONT STYLE="white-space:nowrap">752-2000</FONT></B></FONT></P></TD></TR>
</TABLE> <center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%"> </P></center>
<P STYLE="margin-top:3px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">Approximate date of commencement of proposed sale to the public:<B></B><B> As soon as practicable after the effective date of this registration statement.</B>
</FONT></P> <P STYLE="margin-top:3px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act
of 1933, check the following box. <FONT STYLE="font-family:Times New Roman" SIZE="1">☐</FONT> </FONT></P> <P STYLE="margin-top:3px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">If this Form is filed to register
additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering. <FONT STYLE="font-family:Times New Roman" SIZE="1">☐</FONT> </FONT></P> <P STYLE="margin-top:3px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">If this Form is a post-effective amendment filed pursuant to Rule
462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering. <FONT STYLE="font-family:Times New Roman" SIZE="1">☐</FONT> </FONT></P> <P STYLE="margin-top:3px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">If this Form is a post-effective amendment filed pursuant to Rule
462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering. <FONT STYLE="font-family:Times New Roman" SIZE="1">☐</FONT> </FONT></P> <P STYLE="margin-top:3px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, <FONT STYLE="white-space:nowrap">a non-accelerated filer,</FONT> a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,”
“accelerated filer,” “smaller reporting company” and “emerging growth company” in <FONT STYLE="white-space:nowrap">Rule 12b-2 of</FONT> the Exchange Act. </FONT></P>
<P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">
<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">Large accelerated filer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><FONT STYLE="font-family:Times New Roman" SIZE="1">☐</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">Accelerated filer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><FONT STYLE="font-family:Times New Roman" SIZE="1">☐</FONT></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><FONT STYLE="white-space:nowrap">Non-accelerated filer</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><FONT STYLE="font-family:Times New Roman" SIZE="1">☒</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">Smaller reporting company</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><FONT STYLE="font-family:Times New Roman" SIZE="1">☒</FONT></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">Emerging growth company</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><FONT STYLE="font-family:Times New Roman" SIZE="1">☒</FONT></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:3px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided to Section 7(a)(2)(B) of the Securities Act. <FONT STYLE="font-family:Times New Roman" SIZE="1">☐</FONT> </FONT></P>
<P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px"> </P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%"> </P></center>
<P STYLE="margin-top:3px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>CALCULATION OF REGISTRATION FEE </B></FONT></P> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">
<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>Title of each class of securities to be registered</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>Proposed maximum</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>aggregate</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>offering price(1)</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>Amount of</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>registration fee(2)</B></FONT></P></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Common Stock, $0.0001 par value per share</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1">$ </FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1">$ </FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD></TR>
</TABLE> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended. Includes shares of common stock that
the underwriters have an option to purchase. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Calculated pursuant to Rule 457(o) based on an estimate of the proposed maximum aggregate offering price. </FONT></TD></TR></TABLE>
<P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px"> </P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%"> </P></center> <P STYLE="margin-top:3px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="1"><B>The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that
this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said
Section 8(a), may determine. </B></FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px"> </P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000"> </P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2" COLOR="#cc062a"><B>The information in this preliminary prospectus is not complete and may be changed. We may not
sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any
jurisdiction where such offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2" COLOR="#cc062a"><B>Subject to completion, dated , 2021
</B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>Preliminary prospectus </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><I> shares </I></B></FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P> <P STYLE="margin-top:0px;margin-bottom:0px">
<IMG SRC="g166948g01s66.jpg" ALT="LOGO">
</P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><I>Common stock </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We
are offering shares of our common stock. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our common
stock is listed on the Nasdaq Global Select Market under the symbol “ALGS.” The last reported sale price of our common stock on the Nasdaq Global Select Market
on , 2021 was $ per share. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are an “emerging growth company” as defined under the federal securities laws and, as such, have elected to comply with certain reduced public company
reporting requirements for this prospectus and may elect to do so in future filings. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">
<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2px solid #000000"> </TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2px solid #000000"> </TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2px solid #000000"> </TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"> <FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Per share</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Total</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Public offering price</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Underwriting discounts(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Proceeds, before expenses, to us</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD></TR>
</TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">See the section titled “Underwriting” on page 106 for additional information regarding compensation payable to the underwriters. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have granted the underwriters an option to purchase up to an
additional shares from us at the public offering price less the underwriting discounts and commissions. The underwriters may exercise this right at any
time within 30 days after the date of this prospectus. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have two classes of common stock: the voting common stock offered hereby and <FONT
STYLE="white-space:nowrap">non-voting</FONT> common stock. For a description of the rights of the voting common stock and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock, please see “Description of capital stock” beginning
on page 94 of this prospectus. We are offering voting common stock in this offering, and unless otherwise noted, all references in this prospectus to our “common stock,” “common shares” or “shares” refers to our
voting common stock. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>Investing in our common stock involves a high degree of risk. See the section titled “<A HREF="#toc166948_3">Risk
factors</A>” beginning on page 15 of this prospectus to read about factors you should consider before buying shares of our common stock. </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>Neither the Securities and Exchange Commission nor any other state securities commission has approved or disapproved of these securities, or passed upon the
adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The underwriters expect to deliver the shares
against payment on , 2021. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">
<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="5"><B>J.P. Morgan</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="5"><B>Jefferies</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="5"><B>Piper Sandler</B></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="5"><B>Cantor</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>Prospectus dated , 2021
</B></FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="toc"></A>Table of contents </B></FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">
<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>Page</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#toc166948_1">Prospectus summary</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#toc166948_2">The offering</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">11</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#toc166948_3">Risk factors</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">15</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#toc166948_4">Special note regarding forward-looking statements</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">84</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#toc166948_5">Market and industry data</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">86</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#toc166948_6">Use of proceeds</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">87</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#toc166948_7">Dividend policy</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">88</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#toc166948_8">Capitalization</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">89</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#toc166948_9">Dilution</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">91</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#toc166948_10">Description of capital stock</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">93</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#toc166948_11">Shares eligible for future sale</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">99</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#toc166948_12">Material U.S. federal income tax consequences
<FONT STYLE="white-space:nowrap">to non-U.S. holders</FONT></A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">101</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#toc166948_13">Underwriting</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">105</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#toc166948_14">Legal matters</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">118</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#toc166948_15">Experts</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">118</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#toc166948_16">Where you can find more information</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">118</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#toc166948_17">Incorporation of certain information by reference</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">118</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Neither we nor the underwriters have authorized anyone to provide you with information that is different from that, or to make any
representations other than those, contained or incorporated by reference in this prospectus or in any free writing prospectus we may authorize to be delivered or made available to you. We and the underwriters take no responsibility for, and can
provide no assurance as to the reliability of, any other information that others may give you. We and the underwriters are offering to sell shares of common stock and seeking offers to buy shares of common stock only in jurisdictions where offers
and sales are permitted. The information contained or incorporated by reference in this prospectus or in any applicable free writing prospectus is accurate only as of the date on the front of this prospectus or any such free writing prospectus or in
the applicable document incorporated by reference, as applicable, or other earlier date stated in this prospectus or such free writing prospectus, regardless of the time of delivery of this prospectus or such free writing prospectus or any sale of
shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">No action is being
taken in any jurisdiction outside the United States to permit a public offering of our common stock or possession or distribution of this prospectus in that jurisdiction. Persons who come into possession of this prospectus in jurisdictions outside
the United States are required to inform themselves about and to observe any restrictions as to this offering and the distribution of this prospectus applicable to that jurisdiction. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:arial" SIZE="2">Aligos<FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">®</SUP></FONT> and
our logo are some of our trademarks used in this prospectus. This prospectus also includes trademarks, tradenames and service marks that are the property of other organizations. Solely for convenience, our trademarks, service marks and tradenames
referred to in this prospectus may appear without
the <FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">®</SUP></FONT> and </FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">™</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2"> symbol, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent
under applicable law, our rights, or the right of the applicable licensor to these trademarks, service marks and tradenames. </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="toc166948_1"></A>Prospectus summary </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I>This summary highlights information contained elsewhere or incorporated by reference in this prospectus. This summary does not contain all of the information you should consider before investing in our common
stock. You should read this entire prospectus carefully, including information in our filings with the Securities and Exchange Commission (SEC), incorporated by reference in this prospectus, especially the section titled “Risk factors” and
our consolidated financial statements and the related notes thereto incorporated by reference in this prospectus. As used in this prospectus, unless the context otherwise requires, references to “we,” “us,” “our,”
“our company,” “the Company”, “Aligos” and “Aligos Therapeutics” refer to Aligos Therapeutics, Inc. and its subsidiaries, taken as a whole. </I></FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Overview </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are a clinical-stage biopharmaceutical company currently focused on developing novel
therapeutics to address unmet medical needs in viral and liver diseases. We utilize our proprietary oligonucleotide and small molecule platforms to develop pharmacologically optimized drug candidates for use in combination regimens designed to
achieve improved treatment outcomes. Our lead effort is to develop a functional cure for Chronic Hepatitis B (CHB), which often results in other life-threatening conditions such as
<FONT STYLE="white-space:nowrap">cirrhosis, end-stage liver</FONT> disease (ESLD) and the most common form of liver cancer, hepatocellular carcinoma (HCC). The most widely used treatment for CHB, nucleos(t)ide analogs, suppresses viral
replication but only achieves low rates of functional cure and often requires long-term administration. To address this issue, we have developed a portfolio of differentiated drug candidates for CHB, including <FONT
STYLE="white-space:nowrap">an S-antigen Transport-inhibiting Oligonucleotide</FONT> Polymers (STOPS) molecule, a small molecule Capsid Assembly Modulator (CAM), and oligonucleotides (ASO and siRNA), each of which is designed against
clinically validated targets in the Hepatitis B Virus (HBV) life cycle. We believe that combination regimens utilizing our portfolio of CHB drug candidates may lead to higher rates of functional cure. Initial Phase 1a studies in healthy volunteers
for our STOPS molecule and CAM have been completed, and Phase 1b proof of concept trials evaluating the properties of our STOPS molecule and CAM in CHB patients are approved in New Zealand, Hong Kong and Moldova, and we have begun dosing in patients
with both of these compounds. We may also in the future conduct clinical trials for our STOPS molecule and CAM and other drug candidates in other countries and territories. Our second area of focus is in
<FONT STYLE="white-space:nowrap">non-alcoholic</FONT> steatohepatitis (NASH), a complex, chronic liver disease where combination regimens may likewise prove beneficial. Our most advanced drug candidate for NASH
<FONT STYLE="white-space:nowrap">is ALG-055009, a</FONT> small <FONT STYLE="white-space:nowrap">molecule THR-ß agonist</FONT> currently in nonclinical studies to enable <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">a first-in-human clinical</FONT></FONT> trial. We <FONT STYLE="white-space:nowrap">believe ALG-055009 has</FONT> the potential to become an integral component of future combination regimens for NASH.
Our third area of focus is to develop drug candidates <FONT STYLE="white-space:nowrap">with pan-coronavirus activity,</FONT> including Severe Acute Respiratory Syndrome coronavirus 2 <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">(SARS-CoV-2),</FONT></FONT> the virus responsible <FONT STYLE="white-space:nowrap">for COVID-19.</FONT> </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our
oligonucleotide and small molecule platforms allow us to discover drug candidates that can be used to develop <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">potentially best-in-class combination</FONT></FONT> regimens.
Oligonucleotide approaches enable specific inhibition of the translation of viral or host genes to affect a desired outcome that would be challenging to achieve with traditional small molecules. We believe the diversity of chemical matter we can
generate with these complementary modalities broadens the range of therapeutic targets we can address with our platforms, and provides us with a differentiated set <FONT STYLE="white-space:nowrap">of in-house capabilities</FONT> to use in
developing novel, optimized combination regimens across all of our current areas of focus. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our approach of combining multiple mechanisms from these
distinct modalities is based on the observation that most chronic diseases, whether extrinsic (e.g., HIV and Hepatitis C) or intrinsic (e.g., metabolic syndrome </FONT></P>
</div></div>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">1 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
conditions such as hypertension and diabetes), often require combination therapy to achieve optimal outcomes. Combination approaches have the advantage of simultaneously targeting multiple
pathways and can act broadly and potentially synergistically. Particularly in the case of viral diseases, the simultaneous use of multiple drugs in combination can increase the barrier to viral resistance. As part of our drug candidate screening
paradigm, we perform in vitro combination studies to ensure that none of the combinations we plan to evaluate clinically demonstrate antagonistic interactions. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Our approach to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">developing best-in-class regimens</FONT></FONT> for our therapeutic areas of interest leverages the most promising
modalities from our oligonucleotide and small molecule platforms with the goal to advance rapidly from monotherapy Phase 1 trials into Phase 2 combination trials. As a first step, we evaluate the safety and activity of each drug candidate in healthy
volunteers and patients with the disease of interest. We intend to then efficiently evaluate drug candidates shown to have activity in Phase 1 in various combinations in Phase 2 platform protocols to enable us to identify optimized combination
regimens that will then be evaluated in Phase 3 pivotal trials. The combinations we evaluate may include additional drug candidates or current standard of care. Throughout all phases of clinical
<FONT STYLE="white-space:nowrap">development, pre-specified adaptive</FONT> study rules allow real-time adjustment of trial conduct based on emerging clinical trial data. These practices allow us to gain a rapid understanding of
the risk/benefit profile for our individual drug candidates and combination regimens, and iteratively refine our strategy based on emerging data. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our
management team consists of a group of highly collaborative, culturally diverse executives with decades of drug discovery and development experience and a proven track record of success in the areas of viral infections and liver diseases. Most
members of our management team have worked together across multiple companies, many for over a decade, and have been collectively involved in the discovery and/or development of a number of drugs that have been successfully commercialized, including
Ganovo, Olysio, Sovaldi, Hepsera, Infergen, Valtrex, Sirturo, Neupogen, Andexxa and Esbriet, among others. In support of our management team, we also have assembled an industry-leading board of directors and a world-class group
of scientific advisors with significant experience in drug development for viral and liver diseases. </FONT></P>
</div></div>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">2 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Our pipeline </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We are focused on viral and liver diseases, areas in which our employees have expertise and decades of experience. Our most advanced drug candidates are designed for use in CHB to achieve higher rates of functional
cure, which we believe will require the use of a combination of drugs with complementary mechanisms of action (MOA). Each of our CHB modalities plays an important role in disrupting the HBV life cycle and, in nonclinical studies, certain
combinations have been shown to act additively or synergistically. We are also advancing a <FONT STYLE="white-space:nowrap">THR-ß</FONT> agonist for NASH and purpose-built drug candidates for coronaviruses. We also have a
collaboration with Merck to discover and develop oligonucleotides against an undisclosed target for the treatment of NASH. As with CHB, we believe combination therapy will be critical for improved patient outcomes in these disease settings and
intend to combine our drug candidates with others that have potentially complementary MOAs. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P> <P STYLE="font-size:0px;margin-top:0px;margin-bottom:0px"> </P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">
<IMG SRC="g166948g08s10.jpg" ALT="LOGO">
</P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our most advanced drug candidates are for the treatment of CHB, a disease that affects more than 290 million people
worldwide with approximately 30 million people becoming newly infected every year, despite the availability of an efficacious prophylactic vaccine. Approximately 900,000 people worldwide died from complications of CHB in 2015, according to the
World Health Organization, and CHB is the primary cause of liver cancer worldwide. Currently approved therapies for CHB include pegylated forms <FONT STYLE="white-space:nowrap">of interferon-alfa (peg-IFN</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:SYMBOL">a</FONT></FONT>) and nucleos(t)ide analogs, which are designed to boost the body’s immune response to the virus or inhibit viral replication, respectively. While
these therapies have improved treatment outcomes for some patients with CHB, they have not been able to achieve meaningful rates of functional cure, which is the consensus goal of treatment and defined as a sustained loss of Hepatitis B S-antigen
(HBsAg) with or without hepatitis B surface antibody seroconversion. Functional cure has been shown to greatly reduce the risk of developing certain other more serious downstream liver conditions, such as cirrhosis and ESLD. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our clinical development strategy involves evaluating both Hepatitis <FONT STYLE="white-space:nowrap">B E-antigen (HBeAg)</FONT> positive and HBeAg
negative CHB patient populations. HBeAg is typically present in earlier stages of the disease and is associated with higher rates of viral replication. During the natural course of the disease, HBeAg can be cleared and antibodies develop, resulting
in an HBeAg negative state where viral replication is often lower. Patients with HBeAg negative CHB are typically older and have more progressive disease-related complications (e.g., fibrosis of the liver). In addition, their immune system
is likely to be more exhausted by chronic exposure to HBsAg, which makes viral clearance more difficult. Although we plan to ultimately study both populations, due to the </FONT></P>
</div></div>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">3 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
greater availability of patients with HBeAg negative CHB at investigational sites, we intend to study this population first. </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P> <P STYLE="font-size:0px;margin-top:0px;margin-bottom:0px"> </P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">
<IMG SRC="g166948g09t20.jpg" ALT="LOGO">
</P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Multiple steps in the HBV life cycle, including those involving capsid assembly and production and secretion of HBsAg, are known
to be essential to sustain HBV infection. We have built a portfolio of CHB drug candidates directed against clinically validated targets at several critical stages of the HBV life cycle. Our CHB portfolio includes: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B>STOPS</B> are protein-binding oligonucleotides that share structural similarity with nucleic acid polymers (NAPs), which have been reported in clinical trials
to significantly reduce circulating HBsAg and result in high rates of functional cure when used in combination with nucleos(t)ide analogs and <FONT STYLE="white-space:nowrap">peg-IFN</FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT
STYLE="FONT-FAMILY:SYMBOL">a</FONT></FONT>. Our most advanced STOPS molecule is <FONT STYLE="white-space:nowrap">ALG-010133,</FONT> which is currently being evaluated in a Phase 1 clinical trial, including in CHB patients. In nonclinical
studies, <FONT STYLE="white-space:nowrap">ALG-010133</FONT> has demonstrated higher inhibitory activity than that reported for a reference NAP compound that is currently in clinical development. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B>CAMs</B> are small molecule antiviral agents that accelerate HBV capsid assembly and inhibit pregenomic RNA (pgRNA) encapsidation, which reduces production of
new virions capable of infecting other cells. CAMs may also inhibit the de novo establishment of covalently closed circular DNA (cccDNA), a major factor for the persistence of HBV infection, when introduced at the onset of infection. In clinical
trials, other CAM drug candidates have demonstrated significant reductions in HBV DNA and pgRNA. However, it is likely that CAMs will need to be combined with other modalities that affect HBsAg in order to achieve functional cure. Our most advanced
CAM drug candidate is <FONT STYLE="white-space:nowrap">ALG-000184,</FONT> a prodrug of <FONT STYLE="white-space:nowrap">ALG-001075,</FONT> which is currently being evaluated in a Phase 1 clinical trial, including in CHB patients. In nonclinical
studies, we have shown that <FONT STYLE="white-space:nowrap">ALG-001075</FONT> has significantly enhanced potency compared to other CAMs in clinical development of which we are aware. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B>ASOs</B> are single-stranded DNA or RNA molecules that interfere with viral replication by binding to complementary messenger RNA (mRNA), allowing the
combined ASO and mRNA to be degraded by the enzyme RNase H. Using our oligonucleotide discovery capabilities, we identified <FONT STYLE="white-space:nowrap">ALG-020572,</FONT> an ASO that targets HBV mRNA and can reduce HBsAg production, which we
plan to advance into clinical trials in the </FONT></P></TD></TR></TABLE>
</div></div>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">4 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="top"> <P><FONT STYLE="font-family:arial" SIZE="2">
second half of 2021. In third-party clinical trials, ASOs targeting HBV mRNA have demonstrated significant reductions in HBsAg. Our ASO approach utilizes state of the art bioinformatics,
proprietary stabilization chemistry and liver targeting technology that we believe provides a number of potential benefits compared to other ASO candidates of which we are aware, including increased potency, a higher barrier to resistance and broad
genotype coverage. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B>siRNAs</B> are a class of double-stranded, <FONT STYLE="white-space:nowrap">non-coding</FONT> RNA that interferes with viral replication by silencing gene
expression. Multiple siRNAs have demonstrated significant reductions in HBsAg levels in clinical trials. Our oligonucleotide discovery capabilities resulted in the identification of <FONT STYLE="white-space:nowrap">ALG-125755,</FONT> an siRNA drug
candidate directed at HBV mRNA, which utilizes our proprietary liver targeting technology. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We believe that a combination of drugs
capable of inhibiting HBV DNA replication and RNA packaging (e.g., using CAMs) while simultaneously suppressing HBsAg production (e.g., using STOPS molecules, ASO, and/or siRNA) has the potential to act additively or synergistically and may lead to
a higher rate of functional cure. Our clinical development strategy is designed to evaluate safety and antiviral activity as monotherapy prior to evaluating multiple combinations of our CHB assets, with or without other currently available treatment
modalities such as nucleos(t)ide analogs <FONT STYLE="white-space:nowrap">or peg-IFN</FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:SYMBOL">a</FONT></FONT>, to identify optimized combination regimens.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our second development effort is focused on the treatment of NASH. An estimated 1.5% to 6.5% of the global population, or up to about 450 million
people, was believed to have NASH as of 2015 and this percentage is expected to increase significantly in the coming decade due to the adoption of Western dietary habits. In the absence of lifestyle modifications, the inflammation inherent in NASH
persists and results in progressive fibrosis of the liver, which may lead to cirrhosis, ESLD, HCC, the need for liver transplant, and death. We believe one of the most promising pharmacologic approaches in development for NASH is a selective agonist
of the beta subtype of the thyroid hormone receptor (THR-ß), which, in clinical trials conducted by third parties, has demonstrated significant reduction in liver fat and inflammation, as well as a reduction in lipid levels in the serum,
which may have important advantages in the NASH patient population that is at a high risk of cardiovascular <FONT STYLE="white-space:nowrap">co-morbidities.</FONT> Utilizing our expertise in small molecule drug discovery, we identified <FONT
STYLE="white-space:nowrap">ALG-055009,</FONT> a once-daily oral THR-ß agonist. In nonclinical studies, <FONT STYLE="white-space:nowrap">ALG-055009</FONT> has been shown to be substantially more potent compared to other
THR-ß agonists currently in development of which we are aware and may avoid some of their potential safety liabilities while having the potential to achieve equal or better efficacy. As a result, we
<FONT STYLE="white-space:nowrap">believe ALG-055009 has</FONT> the potential to become an integral component of combination regimens to treat NASH. We intend to <FONT STYLE="white-space:nowrap">advance ALG-055009 into</FONT>
clinical development in the second half of 2021. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our third area of focus is to
<FONT STYLE="white-space:nowrap">develop pan-coronavirus treatment</FONT> regimens. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> is responsible for
<FONT STYLE="white-space:nowrap">the COVID-19 pandemic,</FONT> which has been identified as a cause of more than 2.4 million deaths worldwide as of February 2021. After MERS and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS (SARS-CoV-1), SARS-CoV-2 is</FONT></FONT></FONT></FONT> the third known coronavirus to have crossed over from animal species to humans
in the past 20 years and cause significant morbidity and mortality. While multiple vaccines have recently become available, it is unlikely that vaccination will be fully efficacious and widely adopted, indicating that the need for effective
therapeutic treatments will remain. Many of the drugs currently being evaluated have not been optimized for the treatment of coronavirus infections <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">or SARS-CoV-2,</FONT></FONT>
specifically. There is a need for purpose-built drugs which are suitable across a broad range of coronaviruses, patient populations and clinical settings, including prophylactic and post-exposure settings. We believe that,
similar to CHB, a combination of antiviral and/or immunomodulatory drugs which target multiple points in the viral replication cycle offers the best chance of success. To address this urgent, unmet medical need, we are in early stages of development
for multiple drug candidates including protease inhibitors that are specifically designed to interact with targets that are highly conserved across multiple coronaviruses. These drug </FONT></P>
</div></div>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">5 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
candidates are intended to <FONT STYLE="white-space:nowrap">have pan-coronavirus activity</FONT> and to be used in combination regimens to maximize their antiviral activity. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Our strategy </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our strategy is to develop pharmacologically
optimized drug candidates for use in combination regimens designed to achieve improved treatment outcomes. Our initial areas of focus are viral and liver diseases where our team can leverage
<FONT STYLE="white-space:nowrap">their in-depth knowledge</FONT> and expertise to develop <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">potentially best-in-class combination</FONT></FONT> regimens addressing
large areas of unmet medical need. The core elements of our business strategy include: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Developing improved drug candidates against clinically validated targets; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Creating combination regimens to achieve better outcomes; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Developing a functional cure for CHB; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Expanding our development capabilities and pipeline; and </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Maximizing the value of our drug candidates. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Intellectual property update </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Since the filing of our Annual
Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December 31, 2020 (2020 Annual Report), filed with the SEC on March 23, 2021, incorporated herein by reference, we have continued to advance our intellectual
property portfolio as noted in this section. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Licensed intellectual property </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We have licensed patents and patent applications from various entities, including Emory, Luxna and AM Chemicals. The Emory IP consists of one issued U.S. patent, one pending non-provisional U.S. patent application
as well as three issued foreign patents and 36 foreign patent applications. The issued U.S. patent has an expected expiration of March 2037, excluding any potential patent term extension or adjustment. The Luxna IP is in the oligonucleotide chemical
space, consisting of three issued U.S. patents, two non-provisional U.S. patent applications and 15 issued foreign patents and five foreign patent applications. We have exclusive rights to use this technology in the development of drug
candidates for CHB, as well as rights to certain named targets in NASH and respiratory diseases, including coronaviruses. These U.S. patents have an expected expiration between October 2030 and February 2035, excluding any potential patent term
extension or adjustment. Our AM Chemicals license includes one issued U.S. patent, one U.S. non provisional patent application and two foreign patent applications. The issued U.S. patent has an expected expiration of July 2037. Any patent issuing
from such <FONT STYLE="white-space:nowrap">non-provisional</FONT> applications in this patent estate is projected to expire in July 2037, excluding any potential patent term extension or patent term adjustment. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Aligos intellectual property </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As of May 31,
2021, we have filed 21 <FONT STYLE="white-space:nowrap">U.S. non-provisional patent</FONT> applications, 28 U.S. provisional patent applications (excluding any <FONT STYLE="white-space:nowrap">non-expired</FONT> U.S. provisional
applications to which we have claimed priority), 19 PCT applications and 40 foreign patent applications, including pending applications in Argentina and Taiwan. The projected expiration date of any patent that issues from <FONT
STYLE="white-space:nowrap">our non-provisional U.S.</FONT> and foreign applications is between 2039 to 2041, excluding any additional term from a potential patent term extension and/or patent term adjustment. </FONT></P>
</div></div>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">6 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Drug candidate intellectual property </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">For our drug candidates, although we have filed patent applications and we generally intend to pursue patent protection covering compositions of matter, methods of making, and methods of use. As of May 31,
2021, we do not own any issued patents directed to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ALG-010133, ALG-000184,</FONT></FONT> <FONT STYLE="white-space:nowrap">ALG-020572,</FONT>
<FONT STYLE="white-space:nowrap">ALG-125755</FONT> and <FONT STYLE="white-space:nowrap">ALG-055009</FONT> drug candidates. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Discovery pipeline
intellectual property </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Hepatitis B </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We
have multiple families of applications that include claims to compositions of matter, pharmaceutical compositions and methods of use for the treatment of CHB with our additional drug candidates. As of May 31, 2021, this includes four U.S. <FONT
STYLE="white-space:nowrap">non-provisional</FONT> patent applications, four U.S. provisional patent applications, five PCT patent applications and four foreign patent applications in the small molecule space and two U.S. <FONT
STYLE="white-space:nowrap">non-provisional</FONT> patent applications, two U.S. provisional applications, two PCT patent applications and two foreign patent applications in the oligonucleotide space. These patent families also list combination
therapies with our drug candidates and other compounds for treating CHB. Any patent that issues from a <FONT STYLE="white-space:nowrap">non-provisional</FONT> application in one of these patent families is projected to expire in 2040 to 2041,
excluding any potential patent term extension or patent term adjustment. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>NASH </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We have filed two U.S. <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent applications, six provisional U.S. patent applications, one PCT patent application and one foreign patent application that
include claims to compositions of matter and methods of use with our drug candidates for the treatment of NASH. These applications also disclose combination therapies with our drug candidates and other compounds for treating NASH. Any patent that
issues from <FONT STYLE="white-space:nowrap">a non-provisional application</FONT> in one of these patent families is projected to expire in 2040 to 2041, excluding any potential patent term extension or patent term adjustment. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Coronaviruses </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have filed two U.S. <FONT
STYLE="white-space:nowrap">non-provisional</FONT> patent applications, 13 provisional U.S. patent applications, two PCT patent applications and one foreign patent application that include claims to compositions of matter, pharmaceutical compositions
and methods of use for treating coronaviruses. This includes multiple applications covering both small molecule and oligonucleotide approaches. These patent families also include disclosure relating to combination therapy strategies for treating
coronaviruses. Any patent that issues from a <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application claiming priority to one or more of these U.S. provisional applications is projected to expire in 2041, excluding any potential
patent term extension or patent term adjustment. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">With respect to both our licensed and our owned intellectual property, we cannot be sure that patents
will be granted with respect to any of our pending patent applications or with respect to any patent applications filed by us in the future, nor can we be sure that any current patents or any patents that may be granted to us in the future will be
commercially useful in protecting our platforms and drug candidates and the methods used to manufacture them. Moreover, the time required for development, testing and regulatory review of our candidate drug candidates may shorten the length of
effective patent protection following commercialization. If we do obtain any patents for our drug candidates, the term of such patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which
we file, the patent term is 20 </FONT></P>
</div></div>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">7 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
years from the earliest date of filing of <FONT STYLE="white-space:nowrap">a non-provisional patent</FONT> application. In the United States, the patent term of a patent that covers an
FDA approved drug or biologic may also be eligible for patent term extension, which permits patent term restoration as compensation for the patent term lost during the FDA regulatory review process. The Hatch-Waxman Act permits a patent term
extension of up to five years beyond the expiration of the patent. The length of the patent term extension is related to the length of time that the drug or biologic is under regulatory review. Patent term extension cannot extend the remaining term
of a patent beyond a total of 14 years from the date of product approval and only one patent applicable to an approved drug or biologic may be extended. Similar provisions are available in the EU and other foreign jurisdictions to extend the term of
a patent that covers an approved drug or biologic. In the future, if our drug candidates receive FDA approval and if our patent applications relating to such drug candidates issue as patents, we expect to apply for patent term extensions where
applicable on patents covering those drugs. We plan to seek patent term extensions to our future issued patents in jurisdictions where these are available, however there is no guarantee that the applicable authorities, including the United States
Patent and Trademark Office (USPTO), will agree with our assessment of whether these extensions will be granted, and if granted, the length of these extensions. For this and other risks related to our proprietary technology, inventions,
improvements, platforms and product candidates, see the section titled “Risk Factors—Risks related to intellectual property.” </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Trademarks </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our trademark portfolio contains several
trademark applications and registrations, including U.S. and foreign, as of May 31, 2021. The trademark portfolio includes the marks ALIGOS and STOPS. The mark STOPS is registered in Australia, the EU, Great Britain and Japan, and is pending in
the United States. The mark ALIGOS is registered in the United States, Australia, the EU, Great Britain and Japan. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Risks related to our business
</B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our ability to execute our business strategy is subject to numerous risks, including those described in the section titled “Risk factors”
immediately following this prospectus summary. These risks include the following, among others: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">We are a clinical-stage biopharmaceutical company with a limited operating history and no products approved for commercial sale. We have incurred significant
losses since inception. We expect to incur losses for at least the next several years and may never achieve or maintain profitability, which, together with our limited operating history, makes it difficult to assess our future viability.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">We have never generated revenue from product sales and may never be profitable. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Even if this offering is successful, we will require substantial additional financing to achieve our goals, which may not be available on acceptable terms, or at
all. A failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our product development or commercialization efforts. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">We are early in our development efforts, and our business is dependent on the successful development of our current and future drug candidates. If we are unable
to advance our current or future drug candidates through clinical trials, obtain marketing approval and ultimately commercialize any drug candidates we develop, or experience significant delays in doing so, our business will be materially harmed.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Our current or future drug candidates may cause undesirable side effects or have other properties when used alone or in combination with other approved products
or investigational new drugs that could delay or halt their clinical development, prevent their marketing approval, limit their commercial potential or result in significant negative consequences. </FONT></P></TD></TR></TABLE>
</div></div>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">8 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">We depend on collaborations with third parties for the development of certain of our potential drug candidates, and we may depend on additional collaborations in
the future for the development and commercialization of these or other potential candidates. If our collaborations are not successful, we may not be able to capitalize on the market potential of these drug candidates. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">We intend to develop our current drug candidates, and expect to develop other future drug candidates, in combination with other therapies, which exposes us to
additional risks. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">We face significant competition, and if our competitors develop and market products that are more effective, safer or less expensive than the drug candidates we
develop, our commercial opportunities will be negatively impacted. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">If we and our collaborators are unable to obtain, maintain, protect and enforce sufficient patent and other intellectual property protection for our drug
candidates and technology, our competitors could develop and commercialize products and technology similar or identical to ours, and we may not be able to compete effectively in our market or successfully commercialize any drug candidates we may
develop. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the
outcome of which would be uncertain and could negatively impact the success of our business. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">We have entered into licensing agreements with third parties. If we fail to comply with our obligations in the agreements under which we license intellectual
property rights to or from third parties, or these agreements are terminated, or we otherwise experience disruptions to our business relationships with our licensors or licensees, our competitive position, business, financial condition, results of
operations and prospects could be harmed. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">We are highly dependent on our key personnel, and if we are not successful in attracting, motivating and retaining highly qualified personnel, we may not be able
to successfully implement our business strategy. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Corporate information </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We were founded in February 2018 as a Delaware corporation. Our principal executive offices are located at One Corporate Dr., 2nd Floor, South San Francisco,
California 94080, and our telephone number <FONT STYLE="white-space:nowrap">is (800) 466-6059.</FONT> </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our website address is www.aligos.com.
The information on, or that can be accessed through, our website is not part of this prospectus and is not incorporated by reference herein. We have included our website address as an inactive textual reference only. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Implications of being an emerging growth company </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are an
emerging growth company as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). We will remain an emerging growth company until the earliest of: (1) December 31, 2025, (2) the last day of the fiscal year
in which we have total annual gross revenue of at least $1.07 billion, (3) the last day of the fiscal year in which we are deemed to be a “large accelerated filer” as defined in
<FONT STYLE="white-space:nowrap">Rule 12b-2 under</FONT> the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which would occur if the market value of our common stock held
<FONT STYLE="white-space:nowrap">by non-affiliates exceeded</FONT> $700.0 million as of the last business day of the second fiscal quarter of such year or (4) the date on which we have issued more than $1.0 billion <FONT
STYLE="white-space:nowrap">in non-convertible debt</FONT> securities </FONT></P>
</div></div>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">9 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
during the prior three-year period. An emerging growth company may take advantage of specified reduced reporting requirements and is relieved of certain other significant requirements
that are otherwise generally applicable to public companies. As an emerging growth company: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we intend to avail ourselves of the exemption from the requirement to obtain an attestation and report from our independent registered public accounting firm on
the assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act of 2002; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we provide less extensive disclosure about our executive compensation arrangements; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we do not intend to require stockholder <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory votes on executive compensation or golden parachute
arrangements. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period
for complying with new or revised accounting standards. This provision allows an emerging growth company to delay the adoption of some accounting standards until those standards would otherwise apply to private companies. We have elected to use
the extended transition period for any other new or revised accounting standards during the period in which we remain an emerging growth company; however, we may adopt certain new or revised accounting standards early. </FONT></P>
</div></div>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">10 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="toc166948_2"></A>The offering </B></FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="36%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Common stock offered by us </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2"> shares. </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="36%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Underwriters’ option to purchase additional shares from us </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">We have granted the underwriters <FONT STYLE="white-space:nowrap">a 30-day option</FONT> to purchase up to additional
shares at the public offering price, less underwriting discounts and commissions. </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="36%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Common stock to be outstanding immediately after this offering </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2"> shares (or shares if the underwriters exercise in full
their option to purchase additional shares). </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="36%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B><FONT STYLE="white-space:nowrap">Non-voting</FONT> common stock to be outstanding immediately after this offering </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">3,092,338 shares. </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="43%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Total common stock and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock to be outstanding immediately after this offering </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2"> shares (or shares if the underwriters exercise in full
their option to purchase additional shares). </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="36%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Use of proceeds </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">We estimate that the net proceeds from this offering will be approximately $ million, or approximately
$ million if the underwriters exercise their option to purchase additional shares in full, at the assumed public offering price of
$ per share, the last reported sale price of our common stock on the Nasdaq Global Select Market on
, 2021, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="36%"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">We currently expect to use the net proceeds from this offering, together with our existing cash, cash equivalents and investments, to fund the continued advancement, including
clinical development and drug manufacturing activities, of our STOPS candidate, ALG-010133, our CAM candidate, ALG-000184, and our ASO candidate, ALG-020572, as well as our nonclinical and research and development activities for our siRNA candidate,
ALG-125755, and our NASH THR-ß candidate, ALG-055009, and to fund discovery and research to broaden our pipeline of drug and backup candidates, as well as for other general corporate purposes, which may include the hiring of additional
personnel, capital expenditures and the costs of operating as a public company. See the section titled “Use of proceeds” on page 87 for a more complete description of the intended use of proceeds from this offering.
</FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="36%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Risk factors </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">See the section titled “Risk factors” beginning on page 15 and other information included or incorporated by reference in this prospectus for a discussion of factors that you should
consider carefully before deciding to invest in our common stock. </FONT></TD></TR></TABLE>
</div></div>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">11 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="36%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Nasdaq Global Select Market symbol </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">“ALGS” </FONT></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The total number of shares of common stock and <FONT
STYLE="white-space:nowrap">non-voting</FONT> common stock to be outstanding after this offering is based on 38,147,205 shares of common stock outstanding as of March 31, 2021, and excludes the following: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">5,515,723 shares of common stock issuable upon the exercise of outstanding stock options as of March 31, 2021 having a weighted-average exercise price of
$11.40 per share; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">94,600 shares of common stock issuable upon the exercise of outstanding stock options granted after March 31, 2021 having a weighted-average exercise price
of $24.43 per share; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">2,921,213 shares of common stock reserved for issuance pursuant to future awards under our 2020 Incentive Award Plan, as well as any automatic increases in the
number of shares of our common stock reserved for future issuance under this plan; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">750,107 shares of common stock reserved for issuance under our 2020 Employee Stock Purchase Plan, as well as any automatic increases in the number of shares of
our common stock reserved for future issuance under this plan. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, unless we specifically state otherwise, all information in
this prospectus reflects and assumes the following: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">no exercise of outstanding stock options subsequent to March 31, 2021; and </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">no exercise of the underwriters’ option to purchase additional shares of common stock. </FONT></P></TD></TR></TABLE>
</div></div>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">12 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Summary consolidated financial data </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I>The following tables present our summary consolidated financial data for the periods and as of the dates indicated. You should read this data together with our consolidated financial statements and related notes
incorporated by reference in this prospectus and the information under the captions “Selected consolidated financial data” appearing in our 2020 Annual Report, and “Management’s discussion and analysis of financial condition and
results of operations” appearing in our 2020 Annual Report and in our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended March 31, 2021 (March 2021 Quarterly Report), which are incorporated by
reference herein. </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have derived the following summary consolidated statement of operations data for the years ended December 31, 2019 and
2020 from our audited consolidated financial statements and related notes incorporated by reference herein from our 2020 Annual Report. The summary consolidated statements of operations data for the three months ended March 31, 2020 and 2021
and the summary consolidated balance sheet data as of March 31, 2021 are derived from our unaudited interim consolidated financial statements incorporated by reference herein from our March 2021 Quarterly Report. The unaudited interim financial
statements have been prepared in accordance with generally accepted accounting principles in the United States and on the same basis as the audited consolidated financial statements and, in the opinion of management, reflect all adjustments, which
include only normal recurring adjustments, necessary to state fairly our financial position as of March 31, 2021 and our results of operations for the three months ended March 31, 2020 and 2021. Our historical results are not necessarily
indicative of our future results and results for the three months ended March 31, 2021 are not necessarily indicative of results to be expected for the full year or any other period. </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">
<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2px solid #000000"> </TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2px solid #000000"> </TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2px solid #000000"> </TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Year ended December 31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Three months ended March 31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"> <FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2019</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2020</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2020</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2021</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>(in thousands, except share and per share data)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Consolidated Statements of Operations Data</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Revenue from collaborations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">—</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">—</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">—</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">910</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Operating expenses:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">44,038</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">79,890</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">17,302</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">22,869</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">General and administrative</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10,005</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">17,944</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,419</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5,781</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total operating expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">54,043</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">97,834</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">20,721</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">28,650</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Loss from operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(54,043</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">) </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(97,834</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">) </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(20,721</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">) </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(27,740</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">) </FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Interest and other income (expense), net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,864</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(10,548</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">) </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">692</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">111</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Loss before income tax expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(52,179</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">) </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(108,382</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">) </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(20,029</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">) </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(27,629</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">) </FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Income tax expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(85</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">) </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(161</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">) </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">—</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">) </FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(52,264</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">) </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(108,543</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">) </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(20,029</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">) </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(27,674</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">) </FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other comprehensive (loss) income:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Unrealized gain (loss) on pension plans</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(118</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">) </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(141</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">) </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">166</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">) </FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Unrealized gain on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT>
investments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">—</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">68</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">401</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">41</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Comprehensive loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(52,382</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">) </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(108,616</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">) </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(19,462</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">) </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(27,713</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">) </FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss per share, basic and diluted(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(26.04</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">) </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(10.87</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">) </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(7.56</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">) </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(0.74</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">) </FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Weighted average shares of common stock, basic and diluted(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,007,173</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,988,191</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,648,885</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">37,434,261</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="16" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000"> </P></TD>
<TD> </TD></TR>
</TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">For the calculation of our basic and diluted net loss per share attributable to common stockholders and weighted-average number of shares used in the computation
of the per share amounts, see Note 15 to our consolidated financial statements included in our 2020 Annual Report </FONT></P></TD></TR></TABLE>
</div></div>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">13 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P><FONT STYLE="font-family:arial" SIZE="1">
incorporated by reference herein and Note 14 to our unaudited interim condensed consolidated financial statements included in our March 2021 Quarterly Report incorporated by reference herein.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">
<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2px solid #000000"> </TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2px solid #000000"> </TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>As of March 31, 2021</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"> <FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Actual</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>As<BR>Adjusted(1)</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Consolidated Balance Sheet Data:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cash, cash equivalents and investments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">213,415</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Working capital(2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">194,595</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">234,540</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Current liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(25,231</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">) </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Operating lease liabilities, net of current portion</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(10,183</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">) </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accumulated deficit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(202,414</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">) </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total stockholders’ equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">195,220</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000"> </P></TD>
<TD> </TD></TR>
</TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Each $1.00 increase (decrease) in the assumed public offering price of $ per share,
the last reported sale price of our common stock on the Nasdaq Global Select Market on , 2021 would increase (decrease) the amount of each of cash, cash
equivalents and investments, working capital, total assets and total stockholders’ equity by $ million, assuming the number of shares offered by us,
as set forth on the cover page of this prospectus, remains the same and after deducting the underwriting discount and commissions and estimated offering expenses payable by us. We may also increase (decrease) the number of shares we are offering.
Each increase (decrease) of 1,000,000 in the number of shares we are offering would increase (decrease) the amount of each of cash, cash equivalents and investments, working capital, total assets and total stockholders’ equity by
$ million, assuming the assumed public offering price of
$ per share, the last reported sale price of our common stock on the Nasdaq Global Select Market
on , 2021 remains the same and after deducting the underwriting discount and commissions and estimated offering expenses payable by us. The as adjusted
information is illustrative only and we will adjust this information based on the actual public offering price and other terms of this offering determined at pricing. </FONT></TD></TR></TABLE>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">We define working capital as current assets less current liabilities. See our unaudited interim condensed consolidated financial statements included in our March 2021 Quarterly
Report incorporated by reference herein for details regarding our current assets and current liabilities. </FONT></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><A NAME="toc166948_1"></A>The
preceding table presents our consolidated balance sheet data as of March 31, 2021: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">on an actual basis; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">on an as adjusted basis to give effect to the sale of shares of
common stock in this offering at the assumed public offering price of $ per share, the last reported sale price of our common stock on the Nasdaq Global
Select Market on , 2021 after deducting the underwriting discounts and commissions and estimated offering expenses payable by us.
</FONT></P></TD></TR></TABLE>
</div></div>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">14 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="toc166948_3"></A>Risk factors </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I>Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in this prospectus or incorporated by reference herein
before deciding whether to invest in our common stock. The occurrence of any of the events or developments described below could harm our business, competitive position, financial condition, results of operations, cash flows and prospects. In such
an event, the market price of our common stock could decline, and you may lose all or part of your investment. Many of the following risks and uncertainties and those contained in the documents incorporated by reference herein are, and will be,
exacerbated by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and any worsening of the global business and economic environment as a result. Additional risks and uncertainties not presently known to us or that we currently deem
immaterial also may impair our business operations and the market price of our common stock. </I></FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Risks related to our limited operating history,
financial position and need for additional capital </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We are a clinical-stage biopharmaceutical company with a limited operating history and no
products approved for commercial sale. We have incurred significant losses since inception. We expect to incur losses for at least the next several years and may never achieve or maintain profitability, which, together with our limited operating
history, makes it difficult to assess our future viability. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Biopharmaceutical product development is a highly speculative undertaking and
involves a substantial degree of risk. We are a clinical-stage biopharmaceutical company, and we have only a limited operating history upon which you can evaluate our business and prospects. We currently have no products approved for commercial
sale, have not generated any revenue from sales of products and have incurred losses in each year since our inception in February 2018. In addition, we have limited experience as a company and have not yet demonstrated an ability to successfully
overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the biopharmaceutical industry. Only two of our drug candidates, <FONT STYLE="white-space:nowrap">ALG-010133</FONT>
and <FONT STYLE="white-space:nowrap">ALG-000184,</FONT> are currently in clinical development. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Since inception, we have incurred significant net losses.
Our net losses were $27.7 million for the three months ended March 31, 2021 and $108.5 million for the year ended December 31, 2020. As of March 31, 2021, we had a total stockholders’ equity of $195.2 million. We
have funded our operations to date primarily with proceeds from the sale of common stock, preferred stock and convertible notes. To date, we have devoted substantially all of our resources to organizing and staffing our company, business planning,
raising capital, acquiring and discovering development programs, securing intellectual property rights and conducting discovery, research and development activities for our programs. We have not yet demonstrated our ability to successfully complete
any clinical trials, including pivotal clinical trials, obtain marketing approvals, manufacture a commercial-scale product or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful
product commercialization. Our drug candidates will require substantial additional development time and resources before we will be able to apply for or receive regulatory approvals and, if approved, begin generating revenue from product sales. We
expect to continue to incur significant expenses and operating losses for the foreseeable future. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We have never generated revenue from product
sales and may never be profitable. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our ability to generate revenue from product sales and achieve profitability depends on our ability, alone or
with our collaboration partners, to successfully complete the development of, and obtain the regulatory approvals necessary to commercialize, our drug candidates. We do not anticipate generating revenue from
</FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">15 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
product sales for the next several years, if ever. Our ability to generate revenue from product sales depends heavily on our and our current and potential future collaborators’ success in:
</FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">completing clinical and nonclinical development of drug candidates and programs and identifying and developing new drug candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">seeking and obtaining marketing approvals for any drug candidates that we develop; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">launching and commercializing drug candidates for which we obtain marketing approval by establishing a sales force, marketing, medical affairs and distribution
infrastructure or, alternatively, collaborating with a commercialization partner; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">achieving adequate coverage and reimbursement by third-party payors for drug candidates that we develop; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">establishing and maintaining supply and manufacturing relationships with third parties that can provide adequate, in both amount and quality, products and
services to support clinical development and the market demand for drug candidates that we develop, if approved; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">obtaining market acceptance of drug candidates that we develop as viable treatment options; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">addressing any competing technological and market developments; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter and performing our obligations in such collaborations;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">maintaining, protecting, enforcing and expanding our portfolio of intellectual property rights, including patents, trade secrets and <FONT
STYLE="white-space:nowrap">know-how;</FONT> </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">defending against third-party interference, infringement or other intellectual property-related claims, if any; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">attracting, hiring and retaining qualified personnel. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Even if one or more of the drug candidates that we develop is approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved drug candidate. Our expenses could
increase beyond expectations if we are required by the U.S. Food and Drug Administration (the FDA), the European Medicines Agency (the EMA), or other regulatory agencies to perform clinical trials or studies in addition to those that we currently
anticipate. Even if we are able to generate revenue from the sale of any approved products, we may not become profitable and may need to obtain additional funding to continue operations. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Even if this offering is successful, we will require substantial additional financing to achieve our goals, which may not be available on acceptable terms, or at all. A failure to obtain this necessary
capital when needed could force us to delay, limit, reduce or terminate our product development or commercialization efforts. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our operations
have consumed substantial amounts of cash since our inception. Since our inception, we have invested a significant portion of our efforts and financial resources in research and development activities for our initial nonclinical and clinical drug
candidates. Nonclinical studies and clinical trials and additional research and development activities will require substantial funds to complete. As of March 31, 2021, we had cash, cash equivalents and investments of $213.4 million. In
October 2020, we issued an aggregate of 3,569,630 shares of our Series <FONT STYLE="white-space:nowrap">B-2</FONT> redeemable convertible preferred stock in the second tranche of our Series B convertible preferred stock financing for aggregate
proceeds to us of $40.0 million. In addition, we have received net proceeds of $151.4 million from the sale of an aggregate of 11,150,000 shares of our common stock on </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">16 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
October 20, 2020 and on November 5, 2020 in connection with our IPO. We expect to continue to spend substantial amounts to continue the nonclinical and clinical development of our
current and future programs. If we are able to gain marketing approval for drug candidates that we develop, we will require significant additional amounts of cash in order to launch and commercialize such drug candidates. In addition, other
unanticipated costs may arise. Because the design and outcome of our planned and anticipated clinical trials is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and
commercialization of any drug candidate we develop. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our future capital requirements depend on many factors, including: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the scope, progress, results and costs of researching and developing our drug candidates and programs, and of conducting nonclinical studies and clinical trials;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the timing of, and the costs involved in, obtaining marketing approvals for drug candidates we develop if clinical trials are successful;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the cost of commercialization activities for our current drug candidates, and any future drug candidates we develop, whether alone or in collaboration, including
marketing, sales and distribution costs if our current drug candidates or any future drug candidate we develop is approved for sale; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the cost of manufacturing our current and future drug candidates for clinical trials in preparation for marketing approval and commercialization;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our ability to establish and maintain strategic licenses or other arrangements and the financial terms of such agreements including milestone payments to our
licensors; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the costs involved in preparing, filing, prosecuting, maintaining, expanding, defending and enforcing patent claims, including litigation costs and the outcome
of such litigation; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the timing, receipt and amount of sales of, or profit share or royalties on, our future products, if any; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the emergence of competing therapies for hepatological indications and viral diseases and other adverse market developments; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">any acquisitions or <FONT STYLE="white-space:nowrap">in-licensing</FONT> of other programs or technologies. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We expect to finance our cash needs through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing
arrangements and other marketing or distribution arrangements. In addition, we may seek additional capital to take advantage of favorable market conditions or strategic opportunities even if we believe we have sufficient funds for our current or
future operating plans. Based on our research and development plans, we expect our existing cash, cash equivalents and investments will enable us to fund our operations for at least 12 months following the date of this prospectus. However, our
operating plan may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned. Moreover, it is particularly difficult to estimate with certainty our future expenses given the dynamic
nature of our business, the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and the macro-economic environment generally. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our ability to raise
additional funds will depend on financial, economic and other factors, many of which are beyond our control. In particular, the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic continues to rapidly evolve and has already resulted in a
significant disruption of global financial markets. If the disruption persists or deepens, we could be unable to access additional capital, which could negatively affect our ability to consummate certain corporate
</FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">17 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
development transactions or other important, beneficial or opportunistic investments. If additional funds are not available to us when we need them, on terms that are acceptable to us, or at all,
we may be required to: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">delay, limit, reduce or terminate nonclinical studies, clinical trials or other research and development activities or eliminate one or more of our development
programs altogether; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">delay, limit, reduce or terminate our efforts to establish manufacturing and sales and marketing capabilities or other activities that may be necessary to
commercialize any future approved products, or reduce our flexibility in developing or maintaining our sales and marketing strategy. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Our operating results may fluctuate significantly, which will make our future results difficult to predict and could cause our results to fall below
expectations. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our quarterly and annual operating results may fluctuate significantly, which will make it difficult for us to predict our future
results. These fluctuations may occur due to a variety of factors, many of which are outside of our control and may be difficult to predict, including: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the timing and cost of, and level of investment in, research, development and commercialization activities, which may change from time to time;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the timing and status of enrollment for our clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the timing of regulatory approvals, if any, in the United States and internationally; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the timing of expanding our operational, financial and management systems and personnel, including personnel to support our clinical development, quality
control, manufacturing and commercialization efforts and our operations as a public company; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the cost of manufacturing, as well as building out our supply chain, which may vary depending on the quantity produced, and the terms of any agreements we enter
into with third-party suppliers; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the timing and amount of any milestone, royalty or other payments due under any current or future collaboration or license agreement, including our existing
license agreements with Emory University (Emory) and Luxna Biotech Co., Ltd. (Luxna); </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">coverage and reimbursement policies with respect to any future approved products, and potential future drugs that compete with our products;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the timing and cost to establish a sales, marketing, medical affairs and distribution infrastructure to commercialize any products for which we may obtain
marketing approval and intend to commercialize on our own or jointly with current or future collaborators; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">expenditures that we may incur to acquire, develop or commercialize additional products and technologies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the level of demand for any future approved products, which may vary significantly over time; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">future accounting pronouncements or changes in accounting principles or our accounting policies; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the timing and success or failure of nonclinical studies and clinical trials for our drug candidates or competing drug candidates, or any other change in the
competitive landscape of our industry, including consolidation among our competitors or collaboration partners. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The cumulative effects
of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-to-period</FONT></FONT> basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance. </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">18 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">This variability and unpredictability could also result in our failing to meet the expectations of industry or
financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the
expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even if we have met any previously publicly stated revenue or earnings guidance we may provide. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Our business could be materially adversely affected by the effects of health pandemics or epidemics, including the current outbreak of <FONT
STYLE="white-space:nowrap">COVID-19</FONT> and future coronavirus outbreaks, and in particular in regions where we or third parties on which we rely have significant manufacturing facilities, concentrations of clinical trial sites or other business
operations, including the San Francisco Bay Area where our headquarters are located. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our business could be materially adversely affected by the
effects of health pandemics or epidemics, including the current outbreak of <FONT STYLE="white-space:nowrap">COVID-19,</FONT> which the World Health Organization declared a global pandemic and which has prompted severe lifestyle and commercial
restrictions aimed at reducing the spread of the disease. In March 2020, the San Francisco Bay Area counties issued a joint <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">shelter-in-place</FONT></FONT> order, which was
subsequently followed by a California state-wide shelter order, and other state and local governments implemented similar orders which, among other things, directed individuals to shelter at their places of residence, directed businesses and
governmental agencies to cease <FONT STYLE="white-space:nowrap">non-essential</FONT> operations at physical locations, prohibited certain <FONT STYLE="white-space:nowrap">non-essential</FONT> gatherings, and ordered cessation of <FONT
STYLE="white-space:nowrap">non-essential</FONT> travel. As a result of these developments, we implemented work-from-home policies for most of our employees. Since the availability of <FONT STYLE="white-space:nowrap">COVID-19</FONT> vaccines, the
majority of our U.S. employees have been fully vaccinated and as a result, we are allowing such employees to return to work at our U.S. facility. However, as the global <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and orders and
guidance from state and local governments continue to evolve, we may need to reverse course and again implement work-from-home policies as necessary. Government-imposed quarantines and our work-from-home policies may negatively impact productivity,
disrupt our business and delay our clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions, the potential impact of changing government orders in response to upticks in <FONT
STYLE="white-space:nowrap">COVID-19</FONT> cases and other limitations on our ability to conduct our business in the ordinary course. Although we do not anticipate any impacts to our clinical programs, these and similar, and perhaps more severe,
disruptions in our operations could negatively impact our business, operating results and financial condition in the future. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Quarantines, shutdowns and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">shelter-in-place</FONT></FONT> and similar government orders related to <FONT STYLE="white-space:nowrap">COVID-19</FONT> or other infectious diseases, or the perception that such events,
orders or other restrictions on the conduct of business operations could occur, could impact personnel at third-party manufacturing facilities in the United States and other countries, or the availability or cost of materials, which would disrupt
our supply chain. Although we do not anticipate any clinical supply issues or concerns for our planned clinical trials, restrictions resulting from the <FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak may disrupt our supply chain in the
future and delay or limit our ability to obtain sufficient materials for our drug candidates. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, our current clinical trial and planned
clinical trials may be affected by the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. Site initiation and patient enrollment may be delayed due to prioritization of hospital resources toward the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, and potential patients may not be able or willing to comply with clinical trial protocols, whether due to quarantines impeding patient movement or interrupting healthcare services, or due to
potential patient concerns regarding interactions with medical facilities or staff. Similarly, our ability to recruit and retain principal investigators and site staff who, as healthcare providers, may have heightened exposure to <FONT
STYLE="white-space:nowrap">COVID-19,</FONT> may be delayed or disrupted, which may adversely impact our clinical trial operations. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, the
global <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic has adversely affected, and any future significant outbreak of contagious diseases in the human population could similarly adversely affect, the economies and financial
</FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">19 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
markets of many countries, including the United States, resulting in an economic downturn that could suppress demand for our future products. Any of these events could have a material adverse
effect on our business, financial condition, results of operations or cash flows. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, while the duration and severity of the effects of <FONT
STYLE="white-space:nowrap">COVID-19</FONT> may be difficult to assess or predict, a continuing widespread pandemic could result in significant disruption of global financial markets, reducing our ability to access capital, which could negatively
affect our liquidity and ability to progress our operations. In addition, a recession, down-turn or market correction resulting from the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic could materially adversely affect the value of our
common stock. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Risks related to product development and regulatory process </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>We are early in our development efforts, and our business is dependent on the successful development of our current and future drug candidates. If we are unable to advance our current or future drug
candidates through clinical trials, obtain marketing approval and ultimately commercialize any drug candidates we develop, or experience significant delays in doing so, our business will be materially harmed. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our clinical development efforts across our drug candidates are in an early stage. We have initiated clinical trials for our most advanced drug candidates, <FONT
STYLE="white-space:nowrap">ALG-010133</FONT> and <FONT STYLE="white-space:nowrap">ALG-000184,</FONT> respectively, in New Zealand, Hong Kong and Moldova. Our other programs are in the discovery or nonclinical development stage. We have invested
substantially all of our efforts and financial resources in the identification of targets and nonclinical development of therapeutics to address hepatological indications and viral diseases. However, the biology of these indications and diseases is
complex and not completely understood, and our current and future drug candidates may never achieve expected or functional levels of efficacy or achieve an acceptable safety profile. Our use of clinically validated targets to pursue treatments of
these indications and diseases does not guarantee efficacy or safety or necessarily reduce the risk that our current or future drug candidates will not achieve expected or functional levels of efficacy or achieve an acceptable safety profile.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The success of our business, including our ability to finance our company and generate revenue from products in the future, which we do not expect will
occur for several years, if ever, will depend heavily on the successful development and eventual commercialization of the drug candidates we develop, which may never occur. Our current drug candidates, and any future drug candidates we develop, will
require additional nonclinical and clinical development, management of clinical, nonclinical and manufacturing activities, marketing approval in the United States and other markets, demonstrating effectiveness to pricing and reimbursement
authorities, obtaining sufficient manufacturing supply for both clinical development and commercial production, building of a commercial organization, and substantial investment and significant marketing efforts before we generate any revenues from
product sales. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As an organization, we have not yet completed any clinical trials for any of our drug candidates. Each of our lead drug candidates, <FONT
STYLE="white-space:nowrap">ALG-010133</FONT> and <FONT STYLE="white-space:nowrap">ALG-000184,</FONT> is currently being evaluated in Phase 1 clinical trials in New Zealand, Hong Kong, and Moldova. As a company, we have limited experience in
preparing, submitting and prosecuting regulatory filings. Specifically, we have not previously submitted a new drug application (NDA) to the FDA or similar approval filings to a comparable foreign regulatory authority for any drug candidate. An NDA
or other relevant regulatory filing must include extensive nonclinical and clinical data and supporting information to establish that the drug candidate is safe and effective for each desired indication. The NDA or other comparable regulatory filing
must also include significant information regarding the chemistry, manufacturing and controls for the product. We have had limited interactions with the FDA and cannot be certain how many clinical trials of any of our drug candidates will be
required or whether the FDA will agree with the design or implementation of our clinical trials. In addition, we cannot be certain that our current or future drug candidates will be successful in clinical trials such that the information contained
in an NDA or </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">20 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
comparable regulatory filing would support approval, and thus we cannot guarantee that any of our drug candidates will receive regulatory approval. Further, even if our current or future drug
candidates are successful in clinical trials, such candidates may not receive regulatory approval. If we do not receive regulatory approvals for current or future drug candidates, we may not be able to continue our operations. Even if we
successfully obtain regulatory approval to market a drug candidate, our revenue will depend, in part, upon the size of the markets in the territories for which we gain regulatory approval and have commercial rights, as well as the availability of
competitive products, third-party reimbursement and adoption by physicians. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We plan to seek regulatory approval to commercialize our drug candidates
both in the United States and in select foreign countries. While the scope of regulatory approval in other countries is generally similar to that in the United States, in order to obtain separate regulatory approval in other countries we must comply
with numerous and varying regulatory requirements of such countries regarding safety and efficacy. Other countries also have their own regulations governing, among other things, clinical trials and commercial sales, as well as pricing and
distribution of drugs, and we may be required to expend significant resources to obtain regulatory approval and to comply with ongoing regulations in these jurisdictions. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The success of our current and future drug candidates will depend on many factors, which may include the following: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">sufficiency of our financial and other resources to complete the necessary nonclinical studies and clinical trials, and our ability to raise any additional
required capital on acceptable terms, or at all; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our ability to develop and successfully utilize our drug discovery platforms; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the timely and successful completion of our nonclinical studies and clinical trials, which may be significantly slower or cost more than we currently anticipate
and will depend substantially upon the performance of third-party contractors; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">acceptance of investigational new drug applications (INDs), CTAs and/or similar applications in other jurisdictions for our planned and future clinical trials;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">whether we are required by the FDA or a comparable foreign regulatory agency to conduct additional clinical trials or other studies beyond those planned to
support approval of our drug candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">successful enrollment and completion of clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">successful data from our clinical program that supports an acceptable risk-benefit profile of our drug candidates in the intended populations;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">receipt and maintenance of marketing approvals from applicable regulatory authorities; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">establishing agreements with third-party manufacturers for clinical supply for our clinical trials and commercial manufacturing, if our drug candidates are
approved; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our ability, and the ability of any third parties with whom we contract, to remain in good standing with regulatory agencies and develop, validate and maintain
commercially viable manufacturing processes that are compliant with current good manufacturing practices (cGMPs); </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">entry into collaborations to further the development of our drug candidates in select indications or geographies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">obtaining, maintaining and expanding our portfolio of intellectual property rights, including patents, trade secrets and
<FONT STYLE="white-space:nowrap">know-how;</FONT> </FONT></P></TD></TR></TABLE>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">21 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">enforcing and defending our intellectual property rights and having and successfully executing an intellectual property life cycle management strategy that
supports long-term product development and commercialization goals; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">obtaining and maintaining regulatory exclusivity for our drug candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">successfully launching commercial sales of our drug candidates, if approved; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">acceptance of the drug candidate’s benefits and uses, if approved, by patients, the medical community and third-party payors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the prevalence, duration and severity of potential side effects or other safety issues experienced with our drug candidates following approval;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">effectively competing with other therapies; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">obtaining and maintaining healthcare coverage and adequate reimbursement from third-party payors. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If we are not successful with respect to one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to
successfully obtain approval of or commercialize the drug candidates we develop, which would materially harm our business. If we do not receive marketing approvals for our current or future drug candidates, we may not be able to continue our
operations. Even if regulatory approvals are obtained, we may never be able to successfully commercialize any products. Accordingly, we cannot provide assurances that we will be able to generate sufficient revenue through the sale of products to
continue our business. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Nonclinical development is uncertain. Our nonclinical programs may experience delays or may never advance to clinical
trials, which would adversely affect our ability to obtain regulatory approvals or commercialize our drug candidates on a timely basis or at all, which would have an adverse effect on our business. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In order to obtain approval from the FDA and other major regulatory agencies in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> countries to market a new drug
candidate, we must demonstrate proof of safety and efficacy in humans. To meet these requirements, we will have to conduct adequate and well-controlled clinical trials. Before we can commence clinical trials for a drug candidate, we must complete
extensive nonclinical studies that support our planned INDs or CTAs in the United States and other countries. At this time, we have two drug candidates <FONT STYLE="white-space:nowrap">(ALG-010133</FONT> and
<FONT STYLE="white-space:nowrap">ALG-000184)</FONT> being evaluated in Phase 1 clinical trials in New Zealand, Hong Kong, and Moldova. The rest of our programs are in nonclinical research or earlier stages of development, including our other chronic
hepatitis B (CHB) drug candidates, our nonalcoholic steatohepatitis (NASH) drug candidate and our coronavirus drug candidates. We cannot be certain of the timely completion or outcome of our nonclinical studies and cannot predict if the FDA or other
regulatory authorities will accept our proposed clinical programs or if the outcome of our nonclinical studies will ultimately support further development of our programs. In addition, the FDA may decline to accept the data we obtain from foreign
clinical studies in support of an IND or NDA in the United States, which may require us to repeat or conduct additional nonclinical studies or clinical trials that we did not anticipate in the United States. As a result, we cannot be sure that we
will be able to submit INDs in the United States, or CTAs or similar applications in other jurisdictions, on the timelines we expect, if at all, and we cannot be sure that submission of INDs, CTAs or similar applications will result in the FDA or
other regulatory authorities allowing additional clinical trials to begin. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Conducting nonclinical testing is a complex, lengthy, time-consuming and
expensive process. The length of time may vary substantially according to the type, complexity and novelty of the program, and often can take several years or more per program. Delays associated with programs for which we are directly conducting
nonclinical studies may cause us to incur additional operating expenses. Moreover, we may be affected by delays </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">22 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
associated with the studies of certain programs that are the responsibility of potential future partners, if any, over which we have no control. The commencement and rate of completion of
nonclinical studies and clinical trials for a drug candidate may be delayed by many factors, including: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">inability or failure by us or third parties to comply with regulatory requirements, including the requirements of good laboratory practice (GLP);
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">inability to generate sufficient nonclinical or other in vivo or in vitro data to support the initiation of clinical studies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">delays in reaching a consensus with regulatory agencies on study design and obtaining regulatory authorization to commence clinical trials;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">obtaining sufficient quantities of our drug candidates for use in nonclinical studies and clinical trials from third-party suppliers on a timely basis;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">delays due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, including due to reduced workforce productivity as a result of our implementation of
a temporary work-from-home policy or illness among personnel, or due to delays at our third-party contract research organizations throughout the world for similar reasons or due to restrictions imposed by applicable governmental authorities; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">delays due to other global-scale potentially catastrophic events, including other pandemics, terrorism, war, and climate changes. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Moreover, even if candidates from our drug programs advance into clinical trials, our development efforts may not be successful, and clinical trials that we conduct
or that third parties conduct on our behalf may not demonstrate sufficient safety or efficacy to obtain the requisite regulatory approvals for any drug candidates we develop. Even if we obtain positive results from nonclinical studies or initial
clinical trials, we may not achieve the same success in future trials. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>The regulatory approval processes of the FDA, the EMA and comparable
foreign authorities are lengthy, time-consuming, complex and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our drug candidates, our business will be substantially harmed. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The time required to obtain approval by the FDA, the EMA and comparable foreign authorities is unpredictable but typically takes many years following the
commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval
may change during the course of a drug candidate’s clinical development and may vary across jurisdictions. We have not obtained regulatory approval for any drug candidate and it is possible that none of our current or future drug candidates
will ever obtain regulatory approval. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our current and future drug candidates could fail to receive regulatory approval for many reasons, including the
following: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the FDA, the EMA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we may be unable to demonstrate to the satisfaction of the FDA, the EMA or comparable foreign regulatory authorities that a drug candidate is safe or effective
for its proposed indication; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the results of clinical trials may not meet the level of statistical significance required by the FDA, the EMA or comparable foreign regulatory authorities for
approval; </FONT></P></TD></TR></TABLE>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">23 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we may be unable to demonstrate that a drug candidate’s clinical and other benefits outweigh its safety risks; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the FDA, the EMA or comparable foreign regulatory authorities may disagree with our interpretation of data from clinical trials or nonclinical studies;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the data collected from clinical trials of our drug candidates may not be sufficient to support the submission of an NDA to the FDA or other submission or to
obtain regulatory approval in the United States, the European Union or elsewhere; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the FDA, the EMA or comparable foreign regulatory authorities may find deficiencies with or fail to approve the manufacturing processes or facilities of
third-party manufacturers with which we contract for clinical and commercial supplies; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the approval policies or regulations of the FDA, the EMA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical
data insufficient for approval. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">This lengthy approval process as well as the unpredictability of clinical trial results may result in
our failing to obtain regulatory approval to market any drug candidate we develop, which would significantly harm our business, results of operations and prospects. The FDA, the EMA and other comparable foreign authorities have substantial
discretion in the approval process, and in determining when or whether regulatory approval will be obtained for any drug candidate that we develop. Even if we believe the data collected from future clinical trials of our drug candidates are
promising, such data may not be sufficient to support approval by the FDA, the EMA or any other regulatory authority. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, even if we were to
obtain approval, regulatory authorities may approve any of our drug candidates for fewer or more limited indications than we request, may not approve the price we intend to charge for our products, may grant approval contingent on the performance of
costly post-marketing clinical trials, or may approve a drug candidate with a label that does not include the labeling claims that we believe are necessary or desirable for the successful commercialization of that drug candidate. Any of the
foregoing scenarios could materially harm the commercial prospects for our drug candidates. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We cannot be certain that any of our programs will be
successful in clinical trials or receive regulatory approval. Further, drug candidates we develop may not receive regulatory approval even if they are successful in clinical trials. If we do not receive regulatory approvals for our drug candidates,
we may not be able to continue our operations. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Clinical product development involves a lengthy and expensive process, with uncertain outcomes. We
may experience delays in completing, or ultimately be unable to complete, the development and commercialization of our current and future drug candidates, which could result in increased costs to us, delay or limit our ability to generate revenue
and adversely affect our business, financial condition, results of operations and prospects. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">To obtain the requisite regulatory approvals to
commercialize any of our drug candidates, we must demonstrate through extensive nonclinical studies and clinical trials that our products are safe and effective in humans. Clinical trials are expensive and can take many years to complete, and their
outcomes are inherently uncertain. Failure can occur at any time during the clinical trial process and our future clinical trial results may not be successful. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We may experience delays in completing our clinical trials and initiating or completing additional clinical trials. We may also experience numerous unforeseen events prior to, during, or as a result of our
nonclinical studies </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">24 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
or clinical trials that could delay or prevent our ability to receive marketing approval or commercialize the drug candidates we develop, including: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">regulators, Institutional Review Boards (IRBs) or ethics committees may not authorize us or our investigators to commence a clinical trial or conduct a clinical
trial at a prospective trial site; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we may experience delays in reaching, or fail to reach, agreement on acceptable terms with prospective trial sites and prospective contract research
organizations (CROs); </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the number of patients required for clinical trials may be larger than we anticipate; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">it may be difficult to enroll a sufficient number of suitable patients, or enrollment in these clinical trials may be slower than we anticipate or participants
may drop out of these clinical trials or fail to return for post-treatment <FONT STYLE="white-space:nowrap">follow-up</FONT> at a higher rate than we anticipate; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all, or may
deviate from the clinical trial protocol or drop out of the trial, which may require us to add new clinical trial sites or investigators; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the supply or quality of materials for drug candidates we develop or other materials necessary to conduct clinical trials may be insufficient or inadequate; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we may experience disruptions by <FONT STYLE="white-space:nowrap">man-made</FONT> or natural disasters or public health pandemics or epidemics or other business
interruptions, including the current <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and future outbreaks of the disease. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We
could encounter delays if a clinical trial is suspended or terminated by us, by the IRBs or ethics committees of the institutions in which such trials are being conducted, by a Data Safety Monitoring Board for such trial or by the FDA or other
regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the
clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product, changes in
governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the
denial of marketing approval of our drug candidates. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Further, we are currently conducting a clinical trial for each of
<FONT STYLE="white-space:nowrap">ALG-010133</FONT> and <FONT STYLE="white-space:nowrap">ALG-000184</FONT> in New Zealand, Hong Kong, and Moldova. We may also in the future conduct clinical trials for
<FONT STYLE="white-space:nowrap">ALG-010133,</FONT> <FONT STYLE="white-space:nowrap">ALG-000184</FONT> and other drug candidates in other countries and territories which presents additional risks that may delay completion of our clinical trials.
These risks include the possibility that we could be required to conduct additional nonclinical studies before initiating any clinical trials, may be unable to enroll and retain patients as a result of differences in healthcare services, research
guidelines or cultural customs, or may face additional administrative burdens associated with comparable foreign regulatory schemes, as well as political and economic risks relevant to such foreign countries. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If we experience termination or delays in the completion of any clinical trial of our drug candidates, the commercial prospects of our drug candidates will be
harmed, and our ability to generate product revenues from any of these drug candidates will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our drug candidate development and approval process
and jeopardize our ability to commence product sales and generate revenues. Significant clinical trial delays could also allow our competitors to bring products to market before we do, shorten any periods during which we may have the exclusive right
to commercialize our drug candidates, impair our ability to commercialize our drug candidates and harm our business and results of operations. </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">25 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Specifically, the clinical trial sites for our current drug trials, including for
<FONT STYLE="white-space:nowrap">ALG-010133</FONT> and <FONT STYLE="white-space:nowrap">ALG-000184,</FONT> and future planned trials may be affected by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak due to prioritization of hospital
resources toward <FONT STYLE="white-space:nowrap">COVID-19</FONT> efforts, travel or quarantine restrictions imposed by national, federal, state or local governments, and the inability to access sites for initiation and patient monitoring and
enrollment. As a result, patient screening, new patient enrollment, monitoring and data collection may be affected or delayed. Some of our third-party manufacturers we use for the supply of materials for drug candidates or other materials necessary
to manufacture product to conduct clinical trials are located in countries affected by <FONT STYLE="white-space:nowrap">COVID-19,</FONT> and, should they experience disruptions such as temporary closures or suspension of services, we would likely
experience delays in advancing these trials. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Separately, principal investigators for our clinical trials serve as scientific advisors or consultants to
us from time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or a regulatory authority concludes that the
financial relationship may have affected the interpretation of the clinical trial, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized, which
could result in the delay or rejection of any applications we submit. Any such delay or rejection could prevent or delay us from commercializing our current or future drug candidates. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Any of these occurrences may harm our business, financial condition and prospects significantly. In addition, many of the factors that cause, or could lead to, a delay in the commencement or completion of clinical
trials may also ultimately lead to the denial of regulatory approval of our drug candidates or result in the development of our drug candidates being terminated. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Our pursuit of potential treatments for NASH is at an early stage and we may be unable to produce a therapy that successfully treats NASH. Even if successful, we may be unable to obtain regulatory approval
for and successfully commercialize our drug candidates. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have invested, and will continue to invest, a significant portion of our time and
financial resources in the pursuit of a treatment for NASH. If we cannot successfully develop, obtain regulatory approval for and commercialize our drug candidates for the treatment of NASH, our business may be harmed. The mechanism of action of our
NASH drug candidates is complex, and we do not know the degree to which it will translate into a therapeutic benefit, if any, in NASH or any other indication, and we do not know the degree to which the complex mechanism of action may contribute to
long-term safety issues or adverse events when our drug candidates are taken for prolonged periods, as is inherent in the treatment of NASH. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In
addition, the standards implemented by clinical or regulatory agencies may change at any time and we cannot be certain what efficacy endpoints the FDA or foreign clinical or regulatory agencies may require at the time we plan to conduct clinical
trials with respect to NASH or any other applicable indication.<B><I> </I></B>Also, if we are able to obtain accelerated approval of our drug candidates based on a liver biopsy endpoint, we may be required to conduct a post-approval clinical
outcomes trial to confirm the clinical benefit of the drug candidate; if any such post-approval trial is not successful, we would not be able to continue marketing the product. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">If we are successful and any of our drug candidates are approved for the treatment of NASH, our drug candidates will likely compete with products that may be approved for the treatment of NASH prior to our drug
candidates and/or that have greater efficacy than our drug candidates, either alone or in combination. Behavioral modifications, such as diet and exercise, can also decrease or eliminate the demand for our potential NASH treatments. </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">26 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Our pursuit of potential therapies for <FONT STYLE="white-space:nowrap">COVID-19</FONT> is at an early
stage. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In response to the outbreak of <FONT STYLE="white-space:nowrap">COVID-19,</FONT> the disease caused by the virus <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2,</FONT></FONT> we are pursuing various potential therapies to address the disease, including protease inhibitors and oligonucleotides. Our identification and development of these
potential therapies is at an early stage, and we may be unable to produce in a timely manner a therapy that successfully treats the virus or that has broad clinical applicability, if at all. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">For example, in June 2020, we entered into a Research, Licensing and Commercialization Agreement (the KU Leuven Agreement) with Katholieke Universiteit Leuven (KU Leuven) under which we are collaborating with KU
Leuven’s Rega Institute for Medical Research, as well as its Centre for Drug Design and Discovery, to research, develop, manufacture and commercialize potential protease inhibitors for the treatment of coronaviruses, including <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2.</FONT></FONT> We are in the earliest stages of our collaboration under the KU Leuven Agreement. The KU Leuven Agreement may not result in a therapy that successfully treats <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2.</FONT></FONT> Further, if the KU Leuven Agreement does result in such a therapy, the therapy may not be developed and commercialized in a timely manner. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are also committing significant financial resources and personnel to the development of potential therapies for <FONT STYLE="white-space:nowrap">COVID-19,</FONT>
which may cause delays in or otherwise negatively impact our other development programs, despite uncertainties surrounding the longevity and extent of <FONT STYLE="white-space:nowrap">COVID-19</FONT> as a global health concern. <FONT
STYLE="white-space:nowrap">COVID-19</FONT> may be substantially eradicated prior to our development of a successful therapy or a vaccine may be developed that is highly efficacious and widely adopted, reducing or eliminating the need for therapies
to treat the disease. For instance, the Pfizer/BioNTech BNT162b2, the adenovirus type 26 (Ad26) vaccine by Janssen Pharmaceutical Companies of Johnson & Johnson, and Moderna mRNA-1273 <FONT STYLE="white-space:nowrap">COVID-19</FONT>
vaccines have been authorized for emergency use and are in the process of being widely being administered in various countries throughout the world, which could adversely impact the need for our potential
<FONT STYLE="white-space:nowrap">COVID-19</FONT> therapies. Further, while we hope to develop potential therapies that are effective against other or future coronaviruses, in addition to <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">SARS-CoV-2,</FONT></FONT> we cannot be certain this will be the case. If our potential therapies are not effective against other or future coronaviruses, the value and/or sales potential of our therapies will be reduced or
eliminated. Our business could be negatively impacted by our allocation of significant resources to a global health threat that is unpredictable and could rapidly dissipate or against which our potential therapies, if developed, may not be partially
or fully effective, and may ultimately prove unsuccessful or unprofitable. Furthermore, there are no assurances that our therapy will be approved for inclusion in government stockpile programs, which may be material to the commercial success of any
approved coronavirus-related drug candidate, either in the United States or abroad. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We will also need to enter into manufacturing arrangements in the
future in order to create a supply chain for our <FONT STYLE="white-space:nowrap">COVID-19</FONT> drug candidates that can adequately support demand. Even if we are successful in developing and manufacturing an effective treatment for <FONT
STYLE="white-space:nowrap">COVID-19,</FONT> the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> virus could develop resistance to our treatment, which could affect any long-term demand or sales potential
for our potential therapies. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, another party may be successful in producing a more efficacious therapy for
<FONT STYLE="white-space:nowrap">COVID-19</FONT> or a therapy with a more convenient or preferred route of administration or in producing a therapy in a more timely manner, which may lead to the diversion of funding away from us and toward other
companies or lead to decreased demand for our potential therapies. For instance, Pfizer Inc. recently announced its <FONT STYLE="white-space:nowrap">COVID-19</FONT> experimental drug (an orally administered protease inhibitor) which entered the
clinic in March 2021, may be available by the end of 2021. In such an event, the value and/or market potential of our <FONT STYLE="white-space:nowrap">COVID-19</FONT> protease inhibitor program which is further behind in terms of development process
may be adversely impacted. Further, other therapies that are more affordable than our potential therapies may be used to treat <FONT STYLE="white-space:nowrap">COVID-19,</FONT> including existing generic drugs, which could also hurt the funding of
and demand for our potential therapies. In addition to BioNTech SE (together with Pfizer Inc.), Moderna, Inc. and Janssen Pharmaceutical Companies of </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">27 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
Johnson & Johnson, there are efforts by several other public and private entities to develop a therapy or vaccine for <FONT STYLE="white-space:nowrap">COVID-19,</FONT> including Alexion
Pharmaceuticals Inc., Atea Pharmaceuticals, Inc. (together with Roche), Incyte Corporation, Sanofi S.A., Regeneron Pharmaceuticals, Inc., Amgen Inc. (together with Adaptive Biotechnologies Corporation), Abcellera Biologics, Inc. (together with Eli
Lilly and Company), Vir Biotechnology, Inc. (together with Alnylam Pharmaceuticals, GSK, Biogen Inc. and WuXi Biologics Ltd.), Altimmune, Inc., AstraZeneca PLC (together with Oxford University), GlaxoSmithKline (GSK) (together with Sanofi S.A.),
Heat Biologics, Inc., Inovio Pharmaceuticals, Inc., Merck (together with Ridgeback Bio), Novavax, Inc., Regeneron Pharmaceuticals Inc., Synairgen plc, Takeda Pharmaceutical Company Limited, and Vaxart, Inc., many of which are further along in the
development process than we are. These other entities may be more successful at developing, manufacturing or commercializing a therapy for <FONT STYLE="white-space:nowrap">COVID-19,</FONT> especially given that several of these other organizations
are much larger than we are and have access to larger pools of capital, including U.S. government funding, and broader manufacturing infrastructure. The success or failure of other entities, or perceived success or failure, may adversely impact our
ability to obtain any future funding for our development and manufacturing efforts or to ultimately commercialize a therapy for <FONT STYLE="white-space:nowrap">COVID-19,</FONT> if approved. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>The regulatory pathways for our drug candidates targeting <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2,</FONT></FONT> the virus that causes
<FONT STYLE="white-space:nowrap">COVID-19,</FONT> are continually evolving, and may result in unexpected or unforeseen challenges. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our drug
candidates targeting <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2,</FONT></FONT> the virus that causes <FONT STYLE="white-space:nowrap">COVID-19,</FONT> are in the early discovery stages. The speed at which companies
and institutions are acting to create and test many therapeutics and vaccines for <FONT STYLE="white-space:nowrap">COVID-19</FONT> is unusually rapid, and evolving or changing plans or priorities within the FDA, including changes based on new
knowledge of <FONT STYLE="white-space:nowrap">COVID-19</FONT> and how the disease affects the human body, may significantly affect the regulatory timelines for our <FONT STYLE="white-space:nowrap">COVID-19</FONT> drug candidates. Results from our
continued development and planned clinical trials may raise new questions and require us to redesign proposed nonclinical studies and clinical trials, including revising proposed endpoints or adding new clinical trial sites or cohorts of subjects,
with minimal lead time. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The FDA has the authority to grant an Emergency Use Authorization (EUA) to allow unapproved medical products to be used in an
emergency to diagnose, treat, or prevent serious or life-threatening diseases or conditions when, based on the totality of scientific evidence, there is evidence of effectiveness of the medical product, and there are no adequate, approved, and
available alternatives. For instance, the FDA granted an EUA for each of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> vaccines developed by Pfizer/BioNTech, Moderna and Janssen Pharmaceutical Companies of Johnson & Johnson.
Depending on the outcomes of our planned nonclinical and initial clinical testing for our proposed <FONT STYLE="white-space:nowrap">COVID-19</FONT> therapies, we may seek an EUA for one or more of our drug candidates for use in the ongoing public
health emergency, which would permit us to commercialize a drug candidate prior to FDA approval of an NDA. However, commercialization under an EUA is permitted only during the underlying public health emergency (as declared by the Secretary of the
Department of Health and Human Services), meaning that once the emergency declaration is terminated, we would be required to obtain NDA approval to continue marketing the product. Furthermore, the FDA may revoke an EUA based on a determination that
the product no longer satisfies the criteria for issuance of an EUA—for example, if there is no longer evidence of effectiveness of the product or there are other adequate, approved alternatives. Accordingly, we cannot predict how long, if at
all, an EUA for any of our drug candidates may remain in place. Any termination or revocation of an EUA (if any) for one of our drug candidates could adversely impact our business in a variety of ways, including if one of our <FONT
STYLE="white-space:nowrap">COVID-19</FONT> drug candidates is not yet approved by the FDA and if we and our manufacturing partners have invested in the supply chain to provide one of our <FONT STYLE="white-space:nowrap">COVID-19</FONT> drug
candidates under an EUA. </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">28 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>The results of nonclinical studies and early-stage clinical trials may not be predictive of future results.
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The results of nonclinical studies may not be predictive of the results of clinical trials, and the results of any early-stage clinical trials
we commence may not be predictive of the results of the later-stage clinical trials. Drug candidates in later stages of clinical trials may fail to show the desired safety and efficacy despite having progressed through nonclinical studies and
initial clinical trials. There is a high failure rate for drugs proceeding through clinical trials, and a number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even after
achieving promising results in earlier studies. There can be no assurance that any of our current or future clinical trials will ultimately be successful or support further clinical development of any of our drug candidates. Even if our clinical
trials are completed, the results may not be sufficient to obtain regulatory approval of any products. Any such setbacks in our clinical development could have a material adverse effect on our business and operating results. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Interim, “topline” and preliminary data from our clinical trials may differ materially from the final data. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">From time to time, we may disclose interim data from our clinical trials. Interim data from clinical trials are subject to the risk that one or more of the clinical
outcomes may materially change as patient enrollment continues and more data on existing patients become available. Adverse differences between interim data and final data could significantly harm our business, financial condition, results of
operations and prospects. From time to time, we may also publicly disclose preliminary or “topline” data from our clinical trials, which are based on a preliminary analysis of then-available data, and the results and related findings and
conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have
received or had the opportunity to fully and carefully evaluate all data. As a result, the topline results that we report may differ from future results of the same clinical trials, or different conclusions or considerations may qualify such topline
results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously
published. As a result, topline data should be viewed with caution until the final data are available. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Further, others, including regulatory agencies,
may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or
commercialization of the particular drug candidate or product and the value of our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is typically a summary of extensive
information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect
to future decisions, conclusions, views, activities or otherwise regarding a particular product, drug candidate or our business. If the topline data that we report differ from actual results, or if others, including regulatory authorities, disagree
with the conclusions reached, our ability to obtain approval for, and commercialize, our drug candidates may be harmed, which could harm our business, financial condition, operating results and prospects. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient
number of patients who remain in the trial until its conclusion. We may experience </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">29 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
difficulties in patient enrollment in our clinical trials for a variety of reasons. The enrollment of patients depends on many factors, including: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the patient eligibility criteria defined in the protocol; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the size of the patient population required for analysis of the trial’s primary endpoints; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the proximity of patients to study sites; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the design of the trial; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our ability to recruit clinical trial investigators with the appropriate competencies and experience; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">clinicians’ and patients’ perceptions as to the potential advantages of the drug candidate being studied in relation to other available therapies,
including any new products that may be approved for the indications we are investigating; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our ability to obtain and maintain patient consents for participation in our clinical trials and, where appropriate, biopsies for future patient enrichment
efforts; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the risk that patients enrolled in clinical trials will not remain in the trial through the completion of evaluation; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">disruption by <FONT STYLE="white-space:nowrap">man-made</FONT> or natural disasters, or public health pandemics or epidemics or other business interruptions,
including the current <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and future outbreaks of the virus. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, our
clinical trials will compete with other clinical trials for drug candidates that are in the same therapeutic areas as our current and potential future drug candidates. This competition will reduce the number and types of patients available to us,
because some patients who might have enrolled in our trials may instead opt to enroll in a trial conducted by one of our competitors. Since the number of qualified clinical investigators is limited, we may conduct some of our clinical trials at the
same clinical trial sites that some of our competitors use, which would reduce the number of patients who are available for our clinical trials at such sites. Moreover, because our current and potential future drug candidates may represent a
departure from more commonly used methods for treatment, potential patients and their doctors may be inclined to use conventional therapies rather than enroll patients in our clinical trials. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Delays in patient enrollment may result in increased costs or may affect the timing or outcome of clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the
development of our drug candidates. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Changes in methods of drug candidate manufacturing or formulation may result in additional costs or delay.
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As drug candidates proceed from nonclinical studies to late-stage clinical trials towards potential approval and commercialization, it is common
that various aspects of the development program, such as manufacturing methods and formulation, are altered to optimize results. However, any change could entails additional cost and risks potential delay if the reformulated or otherwise altered
drug candidate performs different than expected or intended, which could require modification to the nonclinical or clinical program. Such changes may also require additional testing, including bridging or comparability testing to demonstrate the
validity of clinical data obtained in clinical trials following manufacturing changes, FDA notification or FDA approval. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Moreover, we have not yet
manufactured or processed on a commercial scale any of our drug candidates. We may make changes as we work to optimize our manufacturing processes, but we cannot be sure that even minor changes in our processes will result in therapies that are safe
and effective or that will be approved for commercial sale. </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">30 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Our current or future drug candidates may cause undesirable side effects or have other properties when used
alone or in combination with other approved products or investigational new drugs that could delay or halt their clinical development, prevent their marketing approval, limit their commercial potential or result in significant negative consequences.
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Undesirable or clinically unmanageable side effects from one or more of our drug candidates or potential future products could occur and cause
us or regulatory authorities to interrupt, delay or terminate clinical trials, could result in a more restrictive label or could cause the delay or denial of marketing approval by the FDA or comparable foreign regulatory authorities. Further,
results of our planned clinical trials could reveal unacceptably severe and prevalent side effects or unexpected characteristics. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If unacceptable
toxicities or other undesirable side effects arise in the development of any of our current or future drug candidates, we could suspend or terminate our trials, or the FDA or comparable foreign regulatory authorities could order us to cease clinical
trials or deny approval of the drug candidate for any or all targeted indications. Treatment-related side effects could also affect patient recruitment or the ability of enrolled subjects to complete the trial, or result in potential product
liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. Inadequately recognizing or managing the potential side effects of our drug candidates could result in patient injury or
death. Any of these occurrences may prevent us from achieving or maintaining market acceptance of the affected drug candidate and may harm our business, financial condition and prospects significantly. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Although our current and future drug candidates will undergo safety testing to the extent possible and, where applicable, under such conditions discussed with
regulatory authorities, not all adverse effects of drugs can be predicted or anticipated. Unforeseen side effects could arise either during clinical development or, if such side effects are more rare, after our products have been approved by
regulatory authorities and the approved product has been marketed, resulting in the exposure of additional patients. To date, we have not demonstrated that any of our drug candidates are safe in humans, and we cannot predict if ongoing or future
clinical trials will do so. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Furthermore, we plan to evaluate our drug candidates in combination with approved and/or experimental therapies. These
combinations may have additional or more severe side effects than caused by our drug candidates as monotherapies or may cause side effects at lower doses. The uncertainty resulting from the use of our drug candidates in combination with other
therapies may make it difficult to accurately predict side effects in potential future clinical trials. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If any of our drug candidates receives marketing
approval and we or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could occur, including: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">regulatory authorities may withdraw their approval of the product; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we may be required to recall a product or change the way such product is administered to patients; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component thereof;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">regulatory authorities may require the addition of labeling statements, such as a “black box” warning or a contraindication;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we may be required to implement a Risk Evaluation and Mitigation Strategy (REMS) or create a Medication Guide outlining the risks of such side effects for
distribution to patients; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we could be sued and held liable for harm caused to patients; </FONT></P></TD></TR></TABLE>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">31 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the product may become less competitive; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our reputation may suffer. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Any of the
foregoing events could prevent us from achieving or maintaining market acceptance of the particular drug candidate, if approved, and result in the loss of significant revenue to us, which would adversely affect our business, financial condition,
results of operations and prospects. In addition, if one or more of our drug candidates prove to be unsafe, our entire technology platform and pipeline could be affected, which would have a material adverse effect on our business, financial
condition, results of operations and prospects. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Even if we complete the necessary nonclinical studies and clinical trials, the marketing approval
process is expensive, time-consuming and uncertain and may prevent us or any of our future collaboration partners from obtaining approvals for the commercialization of our current drug candidates and any other drug candidate we develop.
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Any current or future drug candidates we may develop and the activities associated with their development and commercialization, including their
design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, and distribution, are subject to comprehensive regulation by the FDA and other regulatory authorities in the United States and
by comparable authorities in other countries. Failure to obtain marketing approval for a drug candidate will prevent us from commercializing the drug candidate in a given jurisdiction. We have not received approval to market any drug candidates from
regulatory authorities in any jurisdiction and it is possible that none of our current or future drug candidates will ever obtain regulatory approval. As an organization, we have no experience in filing and supporting the applications necessary to
gain marketing approvals and expect to rely on third-party CROs or regulatory consultants to assist us in this process. Securing regulatory approval requires the submission of extensive nonclinical and clinical data and supporting information to the
various regulatory authorities for each therapeutic indication to establish the drug candidate’s safety and efficacy. Securing regulatory approval also requires the submission of information about the product manufacturing process to, and
inspection of manufacturing facilities by, the relevant regulatory authority. Any drug candidates we develop may not be effective, may be only moderately effective, or may prove to have undesirable or unintended side effects, toxicities or other
characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The process of obtaining marketing approvals,
both in the United States and abroad, is expensive, may take many years if additional clinical trials are required, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity, and
novelty of the drug candidates involved. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application,
may cause delays in the approval or rejection of an application. The FDA and comparable authorities in other countries have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are
insufficient for approval and require additional nonclinical, clinical or other studies. In addition, varying interpretations of the data obtained from nonclinical and clinical testing could delay, limit, or prevent marketing approval of a drug
candidate. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">If we experience delays in obtaining marketing approval or if we fail to obtain marketing approval of any current or future drug candidates we may develop, the commercial prospects for those drug candidates may be
harmed, and our ability to generate revenues will be materially impaired. </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">32 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Even if a current or future drug candidate receives marketing approval, it may fail to achieve the degree of
market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If any
current or future drug candidate we develop receives marketing approval, whether as a single agent or in combination with other therapies, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors, and
others in the medical community, or such participants may prefer existing treatment options such as nucleos(t)ide analogs including tenofovir and entecavir. If the drug candidates we develop do not achieve an adequate level of acceptance, we may not
generate significant product revenues and we may not become profitable. The degree of market acceptance of any drug candidate, if approved for commercial sale, will depend on a number of factors, including: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">efficacy and potential advantages compared to alternative treatments; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the ability to offer our products, if approved, for sale at competitive prices; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">convenience and ease of administration compared to alternative treatments; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the strength of marketing and distribution support; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the ability to obtain sufficient third-party coverage and adequate reimbursement, including with respect to the use of the approved product as a combination
therapy; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">adoption of a companion diagnostic and/or complementary diagnostic (if any); and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the prevalence and severity of any side effects. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Adverse events in our therapeutic areas of focus, including hepatological indications and viral diseases, could damage public perception of our current or
future drug candidates and negatively affect our business. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The commercial success of our products will depend in part on public acceptance of
our therapeutic areas of focus. Adverse events in clinical trials of our drug candidates, or post-marketing activities, or in clinical trials of others developing similar products or targeting similar indications and the resulting publicity, as well
as any other adverse events in our therapeutic areas of focus, including hepatological indications and viral diseases, could result in decreased demand for any product that we may develop. If public perception is influenced by claims that the use of
therapies in our therapeutic areas of focus are unsafe, whether related to our therapies or those of our competitors, our products may not be accepted by the general public or the medical community. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Future adverse events in our therapeutic areas of focus or the biopharmaceutical industry could also result in greater governmental regulation, stricter labeling
requirements and potential regulatory delays in the testing or approvals of our products. Any increased scrutiny could delay or increase the costs of obtaining marketing approval for the drug candidates we have developed, are developing and may in
the future develop. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Negative developments and negative public opinion of technologies on which we rely may damage public perception of our drug
candidates or adversely affect our ability to conduct our business or obtain regulatory approvals for our drug candidates. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The clinical and
commercial success of our drug candidates will depend in part on public acceptance of the use of technologies for the prevention or treatment of human diseases. Adverse public attitudes may adversely impact our ability to enroll clinical trials.
Moreover, our success will depend upon physicians specializing in our </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">33 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
targeted diseases prescribing, and their patients being willing to receive, our drug candidates as treatments in lieu of, or in addition to, existing, more familiar, treatments for which greater
clinical data may be available. Any increase in negative perceptions of the technologies that we rely on may result in fewer physicians prescribing our products (if approved) or may reduce the willingness of patients to utilize our products or
participate in clinical trials for our drug candidates. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Increased negative public opinion or more restrictive government regulations in response
thereto, would have a negative effect on our business, financial condition, results of operations or prospects and may delay or impair the development and commercialization of our drug candidates or demand for such drug candidates. Adverse events in
our nonclinical studies or clinical trials or those of our competitors or of academic researchers utilizing similar technologies, even if not ultimately attributable to drug candidates we may discover and develop, and the resulting publicity could
result in increased governmental regulation, unfavorable public perception, potential regulatory delays in the testing or approval of potential drug candidates we may identify and develop, stricter labeling requirements for those drug candidates
that are approved, a decrease in demand for any such drug candidates and a suspension or withdrawal of approval by regulatory authorities of our drug candidates. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Even if we receive marketing approval of a drug candidate, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense, and we may
be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products, if approved. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Any marketing approvals that we receive for any current or future drug candidate may be subject to limitations on the approved indicated uses for which the product
may be marketed, or contain requirements for potentially costly post-market testing and surveillance to monitor the safety and efficacy of the drug candidate. The FDA may also require a REMS as a condition of approval of any drug candidate, which
could include requirements for a Medication Guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk-minimization tools. In addition, if the FDA or a
comparable foreign regulatory authority approves a drug candidate, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import and export and record keeping for the product will be
subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, establishment registration, as well as continued compliance with current Good Manufacturing
Practice (cGMP), and Good Clinical Practice (GCP), for any clinical trials that we conduct post-approval. Later discovery of previously unknown problems with any approved candidate, including adverse events of unanticipated severity or frequency, or
with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or product recalls; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">fines, untitled and warning letters, or holds on clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">refusal by the FDA or other regulatory authorities to approve pending applications or supplements to approved applications we filed or suspension or revocation
of license approvals; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">product seizure or detention, or refusal to permit the import or export of the product; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">injunctions or the imposition of civil or criminal penalties. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The FDA’s and other regulatory authorities’ policies may change and additional government regulations may be enacted that could prevent, limit or delay marketing approval of a product. We cannot predict
the likelihood, </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">34 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in
existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, and we may not achieve profitability. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Even if we obtain and maintain approval for our drug candidates from the FDA, we may never obtain approval outside the United States, which would limit our
market opportunities. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Approval of a drug candidate in the United States by the FDA does not ensure approval of such drug candidate by regulatory
authorities in other countries or jurisdictions, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries. Sales of our drug candidates outside the United States will be subject
to foreign regulatory requirements governing clinical trials and marketing approval. Even if the FDA grants marketing approval for a drug candidate, comparable foreign regulatory authorities also must approve the manufacturing and marketing of the
drug candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and more onerous than, those in the United States, including additional nonclinical
studies or clinical trials. In many countries outside the United States, a drug candidate must be approved for reimbursement before it can be approved for sale in that country. In some cases, the price that we intend to charge for any drug
candidates, if approved, is also subject to approval. Obtaining approval for our drug candidates in the European Union (the EU) from the European Commission following the opinion of the EMA, if we choose to submit a marketing authorization
application there, would be a lengthy and expensive process. Even if a drug candidate is approved, the EMA may limit the indications for which the product may be marketed, require extensive warnings on the product labeling or require expensive and
time-consuming additional clinical trials or reporting as conditions of approval. Approval of certain drug candidates outside of the United States, particularly those that target diseases that are more prevalent outside of the United States, will be
particularly important to the commercial success of such drug candidates. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or
prevent the introduction of our drug candidates in certain countries. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Further, clinical trials conducted in one country may not be accepted by
regulatory authorities in other countries. For example, we are conducting our initial clinical trials for <FONT STYLE="white-space:nowrap">ALG-010133</FONT> and <FONT STYLE="white-space:nowrap">ALG-000184</FONT> in New Zealand, Hong Kong, and
Moldova, and plan to conduct additional clinical trials in several other countries and territories within the Asia Pacific and/or Europe and our conduct of the trials must satisfy specific requirements in order for the FDA to accept the data in
support of an IND or NDA in the United States. Further, any regulatory approval for our drug candidates may be withdrawn. If we fail to comply with the applicable regulatory requirements, our target market will be reduced and our ability to realize
the full market potential of our drug candidates will be harmed and our business, financial condition, results of operations and prospects could be harmed. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Risks associated with our international operations, including seeking and obtaining approval to commercialize our drug candidates in foreign jurisdictions, could harm our business. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We engage in international operations with offices in the United States and Belgium and intend to seek approval to market our drug candidates outside of the United
States. We may also do so for future drug candidates. We expect that we are or will be subject to additional risks related to these international business markets and relationships, including: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">different regulatory requirements for approval of drug candidates in foreign countries, including challenging processes for marketing biopharmaceutical products;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">reduced protection for and enforcement of intellectual property rights; </FONT></P></TD></TR></TABLE>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">35 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">heightened or different data privacy and information security laws, regulations and policies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">unexpected changes in tariffs, trade barriers and regulatory requirements; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">economic weakness, including inflation or political instability in particular foreign economies and markets; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in
another country; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">foreign reimbursement, pricing and insurance regimes; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">workforce uncertainty in countries where labor unrest is more common than in the United States; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">production shortages resulting from any events affecting raw material supply or manufacturing capabilities; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters including earthquakes, typhoons, floods and fires;
and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">disruptions resulting from the impact of public health pandemics or epidemics (including, for example, the ongoing
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic). </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, there are complex regulatory, tax, labor and other legal
requirements imposed by many of the individual countries in which we may operate, with which we will need to comply. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Disruptions at the FDA and
other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or could otherwise prevent new or modified products from being developed,
approved or commercialized in a timely manner or at all, which could negatively impact our business. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The ability of the FDA to review and
approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA’s ability to hire and retain key personnel and accept the payment of user fees, and
other events that may otherwise affect the FDA’s ability to perform routine functions. Average review times at the agency have fluctuated in recent years as a result. Disruptions at the FDA and other agencies may also slow the time necessary
for new products to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including for 35 days beginning on December 22, 2018, the U.S.
government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Relatedly, in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, on March 10, 2020 the FDA announced its intention to postpone most inspections of foreign manufacturing facilities, and
on March 18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities. Subsequently, on July 10, 2020 the FDA announced its intention to resume certain
<FONT STYLE="white-space:nowrap">on-site</FONT> inspections of domestic manufacturing facilities subject to a risk-based prioritization system. The FDA intends to use this risk-based assessment system to identify the categories of regulatory
activity that can occur within a given geographic area, ranging from mission-critical inspections to resumption of all regulatory activities. The resumption of prioritized domestic inspections is dependent on the current <FONT
STYLE="white-space:nowrap">COVID-19</FONT> data in a given state or county and the rules and guidelines established by state and local government. Regulatory authorities outside the United States may adopt similar restrictions or other policy
measures in response to events such as the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting
their regular inspections, reviews, or other regulatory activities, it could </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">36 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
significantly impair the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>If the market opportunities for our drug candidates are smaller than we believe or any approval we obtain is based on a narrower definition of the
patient population, our business may suffer. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We currently focus our product development on novel therapeutics to address unmet needs in
hepatological indications and viral diseases. Our eligible patient population, pricing estimates and available coverage and reimbursement may differ significantly from the actual market addressable by our drug candidates. Our estimates of both the
number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with our drug candidates, are based on our beliefs and analyses based on a variety of sources, including
scientific literature, patient foundations or market research, and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of the diseases we are targeting. The number of patients may turn out to be lower
than expected, and the potentially addressable patient population for each of our drug candidates may be limited or may not be receptive to treatment with our drug candidates, and new patients may become increasingly difficult to identify or access.
Certain potential patients may have or develop a resistance to our potential therapies or otherwise be unable to be treated with our potential therapies for <FONT STYLE="white-space:nowrap">COVID-19,</FONT> HBV or other viral diseases as a result of
their genetic makeup. In addition, the route of administration for our potential therapies could be inconvenient and/or not commercially viable, which could also limit the potential market for our therapies. If the market opportunities for our drug
candidates are smaller than we estimate, it could have an adverse effect on our business, financial condition, results of operations and prospects. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">For
example, we believe NASH to be one of the most prevalent chronic liver diseases worldwide, however, our projections of the number of people who have NASH, as well as the subset of people with the disease who have the potential to benefit from
treatment with our drug candidates, are based on our beliefs and estimates. The effort to identify patients with NASH is in early stages, and we cannot accurately predict the number of patients for whom treatment might be possible. NASH is often
undiagnosed and may be left undiagnosed for a long time, partly because a definitive diagnosis of NASH is currently based on a histological assessment of a liver biopsy, which impairs the ability to easily identify patients. If improved diagnostic
techniques for identifying NASH patients who will benefit from treatment are not developed, our market opportunity may be smaller than we currently anticipate. Further, if government authorities and third-party payors choose to limit coverage and
reimbursement of our NASH drug candidate, such as limiting the number of patients’ treatment that would be covered and reimbursable, this could result in a smaller market opportunity for our NASH drug candidate than we anticipate. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, the number of people who have HBV, as well as the subset of people with the disease who have the potential to benefit from treatment with our drug
candidates, may be reduced due to factors including the genotype or variant of HBV, more widespread use of vaccines or alternative therapies, political roadblocks to approval and/or treatment in certain countries and the virus’s development of
resistance to our potential treatments after long-term and persistent exposure to antiviral therapy. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We intend to develop our current drug
candidates, and expect to develop other future drug candidates, in combination with other therapies, which exposes us to additional risks. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We
intend to develop our current drug candidates, and expect to develop other future drug candidates, in combination with one or more therapies, including therapies that we develop and those developed externally. Even if a drug candidate we develop
were to receive marketing approval or be commercialized for use in combination with other therapies, we would face the risk that the FDA or similar regulatory authority outside of the United States could revoke approval of the therapy used in
combination with our drug candidate or that </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">37 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
safety, efficacy, manufacturing or supply issues could arise with these other therapies. Combination therapies are commonly used for the treatment of viral diseases and it is generally believed
they will be required for NASH, and we would be subject to similar risks if we develop any of our drug candidates for use in combination with other drugs. This could result in our own products, if approved, being removed from the market or suffering
commercially. In addition, we may evaluate our current drug candidates and other future drug candidates in combination with one or more other therapies that may have not yet been approved for marketing by the FDA or similar regulatory authorities
outside of the United States. We will not be able to market and sell any drug candidate we develop in combination with any such unapproved therapies that do not ultimately obtain marketing approval. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If the FDA or similar regulatory authorities outside of the United States do not approve these other drugs or revoke their approval of, or if safety, efficacy,
manufacturing, or supply issues arise with, the drugs we choose to evaluate in combination with or any of our drug candidate, we may be unable to obtain approval of or market any of our combination treatments. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We face significant competition, and if our competitors develop and market products that are more effective, safer or less expensive than the drug candidates
we develop, our commercial opportunities will be negatively impacted. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The life sciences industry is highly competitive. We are currently
developing therapies that will compete, if approved, with other products and therapies that currently exist or are being developed. Products we may develop in the future are also likely to face competition from other products and therapies, some of
which we may not currently be aware of. We have competitors both in the United States and internationally, including major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies, universities
and other research institutions. Many of our competitors have significantly greater financial, manufacturing, marketing, product development, technical and human resources than we do. Large pharmaceutical companies, in particular, have extensive
experience in clinical testing, obtaining marketing approvals, recruiting patients and manufacturing pharmaceutical products. These companies also have significantly greater research and marketing capabilities than we do and may also have products
that have been approved or are in late stages of development, and collaborative arrangements in our target markets with leading companies and research institutions. Established pharmaceutical companies may also invest heavily to accelerate discovery
and development of novel compounds or to <FONT STYLE="white-space:nowrap">in-license</FONT> novel compounds that could make the drug candidates that we develop obsolete. Further, mergers and acquisitions in the pharmaceutical and biotechnology
industries may result in even more resources being concentrated among a smaller number of our competitors. As a result of all of these factors, our competitors may succeed in obtaining patent protection and/or marketing approval or discovering,
developing and commercializing products in our field before we do. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">There are a number of companies developing or marketing treatments for CHB, including
Roche Holding AG (Roche), Gilead, Bristol-Myers Squibb Company, Arbutus Biopharma Corporation, Dicerna Pharmaceuticals, Inc. (together with Roche), Ionis Pharmaceuticals, Inc. (together with GSK), Arrowhead Pharmaceuticals, Inc. (together with
Janssen Pharmaceuticals Company (Janssen)), Vir Biotechnology, Inc. (together with Alnylam Pharmaceuticals, Inc.), Johnson & Johnson, Assembly Biosciences Inc., Enanta Pharmaceuticals, Altimmune, Inc., GSK, Janssen, Transgene SA, Dynavax
Technologies, Inc., Merck and Replicor, Inc. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">There are also companies developing or marketing treatments or vaccines for
<FONT STYLE="white-space:nowrap">COVID-19,</FONT> including Soliris by Alexion Pharmaceuticals Inc., Atea Pharmaceuticals, Inc. (together with Roche), Jakafi by Incyte Corporation, Kevzara by Sanofi S.A./Regeneron Pharmaceuticals, Inc., Amgen Inc.
(together with Adaptive Biotechnologies Corporation), Abcellera Biologics, Inc. (together with Eli Lilly and Company), Vir Biotechnology, Inc. (together with GSK, Biogen Inc. and WuXi Biologics Ltd.), Altimmune, Inc., AstraZeneca PLC (together with
Oxford </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">38 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
University), BioNTech SE (together with Pfizer Inc.), GlaxoSmithKline plc (GSK) (together with Sanofi S.A.), Heat Biologics, Inc., Inovio Pharmaceuticals, Inc., Johnson & Johnson,
Moderna, Inc., Novavax, Inc., Regeneron Pharmaceuticals Inc., and Vaxart, Inc. For example, BioNTech SE (together with Pfizer Inc.), Janssen Pharmaceutical Companies of Johnson & Johnson and Moderna Inc. have developed <FONT
STYLE="white-space:nowrap">COVID-19</FONT> vaccines that have received authorization for emergency use and are being widely administered. In addition, Pfizer, Inc. recently announced its <FONT STYLE="white-space:nowrap">COVID-19</FONT> experimental
drug (an orally administered protease inhibitor) which entered the clinic in March 2021, may be available by the end of 2021. The availability of such <FONT STYLE="white-space:nowrap">COVID-19</FONT> vaccines and Pfizer’s oral <FONT
STYLE="white-space:nowrap">COVID-19</FONT> drug may reduce or eliminate the need for our potential COVID therapies to treat the disease and therefore negatively impact the commercial opportunity therefor. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Furthermore, there are companies developing or marketing treatments for NASH, including AbbVie, Inc., AstraZeneca PLC/MedImmune LLC, Bristol-Myers Squibb Company,
Eli Lilly and Company, FronThera US Pharmaceuticals LLC, Janssen, Merck, Novartis Pharmaceuticals Corporation (together with Pfizer, Inc.), Novo Nordisk A/S, Pfizer Inc., Roche, Sanofi S.A., Takeda Pharmaceutical Company Limited (together with
HemoShear Therapeutics, LLC), 89bio, Inc., Akero Therapeutics, Inc., Blade Therapeutics, Inc., Cirius Therapeutics, Inc., Enanta Pharmaceuticals, Inc., Galectin Therapeutics Inc., Galmed Pharmaceuticals Ltd., Genfit SA, Gilead, Intercept
Pharmaceuticals, Inc., Inventiva Pharma SA, Madrigal Pharmaceuticals, Inc., MediciNova, Inc., NGM Biopharmaceuticals, Inc., Pliant Therapeutics, Inc. (together with Novartis), Terns Pharmaceuticals, Inc. and Viking Therapeutics, Inc. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less
severe effects, are more convenient, have a broader label, are marketed more effectively, including gaining exclusivity for their competing products on formularies thereby excluding our products from such formularies, are reimbursed or are less
expensive than any products that we may develop. Our competitors also may obtain FDA, EMA or other marketing approval for their products more rapidly than we may obtain approval for ours (if at all), which could result in our competitors
establishing a strong market position before we are able to enter the market (if ever). Even if the drug candidates we develop achieve marketing approval, they may be priced at a significant premium over competitive products, resulting in reduced
competitiveness of our products. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Smaller and other early stage companies may also prove to be significant competitors. In addition, academic research
departments and public and private research institutions may be conducting research on compounds that could prove to be competitive. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">These third parties
compete with us not only in drug candidate development, but also in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring
and/or licensing technologies complementary to, or necessary for, our programs. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, the biopharmaceutical industry is characterized by rapid
technological change. If we fail to keep pace with technological change, we may be unable to compete effectively. Technological advances or products developed by our competitors may render our drug candidates obsolete, less competitive or not
economical, thereby adversely affecting our business, financial condition and results of operations. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>If any of our current or future drug
candidates obtain regulatory approval, additional competitors could enter the market with generic versions of such products, which may result in a material decline in sales of our competing products. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act (the FDCA), a
pharmaceutical manufacturer may file an abbreviated new drug application (an ANDA) seeking approval of a generic version of an approved innovator </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">39 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
product. Under the Hatch-Waxman Amendments, a manufacturer may also submit an NDA under section 505(b)(2) of the FDCA that references the FDA’s prior approval of the innovator product. A
505(b)(2) NDA product may be for a new or improved version of the original innovator product. The Hatch-Waxman Amendments also provide for certain periods of regulatory exclusivity, which preclude FDA approval (or in some circumstances, FDA filing
and review) of an ANDA or 505(b)(2) NDA. In addition to the benefits of regulatory exclusivity, an innovator NDA holder may have patents claiming the active ingredient, product formulation or an approved use of the drug, which would be listed with
the product in the FDA publication “Approved Drug Products with Therapeutic Equivalence Evaluations,” known as the Orange Book. If there are patents listed in the Orange Book for a product, a generic or 505(b)(2) applicant that seeks to
market its product before expiration of the patents must include in their applications what is known as a “Paragraph IV” certification, challenging the validity or enforceability, or claiming
<FONT STYLE="white-space:nowrap">non-infringement,</FONT> of the listed patent or patents. Notice of the certification must be given to the patent owner and NDA holder and if, within 45 days of receiving notice, either the patent owner or NDA holder
sues for patent infringement, approval of the ANDA or 505(b)(2) NDA is stayed for up to 30 months. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Accordingly, if any of our future drug candidates are
approved, competitors could file ANDAs for generic versions of these products or 505(b)(2) NDAs that reference our products. If there are patents listed for such drug products in the Orange Book, those ANDAs and 505(b)(2) NDAs would be required to
include a certification as to each listed patent indicating whether the ANDA applicant does or does not intend to challenge the patent. We cannot predict which, if any, patents in our current portfolio or patents we may obtain in the future will be
eligible for listing in the Orange Book, how any generic competitor would address such patents, whether we would sue on any such patents or the outcome of any such suit. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We may not be successful in securing or maintaining proprietary patent protection for products and technologies we develop or license, despite expending a significant amount of resources that could have been
focused on other areas of our business. Moreover, if any of our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents that are listed in the Orange Book are successfully challenged by way of a Paragraph IV certification and subsequent
litigation, the affected product could immediately face generic competition and its sales would likely decline rapidly and materially. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Even if we
are able to commercialize any drug candidates, such products may become subject to unfavorable pricing regulations or third-party coverage and reimbursement policies, which would harm our business. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The regulations that govern marketing approvals, pricing and reimbursement for new products vary widely from country to country. Some countries require approval of
the sale price of a product before it can be marketed. In many countries, the pricing review period begins after marketing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental
control even after initial approval is granted. As a result, we might obtain marketing approval for a drug candidate in a particular country, but then be subject to price regulations that delay our commercial launch of the drug candidate, possibly
for lengthy time periods, and negatively impact the revenues we are able to generate from the sale of the drug candidate in that country, potentially to the point of unviability. Adverse pricing limitations may hinder our ability to recoup our
investment in one or more drug candidates, even if our drug candidates obtain marketing approval. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our ability to successfully commercialize any drug
candidates, whether as a single agent or in combination, will also depend in part on the extent to which coverage and reimbursement for these drug candidates and related treatments is available from government authorities, private health insurers
and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. It is difficult to
</FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">40 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
predict at this time what government authorities and third-party payors may decide with respect to coverage and reimbursement for our programs (if approved). </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities, particularly in the European Union, and third-party
payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular products and requiring substitutions of generic products and/or biosimilars. Increasingly, third-party payors are scrutinizing the prices
charged for drugs. We cannot be sure that coverage will be available for any drug candidate that we commercialize and, if coverage is available, the level of reimbursement. These government authorities and third-party payors are also examining the
cost-effectiveness of drugs, in addition to their safety and efficacy. For example, in some countries, we, or any future collaborators, may be required to conduct a clinical trial that compares the cost-effectiveness of our drug to other therapies
to obtain reimbursement or pricing approval. Reimbursement may impact the demand for, or the price of, any drug candidate for which we obtain marketing approval. If reimbursement is not available or is available only to limited levels, we may not be
able to successfully commercialize any drug candidate for which we obtain marketing approval. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Further, there may be significant delays in obtaining
coverage and reimbursement for newly approved drugs, as the process is time-consuming and costly, and coverage may be more limited than the purposes for which the drug is approved by the FDA or comparable foreign regulatory authorities.
Additionally, no uniform policy requirement for coverage and reimbursement for drug products exists among third-party payors in the United States, which may result in coverage and reimbursement for drug products that differ significantly from payor
to payor. Moreover, eligibility for reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim reimbursement levels for
new drugs, if applicable, may not be sufficient to cover our costs and may not be permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set
for lower-cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation
of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Our inability to promptly obtain coverage and profitable payment rates from both government-funded and private payors
for any approved drugs that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize drugs and our overall financial condition. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We may not be successful in our efforts to identify or discover other drug candidates and may fail to capitalize on programs or drug candidates that may
present a greater commercial opportunity or for which there is a greater likelihood of success. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The success of our business depends upon our
ability to identify, develop and commercialize drug candidates. If we do not successfully develop and eventually commercialize products, we will face difficulty in obtaining product revenue in future periods, resulting in significant harm to our
financial position and adversely affecting our share price. Research programs to identify new drug candidates require substantial technical, financial and human resources, and we may fail to identify potential drug candidates for numerous reasons.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Additionally, because we have limited resources, we may forego or delay pursuit of opportunities with certain programs or drug candidates or for
indications that later prove to have greater commercial potential. For example, we are currently focused on the development of our current drug candidates for hepatological indications. In addition, we are pursuing other drug candidates for viral
diseases. However, the advancement of these drug candidates may ultimately prove to be unsuccessful or less successful than another program in our pipeline that we might have chosen to pursue on a less aggressive basis. However, due to the
significant resources required for the development of our drug candidates, we must focus on specific diseases and disease </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">41 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
pathways and decide which drug candidates to pursue and the amount of resources to allocate to each. Our near-term objective is to demonstrate favorable risk/benefit profiles through Phase 1
clinical trials of our drug candidates, <FONT STYLE="white-space:nowrap">ALG-010133</FONT> and <FONT STYLE="white-space:nowrap">ALG-000184.</FONT> Our estimates regarding the potential market for our drug candidates could be inaccurate and our
decisions concerning the allocation of research, development, collaboration, management and financial resources toward particular drug candidates or therapeutic areas may not lead to the development of any viable commercial product and may divert
resources away from better opportunities. Similarly, any potential decision to delay or terminate development of a drug candidate or program may subsequently also prove to be suboptimal and could cause us to miss valuable opportunities. Further, if
we do not accurately evaluate the commercial potential for a particular drug candidate, we may relinquish valuable rights to that drug candidate through collaboration, licensing or other arrangements in cases in which it would have been more
advantageous for us to retain sole development and commercialization rights to such drug candidate. Alternatively, we may allocate internal resources to a drug candidate in a therapeutic area in which it would have been more advantageous to enter
into a partnering arrangement. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If any of these events occur, we may be forced to abandon or delay our development efforts with respect to a particular
drug candidate or we may fail to develop a potentially successful drug candidate or capitalize on profitable market opportunities, all of which could have a material adverse effect on our business, financial condition, results of operations and
prospects. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We may seek and fail to obtain fast track or breakthrough therapy designations from the FDA for our current or future drug candidates
or priority review designation for any NDA we may submit to the FDA. Even if we are successful, these programs may not lead to a faster development or regulatory review process, and they do not guarantee we will receive approval for any drug
candidate. We may also seek to obtain accelerated approval for one or more of our drug candidates but the FDA may disagree that we have met the requirements for such approval. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">If a product is intended for the treatment of a serious or life-threatening condition and nonclinical or clinical data demonstrate the potential to address an unmet medical need for this condition, the product
sponsor may apply for fast track designation. The FDA has broad discretion whether or not to grant this designation, so even if we believe a particular drug candidate is eligible for this designation, we cannot assure you that the FDA would decide
to grant it. Even if we do receive fast track designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may rescind the fast track designation if it believes that the
designation is no longer supported by data from our clinical development program. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We may also seek breakthrough therapy designation for any drug
candidate that we develop. A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates
that the drug may demonstrate substantial improvement over currently approved therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Like fast track designation,
breakthrough therapy designation is within the discretion of the FDA. Accordingly, even if we believe a drug candidate we develop meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make
such designation. In any event, the receipt of breakthrough therapy designation for a drug candidate may not result in a faster development process, review or approval compared to drugs considered for approval under conventional FDA procedures and
does not assure ultimate approval by the FDA. In addition, even if a drug candidate we develop qualifies as a breakthrough therapy, the FDA may later decide that the drug no longer meets the conditions for qualification and rescind the designation.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Drugs designated as fast track products or breakthrough therapies by the FDA are also eligible for priority review of any NDA submitted for such drug
candidates, which could result in FDA action on the NDA in a shorter </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">42 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
timeframe than under standard review. In order to grant priority review designation, the FDA must find that the product, if approved, would provide a significant improvement in the safety or
effectiveness of the treatment, diagnosis or prevention of a serious disease or condition. However, priority review does not guarantee approval of the NDA and may not result in a shorter overall review timeline if the FDA has significant questions
or additional requests as part of the NDA review. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, the FDA may grant accelerated approval to a product if the FDA determines that it has an
effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible
morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. For example, this is currently the case with drugs for the treatment
of NASH. As a condition of accelerated approval, the FDA will generally require the sponsor to perform adequate and well-controlled post-marketing clinical studies to verify and describe the anticipated effect on irreversible morbidity or mortality
or other clinical benefit. In addition, the FDA requires <FONT STYLE="white-space:nowrap">pre-approval</FONT> of promotional materials for accelerated approval products, once approved. We cannot guarantee that the FDA will conclude that any of our
drug candidates has met the criteria to receive accelerated approval, which would require us to conduct additional clinical testing prior to seeking FDA approval. Even if any of our drug candidates received approval through this pathway, the product
may fail required post-approval confirmatory clinical trials, and we may be required to remove the product from the market or amend the product label in a way that adversely impacts its marketing. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We may seek Orphan Drug Designation for drug candidates we develop, and we may be unsuccessful or may be unable to maintain the benefits associated with
Orphan Drug Designation, including the potential for market exclusivity. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As part of our business strategy, we may seek Orphan Drug Designation
for any drug candidates we develop, and we may be unsuccessful in obtaining such designation. Regulatory authorities in some jurisdictions, including the United States and the EU, may designate drugs for relatively small patient populations as
orphan drugs. Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in
the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the United States, Orphan Drug
Designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and <FONT STYLE="white-space:nowrap">user-fee</FONT> waivers. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Similarly, in the EU, the European Commission grants Orphan Drug Designation after receiving the opinion of the EMA Committee for Orphan Medicinal Products on an
Orphan Drug Designation application. Orphan Drug Designation is intended to promote the development of drugs that are intended for the diagnosis, prevention or treatment of life-threatening or chronically debilitating conditions affecting not more
than 5 in 10,000 persons in Europe and for which no satisfactory method of diagnosis, prevention, or treatment has been authorized (or the product would be a significant benefit to those affected). Additionally, designation is granted for drugs
intended for the diagnosis, prevention, or treatment of a life-threatening, seriously debilitating or serious and chronic condition and when, without incentives, it is unlikely that sales of the drug in Europe would be sufficient to justify the
necessary investment in developing the drug. In Europe, Orphan Drug Designation entitles a party to a number of incentives, such as protocol assistance and scientific advice specifically for designated orphan medicines, and potential fee reductions
depending on the status of the sponsor. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Generally, if a drug with an Orphan Drug Designation subsequently receives the first marketing approval for the
indication for which it has such designation, the drug is entitled to a period of marketing exclusivity, which precludes the EMA or the FDA from approving another marketing application for the same drug and indication
</FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">43 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
for that time period, except in limited circumstances. The applicable period is seven years in the United States and ten years in the EU. The EU exclusivity period can be reduced to six years if
a drug no longer meets the criteria for Orphan Drug Designation or if the drug is sufficiently profitable such that market exclusivity is no longer justified. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Even if we obtain orphan drug exclusivity for a drug candidate, that exclusivity may not effectively protect the drug candidate from competition because different therapies can be approved for the same condition.
Even after an orphan drug is approved, the FDA can subsequently approve the same drug for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major
contribution to patient care. In addition, a designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. Moreover, orphan drug exclusive
marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the
rare disease or condition. Orphan Drug Designation neither shortens the development time or regulatory review time of a drug candidate nor gives the drug candidate any advantage in the regulatory review or approval process. While we may seek Orphan
Drug Designation for applicable indications for our current and any future drug candidates, we may never receive such designations. Even if we do receive such designations, there is no guarantee that we will enjoy the benefits of those designations.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We may be required to make significant payments under our license agreements with Emory and Luxna. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We entered into a License Agreement with Emory in June 2018 (the Emory License Agreement), and a License Agreement with Luxna in December 2018 and an amendment in
April 2020 (as amended, the Luxna Agreement). Under the Emory License Agreement and Luxna Agreement, we are subject to significant obligations, including milestone payments, royalty payments, and certain other
<FONT STYLE="white-space:nowrap">agreed-to</FONT> costs. For more information regarding our license agreements, please see the section titled “Business—License agreements and collaborations” of our Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the year ended December 31, 2020, which is incorporated by reference herein. If these payments become due under the terms of either the Emory License Agreement or Luxna Agreement, we may not have
sufficient funds available to meet our obligations and our development efforts may be materially harmed. Furthermore, if we are forced to raise additional funds, we may be required to delay, limit, reduce or terminate our product development or
future commercialization efforts, or grant rights to develop and market drug candidates that we would otherwise develop and market ourselves. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>If
product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of any approved products. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We face an inherent risk of product liability as a result of the clinical testing of drug candidates and will face an even greater risk if we commercialize any products. For example, we may be sued if any drug
candidate we develop causes or is perceived to cause illness or is found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing,
defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against
product liability claims, we may incur substantial liabilities or be required to limit commercialization of any approved products. Even successful defense would require significant financial and management resources. Regardless of the merits or
eventual outcome, liability claims may result in: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">decreased demand for any approved product; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">injury to our reputation; </FONT></P></TD></TR></TABLE>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">44 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">withdrawal of clinical trial participants; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">initiation of investigations by regulators; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">costs to defend the related litigation; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">a diversion of management’s time and our resources; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">substantial monetary payments to trial participants or patients; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">product recalls, withdrawals or labeling, marketing or promotional restrictions; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">loss of revenue; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">exhaustion of any available insurance and our capital resources; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">adverse effects to our results of operations and business; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the inability to commercialize any drug candidate; and </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">a decline in our share price. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our inability to
obtain sufficient product liability insurance at an acceptable cost or at all to protect against potential product liability claims could prevent or inhibit the commercialization of products we develop, alone or with collaboration partners.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Insurance coverage is increasingly expensive. We may not be able to maintain insurance, including product liability insurance at a reasonable cost or in
an amount adequate to satisfy any liability that may arise, if at all. Our product liability insurance policy contains various exclusions, and we may be subject to a product liability claim for which we have no coverage. We may have to pay any
amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with
current or future collaborators entitle us to indemnification against losses, such indemnification may not be available or adequate should any claim arise. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Healthcare legislative reform measures may have a material adverse effect on our business and results of operations. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in March 2010, the Affordable Care Act (the ACA) was passed, which
substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacted the U.S. pharmaceutical industry. The ACA, among other things, increased the minimum Medicaid rebates owed by manufacturers
under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations, established annual fees and taxes on manufacturers of certain branded prescription drugs, and created a new
Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 70% <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off negotiated prices of applicable brand
drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer’s outpatient drugs being covered under Medicare Part D. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Since its enactment, there have been judicial, executive and Congressional challenges to the ACA. By way of example, the Tax Cuts and Jobs Act of 2017 (the TCJA) was signed into law, which included a provision
repealing, effective January 1, 2019, the <FONT STYLE="white-space:nowrap">tax-based</FONT> shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year,
commonly referred to as the individual mandate. On December 14, 2018, a Texas U.S. District Court Judge ruled that the ACA is unconstitutional in its entirety because the “individual mandate” was repealed by Congress as part of the
TCJA. Additionally, on December 18, 2019, the U.S. Court of Appeals for the 5th Circuit ruled that that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions
of the ACA are invalid as well. The U.S. Supreme Court is currently reviewing this case, although it is unclear how the Supreme Court will rule. It is also unclear how other efforts, if any, to challenge, repeal or replace the ACA will impact the
ACA or our business. </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">45 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. On
August 2, 2011, the Budget Control Act of 2011, among other things, included aggregate reductions of Medicare payments to providers of 2% per fiscal year. These reductions went into effect on April 1, 2013 and, due to subsequent
legislative amendments to the statute, will remain in effect through 2030, with the exception of a temporary suspension from May 1, 2020 through March 31, 2021, unless additional Congressional action is taken. In addition, on
January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. We expect that additional state and federal healthcare reform measures will be adopted in the future,
any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in additional pricing pressure or reduced demand for any drug candidate we develop or complementary or
companion diagnostics. For example, it is possible that additional governmental action will be taken to address the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, which could impact our business in an
<FONT STYLE="white-space:nowrap">as-yet</FONT> unknown manner. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Additionally, there has been increasing legislative and enforcement interest in the
United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation and regulation designed to, among other things, bring
more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. It is unclear
whether the Biden administration will work to reverse these measures or pursue similar policy initiatives to control drug costs. Any reduction in reimbursement from Medicare and other government programs may result in a similar reduction in payments
from private payers. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Actual or perceived failure to comply with current or future federal, state and foreign laws and regulations and industry
standards relating to privacy and data protection laws could lead to government enforcement actions, which could include civil or criminal penalties, private litigation, and/or adverse publicity and could negatively affect our operating results and
business. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We and our partners may be subject to federal, state and foreign data privacy and security laws and regulations. Failure by us or our
third-party vendors, collaborators, contractors and consultants to comply with any of these laws and regulations could result in notification obligations or enforcement actions against us, which could result in, among other things, fines, claims for
damages by affected individuals, damage to our reputation and loss of goodwill, any of which could have a material adverse effect on our business, financial condition, results of operations or prospects. These laws, rules and regulations evolve
frequently and their scope may continually change, through new legislation, amendments to existing legislation and changes in enforcement, and may be inconsistent from one jurisdiction to another. The interpretation and application of consumer,
health-related and data protection laws in the United States, the EU and elsewhere, are often uncertain, contradictory and in flux. As a result, implementation standards and enforcement practices are likely to remain uncertain for the foreseeable
future. As our operations and business grow, we may become subject to or affected by new or additional data protection laws and regulations and face increased scrutiny or attention from regulatory authorities. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In the United States, numerous federal and state laws and regulations, including federal health information privacy laws, state data breach notification laws, state
health information privacy laws and federal and state consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act), which govern the collection, use, disclosure and protection of health-related and other personal information
could apply to our operations or the operations of our collaborators. In addition, we may obtain health information from third parties (including research institutions from which we obtain clinical trial data) that are subject to privacy and
security </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">46 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
requirements under the Health Insurance Portability and Accountability Act (HIPAA), as amended by Health Information Technology for Economic and Clinical Health Act (HITECH). Depending on the
facts and circumstances, we could be subject to criminal penalties if we knowingly obtain, use, or disclose individually identifiable health information provided to us by a HIPAA-covered entity in a manner that is not authorized or permitted by
HIPAA. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Many states have also adopted comparable privacy and security laws and regulations, some of which may be more stringent than HIPAA. Such laws and
regulations will be subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us and our future customers and strategic partners. In addition, the California Consumer
Privacy Act of 2018 (CCPA) went into effect on January 1, 2020. The CCPA, among other things, creates individual privacy rights for California consumers, such as the right to access and delete their personal information, <FONT
STYLE="white-space:nowrap">opt-out</FONT> of certain sales of personal information and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of
action for data breaches that is expected to increase the frequency of data breach litigation. The CCPA may increase our compliance costs and potential liability, and many similar laws have been proposed at the federal level and in other states.
Further, the California Privacy Rights Act (CPRA) recently passed in California, which will impose additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit
requirements for higher risk data, and opt outs for certain uses of sensitive data. It will also create a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information
security enforcement. The majority of the provisions will go into effect on January 1, 2023, and additional compliance investment and potential business process changes may be required. In the event that we are subject to or affected by HIPAA,
the CCPA or other domestic privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We currently operate in countries outside of the United States, including Belgium and Australia, where laws may in some cases be more stringent than the requirements in the United States. For example, in Europe,
the General Data Protection Regulation (GDPR) went into effect in May 2018 and imposes strict requirements for the collection, storage, use, disclosure, transfer and other processing of the personal data of individuals within the European Economic
Area (EEA). The GDPR applies extra-territorially under certain circumstances and imposes stringent requirements on controllers and processors of personal data, including, for example, requirements to obtain consent or other legal bases from
individuals to process their personal data, provide robust disclosures to individuals, accommodate a set of individual data rights, provide data security breach notifications, limit retention of personal information and apply enhanced protections to
health data and other special categories of personal data. The GDPR also applies to pseudonymized data, which is defined as “the processing of personal data in such a way that the data can no longer be attributed to a specific data subject
without the use of additional information,” and imposes additional obligations when we contract with third-party processors in connection with the processing of any personal data. The GDPR provides that EU and EEA member states may make their
own further laws and regulations limiting the processing of personal data, including genetic, biometric or health data, which could limit our ability to use and share personal data, could cause our costs to increase and could harm our financial
condition. Failure to comply with the requirements of the GDPR could result in fines of up to <FONT STYLE="font-family:Times New Roman" SIZE="2">€</FONT>20 million or 4% of the total worldwide annual turnover of our preceding fiscal year,
whichever is higher, and other administrative penalties. Further, from January 1, 2021, we have to comply with the GDPR and also the United Kingdom GDPR (UK GDPR), which, together, with the amended Data Protection Act 2018, retains the GDPR in
UK national law, the latter regime having the ability to separately fine up to the greater of £17.5 million or 4% of global turnover. The relationship between the United Kingdom and the EU in relation to certain aspects of data protection
law remains unclear, and it is unclear how United Kingdom data protection laws and regulations will develop in the medium to longer term, and how data </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">47 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
transfers to and from the United Kingdom will be regulated in the long term. Currently there is a four to <FONT STYLE="white-space:nowrap">six-month</FONT> grace period agreed in the EU and U.K.
Trade and Cooperation Agreement, ending June 30, 2021 at the latest, whilst the parties discuss an adequacy decision. The European Commission published a draft adequacy decision on February 19, 2021. If adopted, the decision will enable
data transfers from EU member states to the United Kingdom for a four-year period, subject to subsequent extensions. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The GDPR further prohibits, without
an appropriate legal basis, the transfer of personal data to countries outside of the EEA, such as the United States, which are not considered by the European Commission to provide an adequate level of data protection. Recent legal developments in
Europe have created complexity and uncertainty regarding transfers of personal data from the EEA to the United States. For example, on July 16, 2020, the Court of Justice of the European Union (CJEU) invalidated the <FONT
STYLE="white-space:nowrap">EU-US</FONT> Privacy Shield Framework (the Privacy Shield) under which personal data could be transferred from the EEA to United States entities that had self-certified under the Privacy Shield scheme. While the CJEU
upheld the adequacy, subject to certain conditions, of the standard contractual clauses (a standard form of contract approved by the European Commission as an adequate personal data transfer mechanism), future regulatory guidance could result in
changes to the use of standard contractual clauses. Failure to comply with the GDPR and other countries’ privacy or data security-related laws, rules or regulations could result in material penalties imposed by regulators, affect our compliance
with contracts entered into with our collaborators and other third-party payors, and have an adverse effect on our business and financial condition. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Compliance with U.S. and foreign privacy and security laws, rules and regulations could require us to take on more onerous obligations in our contracts, require us
to engage in costly compliance exercises, restrict our ability to collect, use and disclose data, or in some cases, impact our or our partners’ ability to operate in certain jurisdictions. Each of these evolving laws can be subject to varying
interpretations. Failure to comply with U.S. and foreign data protection laws and regulations could result in government investigations and enforcement actions (which could include civil or criminal penalties), fines, private litigation, and/or
adverse publicity and could negatively affect our operating results and business. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Our internal computer systems, or those used by our CROs,
vendors, or other contractors or consultants, may fail or suffer security breaches. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Despite the implementation of security measures, our
internal computer systems and those of our CROs and other contractors and consultants are vulnerable to damage from cyber-attacks, computer hacks, theft, viruses, malicious software, phishing, employee error, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">denial-of-service</FONT></FONT> attacks, unauthorized access and other security breaches that could jeopardize the performance of our software and computer systems, and could expose us to financial and reputational harm.
Attacks upon information technology systems are increasing in their frequency, levels of persistence, sophistication and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives and
expertise. As a result of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, we may also face increased cybersecurity risks due to our reliance on internet technology and the number of our employees who are working remotely, which may
create additional opportunities for cybercriminals to exploit vulnerabilities. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a
target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period. While we have not, to our knowledge, experienced any
such material system failure or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations. For example, the
loss of clinical trial data from completed or future clinical trials could result in delays in our marketing approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on third parties for the
manufacture of our drug candidates and to conduct clinical trials, and similar events relating to their computer systems could also have </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">48 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
a material adverse effect on our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of
confidential or proprietary information, we could incur liability and the development and commercialization of our future drug candidates could be delayed. We have also outsourced elements of our information technology infrastructure, and as a
result a number of third party vendors may or could have access to our confidential information. If our third party vendors fail to protect their information technology systems and our confidential and proprietary information, we may be vulnerable
to disruptions in service and unauthorized access to our confidential or proprietary information and we could incur liability and reputational damage, which could negatively affect our operating results and business. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Risks related to reliance on third parties </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We depend
on collaborations with third parties for the development of certain of our potential drug candidates, and we may depend on additional collaborations in the future for the development and commercialization of these or other potential candidates. If
our collaborations are not successful, we may not be able to capitalize on the market potential of these drug candidates. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are currently
collaborating with third parties to develop certain of our potential drug candidates. For example, we are collaborating with the Rega Institute and Centre for Drug Design and Discovery at KU Leuven with respect to potential protease inhibitors for
the treatment of coronaviruses, including <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2,</FONT></FONT> with Emory with respect to certain aspects of our small molecule CHB program and with Merck with respect to the
discovery, research and development of oligonucleotides against an undisclosed NASH target. In the future, we may form or seek strategic alliances, joint ventures, or collaborations, or enter into additional licensing arrangements with third parties
that we believe will complement or augment our development and commercialization efforts with respect to drug candidates we develop. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Collaborations
involving our current and future drug candidates may pose the following risks to us: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial, abandon a drug candidate, repeat or
conduct new clinical trials or require a new formulation of a drug candidate for clinical testing; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products (if any) or drug
candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">a collaborator with marketing, manufacturing and distribution rights to one or more products may not commit sufficient resources to or may otherwise not perform
satisfactorily in carrying out these activities; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">collaborators may not properly prosecute, maintain, enforce or defend our intellectual property rights or may use our proprietary information in a way that gives
rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation, or other intellectual property proceedings; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">collaborators may own or <FONT STYLE="white-space:nowrap">co-own</FONT> intellectual property covering products that result from our collaboration with them, and
in such cases, we may not have the exclusive right to develop, license or commercialize such intellectual property; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">disputes may arise with respect to ownership of any intellectual property developed pursuant to our collaborations; </FONT></P></TD></TR></TABLE>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">49 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">disputes may arise between a collaborator or strategic partner and us that cause the delay or termination of the research, development or commercialization of
the drug candidate, or that result in costly litigation or arbitration that diverts management attention and resources; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">if a current or future collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or
commercialization program under such collaboration could be delayed, diminished or terminated. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As a result, if we enter into
additional collaboration agreements and strategic partnerships or license our intellectual property, products or businesses, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our
existing operations, which could delay our timelines or otherwise adversely affect our business. We also cannot be certain that, following a strategic transaction or license, we will achieve the revenue or specific net income that justifies such
transaction. Any delays in entering into new collaborations or strategic partnership agreements related to any drug candidate we develop could delay the development and commercialization of our drug candidates, which would harm our business
prospects, financial condition, and results of operations. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We may seek to establish additional collaborations, and, if we are not able to
establish them on commercially reasonable terms, we may have to alter our development and commercialization plans. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The advancement of our drug
candidates and development programs and the potential commercialization of our current and future drug candidates will require substantial additional cash to fund expenses. For some of our programs, we may decide to collaborate with other
pharmaceutical and biotechnology companies with respect to development and potential commercialization. Any of these relationships may require us to incur <FONT STYLE="white-space:nowrap">non-recurring</FONT> and other charges, increase our near-
and long-term expenditures, issue securities that dilute our existing stockholders, divert our management’s attention and disrupt our business. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We
face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Whether we reach a definitive agreement for any other collaborations will depend, among other things, upon our
assessment of the collaborator’s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator’s evaluation of a number of factors. Those factors may include the design or results of clinical
trials, the progress of our clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject drug candidate, the costs and complexities of manufacturing and
delivering such drug candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the
challenge and industry and market conditions generally. The collaborator may also consider alternative drug candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more
attractive than the one with us for our drug candidate. Further, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for future drug candidates because they may be deemed to be at too early
of a stage of development for collaborative efforts and third parties may not view them as having the requisite potential to demonstrate safety and efficacy. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We may also be restricted under future collaboration agreements from entering into additional agreements on certain terms with potential collaborators. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development
of the drug candidate for which we are seeking to </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">50 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing
activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain
additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our drug candidates or bring them to market and generate product revenue. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>If conflicts arise between us and our collaborators or strategic partners, these parties may act in a manner adverse to us and could limit our ability to
implement our strategies. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If conflicts arise between our academic collaborators or strategic partners and us, the other party may act in a
manner adverse to us and could limit our ability to implement our strategies. Current or future collaborators or strategic partners may develop, either alone or with others, products in related fields that are competitive with the products or
potential products that are the subject of these collaborations. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our current or future collaborators or strategic partners may preclude us from entering
into collaborations with their competitors, fail to obtain timely regulatory approvals, terminate their agreements with us prematurely, or fail to devote sufficient resources to the development and commercialization of products. Furthermore,
competing products, either developed by our current or future collaborators or strategic partners or to which our collaborators or strategic partners may have rights, may result in the withdrawal of partner support for our drug candidates. Any of
these developments could harm our product development efforts. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We rely on third parties to conduct our ongoing and planned clinical trials and
certain of our nonclinical studies for drug candidates we develop. If these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, we may not be able to obtain marketing
approval for or commercialize the drug candidates we are developing and our business could be substantially harmed. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We do not have the ability
to independently conduct certain nonclinical studies and clinical trials. We rely on medical institutions, clinical investigators, contract laboratories, and other third parties, such as CROs, to conduct or otherwise support certain nonclinical
studies and clinical trials for our drug candidates, including <FONT STYLE="white-space:nowrap">ALG-010133</FONT> and <FONT STYLE="white-space:nowrap">ALG-000184,</FONT> and we control only certain aspects of their activities. Nevertheless, we are
responsible for ensuring that each of our nonclinical studies and clinical trials is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards, and our reliance on CROs will not relieve us of
our regulatory responsibilities. For any violations of laws and regulations during the conduct of our nonclinical studies or clinical trials, we could be subject to untitled and warning letters or enforcement action that may include civil penalties
up to and including criminal prosecution. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We and our CROs are required to comply with regulations and requirements, including GLP and GCP, for
conducting, monitoring, recording and reporting the results of nonclinical studies and clinical trials, respectively, to ensure that the data and results are scientifically credible and accurate, and that the trial patients are adequately informed
of the potential risks of participating in clinical trials and their rights are protected. These regulations are enforced by the FDA, the Competent Authorities of the Member States of the EEA and comparable foreign regulatory authorities for any
drugs in clinical development. The FDA enforces GLP and GCP requirements through periodic inspections of laboratories conducting studies, clinical trial sponsors, principal investigators and trial sites. If we or our CROs fail to comply with
applicable GLP or GCP, the data generated in our nonclinical studies or clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional nonclinical studies before allowing us to
proceed with clinical trials or additional clinical trials before approving our marketing applications. We cannot </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">51 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
assure you that, upon inspection, the FDA will determine that any of our future nonclinical studies or clinical trials will comply with GLP or GCP, as applicable. In addition, our nonclinical
studies and clinical trials must be conducted with drug candidates produced under cGMP regulations. Our failure or the failure of our CROs to comply with these regulations may require us to delay or repeat nonclinical studies or clinical trials,
which would delay the marketing approval process and could also subject us to enforcement action. We also are required to register certain ongoing clinical trials and provide certain information, including information relating to the trial’s
protocol, on a government-sponsored database, ClinicalTrials.gov, within specific timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Although we intend to design the nonclinical studies and clinical trials for our drug candidates, CROs conduct all of the clinical trials and certain nonclinical studies. As a result, many important aspects of our
nonclinical and clinical development, including their conduct and timing, will be outside of our direct control. Our reliance on third parties to conduct future nonclinical studies and clinical trials will also result in less direct control over the
management of data developed through nonclinical studies or clinical trials than would be the case if we were relying entirely upon our own staff. Communicating with outside parties can also be challenging, potentially leading to mistakes as well as
difficulties in coordinating activities. Outside parties may: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">have staffing difficulties; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">fail to comply with contractual obligations; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">experience regulatory compliance issues; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">undergo changes in priorities; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">become financially distressed; or </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">form relationships with other entities, some of which may be our competitors. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">These factors may materially adversely affect the willingness or ability of third parties to conduct our nonclinical studies or clinical trials and may subject us to unexpected cost increases and/or delays that are
beyond our control. If the CROs do not perform nonclinical studies or clinical trials in a satisfactory manner, breach their obligations to us or fail to comply with regulatory requirements, the development, marketing approval and commercialization
of our drug candidates may be delayed, we may not be able to obtain marketing approval and commercialize our drug candidates, or our development program may be materially and irreversibly harmed. If we are unable to rely on nonclinical or clinical
data collected by our CROs, we could be required to repeat, extend the duration of, or increase the size of any nonclinical studies or clinical trials we conduct and this could significantly delay commercialization and require significantly greater
expenditures. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If any of our relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs on
commercially reasonable terms, or at all. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced, if the quality or accuracy of the nonclinical or clinical data they
obtain are compromised due to the failure to adhere to our protocols, regulatory requirements or for other reasons, or if they are negatively impacted by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, any nonclinical studies or
clinical trials such CROs are associated with may be extended, delayed or terminated, and we may not be able to obtain marketing approval for or successfully commercialize our drug candidates. As a result, we believe that our financial results and
the commercial prospects for our drug candidates in the subject indication would be harmed, our costs would increase and our ability to generate revenue would be delayed. </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">52 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We rely on third parties to manufacture nonclinical and clinical drug supplies, and we intend to rely on
third parties to produce commercial supplies of any approved product which increases the risk that we will not have sufficient quantities of such drug candidates or products or such quantities at an acceptable cost, which could delay, prevent or
impair our development or commercialization efforts. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We do not own or operate manufacturing facilities for the production of nonclinical,
clinical or commercial supplies of the drug candidates that we are developing or evaluating in our development programs. We have limited personnel with experience in drug manufacturing and lack the resources and the capabilities to manufacture any
of our drug candidates on a nonclinical, clinical or commercial scale. We rely on third parties for supply of our nonclinical and clinical drug supplies (including key starting and intermediate materials), and our strategy is to outsource all
manufacturing of our drug candidates and products to third parties. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In order to conduct clinical trials of drug candidates, we will need to have them
manufactured in potentially large quantities. Our third-party manufacturers may be unable to successfully increase the manufacturing capacity for any of our clinical drug supplies (including key starting and intermediate materials) in a timely or
cost-effective manner, or at all. In addition, quality issues may arise during <FONT STYLE="white-space:nowrap">scale-up</FONT> activities and at any other time. For example, ongoing data on the stability of our drug candidates may shorten the
expiry of our drug candidates and lead to clinical trial material supply shortages, and potentially clinical trial delays. If these third-party manufacturers are unable to successfully scale up the manufacture of our drug candidates in sufficient
quality and quantity, the development, testing and clinical trials of that drug candidate may be delayed or infeasible, and regulatory approval or commercial launch of that drug candidate may be delayed or not obtained, which could significantly
harm our business. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our use of new third-party manufacturers increases the risk of delays in production or insufficient supplies of our drug candidates
(and the key starting and intermediate materials for such drug candidates) as we transfer our manufacturing technology to these manufacturers and as they gain experience manufacturing our drug candidates (and the key starting and intermediate
materials for such drug candidates). </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Even after a third-party manufacturer has gained significant experience in manufacturing our drug candidates (or
the key starting and intermediate materials for such drug candidates) or even if we believe we have succeeded in optimizing the manufacturing process, there can be no assurance that such manufacturer will produce sufficient quantities of our drug
candidates (or the key starting and intermediate materials for such drug candidates) in a timely manner or continuously over time, or at all. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We may be
delayed if we need to change the manufacturing process used by a third party. Further, if we change an approved manufacturing process, then we may be delayed if the FDA or a comparable foreign authority needs to review the new manufacturing process
before it may be used. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We do not currently have any agreements with third-party manufacturers for long-term commercial supply. In the future, we may be
unable to enter into agreements with third-party manufacturers for commercial supplies of any drug candidate that we develop, or may be unable to do so on acceptable terms. Even if we are able to establish and maintain arrangements with third-party
manufacturers, reliance on third-party manufacturers entails risks, including: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">reliance on the third party for regulatory compliance and quality assurance; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the possible breach of the manufacturing agreement by the third party; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the possible misappropriation of our proprietary information, including our trade secrets and <FONT STYLE="white-space:nowrap">know-how;</FONT> and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the possible termination or <FONT STYLE="white-space:nowrap">non-renewal</FONT> of the agreement by the third party at a time that is costly or inconvenient for
us. </FONT></P></TD></TR></TABLE>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">53 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Third-party manufacturers may not be able to comply with cGMP requirements or similar regulatory requirements
outside the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable requirements could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or
withdrawal of approvals, license revocation, seizures or recalls of drug candidates or products, operating restrictions and/or criminal prosecutions, any of which could significantly and adversely affect supplies of our drug candidates. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our future drug candidates and any products that we may develop may compete with other drug candidates and products for access to manufacturing facilities. There
are a limited number of manufacturers that operate under cGMP requirements and that might be capable of manufacturing for us. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If the third parties that
we engage to supply any materials or manufacture product for our nonclinical studies and clinical trials should cease to continue to do so for any reason, we likely would experience delays in advancing these studies and trials while we identify and
qualify replacement suppliers or manufacturers and we may be unable to obtain replacement supplies on terms that are favorable to us or at all. In addition, if we are not able to obtain adequate supplies of our drug candidates or the substances used
to manufacture them, it will be more difficult for us to develop our drug candidates and compete effectively. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Some of our third-party manufacturers
which we use for the supply of materials for drug candidates or other materials necessary to manufacture product to conduct clinical trials are located in countries affected by <FONT STYLE="white-space:nowrap">COVID-19,</FONT> and should they
experience disruptions, such as temporary closures or suspension of services, we would likely experience delays in advancing our clinical development. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our current and anticipated future dependence upon others for the manufacture of our drug candidates (or the key starting and intermediate materials for such drug
candidates) may adversely affect our future profit margins and our ability to develop drug candidates and commercialize any products that receive marketing approval on a timely and competitive basis. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Our future relationships with customers and third-party payors in the United States and elsewhere may be subject, directly or indirectly, to applicable
anti-kickback, fraud and abuse, false claims, transparency, and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm, administrative burdens and diminished
profits and future earnings. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Healthcare providers, physicians and third-party payors in the United States and elsewhere will play a primary role
in the recommendation and prescription of any drug candidates for which we obtain marketing approval. Our future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and
regulations, including, without limitation, the federal Anti-Kickback Statute and the federal False Claims Act (the FCA), which may constrain the business or financial arrangements and relationships through which we sell, market and distribute any
products for which we obtain marketing approval. In addition, we may be subject to transparency laws by the U.S. federal and state governments and by governments in foreign jurisdictions in which we conduct our business. The applicable federal,
state and foreign healthcare laws and regulations that may affect our ability to operate include: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the federal Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully soliciting, receiving, offering or paying any remuneration
(including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the purchase, lease, order or recommendation of any good, facility,
item or service for which payment may be made, in whole or in part, under the Medicare and Medicaid programs or other federal healthcare programs. A person or entity can be found guilty of violating the statute without actual knowledge of the
statute or specific intent to violate it. The Anti-Kickback Statute has been interpreted to apply to </FONT></P></TD></TR></TABLE>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">54 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="top"> <P><FONT STYLE="font-family:arial" SIZE="2">
arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers, and formulary managers on the other; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the federal civil and criminal false claims laws, including the FCA, which prohibit any person or entity from, among other things, knowingly presenting, or
causing to be presented, a false, fictitious or fraudulent claim for payment to, or approval by, the federal government or knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to
the federal government. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">HIPAA, which created federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare
benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or
private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services
relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity can be found guilty of violating HIPAA without actual knowledge of the statutes or specific intent to violate them; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the Physician Payments Sunshine Act, created under the ACA, and its implementing regulations, which requires manufacturers of drugs, devices, biologics and
medical supplies for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program (with certain exceptions) to report annually to CMS information related to payments or other transfers of value made to
physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Beginning in 2022, such
obligations will include payments and other transfers of value provided in the previous year to certain other healthcare professionals, including physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists,
anesthesiology assistants and certified nurse-midwives; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">analogous state laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and healthcare items
or services reimbursed by <FONT STYLE="white-space:nowrap">non-governmental</FONT> third-party payors, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary
compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers; state laws that require drug manufacturers to report information related to
payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and healthcare laws in the EU and other jurisdictions, including reporting requirements detailing interactions with and payments to
healthcare providers. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors
available under such laws, it is possible that some of our business activities could be subject to challenge under one or more of such laws. The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current
environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare
providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Ensuring that our business arrangements with third parties comply with applicable healthcare laws, as well as responding to
investigations </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">55 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
by government authorities, can be time- and resource-consuming and can divert management’s attention from the business. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">If our operations are found to be in violation of any of the laws described above or any other government regulations that apply to us, we may be subject to penalties, including civil, criminal and administrative
penalties, damages, fines, disgorgement, individual imprisonment, possible exclusion from participation in federal- and state-funded healthcare programs, contractual damages and the curtailment or restricting of our operations, as well as additional
reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws, any of which could harm our ability to
operate our business and our financial results. Further, if the physicians or other providers or entities with whom we expect to do business are found not to be in compliance with applicable laws, they may be subject to criminal, civil or
administrative sanctions, including exclusions from government funded healthcare programs. In addition, the approval and commercialization of any drug candidate we develop outside the United States will also likely subject us to foreign equivalents
of the healthcare laws mentioned above, among other foreign laws. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Risks related to intellectual property </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>If we and our collaborators are unable to obtain and maintain sufficient patent and other intellectual property protection for our drug candidates and
technology, our competitors could develop and commercialize products and technology similar or identical to ours, and we may not be able to compete effectively in our market or successfully commercialize any drug candidates we may develop.
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our success depends in significant part on our ability and the ability of our current or future collaborators and licensors to obtain, maintain,
enforce and defend patents and other intellectual property rights with respect to our drug candidates and technology and to operate our business without infringing, misappropriating, or otherwise violating the intellectual property rights of others.
If we and our current or future collaborators and licensors are unable to obtain and maintain sufficient intellectual property protection for our drug candidates or other drug candidates that we may identify, or if the scope of the intellectual
property protection obtained is not sufficiently broad, our competitors and other third parties could develop and commercialize drug candidates similar or identical to ours, and our ability to successfully commercialize our drug candidates and other
drug candidates that we may pursue may be impaired. We do not own any issued patents with respect to our programs, including our CHB and NASH programs, and we do not own or <FONT STYLE="white-space:nowrap">in-license</FONT> any issued patents with
claims that specifically recite our <FONT STYLE="white-space:nowrap">ALG-010133,</FONT> <FONT STYLE="white-space:nowrap">ALG-000184,</FONT> <FONT STYLE="white-space:nowrap">ALG-020572,</FONT> <FONT STYLE="white-space:nowrap">ALG-125755</FONT> and <FONT
STYLE="white-space:nowrap">ALG-055009</FONT> drug candidates. We can provide no assurance that any of our current or future patent applications will result in issued patents or that any issued patents will provide us with any competitive advantage.
We cannot be certain that there is no invalidating prior art of which we and the patent examiner are unaware or that our interpretation of the relevance of prior art is correct. For example, there are certain patents and patent applications (and
there may be other patents and patent applications) that are owned by third parties, including our competitors, that have (or may have) an earlier filing date, and could be determined to have an earlier priority date, than our patent applications
relating to our STOPS candidate, <FONT STYLE="white-space:nowrap">ALG-010133.</FONT> If a patent or patent application is determined to have an earlier priority date, it may prevent our patent applications from issuing at all or issuing in a form
that provides any competitive advantage for our product candidates. Failure to obtain issued patents could have a material adverse effect on our ability to develop and commercialize our drug candidates. Even if our patent applications do issue as
patents, third parties may be able to challenge the validity and enforceability of our patents on a variety of grounds, including that such third party’s patents and patent applications have an earlier priority date, and if such challenges are
successful we may be required to obtain one or more licenses from such third parties, or be prohibited from commercializing our product candidates. We may not be able to obtain these licenses on acceptable or commercially reasonable terms, if at
</FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">56 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
all, or these licenses may be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> which could result in our competitors using the same intellectual property. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We seek to protect our proprietary positions by, among other things, filing patent applications in the United States and abroad related to our current drug
candidates and other drug candidates that we may identify. Obtaining, maintaining, defending and enforcing pharmaceutical patents is costly, time consuming and complex, and we may not be able to file and prosecute all necessary or desirable patent
applications, or maintain, enforce and license any patents that may issue from such patent applications, at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development
output before it is too late to obtain patent protection. Moreover, under certain of our license or collaboration agreements, we may not have the right to control the preparation, filing, prosecution and maintenance of patent applications, or to
maintain the rights to patents licensed to or from third parties. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We currently are the assignee of a number of U.S. provisional patent applications.
U.S. provisional patent applications are not eligible to become issued patents until, among other things, we file a <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application within 12 months of filing of one or more of our related
provisional patent applications. With regard to such U.S. provisional patent applications, if we do not timely file any <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent applications, we may lose our priority dates with respect to our
provisional patent applications and any patent protection on the inventions disclosed in our provisional patent applications. Further, in the event that we do timely file <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent applications
relating to our provisional patent applications, we cannot predict whether any such patent applications will result in the issuance of patents or if such issued patents will provide us with any competitive advantage. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Although we enter into confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as
our employees, collaborators, CROs, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach these agreements and disclose such output before a patent application is filed, thereby jeopardizing our
ability to seek patent protection. Further, we may not be aware of all third-party intellectual property rights potentially relating to our drug candidates. Publications of discoveries in the scientific literature often lag behind the actual
discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing or, in some cases, not at all. Therefore, we cannot know with certainty whether we were the first to make the
inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The patent
position of pharmaceutical companies generally is highly uncertain, involves complex legal, technological and factual questions and has, in recent years, been the subject of much debate and litigation throughout the world. In addition, the laws of
foreign countries may not protect our rights to the same extent as the laws of the United States, or vice versa. As a result, the issuance, scope, validity, enforceability, and commercial value of our patent rights are highly uncertain. The subject
matter claimed in a patent application can be significantly reduced or eliminated before the patent issues, if at all, and its scope can be reinterpreted or narrowed after issuance. Therefore, our pending and future patent applications may not
result in patents being issued in relevant jurisdictions that protect our drug candidates, in whole or in part, or that effectively prevent others from commercializing competitive drug candidates, and even if our patent applications issue as patents
in relevant jurisdictions, they may not issue in a form that will provide us with any meaningful protection for our drug candidates or technology, prevent competitors from competing with us or otherwise provide us with any competitive advantage.
Additionally, our competitors may be able to circumvent our patents by challenging their validity or by developing similar or alternative drug candidates or technologies in a <FONT STYLE="white-space:nowrap">non-infringing</FONT> manner. </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">57 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our
patents may be challenged in the courts or patent offices in the United States and abroad. We may be subject to a third-party preissuance submission of prior art to the United States Patent and Trademark Office (the USPTO), or become involved in
opposition, derivation, revocation, reexamination, <I>inter partes</I> review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others, or other proceedings in the USPTO or applicable foreign
offices that challenge priority of invention or other features of patentability. An adverse determination in any such submission, proceeding or litigation could result in loss of exclusivity or ability to sell our products free from infringing the
patents of third parties, patent claims being narrowed, invalidated or held unenforceable, in whole or in part, and limitation of the scope or duration of the patents directed to our drug candidates, all of which could limit our ability to stop
others from using or commercializing similar or identical drug candidates or technology to compete directly with us, without payment to us, or result in our inability to manufacture or commercialize drug candidates or approved products (if any)
without infringing third-party patent rights. In addition, if the breadth or strength of the claims of our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license,
develop or commercialize current or future drug candidates, or could have a material adverse effect on our ability to raise funds necessary to continue our research programs or clinical trials. Such proceedings also may result in substantial cost
and require significant time from our scientists and management, even if the eventual outcome is favorable to us. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, given the amount of time
required for the development, testing and regulatory review of new drug candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with
sufficient rights to exclude others from commercializing products or technology similar or identical to ours for a meaningful amount of time, or at all. Moreover, some of our licensed patents and owned or licensed patent applications may in the
future be <FONT STYLE="white-space:nowrap">co-owned</FONT> with third parties. If we are unable to obtain exclusive licenses to any such <FONT STYLE="white-space:nowrap">co-owners’</FONT> interest in such patents or patent applications, such <FONT
STYLE="white-space:nowrap">co-owners</FONT> may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. In addition, we may need the cooperation of any
such <FONT STYLE="white-space:nowrap">co-owners</FONT> in order to enforce such patents against third parties, and such cooperation may not be provided to us. Any of the foregoing could harm our competitive position, business, financial condition,
results of operations and prospects. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We have entered into licensing and collaboration agreements with third parties. If we fail to comply with our
obligations in the agreements under which we license intellectual property rights to or from third parties, or these agreements are terminated, or we otherwise experience disruptions to our business relationships with our licensors or licensees, our
competitive position, business, financial condition, results of operations and prospects could be harmed. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition to patent and other
intellectual property rights we own or <FONT STYLE="white-space:nowrap">co-own,</FONT> we have licensed, and may in the future license, patent and other intellectual property rights to and from other parties. In particular, we have <FONT
STYLE="white-space:nowrap">in-licensed</FONT> significant intellectual property rights from Emory and Luxna. Licenses may not provide us with exclusive rights to use the applicable intellectual property and technology in all relevant fields of use
and in all territories in which we may wish to develop or commercialize our drug candidates, products (if approved) and technology in the future. As a result, we may not be able to prevent competitors from developing and commercializing competitive
products or technologies. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent
applications or to maintain, defend and enforce the patents that we license to or from third parties, and we may have to rely on our partners to fulfill these responsibilities. For example, under the Luxna Agreement, we obtained a license from Luxna
under patents relevant to certain aspects of our HBV programs as </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">58 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
well as to various potential therapies, which we are pursuing to address <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2.</FONT></FONT> Although we have review and
comment rights regarding prosecution of patents that we license under the Luxna Agreement, Luxna retains ultimate decision-making control with respect to the prosecution of these patents. Additionally, under the Emory License Agreement, we obtained
a license from Emory University under patents relevant to certain aspects of our small molecule CHB program. Although we direct prosecution of patents licensed under the Emory License Agreement, we are obligated to consult with Emory University with
respect to prosecution of these patents and Emory and its counsel are responsible for making all filings related to such prosecution. Similarly, although we will control the prosecution of jointly developed patents resulting from our collaboration
with the Rega Institute for Medical Research and the Centre for Drug Design and Discovery under the KU Leuven Agreement, we are obligated to consult with such parties with respect to prosecution of these patents. Consequently, any such licensed
patents and applications may not be prepared, filed, prosecuted, maintained, enforced, and defended in a manner consistent with the best interests of our business. If our current or future licensors, licensees or collaborators fail to prepare, file,
prosecute, maintain, enforce, and defend licensed patents and other intellectual property rights, such rights may be reduced or eliminated, and our right to develop and commercialize any of our drug candidates or technology that are the subject of
such licensed rights could be adversely affected. In addition, our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing
or otherwise violating the licensor’s rights. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If we fail to comply with our obligations, including the obligation to make various milestone
payments and royalty payments, under any of the agreements under which we license intellectual property rights from third parties, such as the Emory License Agreement or Luxna Agreement, the licensor may have the right to terminate the license.
Under some of our <FONT STYLE="white-space:nowrap">in-license</FONT> agreements, as a sublicensee, we may be obligated to comply with applicable requirements, limitations or obligations of our sublicensors to other third parties. For example, the
Luxna Agreement includes rights that Luxna <FONT STYLE="white-space:nowrap">in-licensed</FONT> from Osaka University (Osaka), which are in turn sublicensed to us. Prior to granting such rights to Luxna, Osaka granted certain rights to third parties
and therefore the rights we <FONT STYLE="white-space:nowrap">in-license</FONT> from Luxna are subject to such third-party rights. Although we understand that these rights granted to such third parties are for uses outside the scope of our business,
license agreements are complex, subject to multiple interpretations and disputes may arise regarding scope of such licensed rights. Further, under the Luxna Agreement and other <FONT STYLE="white-space:nowrap">in-licenses</FONT> under which we
sublicense certain rights, we rely on Luxna and our other sublicensors to comply with their obligations under their upstream license agreements, where we may have no relationship with the original licensor of such rights. If our sublicensors fail to
comply with their obligations under their upstream license agreements, and the upstream license agreements are consequently terminated, such termination may result in the termination of our sublicenses. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If any of our license agreements are terminated, the underlying licensed patents fail to provide the intended exclusivity or we otherwise experience disruptions to
our business relationships with our licensors, we could lose intellectual property rights that are important to our business or be prevented from developing and commercializing our drug candidates, and competitors could have the freedom to seek
regulatory approval of, and to market, products identical to ours. Termination of these agreements or reduction or elimination of our rights under these agreements may also result in our having to negotiate new or reinstated agreements with less
favorable terms, cause us to lose our rights under these agreements, including our rights to important intellectual property or technology, or impede, delay or prohibit the further development or commercialization of one or more drug candidates that
rely on such agreements. It is possible that we may be unable to obtain any additional licenses at a reasonable cost or on reasonable terms, if at all. In that event, we may be required to expend significant time and resources to redesign our drug
candidates or the methods for manufacturing them </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">59 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In addition, the research resulting in certain of our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent rights and technology may have been funded in part by the U.S. federal or state
governments. As a result, the government may have certain rights, including <FONT STYLE="white-space:nowrap">march-in</FONT> rights, to such patent rights and technology. When new technologies are developed with government funding, the government
generally obtains certain rights in any resulting patents, including a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license authorizing the government to use the invention for noncommercial purposes. These rights may permit the government
to disclose our confidential information to third parties or allow third parties to use our licensed technology. The government can exercise its <FONT STYLE="white-space:nowrap">march-in</FONT> rights if it determines that action is necessary
because we fail to achieve practical application of the government-funded technology, or because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations, or to give preference to U.S. industry. In
addition, our rights in such inventions may be subject to certain requirements to manufacture products embodying such inventions in the United States. Any of the foregoing could harm our competitive position, business, financial condition, results
of operations and prospects. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Licensing of intellectual property is of critical importance to our business and involves complex legal, business and
scientific issues and certain provisions in intellectual property license agreements may be susceptible to multiple interpretations. Disputes may arise between us and our licensing partners regarding intellectual property subject to a license
agreement, including: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the scope of rights granted under the license agreement and other interpretation-related issues; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">whether and the extent to which technology and processes of one party infringe intellectual property of the other party that are not subject to the licensing
agreement; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">rights to sublicense patent and other rights to third parties; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">any diligence obligations with respect to the use of the licensed technology in relation to development and commercialization of our drug candidates, and what
activities satisfy those diligence obligations; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from the joint creation or use of intellectual property;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">rights to transfer or assign the license; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the effects of termination. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The resolution of
any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the
relevant agreement, either of which could harm our business, financial condition, results of operations and prospects. If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing
arrangements on acceptable terms or at all, we may be unable to successfully develop and commercialize the affected drug candidates. Moreover, any dispute or disagreement with our licensing partners may result in the delay or termination of the
research, development or commercialization of our drug candidates or any future drug candidates, and may result in costly litigation or arbitration that diverts management attention and resources away from our <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities, which may adversely affect our business, financial conditions, results of operations and prospects. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Furthermore, current and future collaborators or strategic partners may develop, either alone or with others, products in related fields that are competitive with the products or potential products that are the
subject of these collaborations. Competing products, either developed by our collaborators or strategic partners or to which the collaborators or strategic partners have rights, may result in the withdrawal of partner support for our drug
candidates. Any of these developments could harm our product development efforts. </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">60 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, if our licensors fail to abide by the terms of the license, if the licensors fail to prevent
infringement by third parties or if the licensed patents or other rights are found to be invalid or unenforceable, our business, competitive position, financial condition, results of operations and prospects could be materially harmed. For more
information regarding our license agreements, see the section titled “Business—License agreements and collaborations” of our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December 31, 2020,
which is incorporated by reference herein. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>If we are unable to obtain licenses from third parties on commercially reasonable terms or at all, our
business could be harmed. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our
products (if approved), in which case we would be required to obtain a license from these third parties. The licensing of third-party intellectual property rights is a competitive area, and more established companies may pursue strategies to license
or acquire third-party intellectual property rights that we may consider attractive or necessary. More established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and
commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third party intellectual property rights on terms that would
allow us to make an appropriate return on our investment or at all. If we are unable to license such technology, or if we are forced to license such technology on unfavorable terms, our business could be materially harmed. If we are unable to obtain
a necessary license, we may be unable to develop or commercialize the affected drug candidates, which could materially harm our business, and the third parties owning such intellectual property rights could seek either an injunction prohibiting our
sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation. Even if we are able to obtain a license, it may be or become <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving
our competitors access to the same technologies licensed to us. For example, under the Emory License Agreement we currently have an exclusive license with respect to certain patents and a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license
with respect to certain of Emory’s specified <FONT STYLE="white-space:nowrap">know-how.</FONT> Beginning in June 2022, the license to such patents will become <FONT STYLE="white-space:nowrap">non-exclusive</FONT> with respect to all fields
except for the treatment and prevention of HBV. For more information regarding our license agreements, see the section titled “Business—License agreements and collaborations” of our Annual Report on Form
<FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December 31, 2020, which is incorporated by reference herein. Any of the foregoing could harm our competitive position, business, financial condition, results of operations and
prospects. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party
patent, which might subject us to infringement claims or adversely affect our ability to develop and market our drug candidates. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We cannot
guarantee that any of our or our licensors’ patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we
have identified each and every third-party patent and pending patent application in the United States and abroad that is relevant to or necessary for the commercialization of our drug candidates in any jurisdiction. For example, U.S. patent
applications filed before November 29, 2000 and certain U.S. patent applications filed after that date that will not be filed outside the United States remain confidential until patents issue. As mentioned above, patent applications in the
United States and elsewhere are published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our
drug candidates could have been filed by third parties without our knowledge. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our drug candidates
or the use of our drug candidates. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent’s prosecution history. Our </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">61 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our drug candidates. We may incorrectly
determine that our drug candidates are not covered by a third-party patent or may incorrectly predict whether a third party’s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent
in the United States or abroad that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our drug candidates. Our failure to identify and correctly interpret relevant patents may negatively impact our
ability to develop and market our drug candidates. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are aware of certain third-party issued patents and pending patent applications, including those
of our competitors, that, if issued with their current claim scope, may be construed to cover our drug candidates, including <FONT STYLE="white-space:nowrap">ALG-055009,</FONT> <FONT STYLE="white-space:nowrap">ALG-125755</FONT> and <FONT
STYLE="white-space:nowrap">ALG-010133.</FONT> In the event that any of these patents were asserted against us, we believe that we would have defenses against any such action, including that such patents are not valid. However, if any such patents
were to be asserted against us and our defenses to such assertion were unsuccessful and alternative technology was not available or technologically or commercially practical, unless we obtain a license to such patents, we could be liable for
damages, which could be significant and include treble damages and attorneys’ fees if we are found to willfully infringe such patents, and we could be precluded from commercializing any drug candidates that were ultimately held to infringe such
patents. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, if we fail to identify and correctly interpret relevant patents, we may be subject to infringement claims. We cannot guarantee
that we will be able to successfully settle or otherwise resolve such infringement claims. If we fail in any such dispute, in addition to being forced to pay damages, which may be significant, we may be temporarily or permanently prohibited from
commercializing any of our drug candidates that are held to be infringing. We might, if possible, also be forced to redesign drug candidates so that they no longer infringe the third-party intellectual property rights. Any of these events, even if
we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business and could adversely affect our business, financial condition, results of operations
and prospects. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Patent terms may be inadequate to establish our competitive position on our drug candidates for an adequate amount of time.
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally
20 years from its earliest U.S. <FONT STYLE="white-space:nowrap">non-provisional</FONT> filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our drug
candidates are obtained, once the patent life has expired for a drug candidate, we may be open to competition from competitive medications, including generic versions. Given the amount of time required for the development, testing and regulatory
review of new drug candidates, patents directed towards such drug candidates might expire before or shortly after such drug candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights
to exclude others from commercializing drug candidates similar or identical to ours for a meaningful amount of time, or at all. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Depending upon the
timing, duration and conditions of any FDA marketing approval of our drug candidates, one or more of our owned or licensed U.S. patents may be eligible for limited patent term extension under the Hatch-Waxman Act, and similar legislation in the EU
and certain other countries. The Hatch-Waxman Act permits a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review
process. However, we may not receive an extension if we fail to exercise due diligence during the testing phase or regulatory review process, fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or
otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. Only one patent per approved product can be extended, the extension cannot extend the total patent
</FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">62 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
term beyond 14 years from approval and only those claims for the approved drug, a method for using it or a method for manufacturing it may be extended. If we are unable to obtain patent term
extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for the applicable drug candidate will be shortened and our competitors may obtain approval to market competing products
sooner. As a result, our revenue from applicable products could be reduced. Further, if this occurs, our competitors may take advantage of our investment in development and trials by referencing our clinical and nonclinical data and launch their
product earlier than might otherwise be the case, and our competitive position, business, financial condition, results of operations and prospects could be materially harmed. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Further, there are detailed rules and requirements regarding the patents that may be submitted to the FDA for listing in the Orange Book. We may be unable to obtain patents covering our drug candidates that contain
one or more claims that satisfy the requirements for listing in the Orange Book. Even if we submit a patent for listing in the Orange Book, the FDA may decline to list the patent, or a manufacturer of generic drugs may challenge the listing. If one
of our drug candidates is approved and a patent covering that drug candidate is not listed in the Orange Book, a manufacturer of generic drugs would not have to provide advance notice to us of any abbreviated new drug application filed with the FDA
to obtain permission to sell a generic version of such drug candidate. Any of the foregoing could harm our competitive position, business, financial condition, results of operations and prospects. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We may not be able to protect our intellectual property rights throughout the world. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Filing, prosecuting, maintaining, defending and enforcing patents on our drug candidates in all countries throughout the world would be prohibitively expensive, and consequently our intellectual property rights in
some countries outside the United States may be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United
States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other
jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patents to develop their own products and may export otherwise infringing products to territories where we have patents, but enforcement rights are not
as strong as those in the United States. These products may compete with our drug candidates and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of some
countries do not favor the enforcement or protection of patents, trade secrets and other intellectual property, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our
intellectual property and proprietary rights generally. Proceedings to enforce our intellectual property rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could
put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages
or other remedies awarded, if any, may not be commercially meaningful. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Many foreign countries, including some EU countries, India, Japan and China, have
compulsory licensing laws under which a patent owner may be compelled under specified circumstances to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government
contractors. In those countries, we may have limited remedies if patents are infringed or if we are compelled to grant a license to a third party, which could materially diminish the value of the applicable patents and limit our potential revenue
opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we
</FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">63 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
develop or license, which could adversely affect our business, financial condition, results of operations and prospects. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our drug candidates. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Obtaining and enforcing patents in the pharmaceutical industry is inherently uncertain, due in part to ongoing changes in the patent laws. For example, in the United States, depending on decisions by Congress, the
federal courts, and the USPTO, the laws and regulations governing patents, and interpretation thereof, could change in unpredictable ways that could weaken our and our collaborators’ or licensors’ ability to obtain new patents or to
enforce existing or future patents. For example, the U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in
certain situations. Therefore, there is increased uncertainty with regard to our and our collaborators’ or licensors’ ability to obtain patents in the future, as well as uncertainty with respect to the value of patents once obtained.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our and our collaborators’ or licensors’
patent applications and the enforcement or defense of our or our collaborators’ or licensors’ issued patents. For example, assuming that other requirements for patentability are met, prior to March 2013, in the United States, the first to
invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. After March 2013, under the Leahy-Smith America Invents Act (the Leahy-Smith Act), enacted
in September 2011, the United States transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention
regardless of whether a third party was the first to invent the claimed invention. The Leahy-Smith Act also includes a number of significant changes that affect the way patent applications are prosecuted and may also affect patent litigation. These
include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to challenge the validity of a patent by USPTO-administered post-grant proceedings, including post-grant review, <I>inter
partes</I> review and derivation proceedings. The USPTO has developed new regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, particularly
the first <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">inventor-to-file</FONT></FONT> provisions. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the
Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our or our licensors’ patent applications and the enforcement or defense of our or our licensors’ issued patents. Similarly,
statutory or judicial changes to the patent laws of other countries may increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. All of the foregoing could harm our
business, financial condition, results of operations and prospects. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We may become involved in lawsuits to protect or enforce our patents or other
intellectual property, which could be expensive, time-consuming and unsuccessful, and issued patents directed towards our technology and drug candidates could be found invalid or unenforceable if challenged. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Competitors and other third parties may infringe or otherwise violate our issued patents or other intellectual property or the patents or other intellectual
property of our licensors and collaborators. In addition, our patents or the patents of our licensors and collaborators may become involved in inventorship or priority disputes. To counter infringement or other unauthorized use, we may be required
to file infringement claims, which can be expensive and time-consuming. Significantly, our pending patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues
from such applications. Our ability to enforce patent rights also depends on our ability to detect infringement. It </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">64 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
may be difficult to detect infringers who do not advertise the components or methods that are used in connection with their products and services. Moreover, it may be difficult or impossible to
obtain evidence of infringement in a competitor’s or potential competitor’s product or service. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe
their patents or that our patents are invalid or unenforceable. In a patent infringement proceeding, a court may decide that a patent of ours is invalid or unenforceable, in whole or in part, construe the patent’s claims narrowly or refuse to
stop the other party from using the technology at issue on the grounds that our patents do not cover the technology. An adverse result in any litigation proceeding could put one or more of our owned or licensed patents at risk of being invalidated,
held unenforceable or interpreted narrowly. We may find it impractical or undesirable to enforce our intellectual property against some third parties. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If we were to initiate legal proceedings against a third party to enforce a patent directed to our drug candidates, or one of our future drug candidates, the
defendant could counterclaim that our patent is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an
alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, <FONT STYLE="white-space:nowrap">non-enablement</FONT> or insufficient written description. Grounds for an unenforceability assertion could be an
allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. Third parties may also raise similar claims before the USPTO or an equivalent foreign
body, even outside the context of litigation. Potential proceedings include reexamination, post-grant review, inter partes review, interference proceedings, derivation proceedings and equivalent proceedings in foreign jurisdictions (e.g., opposition
proceedings). Such proceedings could result in the revocation of, cancellation of, or amendment to our patents in such a way that they no longer cover our technology or any drug candidates that we may develop. The outcome following legal assertions
of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art of which we and the patent examiner were unaware during prosecution. If a defendant
were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent rights directed towards the applicable drug candidates or technology related to the patent rendered invalid or
unenforceable. Such a loss of patent rights would materially harm our business, financial condition, results of operations and prospects. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Interference
proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications. An unfavorable outcome could require us to cease using the
related technology or to attempt to license rights to it from the prevailing party. Our business could be materially harmed if the prevailing party does not offer us a license on commercially reasonable terms. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our
confidential information could be compromised by disclosure during this type of litigation. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Some of our competitors are larger than we are and have
substantially greater resources. They are, therefore, likely to be able to sustain the costs of complex patent litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed
intellectual property portfolios. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing, misappropriating or otherwise violating our intellectual property. Even if resolved in our favor, litigation or other
legal proceedings relating to intellectual property claims could result in substantial costs and diversion of management resources, which could harm our business. In addition, the uncertainties associated with litigation could compromise our ability
to raise the funds necessary to continue our clinical trials, continue our internal research programs, or <FONT STYLE="white-space:nowrap">in-license</FONT> needed technology or other drug candidates. There could also be public
</FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">65 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
announcements of the results of the hearing, motions, or other interim proceedings or developments. If securities analysts or investors perceive those results to be negative, it could cause the
price of shares of our common stock to decline. Any of the foregoing events could harm our business, financial condition, results of operation and prospects. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could
negatively impact the success of our business. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our commercial success depends upon our ability to develop, manufacture, market and sell our drug
candidates and use our proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property and other proprietary rights of third parties. There is considerable intellectual property litigation in the
pharmaceutical industry. We may become party to, or threatened with, future adversarial proceedings or litigation regarding intellectual property rights with respect to our drug candidates and their manufacture and our other technology, including
reexamination, interference, post-grant review, inter partes review or derivation proceedings before the USPTO or an equivalent foreign body. Numerous U.S.- and foreign-issued patents and pending patent applications owned by third parties exist in
the fields in which we are developing our drug candidates. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of their merit. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Even if we believe third-party intellectual property claims are without merit, there is no assurance that a court would find in our favor on questions of claim
scope, infringement, validity, enforceability or priority. A court of competent jurisdiction could hold that third-party patents asserted against us are valid, enforceable and infringed, which could materially and adversely affect our ability to
commercialize any drug candidates we may develop and any other drug candidates or technologies covered by the asserted third-party patents. In order to successfully challenge the validity of any such U.S. patent in federal court, we would need to
overcome a presumption of validity. As this burden is a high one requiring us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction would invalidate
the claims of any such U.S. patent. If we are found to infringe, misappropriate or otherwise violate a third party’s intellectual property rights, and we are unsuccessful in demonstrating that such rights are invalid or unenforceable, we could
be required to obtain a license from such a third party in order to continue developing and marketing our products and technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were
able to obtain a license, it could be or may become <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors access to the same technologies licensed to us. We could be forced, including by court order, to cease
commercializing the infringing technology or product. A finding of infringement could prevent us from commercializing our drug candidates or force us to cease some of our business operations. In the event of a successful claim of infringement
against us, we may have to pay substantial damages, including treble damages and attorneys’ fees for willful infringement, pay royalties and other fees, redesign our infringing drug candidate or obtain one or more licenses from third parties,
which may be impossible or require substantial time and monetary expenditure. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business. Any of the
foregoing events would harm our business, financial condition, results of operations and prospects. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We may be subject to claims by third parties
asserting that we or our employees have infringed, misappropriated or otherwise violated their intellectual property rights, or claiming ownership of what we regard as our own intellectual property. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Many of our employees were previously employed at other biotechnology or pharmaceutical companies. Although we try to ensure that our employees, consultants and
advisors do not use the proprietary information or <FONT STYLE="white-space:nowrap">know-how</FONT> of others in their work for us, we may be subject to claims that we or these individuals have used
</FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">66 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual’s former employer. We may also be subject to claims that patents and
applications we have filed to protect inventions made on our behalf by our employees, consultants and advisors, even those related to one or more of our drug candidates, are rightfully owned by their former or concurrent employer. Litigation may be
necessary to defend against these claims. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose
valuable intellectual property rights or personnel. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs, delay development of our drug candidates and be a distraction to management.
Any of the foregoing events would harm our business, financial condition, results of operations and prospects. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We may be subject to claims
challenging the inventorship of our patents and other intellectual property. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We or our licensors may be subject to claims that former employees,
collaborators or other third parties have an interest in our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents, trade secrets, or other intellectual property as an inventor or <FONT STYLE="white-space:nowrap">co-inventor.</FONT>
For example, we or our licensors or collaborators may have inventorship disputes arising from conflicting obligations of employees, consultants or others who are involved in developing our drug candidates. While it is our policy to require our
employees and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops
intellectual property that we regard as our own. Our and their assignment agreements may not be self-executing or may be breached, and litigation may be necessary to defend against these and other claims challenging inventorship or our or our
licensors’ or collaborators’ ownership of our owned or in-licensed patents, trade secrets or other intellectual property. If we or our licensors or collaborators fail in defending any such claims, in addition to paying monetary damages, we
may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our drug candidates. Even if we are successful in defending against such claims, litigation could result in
substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Intellectual property rights do not necessarily address all potential threats. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The degree of future protection, if any, afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to
maintain our competitive advantage. For example: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">others may be able to make products that are similar to any drug candidates we may develop or utilize similar technology but that are not covered by the claims
of the patents that we license or may own in the future; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we, or our current or future licensors or collaborators might not have been the first to make the inventions covered by the issued patent or pending patent
application that we license or may own in the future; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we, or our current or future licensors or collaborators might not have been the first to file patent applications covering certain of our or their inventions;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or licensed intellectual
property rights; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">it is possible that our pending owned or licensed patent applications or those that we may own or license in the future will not lead to issued patents;
</FONT></P></TD></TR></TABLE>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">67 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such
activities to develop competitive products for sale in our major commercial markets; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we may not develop additional proprietary technologies that are patentable; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the intellectual property rights of others may harm our business; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we may choose not to file a patent in order to maintain certain trade secrets or <FONT STYLE="white-space:nowrap">know-how,</FONT> and a third party may
subsequently file a patent directed to such intellectual property. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Should any of these events occur, they could harm our business,
financial condition, results of operations and prospects. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Risks related to employee matters, managing our growth and other risks related to our
business </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We are highly dependent on our key personnel, and if we are not successful in attracting, motivating and retaining highly qualified
personnel, we may not be able to successfully implement our business strategy. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are highly dependent on our management, scientific and medical
personnel, including our Chief Executive Officer, Dr. Blatt, and our President, Dr. Beigelman. The loss of the services of any of them may adversely impact the achievement of our objectives. Any of our executive officers could leave our
employment at any time, as all of our employees are <FONT STYLE="white-space:nowrap">“at-will”</FONT> employees. We currently do not have “key person” insurance on any of our employees. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Recruiting and retaining qualified employees, consultants and advisors for our business, including scientific and technical personnel, also will be critical to our
success. Competition for skilled personnel is intense and the turnover rate can be high. We may not be able to attract and retain personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies and
academic institutions for skilled individuals. In addition, failure to succeed in nonclinical studies, clinical trials or applications for marketing approval may make it more challenging to recruit and retain qualified personnel. The inability to
recruit, or the loss of services of certain executives, significant employees, consultants or advisors, may impede the progress of our research, development and commercialization objectives and have a material adverse effect on our business,
financial condition, results of operations and prospects. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We currently have no sales organization. If we are unable to establish sales
capabilities on our own or through third parties, we may not be able to market and sell any products effectively, if approved, or generate product revenue. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We currently do not have a marketing or sales organization. In order to commercialize any product, if approved, in the United States and foreign jurisdictions, we must build our marketing, sales, distribution,
managerial and other <FONT STYLE="white-space:nowrap">non-technical</FONT> capabilities or make arrangements with third parties to perform these services, and we may not be successful in doing so. In advance of any of our drug candidates receiving
regulatory approval, we expect to establish a sales organization with technical expertise and supporting distribution capabilities to commercialize each such drug candidate, which will be expensive and time-consuming. We have no prior experience in
the marketing, sale and distribution of pharmaceutical products, and there are significant risks involved in building and managing a sales organization, including our ability to hire, retain, and incentivize qualified individuals, generate
sufficient sales leads, provide adequate training to sales and marketing </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">68 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
personnel, and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would
adversely impact the commercialization of our drug candidates. We may choose to collaborate with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in
lieu of our own sales force and distribution systems. If we are unable to enter into such arrangements on acceptable terms or at all, we may not be able to successfully commercialize our drug candidates. If we are not successful in commercializing
products, either on our own or through arrangements with one or more third parties, we may not be able to generate any future product revenue and we would incur significant additional losses. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>We will need to grow the size of our organization, and we may experience difficulties in managing this growth. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">As of March 31, 2021, we had 80 full-time employees, including 64 employees engaged in research and development. As our development and commercialization plans and strategies develop, and as we transition into
operating as a public company, we expect to need additional managerial, operational, sales, marketing, financial and other personnel. Future growth would impose significant added responsibilities on members of management, including: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">identifying, recruiting, integrating, maintaining and motivating additional employees; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">managing our internal development efforts effectively, including the clinical and FDA review process for our current drug candidates and any other drug candidate
we develop, while complying with our contractual obligations to contractors and other third parties; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">expanding and enhancing our operational, financial and management controls, reporting systems and procedures. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our future financial performance and our ability to advance development of and, if approved, commercialize our current drug candidates and any other drug candidate
we develop will depend, in part, on our ability to effectively manage any future growth, and our management may also have to divert a disproportionate amount of its attention away from
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities in order to devote a substantial amount of time to managing these growth activities. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants to provide certain services, including substantially all
aspects of marketing, clinical management, and manufacturing. We cannot assure you that the services of independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed or at a reasonable cost, or
that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, our nonclinical studies and
clinical trials may be extended, delayed or terminated, and we may not be able to obtain marketing approval of any current or future drug candidates or otherwise advance our business. We cannot assure you that we will be able to manage our existing
consultants or find other competent outside contractors and consultants on economically reasonable terms, or at all. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If we are not able to effectively
expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may experience delays or may not be able to successfully implement the tasks necessary to further develop and commercialize our current drug
candidates and any future drug candidates we develop and, accordingly, may not achieve our research, development and commercialization goals. </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">69 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>If we fail to comply with environmental, health and safety laws and regulations, we could become subject to
fines or penalties or incur costs that could have a material adverse effect on the success of our business. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are subject to numerous
environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and
flammable materials, including chemicals and biological and radioactive materials. Our operations also produce hazardous waste products. We cannot eliminate the risk of contamination or injury from these materials, and we generally contract with
third parties for the disposal of these materials and wastes. In the event of contamination or injury resulting from our use or third-party disposal of hazardous materials, we could be held liable for any resulting damages, and any liability could
exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Although we maintain workers’
compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain
insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials, and as such we would have to pay the full amount of any
resultant liability out of pocket, which could significantly impair our financial condition. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We or the third parties upon whom we depend may be
adversely affected by earthquakes or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Our corporate headquarters and other facilities are located in the San Francisco Bay Area, which in the past has experienced both severe earthquakes and wildfires. We are also conducting our initial clinical trials
for <FONT STYLE="white-space:nowrap">ALG-010133</FONT> and <FONT STYLE="white-space:nowrap">ALG-000184</FONT> in New Zealand, an area also known for earthquakes. We do not carry earthquake insurance, and as such we would have to pay the full amount
of any resultant liability out of pocket, which could significantly impair our financial condition. In addition, earthquakes, wildfires or other natural disasters could severely disrupt our operations. If a natural disaster, power outage or other
event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as our enterprise financial systems or manufacturing resource planning and enterprise quality systems, that
delayed our clinical trials, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have
in place currently are limited and are unlikely to prove adequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which,
particularly when taken together with our lack of earthquake insurance, could have a material adverse effect on our business, results of operations, financial condition and prospects. Furthermore, integral parties in our supply chain are similarly
vulnerable to natural disasters or other sudden, unforeseen and severe adverse events. If such an event were to affect our supply chain, it could have a material adverse effect on our business. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Our employees, independent contractors, vendors, principal investigators, CROs, consultants and collaborators may engage in misconduct or other improper
activities, including <FONT STYLE="white-space:nowrap">non-compliance</FONT> with regulatory standards and requirements and insider trading. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We
are exposed to the risk that our employees, independent contractors, vendors, principal investigators, CROs, consultants and collaborators may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include
intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violate the regulations of the FDA and comparable foreign regulatory authorities, including those laws
</FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">70 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
requiring the reporting of true, complete and accurate information to such authorities; healthcare fraud and abuse laws and regulations in the United States and abroad; or laws that require the
reporting of financial information or data accurately. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing
and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to
these laws also involve the improper use of information obtained in the course of clinical trials or creating fraudulent data in our nonclinical studies or clinical trials, which could result in regulatory sanctions and cause serious harm to our
reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or
in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. Additionally, we are subject to the risk that a person could allege such fraud or other misconduct, even
if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and
administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of
our operations, any of which could adversely affect our ability to operate our business and our results of operations. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Risks related to our common
stock and this offering </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>If you purchase our common stock in this offering, you will incur immediate and substantial dilution in the book value
of your shares. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The public offering price of our common stock is substantially higher than the as adjusted net tangible book value per share of
our common stock. Therefore, if you purchase our common stock in this offering, you will pay a price per share that substantially exceeds the as adjusted net tangible book value per share after the completion of this offering. Based on an assumed
public offering price of $ per share, which is the last reported sale price of our common stock on the Nasdaq Global Select Market on
, 2021, you will experience immediate dilution of $ per
share, representing the difference between our as adjusted net tangible book value per share as of March 31, 2021 and the assumed public offering price. Furthermore, if the underwriters exercise their option to purchase additional shares, or
outstanding options are exercised, you could experience further dilution. See “Dilution” for a more detailed description of the dilution to new investors in the offering. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>The price of our common stock has been volatile and our stockholders may not be able to resell shares of our common stock at or above the price they paid. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our stock price has been volatile. The stock market in general and the market for biopharmaceutical companies in particular have experienced extreme volatility that
has often been unrelated to the operating performance of particular companies. The ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, for example, has negatively affected the stock market and investor sentiment and has resulted in
significant volatility. The market price for our common stock may be influenced by many factors, including: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the success of our and competitive products or technologies; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">results of clinical trials and nonclinical studies or those of our competitors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">regulatory or legal developments in the United States and other countries; </FONT></P></TD></TR></TABLE>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">71 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">developments or disputes concerning patent applications, issued patents or other proprietary rights; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the recruitment or departure of key personnel; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the level of expenses related to our drug candidates or clinical development programs; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the results of our efforts to discover, develop, acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> drug candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">variations in our financial results or those of companies that are perceived to be similar to us; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">changes in the structure of healthcare payment systems; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">market conditions in the pharmaceutical and biotechnology sectors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">general economic, political, and market conditions and overall fluctuations in the financial markets in the United States and abroad;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">developments related to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">investors’ general perception of us and our business. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">These and other market and industry factors may cause the market price and demand for our common stock to fluctuate substantially, regardless of our actual operating performance, which may limit or prevent
investors from selling their shares at or above the price paid for the shares and may otherwise negatively affect the liquidity of our common stock. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Some companies that have experienced volatility in the trading price of their shares have been the subject of securities class action litigation. Any lawsuit to
which we are a party, with or without merit, may result in an unfavorable judgment. We also may decide to settle lawsuits on unfavorable terms. Any such negative outcome could result in payments of substantial damages or fines, damage to our
reputation or adverse changes to our business practices. Defending against litigation is costly and time-consuming, and could divert our management’s attention and our resources. Furthermore, during the course of litigation, there could be
negative public announcements of the results of hearings, motions or other interim proceedings or developments, which could have a further negative effect on the market price of our common stock. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>An active trading market for our common stock may not be sustained. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Prior to our initial public offering in October 2020, there was no public market for shares of our common stock and an active trading market for our shares may not be sustained. In the absence of an active trading
market for our common stock, investors may not be able to sell their common stock at a price or at the time that they would like to sell. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">An inactive
market may also impair our ability to raise capital by selling shares and may impair our ability to acquire other drug candidates, businesses, or technologies using our shares as consideration. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We do not intend to pay cash dividends on our common stock so any returns will be limited to the value of our stock. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We do not intend to pay any cash dividends on our common stock for the foreseeable future. We currently intend to invest our future earnings, if any, to fund our
growth. Therefore, investors are not likely to receive any dividends on common stock owned by them for the foreseeable future. Since we do not intend to pay dividends, an investor’s ability to receive a return on its investment will depend on
any future appreciation in the market value of our common stock. There is no guarantee that our common stock will appreciate or even maintain the price at which our holders purchased it. </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">72 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We are an emerging growth company and a smaller reporting company, and we cannot be certain if the reduced
reporting requirements applicable to emerging growth companies and smaller reporting companies will make our common stock less attractive to investors. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the JOBS Act). For as long as we continue to be an emerging growth company, we may take advantage of exemptions from
various reporting requirements that are applicable to other public companies that are not emerging growth companies, including the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, certain disclosure obligations
regarding executive compensation and the requirements of holding nonbinding advisory votes on executive compensation and stockholder approval of any golden parachute payments not previously approved. We will remain an emerging growth company until
the earlier of (1) December 31, 2025, (2) the last day of the fiscal year in which we have total annual gross revenue of at least $1.07 billion, (3) the last day of the fiscal year in which we are deemed to be a large accelerated
filer, which requires the market value of our common stock that is held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> to exceed $700.0 million as of the prior June 30th, or (4) the date on which we have issued more than
$1.0 billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt during the prior three-year period. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Under the JOBS Act, emerging
growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have elected to use the extended transition period for any other new or revised accounting standards
during the period in which we remain an emerging growth company; however, we may adopt certain new or revised accounting standards early. As a result, changes in rules of U.S. generally accepted accounting principles or their interpretation, the
adoption of new guidance or the application of existing guidance to changes in our business could significantly affect our financial position and results of operations. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Even after we no longer qualify as an emerging growth company, we may continue to qualify as a smaller reporting company, which would allow us to rely on certain reduced disclosure requirements, such as an
exemption from providing selected financial data and executive compensation information. We are also exempt from the requirement to obtain an external audit on the effectiveness of internal control over financial reporting provided in
Section 404(b) of the Sarbanes-Oxley Act. These exemptions and reduced disclosures due to our status as a smaller reporting company mean that our auditors do not review our internal controls over financial reporting and may make it harder for
investors to analyze our results of operations and financial prospects. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We cannot predict if investors will find our common stock less attractive
because we may rely on these exemptions as an emerging growth company and a smaller reporting company. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock
price may be more volatile. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Our executive officers, directors and their affiliates have significant influence over our company, which will limit
an investor’s ability to influence corporate matters and could delay or prevent a change in corporate control. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As of March 31, 2021,
our executive officers, directors and their affiliates beneficially own, in the aggregate, approximately 60.7% of our outstanding common stock (assuming all shares of <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock are converted into
voting common stock in accordance with the terms of our amended and restated certificate of incorporation). As a result, these stockholders, if they act together, will be able to influence our management and affairs and the outcome of matters
submitted to our stockholders for approval, including the election of directors and any sale, merger, consolidation or sale of all or substantially all of our assets. In addition, this concentration of ownership might adversely affect the market
price of our common stock by: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">delaying, deferring or preventing a change of control of us; </FONT></P></TD></TR></TABLE>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">73 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">impeding a merger, consolidation, takeover or other business combination involving us; or </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of us. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>The dual class structure of our common stock may limit an investor’s ability to influence corporate matters and may limit the visibility with respect to
certain transactions. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The dual class structure of our common stock may limit an investor’s ability to influence corporate matters. Holders
of our common stock are entitled to one vote per share, while holders of our <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock are not entitled to any votes. Nonetheless, each share of our
<FONT STYLE="white-space:nowrap">non-voting</FONT> common stock may be converted at any time into one share of our common stock at the option of its holder by providing written notice to us, subject to the limitations provided for in our amended and
restated certificate of incorporation. Consequently, the exercise by holders of our <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock of their option to make this conversion will have the effect of increasing the relative voting power
of such holders, and correspondingly decreasing the voting power of the holders of our common stock, which may limit an investor’s ability to influence corporate matters. As of March 31, 2021, we had 3,092,338 shares of <FONT
STYLE="white-space:nowrap">non-voting</FONT> common stock outstanding, which as of such date represented 8.1% our total outstanding shares of common stock. Additionally, stockholders who hold, in the aggregate, more than 10% of our common stock and <FONT
STYLE="white-space:nowrap">non-voting</FONT> common stock, but 10% or less of our common stock, and are not otherwise a company insider, may not be required to report changes in their ownership due to transactions in our <FONT
STYLE="white-space:nowrap">non-voting</FONT> common stock pursuant to Section 16(a) of the Exchange Act of 1934, as amended (the Exchange Act), and may not be subject to the short-swing profit provisions of Section 16(b) of the Exchange
Act. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market, the market price of our common
stock could decline. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As of March 31, 2021, approximately 8,740,647 shares of common stock that are either subject to outstanding options or
reserved for future issuance under our equity incentive plans are eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules, <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements entered into
with the underwriters by our executive officers, directors and certain affiliated stockholders in connection with this offering, and Rule 144 and Rule 701 under the Securities Act. If these additional shares of common stock are sold, or if
it is perceived that they will be sold, in the public market, the market price of our common stock could decline. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, the holders of
approximately 16.3 million shares of our common stock and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock, are entitled to rights with respect to the registration of their shares under the Securities Act described above.
Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act, except for shares purchased by affiliates. Any sales of securities by these stockholders could
have a material adverse effect on the market price of our common stock. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We have broad discretion in how we use the proceeds of this offering and
may not use these proceeds effectively, which could affect our results of operations and cause our stock price to decline. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We will have
considerable discretion in the application of the net proceeds from this offering. As a result, investors will be relying upon management’s judgment with only limited information about our specific intentions for the use of the net proceeds
from this offering. We may use the net proceeds from this offering for purposes that do not yield a significant return or any return at all for our stockholders. In addition, pending their use, we may invest the net proceeds from this offering in a
manner that does not produce income or that loses value. </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">74 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Our ability to utilize our net operating loss carryforwards and certain other tax attributes will be
limited. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the Code), and corresponding provisions of state law,
if a corporation undergoes an “ownership change” (generally defined as a greater than 50 percentage point change (by value) in its equity ownership over a rolling three-year period), the corporation’s ability to use its <FONT
STYLE="white-space:nowrap">pre-change</FONT> net operating loss (NOL) carryforwards and other <FONT STYLE="white-space:nowrap">pre-change</FONT> tax attributes to offset its post-change income may be limited. We performed a Section 382 analysis
in 2020 and determined there was an ownership change that resulted in Section 382 limitations. The ownership change will limit our ability to utilize net operating losses against future taxable income but is not expected to result in any NOLs
expiring unused. We may in the future experience ownership changes as a result of changes in our stock ownership (some of which are not in our control). In addition, under current tax law, federal NOL carryforwards generated in periods after
December 31, 2017, may be carried forward indefinitely but, in taxable years beginning after December 31, 2020, may only be used to offset 80% of our taxable income in any year. For these reasons, our ability to utilize our NOL
carryforwards and other tax attributes to reduce future tax liabilities will be limited. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>If securities analysts do not publish research or reports
about our business or if they publish negative evaluations of our stock, the price of our stock could decline. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The trading market for our common
stock relies, in part, on the research and reports that industry or financial analysts publish about us or our business. If no or few analysts commence coverage of us, the trading price of our stock would likely decrease. If one or more of the
analysts covering our business downgrade their evaluations of our stock or if we fail to meet their published expectations for us, the price of our stock could decline. If one or more of these analysts cease to cover our stock, we could lose
visibility in the market for our stock, which, in turn, could cause our stock price to decline. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>If we fail to implement and maintain proper and
effective internal control over financial reporting, our ability to produce accurate and timely financial statements could be impaired, investors may lose confidence in our financial reporting and the trading price of our common stock may decline.
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Pursuant to Section 404 of Sarbanes-Oxley, our management will be required to report upon the effectiveness of our internal control over
financial reporting beginning with the annual report for our fiscal year ending December 31, 2021. When we lose our status as an “emerging growth company,” our independent registered public accounting firm will be required to attest
to the effectiveness of our internal control over financial reporting. The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation,
testing and possible remediation. To comply with the requirements of being a reporting company under the Exchange Act, we will need to implement additional financial and management controls, reporting systems and procedures and hire additional
accounting and finance staff, all of which will entail additional expense. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We cannot assure you that there will not be material weaknesses in our
internal control over financial reporting in the future. Any failure to implement and maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash
flows. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness in our internal control over financial reporting,
investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities.
Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.
</FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">75 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may
consider favorable and may lead to entrenchment of management. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our amended and restated certificate of incorporation and amended and restated
bylaws contain provisions that could delay or prevent changes in control or changes in our management without the consent of our board of directors. These provisions include the following: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">a classified board of directors with three-year staggered terms, which may delay the ability of stockholders to change the membership of a majority of our board
of directors; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the exclusive right of our board of directors to elect a director to fill a vacancy created by the expansion of the board of directors or the resignation, death
or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the price and other terms of those shares,
including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquiror; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the ability of our board of directors to alter our amended and restated bylaws without obtaining stockholder approval; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the required approval of at least 66 2/3% of the shares entitled to vote at an election of directors to adopt, amend or repeal our amended and restated bylaws or
repeal the provisions of our amended and restated certificate of incorporation regarding the election and removal of directors; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the requirement that a special meeting of stockholders may be called only by our chief executive officer or, in the absence of a chief executive officer,
president or by the board of directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or to propose matters to be acted upon at
a stockholders’ meeting, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror’s own slate of directors or otherwise attempting to obtain control of us.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are also subject to the anti-takeover provisions contained in Section 203 of the Delaware General Corporation Law. Under
Section 203, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among other exceptions, the board of directors has
approved the transaction. For a description of our capital stock, see the section titled “Described of capital stock.” </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Claims for
indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Our amended and restated certificate of incorporation and amended and restated bylaws provide that we will indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law.
</FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">76 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, as permitted by Section 145 of the Delaware General Corporation Law, our amended and restated
bylaws and our indemnification agreements that we have entered into with our directors and officers provide that: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we will indemnify our directors and officers for serving us in those capacities or for serving other business enterprises at our request, to the fullest extent
permitted by Delaware law. Delaware law provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the registrant and,
with respect to any criminal proceeding, had no reasonable cause to believe such person’s conduct was unlawful; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we are required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such directors or officers
shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we will not be obligated pursuant to our amended and restated bylaws to indemnify a person with respect to proceedings initiated by that person against us or our
other indemnitees, except with respect to proceedings authorized by our board of directors; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the rights conferred in our amended and restated bylaws are not exclusive, and we are authorized to enter and have entered into indemnification agreements with
our directors, officers, employees and agents and to obtain insurance to indemnify such persons; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we may not retroactively amend our amended and restated bylaw provisions to reduce our indemnification obligations to directors, officers, employees and agents.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Our amended and restated certificate of incorporation provides for an exclusive forum in the Court of Chancery of the State of
Delaware for certain disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our amended and restated certificate of incorporation specifies that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery
of the State of Delaware is the sole and exclusive forum for any derivative action or proceeding brought on our behalf; any action asserting a breach of fiduciary duty; any action asserting a claim against us arising pursuant to the Delaware General
Corporation Law, our amended and restated certificate of incorporation, our amended and restated bylaws or any action as to which the Delaware General Corporation Law confers jurisdiction to the Court of Chancery of the State of Delaware; or any
action asserting a claim against us that is governed by the internal affairs doctrine. Our amended and restated certificate of incorporation also provides that the federal district courts of the United States of America is the exclusive forum for
the resolution of any complaint asserting a cause of action against us or any of our directors, officers, employees or agents and arising under the Securities Act. We believe these provisions may benefit us by providing increased consistency in the
application of Delaware law and federal securities laws by chancellors and judges, as applicable, particularly experienced in resolving corporate disputes, efficient administration of cases on a more expedited schedule relative to other forums and
protection against the burdens of multi-forum litigation. However, these provisions may have the effect of discouraging lawsuits against our directors and officers. The choice of forum provision requiring that the Court of Chancery of the State of
Delaware or the federal district courts of the United States of America be the exclusive forum for certain actions does not apply to suits brought to enforce any liability or duty created by the Exchange Act. Our exclusive forum provision does not
relieve us of our duties to comply with the federal securities laws and the </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">77 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
rules and regulations thereunder, and our stockholders will not be deemed to have waived our compliance with these laws, rules and regulations. Although our amended and restated certificate of
incorporation contains the choice of forum provisions described above, it is possible that a court could find that such a provision is inapplicable for a particular claim or action or that such provision is unenforceable. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>General risk factors </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Raising additional capital may
cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">To date, we have primarily
financed our operations through the sale of common stock, preferred stock and convertible notes. We will be required to seek additional funding in the future and may to do so through public or private equity offerings or debt financings, credit or
loan facilities, collaborations or a combination of one or more of these funding sources. If we raise additional funds by issuing equity securities, our stockholders may suffer dilution and the terms of any equity financing may adversely affect the
rights of our stockholders. In addition, as a condition to providing additional funds to us, future investors may demand, and may be granted, rights superior to those of existing stockholders. Debt financing, if available, is likely to involve
restrictive covenants limiting our flexibility in conducting future business activities, and, in the event of insolvency, debt holders would be repaid before holders of our equity securities received any distribution of our corporate assets. If we
raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish certain valuable rights to our drug candidates,
technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable to us. Attempting to secure additional financing may also divert our management’s attention from our
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities, which may adversely affect our ability to develop our drug candidates. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Unfavorable global economic conditions could adversely affect our business, financial condition, stock price and results of operations. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. For example, the 2008 global financial crisis caused extreme volatility and
disruptions in the capital and credit markets. A severe or prolonged economic downturn, such as the 2008 global financial crisis, could result in a variety of risks to our business, including, weakened demand for any drug candidates we may develop
and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption. If the current equity and credit markets deteriorate, it
may make any necessary debt or equity financing more difficult, more costly, and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy,
financial performance and stock price and could require us to delay or abandon clinical development plans. In addition, there is a risk that one or more of our current service providers, manufacturers or other partners may not survive such difficult
economic times, which could directly affect our ability to attain our operating goals on schedule and on budget. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and
financial market conditions could adversely impact our business. Furthermore, our stock price may decline due in part to the volatility of the stock market and any general economic downturn. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Our insurance policies are expensive and protect us only from some business risks, which leaves us exposed to significant uninsured liabilities. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We do not carry insurance for all categories of risk that our business may encounter. Some of the policies we currently maintain include general liability,
property, umbrella, clinical trials and directors’ and officers’ </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">78 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
insurance. Any additional insurance coverage we acquire in the future may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming
increasingly expensive and in the future we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. Any significant uninsured liability may require us to pay
substantial amounts, which would adversely affect our cash position and results of operations. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We also expect that operating as a public company will
make it more difficult and more expensive for us to obtain directors’ and officers’ liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar
coverage. As a result, it may be more difficult for us to attract and retain qualified people to serve on our board of directors, our board committees or as executive officers. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>The United Kingdom’s withdrawal from the European Union may have a negative effect on global economic conditions, financial markets and our business. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Following a national referendum and enactment of legislation by the government of the United Kingdom, the United Kingdom formally withdrew from the European Union
and ratified a trade and cooperation agreement governing its future relationship with the European Union. The agreement, which is being applied provisionally from January 1, 2021 until it is ratified by the European Parliament and the Council
of the European Union, addresses trade, economic arrangements, law enforcement, judicial cooperation and a governance framework including procedures for dispute resolution, among other things. Because the agreement merely sets forth a framework in
many respects and will require complex additional bilateral negotiations between the United Kingdom and the European Union as both parties continue to work on the rules for implementation, significant political and economic uncertainty remains about
how the precise terms of the relationship between the parties will differ from the terms before withdrawal. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">These developments, or the perception that
any related developments could occur, have had and may continue to have a material adverse effect on global economic conditions and financial markets, and may significantly reduce global market liquidity, restrict the ability of key market
participants to operate in certain financial markets or restrict our access to capital. Any of these factors could have a material adverse effect on our business, financial condition and results of operations and reduce the price of our common
stock. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and
regulations, violations of which can have serious negative consequences for our business. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">U.S. and foreign anti-corruption, anti-money
laundering, export control, sanctions, and other trade laws and regulations (collectively, Trade Laws), prohibit, among other matters, companies and their employees, agents, clinical research organizations, legal counsel, accountants, consultants,
contractors, and other partners from authorizing, promising, offering, providing, soliciting, or receiving directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector.
Violations of Trade Laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, and reputational harm, among other
consequences. We routinely have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations, and we expect our
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> activities to increase in time. We plan to engage third parties for clinical trials and/or obtain necessary permits, licenses, patent registrations, and other regulatory approvals from such officials,
employees and government agencies and affiliates and we may be held liable for any corrupt or other illegal activities of our personnel, agents, or partners, even if we do not explicitly authorize or have prior knowledge of such activities.
</FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">79 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Obtaining and maintaining our patent protection depends on compliance with various procedural, document
submission, fee payment and other requirements imposed by governmental patent agencies, and our patent rights, if any, could be reduced or eliminated if we fail to comply with these requirements. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Periodic maintenance fees, renewal fees, annuity fees, and various other fees are required to be paid to the USPTO and foreign patent agencies in several stages
over the lifetime of a patent. In certain circumstances, we rely on our collaborators or licensors to pay these fees. The USPTO and various foreign patent agencies also require compliance with a number of procedural, documentary, fee payment and
other similar requirements during the patent application and prosecution process. <FONT STYLE="white-space:nowrap">Non-compliance</FONT> events that could result in abandonment or lapse of a patent or patent application include failure to respond to
official communications within prescribed time limits, <FONT STYLE="white-space:nowrap">non-payment</FONT> of fees and failure to properly legalize and submit formal documents. While an inadvertent lapse can in some cases be cured by payment of a
late fee or by other means in accordance with the applicable rules, there are situations in which <FONT STYLE="white-space:nowrap">non-compliance</FONT> can result in irrevocable abandonment or lapse of the patent or patent application, resulting in
partial or complete loss of patent rights in the relevant jurisdiction. If we or our licensors fail to maintain the patents and patent applications covering our drug candidates, our competitors might be able to enter the market with similar or
identical products or technology, which would harm our business, financial condition, results of operations and prospects. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Intellectual property
litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Even if resolved in our
favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could
be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our
common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient
financial or other resources to conduct such litigation or proceedings adequately. As noted above, some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater
financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace, including compromising our ability to raise the funds necessary
to continue our clinical trials, continue our research programs, license necessary technology from third parties, or enter into development collaborations that would help us commercialize our drug candidates, if approved. Any of the foregoing events
would harm our business, financial condition, results of operations and prospects. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>If we are unable to protect the confidentiality of our trade
secrets, our business and competitive position would be harmed. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We rely on confidential methodologies and processes and confidentiality
agreements to protect our unpatented <FONT STYLE="white-space:nowrap">know-how,</FONT> technology and other proprietary information and to maintain our competitive position. Trade secrets and <FONT STYLE="white-space:nowrap">know-how</FONT> can be
difficult to protect. We seek to protect these trade secrets and other proprietary technology, in part, by entering into <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with parties who have access to them, such
as our employees, licensors, collaborators, CROs, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. We cannot
guarantee that we have entered into such agreements with each party that may have or has had access to our trade secrets or proprietary technology and processes. Despite these efforts, any of these parties may breach the agreements and disclose our
proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">80 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
breaches. Unauthorized parties may also attempt to copy or reverse engineer certain aspects of our drug candidates that we consider proprietary. Monitoring unauthorized uses and disclosures is
difficult, and we do not know whether the steps we have taken to protect our proprietary information will be effective. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We also seek to preserve the
integrity and confidentiality of our confidential proprietary information by maintaining physical security of our premises and physical and electronic security of our information technology systems, but it is possible that these security measures
could be breached. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are
less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or
information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third party, our competitive position would be materially and adversely harmed. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business
may be adversely affected. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared
generic or determined to be infringing other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential collaborators or customers in our markets of interest. At
times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims
brought by owners of other trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names,
then we may not be able to compete effectively and our business may be adversely affected. Further, we may license our trademarks and trade names to third parties, such as distributors. Though these license agreements may provide guidelines for how
our trademarks and trade names may be used, a breach of these agreements or misuse of our trademarks and tradenames by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names. Our efforts to
enforce or protect our proprietary rights related to trademarks, trade names, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could
adversely affect our business, financial condition, results of operations and prospects. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We may in the future engage in strategic transactions;
such transactions could affect our liquidity, dilute our existing stockholders, increase our expenses and present significant challenges in focus and energy to our management or prove not to be successful. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">From time to time, we may consider strategic transactions, such as acquisitions of companies, asset purchases and
<FONT STYLE="white-space:nowrap">out-licensing</FONT> or <FONT STYLE="white-space:nowrap">in-licensing</FONT> of intellectual property, products or technologies. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Such potential transactions that we may consider in the future include a variety of business arrangements, including spin-offs, strategic partnerships, joint ventures, restructurings, divestitures, business
combinations, investments and licensings. Any future transactions could result in potentially dilutive issuances of our equity securities, including our common stock, or the incurrence of debt, contingent liabilities, amortization expenses or
acquired <FONT STYLE="white-space:nowrap">in-process</FONT> research and development expenses, any of which could affect our financial condition, liquidity and results of operations. Future acquisitions may also require us to obtain additional
financing, which may not be available on favorable terms or at all. These transactions may never be successful and may require significant time and attention of management. In addition, the integration of any business that we may acquire
</FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">81 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
in the future may disrupt our existing business and may be a complex, risky and costly endeavor for which we may never realize the full benefits of the acquisition. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Public health pandemics or epidemics, political instability, terrorist attacks, other acts of violence or war, or other unexpected events could
materially and adversely impact us. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Public health pandemics or epidemics, political instability, terrorist attacks, other acts of violence
or war or other unexpected events could materially interrupt our business operations (or those of the third parties upon whom we depend), cause consumer confidence and spending to decrease or result in increased volatility in the United
States and worldwide financial markets and economy. They also could result in or prolong an economic recession in the United States. Any of these occurrences could materially and adversely affect us. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Current or future litigation or administrative proceedings could have a material adverse effect on our business, our financial condition and our results of
operations. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We may be involved in legal proceedings, administrative proceedings, claims, and other litigation that arise in the ordinary course
of business. Unfavorable outcomes or developments relating to proceedings to which we are a party or transactions involving our current or future drug candidates, such as judgments for monetary damages, injunctions, or denial or revocation of
permits, could have a material adverse effect on our business, our financial condition, and our results of operations. In addition, settlement of claims could adversely affect our financial condition and our results of operations. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We incur significantly increased costs as a result of operating as a public company, and our management is required to devote substantial time to new
compliance initiatives and corporate governance practices. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As a public company, we are incurring significant legal, accounting and other
expenses that we did not previously incur as a private company. We are subject to the reporting requirements of the Exchange Act, which requires, among other things, that we file with the SEC, annual, quarterly and current reports with respect to
our business and financial condition. In addition, the Sarbanes-Oxley Act, as well as rules subsequently adopted by the SEC and Nasdaq to implement provisions of the Sarbanes-Oxley Act, impose significant requirements on public companies, including
requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. Further, in July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act (the Dodd-Frank Act) was
enacted. There are significant corporate governance and executive compensation-related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas, such as “say on pay” and proxy access.
Recent legislation permits emerging growth companies to implement many of these requirements over a longer period and up to five years from the pricing of the IPO. We intend to take advantage of this legislation, but cannot guarantee that we will
not be required to implement these requirements sooner than budgeted or planned and thereby incur unexpected expenses. Stockholder activism, the current political environment and the current high level of government intervention and regulatory
reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We expect the rules and regulations applicable to public companies to substantially increase our legal and financial compliance costs and to make some activities
more time-consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business, financial condition, results of operations and
prospects. The increased costs will decrease our net income or increase our net loss, and may require us to reduce costs in other areas of our business or increase the prices of our products or services (if approved). For example, we expect these
rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain the same or similar coverage. We
</FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">82 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to
attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We may experience
fluctuations in our tax obligations and effective tax rate, which could materially and adversely affect our results of operations. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are
subject to U.S. federal and state income taxes and taxes in certain other <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions. Tax laws, regulations and administrative practices in various jurisdictions may be subject to significant
change, with or without advance notice, due to economic, political and other conditions, and significant judgment is required in evaluating and estimating our provision and accruals for these taxes. There are many transactions that occur during the
ordinary course of business for which the ultimate tax determination is uncertain. Our effective tax rates could be affected by numerous factors, such as changes in tax, accounting and other laws, regulations, administrative practices, principles
and interpretations, the mix and level of earnings in a given taxing jurisdiction or our ownership or capital structures. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>If we sell shares of our
common stock in future financings, stockholders may experience immediate dilution and, as a result, our stock price may decline. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We may from
time to time issue additional shares of common stock at a discount from the current trading price of our common stock. As a result, our stockholders would experience immediate dilution upon the purchase of any shares of our common stock sold at such
discount. In addition, as opportunities present themselves, we may enter into financing or similar arrangements in the future, including the issuance of debt securities, preferred stock or common stock. If we issue common stock or securities
convertible into common stock, our common stockholders would experience additional dilution and, as a result, our stock price may decline. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>If our
estimates or judgments relating to our critical accounting policies are based on assumptions that change or prove to be incorrect, our operating results could fall below our publicly announced guidance or the expectations of securities analysts and
investors, resulting in a decline in the market price of our common stock. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The preparation of financial statements in conformity with U.S. GAAP
requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe
to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets, liabilities, equity, revenue and expenses that are not readily apparent from other sources. If our assumptions
change or if actual circumstances differ from our assumptions, our operating results may be adversely affected and could fall below our publicly announced guidance or the expectations of securities analysts and investors, resulting in a decline in
the market price of our common stock. </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">83 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="toc166948_4"></A>Special note regarding forward-looking statements </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">This prospectus contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning our business, operations
and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial performance and condition. Any statements contained herein that are not statements of historical facts may be
deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,”
“continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,”
“positioned,” “seek,” “should,” “target,” “will,” “would,” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms
or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:</FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the scope, progress, results and costs of developing our drug candidates or any other future drug candidates, and conducting nonclinical studies and clinical
trials, including our <FONT STYLE="white-space:nowrap">ALG-010133</FONT> and <FONT STYLE="white-space:nowrap">ALG-000184</FONT> Phase 1 clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the scope, progress, results and costs related to the research and development of our pipeline; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the timing of and costs involved in obtaining and maintaining regulatory approval for any of our current or future drug candidates, and any related restrictions
or limitations; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the impact of developments related to <FONT STYLE="white-space:nowrap">COVID-19</FONT> on our business and operations, including clinical trials, manufacturing
suppliers, collaborators, use of contract research organizations and employees; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our expectations regarding the potential market size and size of the potential patient populations for <FONT STYLE="white-space:nowrap">ALG-010133</FONT> and <FONT
STYLE="white-space:nowrap">ALG-000184,</FONT> our other drug candidates and any future drug candidates, if approved for commercial use; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our ability to maintain existing, and establish new, collaborations, licensing or other arrangements and the financial terms of any such agreements;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our commercialization, marketing and manufacturing capabilities and expectations; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the rate and degree of market acceptance of our drug candidates, as well as the pricing and reimbursement of our drug candidates, if approved;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the implementation of our business model and strategic plans for our business, drug candidates and technology, including additional indications for which we may
pursue; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the scope of protection we are able to establish and maintain for intellectual property rights covering our drug candidates, including the projected term of
patent protection; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">estimates of our expenses, future revenue, capital requirements, our needs for additional financing and our ability to obtain additional capital;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">developments and projections relating to our competitors and our industry, including competing therapies and procedures; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">regulatory and legal developments in the United States and foreign countries; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the performance of our third-party suppliers and manufacturers; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our ability to attract and retain key management, scientific and medical personnel; </FONT></P></TD></TR></TABLE>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">84 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our expectations regarding the period during which we will qualify as an emerging growth company under the Jumpstart Our Business Startups Act of 2012;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our use of the net proceeds from this offering; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">other risks and uncertainties, including those listed under the caption “Risk factors” and elsewhere and incorporated by reference in this prospectus.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">These forward-looking statements are based on management’s current expectations, estimates, forecasts and projections about our
business and the industry in which we operate and management’s beliefs and assumptions and are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases
beyond our control. As a result, any or all of our forward-looking statements in, or incorporated by reference in, this prospectus may turn out to be inaccurate. Factors that may cause actual results to differ materially from current expectations
include, among other things, those listed under the section titled “Risk factors” and elsewhere in, or incorporated by reference in, this prospectus. Potential investors are urged to consider these factors carefully in evaluating the
forward-looking statements. These forward-looking statements speak only as of the date of this prospectus. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new
information becomes available in the future. You should, however, review the factors and risks we describe in the reports we will file from time to time with the SEC after the date of this prospectus. See the section titled “Where you can find
more information.”</FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">85 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="toc166948_5"></A>Market and industry data </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">This prospectus, including the information incorporated by reference herein, contains estimates, projections and other information concerning our industry and business, as well as data regarding market research,
estimates and forecasts prepared by our management. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ
materially from events and circumstances that are assumed in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from reports, research surveys, studies and similar data prepared by market
research firms and other third parties, industry, medical and general publications, government data and similar sources. In some cases, we do not expressly refer to the sources from which this data is derived. In that regard, when we refer to one or
more sources of this type of data in any paragraph, you should assume that other data of this type appearing in the same paragraph is derived from the same sources, unless otherwise expressly stated or the context otherwise requires. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">This industry, business, market and other information involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such
estimates. We have not independently verified any third-party information and cannot assure you of its accuracy or completeness. Although we are responsible for all of the disclosure contained in this prospectus and we believe the market position,
market opportunity, market size and other information included or incorporated by reference in this prospectus is reliable, such information is inherently imprecise. In addition, projections, assumptions and estimates of our future performance and
the future performance of the industry in which we operate is necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described in the section titled “Risk factors” and elsewhere in this
prospectus or in the documents incorporated by reference herein. These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by us. </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">86 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="toc166948_6"></A>Use of proceeds </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We estimate that the net proceeds to us from the sale of shares of our common stock in this offering will be approximately
$ million at the assumed public offering price of $ per share, the last reported sale price of our common stock on the Nasdaq Global Select Market
on , 2021, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. If the underwriters exercise their
option to purchase additional shares in full, we estimate that the net proceeds will be approximately $ million at the assumed public offering price of $
per share, the last reported sale price of our common stock on the Nasdaq Global Select Market on , 2021, after deducting the underwriting discounts and
commissions and estimated offering expenses payable by us. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Each $1.00 increase (decrease) in the assumed public offering price of
$ per share, the last reported sale price of our common stock on the Nasdaq Global Select Market on ,
2021, would increase (decrease) the net proceeds to us from this offering, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us, by $ million,
assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same. We may also increase or decrease the number of shares we are offering. Each increase (decrease) of 1,000,000 in the number of
shares we are offering would increase (decrease) the net proceeds to us from this offering, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us, by
$ million, assuming the assumed public offering price stays the same. We do not expect that a change in the offering price or the number of shares by these amounts would have a material effect on our
intended uses of the net proceeds from this offering, although it may impact the amount of time prior to which we may need to seek additional capital. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We currently expect to use the net proceeds from this offering, together with our existing cash, cash equivalents and investments, to fund the continued
advancement, including clinical development and drug manufacturing activities, of our STOPS candidate, ALG-010133, our CAM candidate, ALG-000184, and our ASO candidate, ALG-020572, as well as our nonclinical and research and development activities
for our siRNA candidate, ALG-125755, and our NASH THR-ß candidate, ALG-055009, and to fund discovery and research to broaden our pipeline of drug and backup candidates, as well as for other general corporate purposes, which may include the
hiring of additional personnel, capital expenditures and the costs of operating as a public company. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Due to the uncertainties inherent in the discovery,
nonclinical and clinical development process and related regulatory approval processes, it is difficult to estimate with certainty the exact amounts of the net proceeds from this offering that may be used for the above purposes. As such, our
management will retain broad discretion over the use of the net proceeds from this offering. The amounts and timing of our expenditures may depend upon numerous factors, including: (i) the time and cost necessary to advance our drug candidates
through nonclinical studies and clinical trials; (ii) the time and cost associated with our research and development activities for our pipeline; (iii) the time and cost associated with the manufacture and supply of drug candidates for
clinical development; (iv) our ability to obtain regulatory approval for and subsequently commercialize our drug candidates; and (v) potential payments under our licensing agreements. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We believe that our existing cash, cash equivalents and investments, will enable us to fund our operations for at least 12 months following the date of this
prospectus. After this offering, we will require substantial capital in order to advance our current and future drug candidates through clinical trials, regulatory approval and, if approved, commercialization. For additional information regarding
our potential capital requirements, see “Risk factors—Even if this offering is successful, we will require substantial additional financing to achieve our goals, which may not be available on acceptable terms, or at all. A failure to
obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our product development or commercialization efforts.” </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Pending the use of the proceeds from this offering, we intend to invest the net proceeds in interest-bearing, investment-grade securities, certificates of deposit
or government securities. </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">87 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="toc166948_7"></A>Dividend policy </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We have never declared or paid cash dividends on our capital stock. We intend to retain all available funds and any future earnings, if any, to fund the development and expansion of our business, and we do not
anticipate paying any cash dividends in the foreseeable future. Any future determination related to dividend policy will be made at the discretion of our board of directors and will depend upon, among other factors, our results of operations,
financial condition, capital requirements, contractual restrictions, business prospects and other factors our board of directors might deem relevant. </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">88 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="toc166948_8"></A>Capitalization </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The following table sets forth our cash, cash equivalents and investments and capitalization as of March 31, 2021: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">on an actual basis; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">on an as adjusted basis to give effect to the sale of shares of common stock in this
offering at the assumed public offering price of $ per share, the last reported sale price of our common stock on the Nasdaq Global Select Market
on , 2021 after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">You should read this table together with “Management’s discussion and analysis of financial condition and results of operations” and our consolidated
financial statements and related notes incorporated by reference in this prospectus. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">
<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2px solid #000000"> </TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2px solid #000000"> </TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>As of March 31, 2021</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"> <FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B> Actual</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B> As adjusted(1)</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"> <FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>(in thousands, except share and<BR>per share data)</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cash, cash equivalents and investments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">213,415</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD>
<TD> </TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Stockholders’ equity:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Preferred stock, $0.0001 par value per share; 10,000,000 shares authorized, no shares issued and outstanding, actual; 10,000,000
shares authorized, no shares issued and outstanding, as adjusted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">—</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Common stock, $0.0001 par value per share; 300,000,000 shares authorized, 38,147,205 shares issued and outstanding, actual;
300,000,000 shares authorized, shares issued and outstanding, as adjusted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">Non-voting</FONT> Common Stock, $0.0001 par value per share; 20,000,000 shares authorized, 3,092,338
shares issued and outstanding, actual; 20,000,000 shares authorized, 3,092,338 shares issued and outstanding, as adjusted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">—</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">397,857</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accumulated other comprehensive income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(227</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">) </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accumulated deficit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(202,414</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">) </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD>
<TD> </TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total stockholders’ equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">195,220</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD>
<TD> </TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total capitalization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">195,220</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="top"> <P STYLE="border-bottom:1px solid #000000"> </P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000"> </P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000"> </P></TD>
<TD> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000"> </P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000"> </P></TD>
<TD> </TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD COLSPAN="8" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">A $1.00 increase (decrease) in the assumed public offering price of $ per share, the last reported sale price of our common stock
on the Nasdaq Global Select Market on , 2021 would increase (decrease) the amount of each of cash, cash equivalents and investments, additional <FONT
STYLE="white-space:nowrap">paid-in</FONT> capital, total stockholders’ equity and total capitalization by $ million, assuming the number of shares offered by us, as set forth on the cover page of
this prospectus, remains the same and after deducting underwriting discounts and commissions and estimated offering expenses payable by us. We may also increase or decrease the number of shares we are offering. Each increase (decrease) of 1,000,000
shares in the number of shares offered by us would increase (decrease) each of cash, cash equivalents and investments, additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital, total stockholders’ equity and total capitalization by
$ million, assuming the assumed public offering price of $ per share, the last reported sale price of our common stock on the Nasdaq Global Select Market
on , 2021 remains the same, and after deducting underwriting discounts and commissions and estimated offering expenses payable by us. The as adjusted
information discussed above is illustrative only and will be adjusted based on the actual public offering price and other terms of this offering determined at pricing. </FONT></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The foregoing table and calculations above are based on 38,147,205 shares of common stock outstanding as of March 31, 2021 and exclude the following: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">5,515,723 shares of common stock issuable upon the exercise of outstanding stock options as of March 31, 2021 having a weighted-average exercise price of
$11.40 per share; </FONT></P></TD></TR></TABLE>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">89 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">94,600 shares of common stock issuable upon the exercise of stock options granted after March 31, 2021 having a weighted-average exercise price of $24.43
per share; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">2,921,213 shares of common stock reserved for issuance pursuant to future awards under our 2020 Incentive Award Plan, as well as any automatic increases in the
number of shares of common stock reserved for future issuance under this plan; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">750,107 shares of common stock reserved for issuance under our 2020 Employee Stock Purchase Plan, as well as any automatic increases in the number of shares of
our common stock reserved for future issuance under this plan. </FONT></P></TD></TR></TABLE>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">90 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="toc166948_9"></A>Dilution </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">If you invest in our common stock in this offering, your ownership interest will be immediately diluted to the extent of the difference between the public offering price per share of our common stock in this
offering and the net tangible book value per share of our common stock after this offering. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As of March 31, 2021, we had a historical net tangible
book value of $195.2 million, or $5.12 per share of common stock. Our net tangible book value represents total tangible assets less total liabilities, divided by 38,147,205 shares of common stock outstanding on March 31, 2021.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">After giving effect to the sale of shares of common
stock in this offering at an assumed public offering price of $ per share, the last reported sale price of our common stock on the Nasdaq Global Select Market
on , 2021, and after deducting the underwriting discounts and commissions and estimated offering expenses payable by us, our as adjusted net tangible book
value as of March 31, 2021 would have been $ million, or $ per share. This represents an immediate increase in as adjusted net tangible book value
of $ per share to existing stockholders and an immediate dilution of $ per share to new investors. The following table illustrates this per share
dilution: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">
<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:2px solid #000000"> </P></TD>
<TD> </TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Assumed public offering price per share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Historical net tangible book value per share as of March 31, 2021</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5.12</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Increase in net tangible book value per share attributable to new investors purchasing shares in this offering</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD>
<TD> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">As adjusted net tangible book value per share after this offering</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD>
<TD> </TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Dilution per share to new investors purchasing shares in this offering</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000"> </P></TD>
<TD> </TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Each $1.00 increase (decrease) in the assumed public offering price of $ per share,
the last reported sale price of our common stock on the Nasdaq Global Select Market on , 2021, would increase (decrease) our as adjusted net tangible
book value as of March 31, 2021 after this offering by $ million, or $ per share, and would increase (decrease) dilution to investors in this
offering by $ per share, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same, after deducting the underwriting discounts and
commissions and estimated offering expenses payable by us. We may also increase or decrease the number of shares we are offering. Assuming the assumed public price of $ per share, the last reported
sale price of our common stock on the Nasdaq Global Select Market on , 2021, remains the same, after deducting the underwriting discounts and commissions
and estimated offering expenses payable by us, each increase of 1,000,000 in the number of shares we are offering would increase our as adjusted net tangible book value as of March 31, 2021 after this offering by approximately
$ million, or $ per share, and would decrease dilution to investors in this offering by
$ per share, and a decrease of 1,000,000 in the number of shares we are offering would decrease our as adjusted net tangible book value as of
March 31, 2021 after this offering by $ million, or $ per share, and would increase dilution to investors in this offering by
$ per share. The as adjusted information is illustrative only, and we will adjust this information based on the actual public offering price and other terms of this offering determined at pricing.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If the underwriters exercise in full their option to purchase additional shares, as adjusted net tangible book value after this offering would increase
to $ per share, and there would be an immediate dilution of $ per share to new investors, in each case assuming the assumed public offering price of
$ per share, the last reported sale price of our common stock on the Nasdaq Global Select Market on , 2021
remains the same. </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">91 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">To the extent that outstanding options with an exercise price per share that is less than the as adjusted net
tangible book value per share are exercised, new investors will experience further dilution. In addition, we may choose to raise additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for
our current or future operating plans. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our stockholders. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The foregoing tables and calculations above are based on 38,147,205 shares of common stock outstanding as of March 31, 2021 and exclude the following:
</FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">5,515,723 shares of common stock issuable upon the exercise of outstanding stock options as of March 31, 2021 having a weighted-average exercise price of
$11.40 per share; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">94,600 shares of common stock issuable upon the exercise of stock options granted after March 31, 2021 having a weighted-average exercise price of $24.43
per share; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">2,921,213 shares of common stock reserved for issuance pursuant to future awards under our 2020 Incentive Award Plan, as well as any automatic increases in the
number of shares of common stock reserved for future issuance under this plan; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">750,107 shares of common stock reserved for issuance under our 2020 Employee Stock Purchase Plan, as well as any automatic increases in the number of shares of
our common stock reserved for future issuance under this plan. </FONT></P></TD></TR></TABLE>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">92 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="toc166948_10"></A>Description of capital stock </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>The following summary describes our capital stock and certain provisions of our amended and restated certificate of incorporation and our amended and restated
bylaws, the amended and restated investors’ rights agreement to which we and certain of our stockholders are parties and of the Delaware General Corporation Law. Because the following is only a summary, it does not contain all of the
information that may be important to you. For a complete description, you should refer to our amended and restated certificate of incorporation, amended and restated bylaws and amended and restated investors’ rights agreement, copies of which
are incorporated by reference as exhibits to the registration statement of which this prospectus is part. </I></FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>General </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our amended and restated certificate of incorporation authorizes 300,000,000 shares of common stock, $0.0001 par value per share, 20,000,000 shares of <FONT
STYLE="white-space:nowrap">non-voting</FONT> common stock, $0.0001 par value per share, and 10,000,000 shares of preferred stock, $0.0001 par value per share. As of March 31, 2021, there were outstanding: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">5,515,723 shares of our common stock issuable upon exercise of outstanding stock options; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">38,147,205 shares of our common stock, held by approximately 99 stockholders of record. This number is comprised of 35,054,867 shares of voting common stock and
3,092,338 shares of <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock. The number of stockholders of record does not include beneficial owners whose shares are held by nominees in street name. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Common stock and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The holders of our common stock and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock have identical rights, provided that, (i) except as otherwise expressly provided in our amended and restated
certificate of incorporation or as required by applicable law, on any matter that is submitted to a vote by our stockholders, holders of our common stock are entitled to one vote per share of common stock, and holders of our <FONT
STYLE="white-space:nowrap">non-voting</FONT> common stock are not entitled to any votes per share of <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock, including for the election of directors, and (ii) holders of our common stock
have no conversion rights, while holders of our <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock have the right to convert each share of <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock into one share of common stock at
such holder’s election, provided that as a result of such conversion, such holder, together with its affiliates and any members of a Schedule 13(d) group with such holder, would not beneficially own in excess of 4.99% of our common stock
immediately prior to and following such conversion, unless otherwise expressly provided for in our amended and restated certificate of incorporation. However, this ownership limitation may be increased to any other percentage designated by such
holder of <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock upon 61 days’ notice to us or decreased at any time upon notice to us. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Each holder of our common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors.
Our stockholders do not have cumulative voting rights in the election of directors. Accordingly, holders of a majority of the voting shares are able to elect all of the directors. In addition, the affirmative vote of holders of <FONT
STYLE="white-space:nowrap">66-2/3%</FONT> of the voting power of all of the then outstanding voting stock will be required to take certain actions, including amending certain provisions of our amended and restated certificate of incorporation, such
as the provisions relating to amending our amended and restated bylaws, our classified board and director liability. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Subject to preferences that may be
applicable to any then outstanding preferred stock, holders of our common stock and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock are entitled to receive dividends, if any, as may be declared from time to time by our board of
directors out of legally available funds. </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">93 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In the event of our liquidation, dissolution or winding up, holders of our common stock and <FONT
STYLE="white-space:nowrap">non-voting</FONT> common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities and the satisfaction of any
liquidation preference granted to the holders of any then outstanding shares of preferred stock. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Holders of our common stock and <FONT
STYLE="white-space:nowrap">non-voting</FONT> common stock have no preemptive, conversion, subscription or other rights, and there are no redemption or sinking fund provisions applicable to our common stock or
<FONT STYLE="white-space:nowrap">non-voting</FONT> common stock. The rights, preferences and privileges of the holders of our common stock and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock are subject to and may be adversely
affected by the rights of the holders of shares of any series of our preferred stock that we may designate in the future. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">All of our outstanding shares
of common stock and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock are, and the shares of common stock to be issued in this offering will be, fully paid and nonassessable. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Preferred stock </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our board of directors has the authority, without further action by our stockholders, to issue
up to 10,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms
of redemption, liquidation preferences, sinking fund terms and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of common stock. The issuance of our preferred stock could
adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon our liquidation. In addition, the issuance of preferred stock could have the effect of delaying,
deferring or preventing a change in control of our company or other corporate action. No shares of preferred stock are currently outstanding, and we have no present plan to issue any shares of preferred stock. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Options </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As of March 31, 2021, we had outstanding
options to purchase 5,515,723 shares of our common stock, with a per share weighted average exercise price of $11.40, under our 2020 Incentive Award Plan and our 2018 Equity Incentive Plan. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Registration rights </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Under our amended and restated investors’ rights agreement certain holders of our
common stock and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock, or their transferees, have the right to require us to register their shares under the Securities Act so that those shares may be publicly resold, and certain holders
of shares of our common stock and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock, or their transferees, have the right to include their shares in any registration statement we file, in each case as described below. These rights have
been waived with respect to this offering. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I><FONT STYLE="white-space:nowrap">Form S-1 demand</FONT> registration rights
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Certain holders of our common stock and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock, or their transferees, are entitled to
certain <FONT STYLE="white-space:nowrap">Form S-1 demand</FONT> registration rights. The holders of at least 30% of these shares can request that we register all or a portion of their shares (including the shares of common stock into which
any shares of <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by such investors may be converted), so long as such holders request that we register at least 20% of the shares entitled to these demand registration rights and the
aggregate proceeds, net of underwriting discounts and commissions, would exceed $20 million if the first offering or $5 million after the first offering. These stockholders may make up to two requests for registration on <FONT
STYLE="white-space:nowrap">Form S-1.</FONT> </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">94 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I><FONT STYLE="white-space:nowrap">Form S-3 demand</FONT> registration rights </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Certain holders of our common stock and <FONT STYLE="white-space:nowrap">non-voting</FONT> stock, or their transferees, are entitled to certain <FONT
STYLE="white-space:nowrap">Form S-3 demand</FONT> registration rights. If we are eligible to use a <FONT STYLE="white-space:nowrap">Form S-3 registration</FONT> statement, the holders of these shares can request that we register
all or a portion of their shares on a <FONT STYLE="white-space:nowrap">Form S-3 registration</FONT> statement if the anticipated aggregate offering price is at least $2 million, net of underwriting discounts and commissions and
certain other expenses related to the sale of the shares. These stockholders may make unlimited requests for registration on <FONT STYLE="white-space:nowrap">Form S-3, provided</FONT> that we are not obligated to effect, or take any action
to effect, a registration on <FONT STYLE="white-space:nowrap">Form S-3 if</FONT> we have effected two registrations on <FONT STYLE="white-space:nowrap">Form S-3 pursuant</FONT> to requests by these stockholders within the twelve
month period immediately preceding such request. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Piggyback registration rights </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In the event that we determine to register any of our common stock under the Securities Act (subject to certain exceptions), either for our own account or for the account of other security holders, certain holders
of our common stock and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock or their transferees are entitled to certain “piggyback” registration rights allowing the holders to include their shares in such registration, subject
to certain marketing and other limitations and the conversion of <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock into shares of common stock prior to registration thereof. As a result, whenever we propose to file a registration
statement under the Securities Act, other than with respect to certain registrations, including related to the sale of securities to employees pursuant to employee benefit plans, the offer and sale of convertible debt securities, an SEC Rule 145
transaction, or a registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the registerable shares, the holders of these shares are
entitled to notice of the registration and have the right to include their shares of common stock in the registration. In an underwritten offering, the underwriters have the right, subject to specified conditions, to limit the number of shares such
holders may include. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Expenses of registration </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We will pay the registration expenses, excluding underwriting discounts and commissions and certain other expenses, of the holders of the shares registered pursuant to the
<FONT STYLE="white-space:nowrap">Form S-1 demand,</FONT> <FONT STYLE="white-space:nowrap">Form S-3 demand</FONT> and piggyback registration rights described above, including the reasonable expenses of one counsel for the selling
holders not to exceed $50,000. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Expiration of registration rights </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The <FONT STYLE="white-space:nowrap">Form S-1 demand,</FONT> <FONT STYLE="white-space:nowrap">Form S-3 demand</FONT> and piggyback registration rights described above will terminate, with
respect to any particular stockholder, upon the earlier of (i) October 20, 2023, (ii) the date that Rule 144 or another similar exemption under the Securities Act is available to such stockholder for the sale of all of such
stockholder’s shares without limitation during a three-month period, or (iii) upon the consummation of a merger or consolidation. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Anti-takeover effects of provisions of our amended and restated certificate of incorporation, our amended and restated bylaws and Delaware law
</B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Some provisions of Delaware law and our amended and restated certificate of incorporation and our amended and restated bylaws contain provisions
that could make the following transactions more difficult: acquisition of us by means of a tender offer; acquisition of us by means of a proxy contest or otherwise; or removal of our incumbent officers and directors. It is possible that these
provisions could make it more difficult to accomplish </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">95 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
or could deter transactions that stockholders may otherwise consider to be in their best interest or in our best interests, including transactions that might result in a premium over the market
price for our shares. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">These provisions, summarized below, are expected to discourage coercive takeover practices and inadequate takeover bids. These
provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of increased protection of our potential ability to negotiate with the proponent of an
unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Delaware anti-takeover statute </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are
subject to Section 203 of the Delaware General Corporation Law, which prohibits persons deemed “interested stockholders” from engaging in a “business combination” with a publicly-held Delaware corporation for three
years following the date these persons become interested stockholders unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception
applies. Generally, an “interested stockholder” is a person who, together with affiliates and associates, beneficially owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a
corporation’s voting stock. Generally, a “business combination” includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have
an anti-takeover effect with respect to transactions not approved in advance by the board of directors, such as discouraging takeover attempts that might result in a premium over the market price of our common stock. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Undesignated preferred stock </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The ability to
authorize undesignated preferred stock makes it possible for our board of directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to institute a change of control of our company.
These and other provisions may have the effect of deterring hostile takeovers or delaying changes in control or management of our company. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Special stockholder meetings </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our amended and
restated bylaws provide that a special meeting of stockholders may only be called by our board of directors, Chief Executive Officer or, in the absence of a chief executive officer, our President. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Requirements for advance notification of stockholder nominations and proposals </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Our amended and restated bylaws establish advance notice procedures with respect to stockholder proposals and the nomination of candidates for election as directors, other than nominations made by or at the
direction of the board of directors or a committee of the board of directors. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Elimination of stockholder action by written consent
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our amended and restated certificate of incorporation and our amended and restated bylaws eliminate the right of stockholders to act by written
consent without a meeting. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Classified board; election and removal of directors; filling vacancies </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our board of directors is divided into three classes. The directors in each class serve for a three-year term, one class being elected each year by our
stockholders. Only one class of directors will be elected at each annual </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">96 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms. Because our stockholders do not have cumulative voting rights, our
stockholders holding a majority of the shares of common stock outstanding will be able to elect all of our directors. Our amended and restated certificate of incorporation provides for the removal of any of our directors only for cause and requires
a stockholder vote by the holders of at least <FONT STYLE="white-space:nowrap">a 66-2/3% of</FONT> the voting power of the then outstanding voting stock. Furthermore, any vacancy on our board of directors, however occurring, including a
vacancy resulting from an increase in the size of the board, may only be filled by a resolution of the board of directors unless the board of directors determines that such vacancies will be filled by the stockholders. This system of electing and
removing directors and filling vacancies may tend to discourage a third party from making a tender offer or otherwise attempting to obtain control of us, because it generally makes it more difficult for stockholders to replace a majority of our
directors. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Choice of forum </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our amended
and restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware is the sole and exclusive forum for any derivative action or proceeding
brought on our behalf; any action asserting a breach of fiduciary duty; any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our amended and restated certificate of incorporation, our amended and restated
bylaws or as to which the Delaware General Corporation Law confers jurisdiction to the Court of Chancery of the State of Delaware; or any action asserting a claim against us that is governed by the internal affairs doctrine. Our amended and restated
certificate of incorporation also provides that the federal district courts of the United States of America are the exclusive forum for the resolution of any complaint asserting a cause of action against us or any of our directors, officers,
employees or agents and arising under the Securities Act. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We believe these provisions may benefit us by providing increased consistency in the
application of Delaware law and federal securities laws by chancellors and judges, as applicable, particularly experienced in resolving corporate disputes, efficient administration of cases on a more expedited schedule relative to other forums and
protection against the burdens of multi-forum litigation. However, these provisions may have the effect of discouraging lawsuits against our directors and officers. The choice of forum provision requiring that the Court of Chancery of the State of
Delaware or the federal district courts of the United States of America be the exclusive forum for certain actions would not apply to suits brought to enforce any liability or duty created by the Exchange Act. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our exclusive forum provision will not relieve us of our duties to comply with the federal securities laws and the rules and regulations thereunder, and our
stockholders are not be deemed to have waived our compliance with these laws, rules and regulations. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Although our amended and restated certificate of
incorporation contains the choice of forum provisions described above, it is possible that a court could find that such a provision is inapplicable for a particular claim or action or that such provision is unenforceable. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Amendment of certificate of incorporation provisions </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The amendment of any of the above provisions, except for the provision making it possible for our board of directors to issue undesignated preferred stock, would
require approval by a stockholder vote by the holders of at least <FONT STYLE="white-space:nowrap">a 66-2/3% of</FONT> the voting power of the then outstanding voting stock. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The provisions of the Delaware General Corporation Law, our amended and restated certificate of incorporation and our amended and restated bylaws could have the effect of discouraging others from attempting hostile
</FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">97 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These
provisions may also have the effect of preventing changes in our management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Nasdaq Global Select Market listing </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our common stock is
listed on the Nasdaq Global Select Market under the symbol “ALGS.” </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Transfer agent and registrar </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The transfer agent and registrar for our common stock is Continental Stock Transfer & Trust Co. The transfer agent and registrar’s address is 1 State
Street, 30th Floor, New York, NY 10004. </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">98 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="toc166948_11"></A>Shares eligible for future sale </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Future sales of our common stock, including shares issued upon the exercise of outstanding options, in the public market after this offering, or the perception that
those sales may occur, could cause the prevailing market price for our common stock to fall or impair our ability to raise equity capital in the future. As described below, only a limited number of shares of our common stock will be available for
sale in the public market after consummation of this offering due to contractual and legal restrictions on resale described below. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Future sales of our
common stock in the public market either before (to the extent permitted) or after restrictions lapse, or the perception that those sales may occur, could adversely affect the prevailing market price of our common stock at such time and our ability
to raise equity capital at a time and price we deem appropriate. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Based on the number of shares of our common stock outstanding as of March 31,
2021, upon the consummation of this offering and assuming (1) no exercise of the underwriters’ option to purchase additional shares of common stock and (2) no exercise of outstanding options after March 31, 2021, we will have
outstanding an aggregate of shares of common stock. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">All
of the shares of common stock to be sold in this offering, and any shares sold upon exercise of the underwriters’ option to purchase additional shares, will be freely tradable in the public market without restriction or further registration
under the Securities Act, unless the shares are held by any of our “affiliates” as such term is defined in Rule 144 of the Securities Act. Certain of the remaining shares of common stock held by existing stockholders immediately prior to
the consummation of this offering will be “restricted securities” as such term is defined in Rule 144. These restricted securities were issued and sold by us, or will be issued and sold by us, in private transactions and are eligible for
public sale only if registered under the Securities Act or if they qualify for an exemption from registration under the Securities Act, including the exemptions provided by Rule 144 or Rule 701, which rules are summarized below. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B><FONT STYLE="white-space:nowrap">Lock-up</FONT> agreements </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In connection with this offering, we, and our directors and executive officers and certain affiliated stockholders have agreed, subject to certain exceptions, with
the underwriters not to dispose of or hedge any shares of our common stock or securities convertible into or exchangeable for shares of common stock during the period from the date of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement
continuing through the date 60 days after the date of this prospectus, except with the prior written consent of J.P. Morgan Securities LLC, Jefferies LLC, and Piper Sandler & Co. See the section titled “Underwriting” for
additional information. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Following the <FONT STYLE="white-space:nowrap">lock-up</FONT> period set forth above, and assuming that J.P. Morgan Securities
LLC, Jefferies LLC, and Piper Sandler & Co. do not release any parties from such <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement entered into in connection with this offering, all of the shares of our common stock that are
restricted securities or are held by our affiliates as of the date of this prospectus will be eligible for sale in the public market in compliance with Rule 144 under the Securities Act. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Rule 144 </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In general, under Rule 144, as currently in effect, a person (or persons whose shares are required to
be aggregated) who is not deemed to have been one of our “affiliates” for purposes of Rule 144 at any time during the three months preceding a sale, and who has beneficially owned restricted securities within the meaning of Rule 144 for at
least six months, including the holding period of any prior owner other than one of our “affiliates,” is entitled to sell those shares in the public market (subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements referred
to </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">99 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
above, if applicable) without complying with the manner of sale, volume limitations or notice provisions of Rule 144, but subject to compliance with the public information requirements of Rule
144. If such a person has beneficially owned the shares proposed to be sold for at least one year, including the holding period of any prior owner other than “affiliates,” then such person is entitled to sell such shares in the public
market without complying with any of the requirements of Rule 144 (subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement referred to above, if applicable). In general, under Rule 144, as currently in effect, our
“affiliates,” as defined in Rule 144, who have beneficially owned the shares proposed to be sold for at least six months are entitled to sell in the public market, upon expiration of any applicable
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreements and within any three-month period, a number of those shares of our common stock that does not exceed the greater of: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">1% of the number of shares of common stock and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock then outstanding, which will equal approximately
381,472 shares of common stock immediately after this offering (calculated as of March 31, 2021 on the basis of the assumptions (1)-(2) described above); or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the average weekly trading volume of our common stock on the Nasdaq Global Select Market during the four calendar weeks preceding the filing of a notice on Form
144 with respect to such sale. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Such sales under Rule 144 by our “affiliates” or persons selling shares on behalf of our
“affiliates” are also subject to certain manner of sale provisions, notice requirements and to the availability of current public information about us. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Rule 701 </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Rule 701 generally provides that a stockholder who purchased shares of our common stock pursuant to a
written compensatory benefit plan or contract and who is not deemed to have been one of our affiliates at any time during the preceding 90 days may sell such shares (to the extent such shares are not subject to a
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreement) in reliance upon Rule 144 without complying with the current public information or holding period conditions of Rule 144. Rule 701 also provides that a stockholder who purchased shares of
our common stock pursuant to a written compensatory benefit plan or contract and who is deemed to have been one of our affiliates during the preceding 90 days may sell such shares under Rule 144 without complying with the holding period
condition of Rule 144 (subject to any applicable <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement). </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Registration rights </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Under our amended and restated investors’ rights agreement certain holders of our common stock and <FONT STYLE="white-space:nowrap">non-voting</FONT> common
stock, or their transferees (and subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above), are entitled to certain rights with respect to the registration of the offer and sale of those shares under the Securities
Act. For a description of these registration rights, see “Description of capital stock—Registration rights.” If the offer and sale of these shares are registered, they will be freely tradable without restriction under the Securities
Act. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Stock plans </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have filed with the SEC a
registration statement under the Securities Act covering the shares of common stock reserved for issuance under our 2018 Equity Incentive Plan, our 2020 Incentive Award Plan and our 2020 Employee Stock Purchase Plan. Accordingly, shares registered
under such registration statement are available for sale in the open market, subject to Rule 144 volume limitations and the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above, if applicable. </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">100 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B><A NAME="toc166948_12"></A>Material U.S. federal income tax consequences to
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following discussion is a summary of the material U.S. federal income tax consequences
to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders (as defined below) of the purchase, ownership and disposition of our common stock issued pursuant to this offering, but does not purport to be a complete analysis of all potential tax
effects. The effects of other U.S. federal tax laws, such as estate and gift tax laws, and any applicable state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax laws are not discussed. This discussion is based on the U.S. Internal
Revenue Code of 1986, as amended (the “Code”), Treasury Regulations promulgated thereunder, judicial decisions, and published rulings and administrative pronouncements of the U.S. Internal Revenue Service (the “IRS”), in each
case in effect as of the date hereof. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">These authorities may change or be subject to differing interpretations. Any such change or differing
interpretation may be applied retroactively in a manner that could adversely affect a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder. We have not sought and will not seek any rulings from the IRS regarding the matters discussed below. There
can be no assurance the IRS or a court will not take a contrary position to that discussed below regarding the tax consequences of the purchase, ownership and disposition of our common stock. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">This discussion is limited to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders that hold our common stock as a “capital asset” within the meaning of Section 1221 of the Code (generally,
property held for investment). This discussion does not address all U.S. federal income tax consequences relevant to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder’s particular circumstances, including the impact of the Medicare
contribution tax on net investment income or the alternative minimum tax. In addition, it does not address consequences relevant to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders subject to special rules, including, without limitation:
</FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">U.S. expatriates and former citizens or long-term residents of the United States; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">persons holding our common stock as part of a straddle or other risk reduction strategy or as part of a conversion transaction; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">banks, insurance companies and other financial institutions; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">brokers, dealers or traders in securities; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">“controlled foreign corporations,” “passive foreign investment companies” and corporations that accumulate earnings to avoid U.S. federal
income tax; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">partnerships or other entities or arrangements treated as partnerships for U.S. federal income tax purposes (and investors therein);
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations or governmental organizations; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">persons deemed to sell our common stock under the constructive sale provisions of the Code; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plans; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">“qualified foreign pension funds” as defined in Section 897(l)(2) of the Code and entities all of the interests of which are held by qualified
foreign pension funds. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If an entity treated as a partnership for U.S. federal income tax purposes holds our common stock, the tax
treatment of a partner in the partnership will depend on the status of the partner, the activities of the partnership and certain determinations made at the partner level. Accordingly, partnerships holding our common stock and the partners in such
partnerships should consult their tax advisors regarding the U.S. federal income tax consequences to them. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">THIS DISCUSSION IS NOT TAX ADVICE. INVESTORS
SHOULD CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE APPLICATION OF THE U.S. FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATIONS AS WELL AS </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">101 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
ANY TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP AND DISPOSITION OF OUR COMMON STOCK ARISING UNDER THE U.S. FEDERAL ESTATE OR GIFT TAX LAWS OR UNDER THE LAWS OF ANY STATE, LOCAL OR <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> TAXING JURISDICTION OR UNDER ANY APPLICABLE INCOME TAX TREATY. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Definition of <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">For purposes of this discussion, a <FONT STYLE="white-space:nowrap">“Non-U.S.</FONT>
Holder” is any beneficial owner of our common stock that is neither a “U.S. person” nor an entity treated as a partnership for U.S. federal income tax purposes. A U.S. person is any person that, for U.S. federal income tax purposes,
is or is treated as any of the following: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">an individual who is a citizen or resident of the United States; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">a corporation created or organized under the laws of the United States, any state thereof or the District of Columbia; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">a trust that (1) is subject to the primary supervision of a U.S. court and all substantial decisions of which are subject to the control of one or more
“United States persons” (within the meaning of Section 7701(a)(30) of the Code), or (2) has a valid election in effect to be treated as a United States person for U.S. federal income tax purposes. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Distributions </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As described in the section titled
“Dividend policy,” we have never declared or paid cash dividends on our capital stock, and we do not anticipate paying any cash dividends in the foreseeable future. However, if we do make distributions of cash or property on our common
stock, such distributions will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Amounts not treated as
dividends for U.S. federal income tax purposes will constitute returns of capital and first be applied against and reduce a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder’s adjusted tax basis in its common stock, but not below zero.
Any excess will be treated as capital gain and will be treated as described below under “—Sale or other taxable disposition.” </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Subject to
the discussion below regarding effectively connected income, dividends paid to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will be subject to U.S. federal withholding tax at a rate of 30% of the gross amount of the dividends (or such
lower rate specified by an applicable income tax treaty, provided the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder furnishes a valid IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or IRS Form <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (or other applicable documentation) certifying qualification for the lower treaty rate). A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that does not timely furnish the required
documentation, but that qualifies for a reduced treaty rate, may obtain a refund of any excess amounts withheld by timely filing an appropriate claim for refund with the IRS. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult
their tax advisors regarding their entitlement to benefits under any applicable tax treaties. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If dividends paid to a
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder are effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder’s conduct of a trade or business within the United States (and, if required by an applicable
income tax treaty, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder maintains a permanent establishment in the United States to which such dividends are attributable), the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will be
exempt from the U.S. federal withholding tax described above. To claim the exemption, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder must furnish to the applicable withholding agent a valid IRS Form
<FONT STYLE="white-space:nowrap">W-8ECI,</FONT> certifying that the dividends are effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder’s conduct of a trade or business within the United States. Any such
effectively connected dividends will be subject to U.S. federal income tax on a net income basis at the regular rates. A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that is a corporation also may be subject to a branch profits tax at a
rate of 30% (or such lower rate specified by an applicable income tax treaty) on such effectively </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">102 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
connected dividends, as adjusted for certain items. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding any applicable tax treaties that may
provide for different rules. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Sale or other taxable disposition </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Subject to the discussion below regarding backup withholding, a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will not be subject to U.S. federal income tax on any gain realized upon the sale or other
taxable disposition of our common stock unless: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the gain is effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder’s conduct of a trade or business within the United States
(and, if required by an applicable income tax treaty, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder maintains a permanent establishment in the United States to which such gain is attributable); </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is a nonresident alien individual present in the United States for 183 days or more during the
taxable year of the disposition and certain other requirements are met; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our common stock constitutes a U.S. real property interest (“USRPI”), by reason of our status as a U.S. real property holding corporation
(“USRPHC”), for U.S. federal income tax purposes. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Gain described in the first bullet point above generally will be subject
to U.S. federal income tax on a net income basis at the regular rates. A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that is a corporation also may be subject to a branch profits tax at a rate of 30% (or such lower rate specified by an
applicable income tax treaty) on such effectively connected gain, as adjusted for certain items. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT>
Holder described in the second bullet point above will be subject to U.S. federal income tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on gain realized upon the sale or other taxable disposition of our common
stock, which may be offset by certain U.S.-source capital losses of the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder (even though the individual is not considered a resident of the United States), provided the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder has timely filed U.S. federal income tax returns with respect to such losses. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">With respect to the
third bullet point above, we believe we currently are not, and do not anticipate becoming, a USRPHC. Because the determination of whether we are a USRPHC depends, however, on the fair market value of our USRPIs relative to the fair market value of
our <FONT STYLE="white-space:nowrap">non-U.S.</FONT> real property interests and our other business assets, there can be no assurance that we currently are not a USRPHC or will not become one in the future. Even if we are or were to become a USRPHC,
gain arising from the sale or other taxable disposition by a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will not be subject to U.S. federal income tax if our common stock is “regularly traded,” as defined by applicable
Treasury Regulations, on an established securities market, and such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder owned, actually and constructively, 5% or less of our common stock throughout the shorter of the five-year period ending on
the date of the sale or other taxable disposition or the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder’s holding period. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding any applicable tax treaties that may provide for different rules. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Information reporting and backup withholding </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Payments of dividends on our common stock will not be subject to
backup withholding, provided the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder certifies its <FONT STYLE="white-space:nowrap">non-U.S.</FONT> status, such as by furnishing a valid IRS Form <FONT STYLE="white-space:nowrap">W-8BEN,</FONT> <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or <FONT STYLE="white-space:nowrap">W-8ECI,</FONT> or otherwise establishes an exemption. However, information returns are required to be filed with the IRS in
connection with any distributions on our common stock paid to the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder, regardless of whether any tax was actually withheld. In addition, proceeds of the sale or other taxable disposition of our
common stock within the United States or conducted through certain U.S.-related brokers generally will not be subject to backup withholding or information reporting if the applicable withholding agent receives the certification
</FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">103 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
described above or the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder otherwise establishes an exemption. Proceeds of a disposition of our common stock conducted through a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> office of a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> broker that does not have certain enumerated relationships with the United States generally will not be subject to backup withholding or
information reporting. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Copies of information returns that are filed with the IRS may also be made available under the provisions of an applicable treaty
or agreement to the tax authorities of the country in which the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder resides or is established. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be allowed as a refund or a credit against a <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder’s U.S. federal income tax liability, provided the required information is timely furnished to the IRS. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Additional withholding tax on payments made to foreign accounts </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Withholding taxes may be imposed under
Sections 1471 to 1474 of the Code (such Sections commonly referred to as the Foreign Account Tax Compliance Act (“FATCA”)) on certain types of payments made to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> financial institutions and
certain other <FONT STYLE="white-space:nowrap">non-U.S.</FONT> entities. Specifically, a 30% withholding tax may be imposed on dividends on, or (subject to the proposed Treasury Regulations discussed below) gross proceeds from the sale or other
disposition of, our common stock paid to a “foreign financial institution” or a <FONT STYLE="white-space:nowrap">“non-financial</FONT> foreign entity” (each as defined in the Code), unless (1) the foreign financial
institution undertakes certain diligence and reporting obligations, (2) the <FONT STYLE="white-space:nowrap">non-financial</FONT> foreign entity either certifies it does not have any “substantial United States owners” (as defined in
the Code) or furnishes identifying information regarding each substantial United States owner, or (3) the foreign financial institution or <FONT STYLE="white-space:nowrap">non-financial</FONT> foreign entity otherwise qualifies for an exemption
from these rules. If the payee is a foreign financial institution and is subject to the diligence and reporting requirements in (1) above, it must enter into an agreement with the U.S. Department of the Treasury requiring, among other things,
that it undertakes to identify accounts held by certain “specified United States persons” or “United States owned foreign entities” (each as defined in the Code), annually reports certain information about such accounts, and
withholds 30% on certain payments to <FONT STYLE="white-space:nowrap">non-compliant</FONT> foreign financial institutions and certain other account holders. Foreign financial institutions located in jurisdictions that have an intergovernmental
agreement with the United States governing FATCA may be subject to different rules. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Under the applicable Treasury Regulations and administrative
guidance, withholding under FATCA generally applies to payments of dividends on our common stock. While, beginning on January 1, 2019, withholding under FATCA would have applied also to payments of gross proceeds from the sale or other
disposition of our common stock, proposed Treasury Regulations eliminate FATCA withholding on payments of gross proceeds entirely. Taxpayers generally may rely on these proposed Treasury Regulations until final Treasury Regulations are issued.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Prospective investors should consult their tax advisors regarding the potential application of withholding under FATCA to their investment in our common
stock. </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">104 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="toc166948_13"></A>Underwriting </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We are offering the shares of common stock described in this prospectus through a number of underwriters. J.P. Morgan Securities LLC, Jefferies LLC and Piper Sandler & Co. are acting as joint book-running
managers of the offering and as representatives of the underwriters. We have entered into an underwriting agreement with the underwriters. Subject to the terms and conditions of the underwriting agreement, we have agreed to sell to the underwriters,
and each underwriter has severally agreed to purchase, at the public offering price less the underwriting discounts and commissions set forth on the cover page of this prospectus, the number of shares of common stock listed next to its name in the
following table: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">
<TR>
<TD WIDTH="90%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2px solid #000000"> </TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2px solid #000000"> </TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Name</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Number of<BR>shares</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">J.P. Morgan Securities LLC</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Jefferies LLC</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Piper Sandler & Co.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cantor Fitzgerald & Co.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000"> </P></TD>
<TD> </TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The underwriters are committed to purchase all the shares of common stock offered by us if they purchase any shares. The
underwriting agreement also provides that if an underwriter defaults, the purchase commitments of <FONT STYLE="white-space:nowrap">non-defaulting</FONT> underwriters may also be increased or the offering may be terminated. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The underwriters propose to offer the shares of common stock directly to the public at the public offering price set forth on the cover page of this prospectus and
to certain dealers at that price less a concession not in excess of $ per share. After the initial offering of the shares to the public, if all of the
shares of common stock are not sold at the public offering price, the underwriters may change the offering price and the other selling terms. Sales of any shares made outside of the United States may be made by affiliates of the underwriters.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The underwriters have an option to buy up to additional
shares of common stock from us. The underwriters have 30 days from the date of this prospectus to exercise this option to purchase additional shares. If any shares are purchased with this option to purchase additional shares, the underwriters will
purchase shares in approximately the same proportion as shown in the table above. If any additional shares of common stock are purchased, the underwriters will offer the additional shares on the same terms as those on which the shares are being
offered. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The underwriting fee is equal to the public offering price per share of common stock less the amount paid by the underwriters to us per share
of common stock. The underwriting fee is $ per share. The following table shows the per share and total underwriting discounts and commissions to be paid
to the underwriters assuming both no exercise and full exercise of the underwriters’ option to purchase additional shares. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">
<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2px solid #000000"> </TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2px solid #000000"> </TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2px solid #000000"> </TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"> <FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Without<BR>option to<BR>purchase<BR>additional<BR>shares<BR>exercise</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>With full<BR>option to<BR>purchase<BR>additional<BR>shares<BR>exercise</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Per Share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000"> </P></TD>
<TD> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000"> </P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000"> </P></TD>
<TD> </TD></TR>
</TABLE>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">105 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We estimate that the total expenses of this offering, including registration, filing and listing fees, printing
fees and legal and accounting expenses, but excluding the underwriting discounts and commissions, will be approximately $ . We have agreed to reimburse
the underwriters for expenses of up to $40,000 relating to the clearance of this offering with the Financial Industry Regulatory Authority. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">A prospectus
in electronic format may be made available on the websites maintained by one or more underwriters, or selling group members, if any, participating in the offering. The underwriters may agree to allocate a number of shares to underwriters and selling
group members for sale to their online brokerage account holders. Internet distributions will be allocated by the representatives to underwriters and selling group members that may make Internet distributions on the same basis as other allocations.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We<I> </I>have agreed that we will not (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or
contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, or submit to, or file with, the SEC a registration statement under the Securities Act relating to, any shares of our
common stock or securities convertible into or exercisable or exchangeable for any shares of our common stock, or publicly disclose the intention to make any offer, sale, pledge, loan, disposition or filing, or (ii) enter into any swap or other
arrangement that transfers all or a portion of the economic consequences associated with the ownership of any shares of common stock or any such other securities (regardless of whether any of the transactions described in clause (i) or (ii) are
to be settled by the delivery of shares of common stock or such other securities, in cash or otherwise), in each case without the prior written consent of J.P. Morgan Securities LLC, Jefferies LLC and Piper Sandler & Co. for a period of 60
days after the date of the final prospectus, other than the shares of our common stock to be sold in this offering. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The restrictions on our actions, as
described above, do not apply to certain transactions, including (i) the issuance of shares of our common stock or securities convertible into or exercisable for shares of our common stock pursuant to the conversion or exchange of convertible
or exchangeable securities or the exercise of warrants or options (including net exercise) or the settlement of RSUs (including net settlement), in each case outstanding on the date of the underwriting agreement and described in this prospectus;
(ii) grants of stock options, stock awards, restricted stock, RSUs, or other equity awards and the issuance of shares of our common stock or securities convertible into or exercisable or exchangeable for shares of our common stock (whether upon
the exercise of stock options or otherwise) to our employees, officers, directors, advisors, or consultants pursuant to the terms of an equity compensation plan in effect as of the closing of this offering and described in this prospectus; or
(iii) in connection with the issuance of up to 10% of the shares of common stock outstanding immediately following the closing of this offering in acquisitions or other strategic transactions, provided that, in each case, such recipients enter
into a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement with the underwriters. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our directors and executive officers, and certain affiliated
stockholders (such persons, the <FONT STYLE="white-space:nowrap">“lock-up</FONT> parties”) have entered into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the underwriters prior to the commencement of this offering
pursuant to which each <FONT STYLE="white-space:nowrap">lock-up</FONT> party, with limited exceptions, for a period of 60 days after the date of the final prospectus (such period, the “restricted period”), may not (and may not cause any of
their direct or indirect affiliates to), without the prior written consent of J.P. Morgan Securities LLC, Jefferies LLC and Piper Sandler & Co., (1) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase
any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any shares of our common stock or any securities convertible into or exercisable or exchangeable for
our common stock (including, without limitation, common stock or such other securities which may be deemed to be beneficially owned by such <FONT STYLE="white-space:nowrap">lock-up</FONT> parties in accordance with the rules and regulations of the
SEC and securities which may be issued upon exercise of a stock option or warrant (collectively with the common stock, the <FONT STYLE="white-space:nowrap">“lock-up</FONT> securities”)), (2) enter into any hedging, swap or other agreement
or transaction that transfers, in whole or in part, any of the economic consequences of ownership of the <FONT STYLE="white-space:nowrap">lock-up</FONT> securities, whether any such transaction described in clause (1) or (2) above is to be
settled by delivery of <FONT STYLE="white-space:nowrap">lock-up</FONT> </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">106 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
securities, in cash or otherwise, (3) make any demand for, or exercise any right with respect to, the registration of any <FONT STYLE="white-space:nowrap">lock-up</FONT> securities, or
(4) publicly disclose the intention to do any of the foregoing. Such persons or entities have further acknowledged that these undertakings preclude them from engaging in any hedging or other transactions or arrangements (including, without
limitation, any short sale or the purchase or sale of, or entry into, any put or call option, or combination thereof, forward, swap or any other derivative transaction or instrument, however described or defined) designed or intended, or which could
reasonably be expected to lead to or result in, a sale or disposition or transfer (by any person or entity, whether or not a signatory to such agreement) of any economic consequences of ownership, in whole or in part, directly or indirectly, of any <FONT
STYLE="white-space:nowrap">lock-up</FONT> securities, whether any such transaction or arrangement (or instrument provided for thereunder) would be settled by delivery of <FONT STYLE="white-space:nowrap">lock-up</FONT> securities, in cash or
otherwise. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The restrictions described in the immediately preceding paragraph and contained in the <FONT STYLE="white-space:nowrap">lock-up</FONT>
agreements between the underwriters and the <FONT STYLE="white-space:nowrap">lock-up</FONT> parties do not apply, subject in certain cases to various conditions, to certain transactions, including (a) transfers or disposals of <FONT
STYLE="white-space:nowrap">lock-up</FONT> securities: (i) as bona fide gifts, or for bona fide estate planning purposes, (ii) by will, other testamentary document or intestacy, (iii) to any trust for the direct or indirect benefit of
the <FONT STYLE="white-space:nowrap">lock-up</FONT> party or any immediate family member, (iv) to a corporation, partnership, limited liability company or other entity of which the <FONT STYLE="white-space:nowrap">lock-up</FONT> party and/or
its immediate family members are, directly or indirectly, the legal and beneficial owner of all of the outstanding equity securities or similar interests, (v) to a nominee or custodian of a person or entity to whom a disposition or transfer
would be permissible under clauses (i) through (iv), (vi) in the case of a corporation, partnership, limited liability company, trust or other business entity, (A) to another corporation, partnership, limited liability company, trust or
other business entity that is an affiliate of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party, or to any investment fund or other entity controlling, controlled by, managing or managed by or under common control with the <FONT
STYLE="white-space:nowrap">lock-up</FONT> party or its affiliates or (B) as part of a distribution to affiliates, direct or indirect members, partners, stockholders or other equityholders of the <FONT STYLE="white-space:nowrap">lock-up</FONT>
party; (vii) by operation of law, (viii) to us from an employee or service provider upon death, disability or termination of employment of such employee or service provider, (ix) as part of a sale of
<FONT STYLE="white-space:nowrap">lock-up</FONT> securities acquired in open market transactions after the closing of this offering or from the underwriters in this offering; (x) as part of a sale of common stock made pursuant to a trading plan
that complies with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Rule 10b-5-1</FONT></FONT> under the Exchange Act that has been entered into by the <FONT STYLE="white-space:nowrap">lock-up</FONT> party prior to the date of
the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement, (xi) to us in connection with the vesting, settlement or exercise of restricted stock units, options, warrants or other rights to purchase shares of our common stock (including
“net” or “cashless” exercise), including for the payment of exercise price and tax and remittance payments, or (xii) pursuant to a bona fide third-party tender offer, merger, consolidation or other similar transaction
approved by our board of directors and made to all stockholders involving a change in control, provided that if such transaction is not completed, all such <FONT STYLE="white-space:nowrap">lock-up</FONT> securities would remain subject to the
restrictions in the immediately preceding paragraph, provided in the case of any transfer, distribution or other disposition pursuant to clauses (i), (ii), (iii), (iv), (v), (vi) and (ix) above, no filing by any party under the Securities
Exchange Act of 1934, as amended, or other public announcement shall be required or shall be made voluntarily in connection with such transfer or distribution (other than a filing on a Form 5 made after the expiration of the restricted period
referred to above or a filing on Schedule 13F or 13G that is required to be filed during the restricted period); (b) the exercise of options, the settlement of RSUs or other equity awards, or the exercise of warrants granted pursuant to
plans described in this prospectus, provided that any <FONT STYLE="white-space:nowrap">lock-up</FONT> securities received upon such exercise, vesting or settlement would be subject to restrictions similar to those in the immediately preceding
paragraph; (c) the conversion of outstanding preferred stock, warrants to acquire preferred stock, or convertible securities into shares of our common stock or warrants to acquire shares of our common stock, provided that any common stock or
warrant received upon such conversion would be subject to restrictions similar to those in the immediately preceding paragraph; and (d) the establishment by <FONT STYLE="white-space:nowrap">lock-up</FONT>
</FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">107 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
parties of trading plans under Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act, provided that any such plan does not provide for the transfer of <FONT
STYLE="white-space:nowrap">lock-up</FONT> securities during the restricted period. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">J.P. Morgan Securities LLC, Jefferies LLC and Piper
Sandler & Co., in their sole discretion, may release the securities subject to any of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the underwriters described above, in whole or in part at any time. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act of 1933. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our common stock is listed on Nasdaq Global Select Market under the symbol “ALGS”. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In connection with this offering, the underwriters may engage in stabilizing transactions, which involves making bids for, purchasing and selling shares of common stock in the open market for the purpose of
preventing or retarding a decline in the market price of the common stock while this offering is in progress. These stabilizing transactions may include making short sales of common stock, which involves the sale by the underwriters of a greater
number of shares of common stock than they are required to purchase in this offering, and purchasing shares of common stock on the open market to cover positions created by short sales. Short sales may be “covered” shorts, which are short
positions in an amount not greater than the underwriters’ option to purchase additional shares referred to above, or may be “naked” shorts, which are short positions in excess of that amount. The underwriters may close out any covered
short position either by exercising their option to purchase additional shares, in whole or in part, or by purchasing shares in the open market. In making this determination, the underwriters will consider, among other things, the price of shares
available for purchase in the open market compared to the price at which the underwriters may purchase shares through the option to purchase additional shares. A naked short position is more likely to be created if the underwriters are concerned
that there may be downward pressure on the price of the common stock in the open market that could adversely affect investors who purchase in this offering. To the extent that the underwriters create a naked short position, they will purchase shares
in the open market to cover the position. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The underwriters have advised us that, pursuant to Regulation M of the Securities Act of 1933, they may also
engage in other activities that stabilize, maintain or otherwise affect the price of the common stock, including the imposition of penalty bids. This means that if the representatives of the underwriters purchase common stock in the open market in
stabilizing transactions or to cover short sales, the representatives can require the underwriters that sold those shares as part of this offering to repay the underwriting discount received by them. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">These activities may have the effect of raising or maintaining the market price of the common stock or preventing or retarding a decline in the market price of the
common stock, and, as a result, the price of the common stock may be higher than the price that otherwise might exist in the open market. If the underwriters commence these activities, they may discontinue them at any time. The underwriters may
carry out these transactions on the Nasdaq Global Select Market, in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Other relationships </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Certain of the underwriters and their affiliates have provided in the past to us and our
affiliates and may provide from time to time in the future certain commercial banking, financial advisory, investment banking and other services for us and such affiliates in the ordinary course of their business, for which they have received and
may continue to receive customary fees and commissions. In addition, from time to time, certain of the underwriters and their affiliates may effect transactions for their own account or the account of customers, and hold on behalf of themselves or
their customers, long or short positions in our debt or equity securities or loans, and may do so in the future. </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">108 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Selling restrictions </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Other than in the United States, no action has been taken by us or the underwriters that would permit a public offering of the securities offered by this prospectus in any jurisdiction where action for that purpose
is required. The securities offered by this prospectus may not be offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in connection with the offer and sale of any such securities be
distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus comes are advised to inform
themselves about and to observe any restrictions relating to the offering and the distribution of this prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in
any jurisdiction in which such an offer or a solicitation is unlawful. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Notice to prospective investors in the European Economic Area
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In relation to each Member State of the European Economic Area, (each a “Relevant State”), no shares of common stock have been offered
or will be offered pursuant to the offering to the public in that Relevant State prior to the publication of a prospectus in relation to the shares of common stock which has been approved by the competent authority in that Relevant State, all in
accordance with the Prospectus Regulation, except that offers of shares of common stock may be made to the public in that Relevant State at any time under the following exemptions under the Prospectus Regulation: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">a)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">to any legal entity which is a qualified investor as defined in the Prospectus Regulation; </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">b)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">to fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus Regulation), subject to obtaining the prior consent of the representatives
for any such offer; or </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">c)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">in any other circumstances falling within Article 1(4) of the Prospectus Regulation, </FONT></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">provided that no such offer of shares of common stock shall require us or any underwriter to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23
of the Prospectus Regulation and each person who initially acquires any shares of common stock or to whom any offer is made will be deemed to have represented, acknowledged and agreed to and with each of the representatives and us that it is a
“qualified investor” within the meaning of Article 2(e) of the Prospectus Regulation. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In the case of any shares of common stock being offered
to a financial intermediary as that term is used in Article 5 of the Prospectus Regulation, each such financial intermediary will be deemed to have represented, acknowledged and agreed that the shares of common stock acquired by it in the offer have
not been acquired on a <FONT STYLE="white-space:nowrap">non-discretionary</FONT> basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer of any shares of
common stock to the public other than their offer or resale in a Relevant State to qualified investors as so defined or in circumstances in which the prior consent of the representatives has been obtained to each such proposed offer or resale.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">For the purposes of this provision, the expression an “offer to the public” in relation to any shares of common stock in any Relevant State
means the communication in any form and by any means of sufficient information on the terms of the offer and the shares of common stock to be offered so as to enable an investor to decide to purchase or subscribe for the shares of common stock and
the expression “Prospectus Regulation” means Regulation (EU) 2017/1129. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have not authorized and do not authorize the making of any offer of
shares of common stock </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">109 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">any financial intermediary on their behalf, other than offers made by the underwriters with a view to the final
placement of the shares of common stock in this document. Accordingly, no purchaser of the shares of common stock, other than the underwriters, is authorized to make any further offer of the shares on behalf of us or the underwriters. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Notice to prospective investors in the United Kingdom </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In relation to the United Kingdom, no shares of common stock have been offered or will be offered pursuant to this offering to the public in the United Kingdom
prior to the publication of a prospectus in relation to the shares of common stock that either (i) has been approved by the Financial Conduct Authority, or (ii) is to be treated as if it had been approved by the Financial Conduct Authority
in accordance with the transitional provision in Regulation 74 of the Prospectus (Amendment etc.) (EU Exit) Regulations 2019, except that offers of shares may be made to the public in the United Kingdom at any time under the following exemptions
under the UK Prospectus Regulation: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">to any legal entity which is a qualified investor as defined in Article 2 of the UK Prospectus Regulation; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">to fewer than 150 natural or legal persons (other than qualified investors as defined in Article 2 of the UK Prospectus Regulation; or
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">in any other circumstances falling within Section 86 of the Financial Services and Markets Act 2000 (“FSMA”), </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">provided that no such offer of shares of common stock shall require us or any representative to publish a prospectus pursuant to Section 85 of the FSMA or
supplement a prospectus pursuant to Article 23 of the UK Prospectus Regulation. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">For the purposes of this provision, the expression an “offer to the
public” in relation to any shares of common stock in any relevant state means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to decide
to purchase or subscribe for any shares, and the expression “UK Prospectus Regulation” means Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have not authorized and do not authorize the making of any offer of shares of common stock through any financial intermediary on their behalf, other than offers
made by the underwriters with a view to the final placement of the shares of common stock as contemplated in this prospectus. Accordingly, no purchaser of the shares of common stock, other than the underwriters, is authorized to make any further
offer of the shares on behalf of us or the underwriters. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, in the United Kingdom, this document is being distributed only to, and is directed
only at, and any offer subsequently made may only be directed at persons who are “qualified investors” (as defined in Article 2 of the UK Prospectus Regulation) (i) who have professional experience in matters relating to investments
falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended, or the Order, and/or (ii) who are high net worth companies (or persons to whom it may otherwise be lawfully communicated)
falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “relevant persons”) or otherwise in circumstances which have not resulted and will not result in an offer to the public of the shares
in the United Kingdom within the meaning of the FSMA. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Any person in the United Kingdom that is not a relevant person should not act or rely on the
information included in this document or use it as basis for taking any action. In the United Kingdom any investment or investment activity that this document relates to may be made or taken exclusively by relevant persons. </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">110 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Notice to prospective investors in Switzerland </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The shares of common stock may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange (the “SIX”) or on any other stock
exchange or regulated trading facility in Switzerland. This document does not constitute a prospectus within the meaning of, and has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of
the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document nor
any other offering or marketing material relating to the shares or the offering may be publicly distributed or otherwise made publicly available in Switzerland. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Neither this document nor any other offering or marketing material relating to the offering, the Company, the shares have been or will be filed with or approved by any Swiss regulatory authority. In particular,
this document will not be filed with, and the offer of shares will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA (the “FINMA”), and the offer of shares of common stock has not been and will not be authorized
under the Swiss Federal Act on Collective Investment Schemes (the “CISA”). The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of shares. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Notice to prospective investors in France </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">This
prospectus (including any amendment, supplement or replacement thereto) is not being distributed in the context of a public offering in France within the meaning of Article L. <FONT STYLE="white-space:nowrap">411-1</FONT> of the French Monetary and
Financial Code (Code monétaire et financier). This prospectus has not been and will not be submitted to the French Autorité des marchés financiers (the “AMF”) for approval in France and accordingly may not and will not
be distributed to the public in France. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Pursuant to Article <FONT STYLE="white-space:nowrap">211-3</FONT> of the AMF General Regulation, French
residents are hereby informed that: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">1.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">the transaction does not require a prospectus to be submitted for approval to the AMF; </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">2.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">persons or entities referred to in Point 2°, Section II of Article L. <FONT STYLE="white-space:nowrap">411-2</FONT> of the Monetary and Financial Code may take part in the
transaction solely for their own account, as provided in Articles D. <FONT STYLE="white-space:nowrap">411-1,</FONT> D. <FONT STYLE="white-space:nowrap">734-1,</FONT> D. <FONT STYLE="white-space:nowrap">744-1,</FONT> D.
<FONT STYLE="white-space:nowrap">754-1</FONT> and D. <FONT STYLE="white-space:nowrap">764-1</FONT> of the Monetary and Financial Code; and </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">3.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">the financial instruments thus acquired cannot be distributed directly or indirectly to the public otherwise than in accordance with Articles L.
<FONT STYLE="white-space:nowrap">411-1,</FONT> L. <FONT STYLE="white-space:nowrap">411-2,</FONT> L. <FONT STYLE="white-space:nowrap">412-1</FONT> and L. <FONT STYLE="white-space:nowrap">621-8</FONT> to L. <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">621-8-3</FONT></FONT> of the Monetary and Financial Code. </FONT></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">This prospectus is not to be further distributed or
reproduced (in whole or in part) in France by the recipients of this prospectus. This prospectus has been distributed on the understanding that such recipients will only participate in the issue or sale of our common stock for their own account and
undertake not to transfer, directly or indirectly, our common stock to the public in France, other than in compliance with all applicable laws and regulations and in particular with Articles L. <FONT STYLE="white-space:nowrap">411-1</FONT> and L. <FONT
STYLE="white-space:nowrap">411-2</FONT> of the French Monetary and Financial Code. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Notice to prospective investors in Germany </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Each person who is in possession of this prospectus is aware of the fact that no German securities prospectus (wertpapierprospekt) within the meaning of the German
Securities Prospectus Act (Wertpapierprospektgesetz, or the Act) of the Federal Republic of Germany has been or will be published with respect to the shares of our </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">111 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
common stock. In particular, each underwriter has represented that it has not engaged and has agreed that it will not engage in a public offering in the Federal Republic of Germany within the
meaning of the Act with respect to any of the shares of our common stock otherwise than in accordance with the Act and all other applicable legal and regulatory requirements </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Notice to prospective investors in Canada </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The shares of common stock may be sold only to purchasers
purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are
permitted clients, as defined in National Instrument <FONT STYLE="white-space:nowrap">31-103</FONT> Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the shares of common stock must be made in accordance with an
exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Securities legislation in certain
provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised
by the purchaser within the time limit prescribed by the securities legislation of the purchaser’s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser’s province or
territory for particulars of these rights or consult with a legal advisor. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Pursuant to section 3A.3 of National Instrument <FONT
STYLE="white-space:nowrap">33-105</FONT> Underwriting Conflicts (NI <FONT STYLE="white-space:nowrap">33-105),</FONT> the underwriters are not required to comply with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT>
regarding underwriter conflicts of interest in connection with this offering. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Notice to prospective investors in Australia </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">This prospectus: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">does not constitute a disclosure document or a prospectus under Chapter 6D.2 of the Corporations Act 2001 (Cth) (the “Corporations Act”);
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">has not been, and will not be, lodged with the Australian Securities and Investments Commission (“ASIC”), as a disclosure document for the purposes of
the Corporations Act and does not purport to include the information required of a disclosure document for the purposes of the Corporations Act; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">may only be provided in Australia to select investors who are able to demonstrate that they fall within one or more of the categories of investors, available
under section 708 of the Corporations Act (“Exempt Investors”). </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The shares of common stock may not be directly or indirectly
offered for subscription or purchased or sold, and no invitations to subscribe for or buy the shares may be issued, and no draft or definitive offering memorandum, advertisement or other offering material relating to any shares may be distributed in
Australia, except where disclosure to investors is not required under Chapter 6D of the Corporations Act or is otherwise in compliance with all applicable Australian laws and regulations. By submitting an application for the shares, you represent
and warrant to us that you are an Exempt Investor. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As any offer of shares of common stock under this document will be made without disclosure in
Australia under Chapter 6D.2 of the Corporations Act, the offer of those securities for resale in Australia within 12 months may, under section 707 of the Corporations Act, require disclosure to investors under Chapter 6D.2 if none of the exemptions
in section 708 applies to that resale. By applying for the shares of common stock, you undertake to </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">112 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
us that you will not, for a period of 12 months from the date of issue of the shares of common stock, offer, transfer, assign or otherwise alienate those shares of common stock to investors in
Australia except in circumstances where disclosure to investors is not required under Chapter 6D.2 of the Corporations Act or where a compliant disclosure document is prepared and lodged with ASIC. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Notice to prospective investors in New Zealand </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">This
prospectus has not been registered, filed with or approved by any New Zealand regulatory authority under the Financial Markets Conduct Act 2013 (the “FMC Act”). The shares of common stock may only be offered or sold in New Zealand (or
allotted with a view to being offered for sale in New Zealand) to a person who: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">is an investment business within the meaning of clause 37 of Schedule 1 of the FMC Act; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">meets the investment activity criteria specified in clause 38 of Schedule 1 of the FMC Act; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">is large within the meaning of clause 39 of Schedule 1 of the FMC Act; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">is a government agency within the meaning of clause 40 of Schedule 1 of the FMC Act; or </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">is an eligible investor within the meaning of clause 41 of Schedule 1 of the FMC Act. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Notice to prospective investors in Japan </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The shares of common stock have not been and will not be
registered pursuant to Article 4, Paragraph 1 of the Financial Instruments and Exchange Act. Accordingly, none of the shares nor any interest therein may be offered or sold, directly or indirectly, in Japan or to, or for the benefit of, any
“resident” of Japan (which term as used herein means any person resident in Japan, including any corporation or other entity organized under the laws of Japan), or to others for <FONT STYLE="white-space:nowrap">re-offering</FONT> or
resale, directly or indirectly, in Japan or to or for the benefit of a resident of Japan, except pursuant to an exemption from the registration requirements of, and otherwise in compliance with, the Financial Instruments and Exchange Act and any
other applicable laws, regulations and ministerial guidelines of Japan in effect at the relevant time. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Notice to prospective investors in Hong
Kong </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The shares of common stock have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than
(a) to “professional investors” as defined in the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) (the “SFO”) of Hong Kong and any rules made thereunder; or (b) in other circumstances which do not
result in the document being a “prospectus” as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong) (the “CO”) or which do not constitute an offer to the public within the meaning
of the CO. No advertisement, invitation or document relating to the shares of common stock has been or may be issued or has been or may be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is
directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to shares which are or are intended to be disposed of
only to persons outside Hong Kong or only to “professional investors” as defined in the SFO and any rules made thereunder. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Notice to
prospective investors in Singapore </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Singapore SFA Product Classification — In connection with Section 309B of the SFA and the CMP
Regulations 2018, unless otherwise specified before an offer of Notes, we have determined, and hereby notifies all relevant persons (as defined in Section 309A(1) of the SFA), that the Notes are ‘‘prescribed capital markets
products’’ (as defined in the CMP Regulations 2018) and Excluded Investment Products (as defined in MAS Notice SFA <FONT STYLE="white-space:nowrap">04-N12:</FONT> </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">113 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
Notice on the Sale of Investment Products and MAS Notice <FONT STYLE="white-space:nowrap">FAA-N16:</FONT> Notice on Recommendations on Investment Products). </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Each representative has acknowledged that this prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, each
representative has represented and agreed that it has not offered or sold any shares of common stock or caused the shares of common stock to be made the subject of an invitation for subscription or purchase and will not offer or sell any shares of
common stock or cause the shares of common stock to be made the subject of an invitation for subscription or purchase, and has not circulated or distributed, nor will it circulate or distribute, this prospectus or any other document or material in
connection with the offer or sale, or invitation for subscription or purchase, of the shares, whether directly or indirectly, to any person in Singapore other than: </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">(a) to an institutional investor (as defined in Section 4A of the Securities and Futures Act (Chapter 289) of Singapore, as modified or amended from time to time (the “SFA”)) pursuant to
Section 274 of the SFA; (b) to a relevant person (as defined in Section 275(2) of the SFA) pursuant to Section 275(1) of the SFA, or any person pursuant to Section 275(1A) of the SFA, and in accordance with the conditions
specified in Section 275 of the SFA; or </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">(c) otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the
SFA. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Where the shares are subscribed or purchased under Section 275 of the SFA by a relevant person which is: </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">(a) a corporation (which is not an accredited investor (as defined in Section 4A of the SFA)) the sole business of which is to hold investments and the entire
share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">(b) a trust (where the trustee is not an
accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor, securities or securities-based derivatives contracts (each term as defined in Section 2(1) of the
SFA) of that corporation or the beneficiaries’ rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the shares pursuant to an offer made under
Section 275 of the SFA except: </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:arial" SIZE="2">i. to an institutional investor or to a relevant person, or to any person arising from an offer
referred to in Section 275(1A) or Section 276(4)(i)(B) of the SFA; </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:arial" SIZE="2">ii. where no consideration is or will be given for the
transfer; </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:arial" SIZE="2">iii. where the transfer is by operation of law; </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:arial" SIZE="2">iv. as specified in Section 276(7) of the SFA; or </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:arial" SIZE="2">v. as specified in Regulation 37A of the
Securities and Futures (Offers of Investments) (Securities and Securities-based Derivatives Contracts) Regulations 2018. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Notice to prospective
investors in China </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">This prospectus will not be circulated or distributed in the PRC and the shares of common stock will not be offered or sold,
and will not be offered or sold to any person for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale directly or indirectly to any residents of the PRC except pursuant to any applicable laws and regulations of the PRC. Neither this
prospectus nor any advertisement or other offering material may be distributed or published in the PRC, except under circumstances that will result in compliance with applicable laws and regulations. </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">114 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Notice to prospective investors in Korea </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The shares of common stock have not been and will not be registered under the Financial Investments Services and Capital Markets Act of Korea and the decrees and regulations thereunder (the “FSCMA”), and
the shares of common stock have been and will be offered in Korea as a private placement under the FSCMA. None of the shares of common stock may be offered, sold or delivered directly or indirectly, or offered or sold to any person for <FONT
STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Korea or to any resident of Korea except pursuant to the applicable laws and regulations of Korea, including the FSCMA and the Foreign Exchange Transaction Law of
Korea and the decrees and regulations thereunder (the “FETL”). The shares of common stock have not been listed on any of securities exchanges in the world including, without limitation, the Korea Exchange in Korea. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Furthermore, the purchaser of the shares of common stock shall comply with all applicable regulatory requirements (including but not limited to requirements under
the FETL) in connection with the purchase of the shares. By the purchase of the shares of common stock, the relevant holder thereof will be deemed to represent and warrant that if it is in Korea or is a resident of Korea, it purchased the shares of
common stock pursuant to the applicable laws and regulations of Korea. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Notice to prospective investors in Taiwan </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The shares of common stock have not been and will not be registered with the Financial Supervisory Commission of Taiwan pursuant to relevant securities laws and
regulations and may not be sold, issued or offered within Taiwan through a public offering or in circumstances which constitutes an offer within the meaning of the Securities and Exchange Act of Taiwan that requires a registration or approval of the
Financial Supervisory Commission of Taiwan. No person or entity in Taiwan has been authorized to offer, sell, give advice regarding or otherwise intermediate the offering and sale of the shares in Taiwan. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Notice to prospective investors in Saudi Arabia </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">This
document may not be distributed in the Kingdom of Saudi Arabia except to such persons as are permitted under the Offers of Securities Regulations as issued by the board of the Saudi Arabian Capital Market Authority (the “CMA”) pursuant to
resolution number <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2-11-2004</FONT></FONT> dated 4 October 2004 as amended by resolution number
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-28-2008,</FONT></FONT> as amended (the “CMA Regulations”). The CMA does not make any representation as to the accuracy or completeness of this document and expressly
disclaims any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this document. Prospective purchasers of the securities offered hereby should conduct their own due diligence on the accuracy of the information
relating to the securities. If you do not understand the contents of this document, you should consult an authorized financial adviser. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Notice to
prospective investors in the Dubai International Financial Centre (“DIFC”) </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">This document relates to an Exempt Offer in accordance with
the Markets Rules 2012 of the Dubai Financial Services Authority (the “DFSA”). This document is intended for distribution only to persons of a type specified in the Markets Rules 2012 of the DFSA. It must not be delivered to, or relied on
by, any other person. The DFSA has no responsibility for reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus supplement nor taken steps to verify the information set forth herein and has
no responsibility for this document. The shares of common stock to which this document relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the shares of common stock offered should conduct their own due
diligence on the securities. If you do not understand the contents of this document, you should consult an authorized financial advisor. </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">115 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In relation to its use in the DIFC, this document is strictly private and confidential and is being distributed to
a limited number of investors and must not be provided to any person other than the original recipient, and may not be reproduced or used for any other purpose. The interests in the securities may not be offered or sold directly or indirectly to the
public in the DIFC. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Notice to prospective investors in the United Arab Emirates </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The shares of common stock have not been, and are not being, publicly offered, sold, promoted or advertised in the United Arab Emirates (including the Dubai International Financial Centre) other than in compliance
with the laws of the United Arab Emirates (and the Dubai International Financial Centre) governing the issue, offering and sale of securities. Further, this prospectus does not constitute a public offer of securities in the United Arab Emirates
(including the Dubai International Financial Centre) and is not intended to be a public offer. This prospectus has not been approved by or filed with the Central Bank of the United Arab Emirates, the Securities and Commodities Authority or the Dubai
Financial Services Authority. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Notice to prospective investors in Bermuda </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Shares of common stock may be offered or sold in Bermuda only in compliance with the provisions of the Investment Business Act of 2003 of Bermuda which regulates the sale of securities in Bermuda. Additionally, <FONT
STYLE="white-space:nowrap">non-Bermudian</FONT> persons (including companies) may not carry on or engage in any trade or business in Bermuda unless such persons are permitted to do so under applicable Bermuda legislation. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Notice to prospective investors in the British Virgin Islands </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The shares of common stock are not being, and may not be offered to the public or to any person in the British Virgin Islands for purchase or subscription by or on behalf of us. The shares of common stock may be
offered to companies incorporated under the BVI Business Companies Act, 2004 (British Virgin Islands),“BVI Companies”), but only where the offer will be made to, and received by, the relevant BVI Company entirely outside of the British
Virgin Islands. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Notice to prospective investors in South Africa </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Due to restrictions under the securities laws of South Africa, no “<I>offer to the public</I>” (as such term is defined in the South African Companies Act, No. 71 of 2008 (as amended or <FONT
STYLE="white-space:nowrap">re-enacted)</FONT> (the “South African Companies Act”)) is being made in connection with the issue of the shares in South Africa. Accordingly, this document does not, nor is it intended to, constitute a
“<I>registered prospectus</I>” (as that term is defined in the South African Companies Act) prepared and registered under the South African Companies Act and has not been approved by, and/or filed with, the South African Companies and
Intellectual Property Commission or any other regulatory authority in South Africa. The shares are not offered, and the offer shall not be transferred, sold, renounced or delivered, in South Africa or to a person with an address in South Africa,
unless one or other of the following exemptions stipulated in section 96 (1) applies: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">
<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Section 96 (1) (a)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">the offer, transfer, sale, renunciation or delivery is to:</FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:arial" SIZE="2">i.    persons whose ordinary business, or part of whose ordinary business, is to deal in
securities, as principal or agent;</FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:arial" SIZE="2">ii.   the South African Public Investment Corporation;</FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:arial" SIZE="2">iii.   persons or entities regulated
by the Reserve Bank of South Africa;</FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:arial" SIZE="2">iv.   authorised financial service providers under South African
law;</FONT></P></TD></TR></TABLE>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">116 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">
<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="top"> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:arial" SIZE="2">v.   financial
institutions recognised as such under South African law;</FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-2.00em"><FONT
STYLE="font-family:arial" SIZE="2">vi.   a wholly-owned subsidiary of any person or entity contemplated in (c), (d) or (e), acting as agent in the capacity of an authorised portfolio manager for a pension fund, or as manager for a
collective investment scheme (in each case duly registered as such under South African law); or</FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:arial" SIZE="2">vii.  any combination of the person in (i) to (vi); or</FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:1px"><FONT SIZE="1"> </FONT></P></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Section 96 (1) (b)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">the total contemplated acquisition cost of the securities, for any single addressee acting as principal is equal to or greater than ZAR1,000,000 or such higher amount as may be promulgated by
notice in the Government Gazette of South Africa pursuant to section 96(2)(a) of the South African Companies Act.</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Information made available in this prospectus should not be considered as “<I>advice</I>” as defined in the South African
Financial Advisory and Intermediary Services Act, 2002. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Notice to prospective investors in Israel </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">This document does not constitute a prospectus under the Israeli Securities Law, 5728-1968, and has not been filed with or approved by the Israel Securities
Authority. In Israel, this prospectus is being distributed only to, and is directed only at, qualified investors listed in the first addendum, or the Addendum, to the Israeli Securities Law. Qualified investors may be required to submit written
confirmation that they fall within the scope of the Addendum. </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">117 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="toc166948_14"></A>Legal matters </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The validity of the issuance of our common stock offered in this prospectus will be passed upon for us by Latham & Watkins LLP, Menlo Park, California. Davis Polk & Wardwell LLP, Menlo Park,
California is acting as counsel for the underwriters in connection with this offering. Latham & Watkins LLP and certain attorneys and investment funds affiliated with the firm own an aggregate of 14,294 shares of common stock of the
Company. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="toc166948_15"></A>Experts </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The
consolidated financial statements of Aligos Therapeutics, Inc. appearing in Aligos Therapeutics, Inc.’s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December 31, 2020, have been audited by
Ernst & Young LLP, independent registered public accounting firm, as set forth in their report thereon, included therein, and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in
reliance upon such report given on the authority of such firm as experts in accounting and auditing. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="toc166948_16"></A>Where you can find
more information </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> under the Securities Act
with respect to the shares of common stock offered hereby. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement or the exhibits and schedules filed
therewith. For further information with respect to Aligos Therapeutics, Inc. and the common stock offered hereby, reference is made to the registration statement and the exhibits and schedules filed therewith or incorporated by reference therein.
Statements contained in, or incorporated by reference in, this prospectus regarding the contents of any contract or any other document that is filed or incorporated by reference as an exhibit to the registration statement are not necessarily
complete, and each such statement is qualified in all respects by reference to the full text of such contract or other document filed or incorporated by reference as an exhibit to the registration statement. The SEC also maintains a website that
contains reports, proxy and information statements and other information regarding registrants that file electronically with the SEC. The address is www.sec.gov. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We are subject to the information and periodic reporting requirements of the Exchange Act and, in accordance therewith, file periodic reports, proxy statements and other information with the SEC. Such periodic
reports, proxy statements and other information are available at the website of the SEC referred to above. We maintain a website at www.aligos.com. You may access our annual reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> quarterly
reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> current reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act with
the SEC free of charge at our website as soon as reasonably practicable after such material is electronically filed with, or furnished to, the SEC. The reference to our website address does not constitute incorporation by reference of the
information contained on our website, and you should not consider the contents of our website in making an investment decision with respect to our common stock. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B><A NAME="toc166948_17"></A>Incorporation of certain information by reference </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The SEC allows us to
“incorporate by reference” information from other documents that we file with it, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered to
be part of this prospectus. Information in this prospectus supersedes information incorporated by reference that we filed with the SEC prior to the date of this prospectus. We </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">118 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
incorporate by reference into this prospectus and the registration statement of which this prospectus is a part the information or documents listed below that we have filed with the SEC
(Commission File <FONT STYLE="white-space:nowrap">No. 001-39617):</FONT> </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1799448/000156459021014872/algs-10k_20201231.htm">Form <FONT
STYLE="white-space:nowrap">10-K</FONT></A> for the year ended December 31, 2020, filed with the SEC on March 23, 2021; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">The information specifically incorporated by reference into our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended
December 31, 2020 from our <A HREF="http://www.sec.gov/Archives/edgar/data/1799448/000119312521134253/d65632ddef14a.htm">Definitive Proxy Statement</A> on Schedule 14A, filed with the SEC on April 27, 2021; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Our Quarterly Report on <A HREF="http://www.sec.gov/Archives/edgar/data/0001799448/000156459021026071/algs-10q_20210331.htm"><FONT STYLE="white-space:nowrap">Form 10-Q
</FONT></A> for the quarter ended March 31, 2021, filed with the SEC on May 10, 2021; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Our Current Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1799448/000119312521134238/d90489d8k.htm"><FONT STYLE="white-space:nowrap">Form
8-K</FONT></A> filed with the SEC on April 27, 2021; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">The description of our common stock which is registered under Section
12 of the Exchange Act, in our registration statement on <A HREF="http://www.sec.gov/Archives/edgar/data/0001799448/000119312520268246/d61469d8a12b.htm"><FONT STYLE="white-space:nowrap">Form 8-A</FONT></A>, filed on October 13, 2020,
including any amendment or reports filed for the purposes of updating this description. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Notwithstanding the statements in the
preceding paragraphs, no document, report or exhibit (or portion of any of the foregoing) or any other information that we have “furnished” to the SEC pursuant to the Exchange Act shall be incorporated by reference into this prospectus.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We will furnish without charge to you, on written or oral request, a copy of any or all of the documents incorporated by reference in this prospectus,
including exhibits to these documents. You should direct any requests for documents to Aligos Therapeutics, Inc., One Corporate Drive, 2nd Floor, South San Francisco, CA 94080. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">You also may access these filings on our website at www.aligos.com. We do not incorporate the information on our website into this prospectus or any supplement to this prospectus and you should not consider any
information on, or that can be accessed through, our website as part of this prospectus or any supplement to this prospectus (other than those filings with the SEC that we specifically incorporate by reference into this prospectus or any supplement
to this prospectus). </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Any statement contained in a document incorporated or deemed to be incorporated by reference in this prospectus will be deemed
modified, superseded or replaced for purposes of this prospectus to the extent that a statement contained in this prospectus modifies, supersedes or replaces such statement. </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">119 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:48px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="5"><B><I> shares
</I></B></FONT></P> <P STYLE="font-size:24px;margin-top:0px;margin-bottom:0px"> </P> <P STYLE="font-size:96px;margin-top:0px;margin-bottom:0px"> </P> <P STYLE="font-size:85px;margin-top:0px;margin-bottom:0px"> </P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">
<IMG SRC="g166948g01s66.jpg" ALT="LOGO">
</P> <P STYLE="margin-top:96px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="5"><B><I>Common stock </I></B></FONT></P> <P STYLE="font-size:48px;margin-top:0px;margin-bottom:0px"> </P>
<P STYLE="font-size:96px;margin-top:0px;margin-bottom:0px"> </P> <P STYLE="margin-top:36px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Prospectus dated
, 2021 </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>PART II </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Information not required in prospectus </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Item 13.
Other expenses of issuance and distribution. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following table sets forth the costs and expenses, other than the underwriting discounts and
commissions, payable by the registrant in connection with the sale of common stock being registered. All amounts are estimates except for the Securities and Exchange Commission (SEC) registration fee and the FINRA filing fee. </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">
<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2px solid #000000"> </TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2px solid #000000"> </TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Item</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Amount paid<BR>or to be paid</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">SEC registration fee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"> *</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">FINRA filing fee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Printing and engraving expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Legal fees and expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accounting fees and expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Transfer agent fees and expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Miscellaneous expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD>
<TD> </TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000"> </P></TD>
<TD> </TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">* To be completed by amendment. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Item 14. Indemnification of directors and officers. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">As permitted by Section 102 of the Delaware General Corporation Law, we have adopted provisions in our amended and restated certificate of incorporation and bylaws that limit or eliminate the personal
liability of our directors for a breach of their fiduciary duty of care as a director. The duty of care generally requires that, when acting on behalf of the corporation, directors exercise an informed business judgment based on all material
information reasonably available to them. Consequently, a director will not be personally liable to us or our stockholders for monetary damages for breach of fiduciary duty as a director, except for liability for: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">any breach of the director’s duty of loyalty to us or our stockholders; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">any act related to unlawful stock repurchases, redemptions or other distributions or payment of dividends; or </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">any transaction from which the director derived an improper personal benefit. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">These limitations of liability do not affect the availability of equitable remedies such as injunctive relief or rescission. Our amended and restated certificate of incorporation also authorizes us to indemnify our
officers, directors and other agents to the fullest extent permitted under Delaware law. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As permitted by Section 145 of the Delaware General
Corporation Law, our amended and restated bylaws provide that: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we shall indemnify our directors and officers, and may indemnify our employees and agents to the fullest extent permitted by the Delaware General Corporation
Law, subject to limited exceptions; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we shall advance expenses to our directors and officers and may advance expenses to our employees and agents in connection with a legal proceeding to the fullest
extent permitted by the Delaware General Corporation Law, subject to limited exceptions; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">•</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the rights provided in our amended and restated bylaws are not exclusive. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Our amended and restated certificate of incorporation and our amended and restated bylaws provide for the indemnification provisions described above and elsewhere herein. We have entered into separate
</FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
indemnification agreements with our directors and officers which may be broader than the specific indemnification provisions contained in the Delaware General Corporation Law. These
indemnification agreements generally require us, among other things, to indemnify our officers and directors against liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising from
willful misconduct. These indemnification agreements also generally require us to advance any expenses incurred by the directors or officers as a result of any proceeding against them as to which they could be indemnified. In addition, we have
purchased a policy of directors’ and officers’ liability insurance that insures our directors and officers against the cost of defense, settlement or payment of a judgment in some circumstances. These indemnification provisions and the
indemnification agreements may be sufficiently broad to permit indemnification of our officers and directors for liabilities, including reimbursement of expenses incurred, arising under the Securities Act of 1933, as amended (the Securities Act).
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The form of Underwriting Agreement, to be attached as Exhibit 1.1 hereto, provides for indemnification by the underwriters of us and our officers
who sign this Registration Statement and directors for specified liabilities, including matters arising under the Securities Act. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Item 15.
Recent sales of unregistered securities. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following list sets forth information as to all securities we have sold since February 5,
2018, which were not registered under the Securities Act. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">1.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">In March and July 2018, we issued an aggregate of 2,011,864 shares of restricted common stock pursuant to restricted stock purchase agreements to our founders, early employees
and academic collaborators at a price of $0.001033865384 per share. </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">2.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">In April and June 2018, we issued convertible promissory notes in an aggregate principal amount of $5 million and warrants to purchase shares of capital stock to 19
accredited investors. </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">3.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">In June 2018, we issued a convertible promissory note in a principal amount of $600,000 to one accredited investor. </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">4.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">In August and September 2018, we issued an aggregate of 10,806,432 shares of Series A convertible preferred stock to 27 accredited investors at a price per share of either (i)
$9.32 in cash or (ii) with respect 612,975 shares of Series A preferred stock issued upon conversion of convertible promissory notes issued by us, $5.7 million in cancellation of indebtedness, for a total amount raised (including the
cancellation of indebtedness and accrued interest thereon) of $100.7 million. </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">5.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">In December 2019, we issued an aggregate of 8,344,034 shares of Series <FONT STYLE="white-space:nowrap">B-1</FONT> convertible preferred stock to 38 accredited investors at a
price per share of $10.1869 for aggregate proceeds to us of $85 million. </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">6.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">In October 2020, we issued an aggregate of 3,569,630 shares of Series <FONT STYLE="white-space:nowrap">B-2</FONT> convertible preferred stock to 38 accredited investors at a
price per share of $11.20563 for aggregate proceeds to us of $40 million. </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">7.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Prior to filing our registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> in October 2020, we granted stock options and stock awards to employees, directors
and consultants covering an aggregate of 4,776,930 shares of common stock, at a weighted-average exercise price of approximately $2.09 per share. Of these, options covering an aggregate of 3,219 shares were cancelled without being exercised.
</FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">8.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Prior to filing our registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> in October 2020, we sold an aggregate of 2,125,374 shares of common stock to
employees, directors and consultants for cash consideration in the aggregate amount of approximately $0.7 million pursuant to stock options and stock awards. </FONT></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We claimed exemption from registration under the Securities Act for the sale and issuance of securities in the transactions described in paragraphs (1) through (6) by virtue of Section 4(a)(2) and/or
Regulation D </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
promulgated thereunder as transactions not involving any public offering. All of the purchasers of unregistered securities for which we relied on Section 4(a)(2) and/or Regulation D
represented that they were accredited investors as defined under the Securities Act. We claimed such exemption on the basis that (a) the purchasers in each case represented that they intended to acquire the securities for investment only and
not with a view to the distribution thereof and that they either received adequate information about the registrant or had access, through employment or other relationships, to such information and (b) appropriate legends were affixed to the
stock certificates issued in such transactions. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We claimed exemption from registration under the Securities Act for the sales and issuances of
securities in the transactions described in paragraphs (7) and (8) above under Section 4(a)(2) of the Securities Act in that such sales and issuances did not involve a public offering or under Rule 701 promulgated under the
Securities Act, in that they were offered and sold either pursuant to written compensatory plans or pursuant to a written contract relating to compensation, as provided by Rule 701. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Item 16. Exhibits and financial statement schedules. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>(a) Exhibits. </I></B></FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">
<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2px solid #000000"> </TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-TOP:2px solid #000000"> </TD>
<TD HEIGHT="4" COLSPAN="12" STYLE="BORDER-TOP:2px solid #000000"> </TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2px solid #000000"> </TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="right" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Incorporated by reference</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Filed<BR>herewith</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Exhibit<BR>number</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Exhibit description</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Form</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Date</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Number</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"> <FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">1.1*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Form of Underwriting Agreement.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">3.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/0001799448/000119312520272852/d46540dex31.htm">Amended and Restated Certificate of Incorporation. </A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">8-K</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10/20/2020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">3.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/0001799448/000119312520272852/d46540dex32.htm">Amended and Restated Bylaws. </A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">8-K</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10/20/2020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">4.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Reference is made to Exhibits 3.1 and 3.2.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">4.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/0001799448/000119312520267346/d31402dex42.htm">Form of Common Stock Certificate. </A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">S-1/A</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10/9/2020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">5.1*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Opinion of Latham & Watkins LLP.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.1(a)†</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/0001799448/000119312520254760/d31402dex101a.htm">Aligos Therapeutics/Emory University License Agreement by and between Aligos Therapeutics, Inc.
and Emory University, dated June 26, 2018. </A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">S-1</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9/25/2020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">(a) </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.1(b)†</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/0001799448/000119312520254760/d31402dex101b.htm">First Amendment to License Agreement by and between Aligos Therapeutics, Inc. and Emory University,
dated June 18, 2020. </A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">S-1</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9/25/2020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">(b) </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.2(a)†</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/0001799448/000119312520254760/d31402dex102a.htm">License Agreement by and between Aligos Therapeutics, Inc. and Luxna Biotech Co., Ltd., dated
December 19, 2018. </A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">S-1</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9/25/2020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">(a) </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.2(b)†</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/0001799448/000119312520254760/d31402dex102b.htm">Amendment to License Agreement by and between Aligos Therapeutics, Inc. and Luxna Biotech Co.,
Ltd., dated April 8, 2020. </A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">S-1</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9/25/2020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">(b) </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/0001799448/000119312520254760/d31402dex103.htm">Lease between Aligos Therapeutics, Inc. and Britannia Biotech Gateway Limited Partnership, dated
June 21, 2018. </A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">S-1</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9/25/2020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.4</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/0001799448/000119312520267346/d31402dex104.htm">Amended and Restated Investors’ Rights Agreement dated October 9, 2020.
</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">S-1/A</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10/9/2020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.5(a)#</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/0001799448/000119312520254760/d31402dex105a.htm">2018 Equity Incentive Plan, as amended. </A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">S-1</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9/25/2020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">(a) </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR></TABLE>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">
<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2px solid #000000"> </TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-TOP:2px solid #000000"> </TD>
<TD HEIGHT="4" COLSPAN="12" STYLE="BORDER-TOP:2px solid #000000"> </TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2px solid #000000"> </TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="right" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Incorporated by reference</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Filed<BR>herewith</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Exhibit<BR>number</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Exhibit description</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Form</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Date</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Number</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"> <FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.5(b)#</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/0001799448/000119312520254760/d31402dex105b.htm">Form of Stock Option Grant Notice and Stock Option Agreement under 2018 Equity Incentive Plan,
as amended. </A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">S-1</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9/25/2020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">(b) </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.5(c)#</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/0001799448/000119312520254760/d31402dex105c.htm">Form of Early Exercise Stock Option Grant Notice and Stock Option Agreement under 2018 Equity
Incentive Plan, as amended. </A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">S-1</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9/25/2020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">(c) </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.5(d)#</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/0001799448/000119312520254760/d31402dex105d.htm">Form of International Stock Option Grant Notice and Stock Option Agreement under 2018 Equity Incentive
Plan, as amended. </A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">S-1</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9/25/2020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">(d) </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.6(a)#</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/0001799448/000119312520267346/d31402dex106a.htm">2020 Incentive Award Plan. </A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">S-1/A</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10/9/2020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">(a) </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.6(b)#</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/0001799448/000119312520267346/d31402dex106b.htm">Form of Stock Option Grant Notice and Stock Option Agreement under the 2020 Incentive Award Plan.
</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">S-1/A</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10/9/2020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">(b) </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.6(c)#</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/0001799448/000119312520267346/d31402dex106c.htm">Form of Restricted Stock Award Agreement under the 2020 Incentive Award Plan.
</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">S-1/A</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10/9/2020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">(c) </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.6(d)#</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/0001799448/000119312520267346/d31402dex106d.htm">Form of Restricted Stock Unit Award Grant Notice under the 2020 Incentive Award Plan.
</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">S-1/A</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10/9/2020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">(d) </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.7#</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/0001799448/000119312520267346/d31402dex107.htm">2020 Employee Stock Purchase Plan. </A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">S-1/A</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10/9/2020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.8#</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/0001799448/000156459021026071/algs-ex102_183.htm">Amended and Restated Employment Agreement, effective as of dated February
10, 2021, by and between the Company and Lawrence M. Blatt, Ph.D. </A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">10-Q</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">05/10/2021</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.9#</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/0001799448/000156459021026071/algs-ex101_184.htm">Amended and Restated Employment Agreement, dated effective as of February
10, 2021, by and between the Company and Leonid Beigelman, Ph.D. </A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">10-Q</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">05/10/2021</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.10#</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/0001799448/000119312520267346/d31402dex1010.htm">Confirmatory Employment Letter by and between Aligos Therapeutics, Inc. and Lucinda Quan, J.D.,
dated May 14, 2019. </A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">S-1/A</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10/9/2020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10.10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.11#</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/0001799448/000156459021026071/algs-ex103_277.htm">Employment Agreement by and between Aligos Therapeutics, Inc. and Julian Symons, D.Phil., dated
May 14, 2019. </A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">10-Q</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5/10/2021</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.12#</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/0001799448/000119312520267346/d31402dex1011.htm"><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Program.
</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">S-1/A</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10/9/2020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10.11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.13#</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/0001799448/000156459021026071/algs-ex104_182.htm">Form of Change in Control and Severance Agreement. </A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">10-Q</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5/10/2021</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.14</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/0001799448/000119312520267346/d31402dex1012.htm">Form of Indemnification Agreement for directors and officers. </A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">S-1/A</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10/9/2020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10.12</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">21.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/0001799448/000119312520254760/d31402dex211.htm">Subsidiaries of Registrant. </A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">S-1</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9/25/2020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">21.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">23.1*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Consent of Independent Registered Public Accounting Firm.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">23.2*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Consent of Latham & Watkins LLP (included in Exhibit 5.1).</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">24.1*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Power of Attorney.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="18" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000"> </P></TD>
<TD> </TD></TR>
</TABLE>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">†</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Portions of the exhibit, marked by brackets, have been omitted because the omitted information (i) is not material and (ii) would likely cause competitive harm if
publicly disclosed. </FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">#</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Indicates management contract or compensatory plan. </FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">*</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">To be filed by amendment. </FONT></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(b) Financial Statement
Schedules.</B> Schedules not listed above have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or notes thereto. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Item 17. Undertakings. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Insofar as
indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the
opinion of the SEC such indemnification is against public policy as expressed in the Securities Act, and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant
of expenses incurred or paid by a director, officer, or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities
being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question of whether such indemnification by it is against public
policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The undersigned Registrant hereby undertakes
that: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">1.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this Registration Statement in reliance
upon Rule 430A and contained in a form of prospectus filed by the Registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this Registration Statement as of the time it was declared
effective. </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">2.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration
statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </FONT></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The undersigned Registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreement certificates in such denominations and registered in such names as required by the
underwriters to permit prompt delivery to each purchaser. </FONT></P>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Signatures </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant has duly caused this Registration Statement
<FONT STYLE="white-space:nowrap">on Form S-1 to</FONT> be signed on its behalf by the undersigned, thereunto duly authorized, in South San Francisco, California on
, 2021. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">
<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Aligos Therapeutics, Inc.</B></FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">By:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></P></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Lawrence M. Blatt, Ph.D.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:arial" SIZE="2"><I>Chief Executive Officer</I></FONT></P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Power of attorney </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Lawrence M. Blatt, Ph.D., Lesley Ann Calhoun and
Lucinda Quan, J.D., and each of them acting individually, as his or her true and lawful <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents, each with full power of substitution, for him in
any and all capacities, to sign any and all amendments to this Registration Statement, including post-effective amendments or any abbreviated registration statement and any amendments thereto filed pursuant to Rule 462(b) increasing the number of
securities for which registration is sought, and to file the same, with all exhibits thereto and other documents in connection therewith, with the SEC, granting unto said attorneys-in-fact and agents, with full power of each to act alone, full power
and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents, or his, her or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates
indicated. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">
<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2px solid #000000"> </TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-TOP:2px solid #000000"> </TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-TOP:2px solid #000000"> </TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Signature</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Title</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Date</B></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Lawrence M. Blatt, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Chief Executive Officer and Director</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><I>(Principal Executive Officer)</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"> , 2021</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Lesley Ann Calhoun</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Executive Vice President, Chief Financial Officer</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><I>(Principal Financial and Accounting Officer)</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"> , 2021</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Leonid Beigelman, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">President and Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"> , 2021</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">K. Peter Hirth, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"> , 2021</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Jack B. Nielsen</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"> , 2021</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Peter Moldt, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"> , 2021</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="5" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000"> </P></TD></TR></TABLE>
</DIV></Center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">CONFIDENTIAL TREATMENT REQUESTED BY ALIGOS THERAPEUTICS, INC. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PURSUANT TO 17 C.F.R. Section 200.83 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">
<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2px solid #000000"> </TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-TOP:2px solid #000000"> </TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-TOP:2px solid #000000"> </TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Signature</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Title</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Date</B></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Carole Nuechterlein</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"> , 2021</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Thomas Woiwode, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"> , 2021</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Kathleen Sereda Glaub</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"> , 2021</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">James Scopa</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"> , 2021</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="5" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000"> </P></TD></TR>
</TABLE>
</DIV></Center>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g166948g01s66.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g166948g01s66.jpg
M_]C_X 02D9)1@ ! 0(!>0%Y #_X<Q[:'1T<#HO+VYS+F%D;V)E+F-O;2]X
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M(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $, 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_ !$( #P
MN ,!$0 "$0$#$0'_Q = " @,! 0$ )"@ (! 8'!0$"_\0
M.A 00# $# P$$!P<% ! (#!08!!P@) !$2"A,4%18A(C(7&",Q-3EV
M-G1UM+6WN$%8<9;7_\0 ' $! (" P$ ,& @<!! 4(_\0
M/Q$ @(! P(#!00(! 4% 0(#! 4 !A$2(0<3,10B05%Q(S)AL146,X&1
MH<'1)$*R\ A6E-7A-#52XO'_V@ , P$ A$#$0 _ '^/330;O.[W#_49\=VV
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M(HD>221UCCCC4N\CN0J(B*"S.S$*JJ"6) ).HW=(U9W941%9W=V"JB*"69F
M) 55 )9B0 23QI<[?'ELZ$Z*VT?S?XO-<.W>6%62-);H/A0Y5#C0[^!2)RM
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M%8BE@GC2:&:-XI8I5#QR1NI5T=&!5D92592"""0=5TY<X[T+QU6;-5]&5)<
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M5X28DLMY8!>4EKE1U, /B?\ ]_@-*K_39[MX=YHUAO[J7J[L'0E0Z=Z7V <
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MJE\K X:4#$18%NL+274GNOY:RE (5Q_F'!_I\/K_ ]-.92G^&R/^XE_\NYZ
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MQHJ1HH1$10J(B@!555 554 * .-97K#66J@]G<)<P=]ZN5J?IS6L?=H
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M3R[6RJ\]O.DL,5@>Y;_U@T)%F.K64RWKFEVN?J3;I*'5ID&PK -*JRK)24-
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M([MJ-8&CGAVF& D8_%:J6X9)I<I.T]K#7).B$&Q@:=6CC' B3@0UZ=#&P*Z
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M:,U UN]QI[<#>MZ<G9CC60E?.[8@0<6++ZHS&(M9GZE^1@]<5C$6LW!"HW&
M<L8]:YW$<4<]F3@@1ACD[IQ8;K'%'VB3V;I$OVH3RNGRQ+]J$Z1+]IU:NV%&
M0&(Q@RQ!R8H51?(Z.]OR4\_J\O[/K\SJZS']F7ZC& G2-5>[PV%</TB@\_:E
MV3"ZJVWM\Z<LX-\F90*-%I5.U$(-;CI<ATPH9&46>\YH&MOQE*QDJ-N4V2TK
MVBW\HM.P<=2\[([BS&,GRV'PR5ZLF/@B>5[UW,.U-(5"(W>I0_2.3ZO\DM*N
MI_:J#7MXWK7E4\+C;\6.R>3>:PER61(UJ5<8JV7E)=E'^(MFE1Z3]Y+4S _9
MGBS7/.XHK?VE=<[>B&4!MW2N#&RD2EY!"J_9PG'HFWUA]YM;B'2JQ:0)B *<
M0M:%D1SBT+6A259K&X\+-M[.9+#3,7-&RR13%2HLU9 LU.TJD A+522&P@(!
M"R@$ CC7OX3*19K$T<G$ HMP*\D8//DV$)BM5R02"U>RDL#$$@M&2"1JG?<L
M_#@[DY4K]OE.A&J+80]^/3<#SC);X%N<Y,0M=HS]7??C^>RA[E("Q!I13S;Q
MJ'(&/62MV34R.\M2KGL2O-)A=VV:<6W3?K/M\06-RQ;?>C!#-9OK;59-QHU*
M-IHT4%8R+$H0"(,R@:K&[IHTRFW8+,F;%.9,RTT."DS*VII88*C5R4PC+:D6
M)V8@N#"G43)P#JSW)B=IIY_H6-RXLV+QC-IS\;NL-V]IIV;I8LZS1?7 <J'<
MO:-:YJ2+FO*E$JLJ911RE'9)5FJ[O_1/ZPY#]"^R^P?X7O0#C'F[[%6_2AQX
MD]X4#D_;#2'W15\KR_L^G7O[;_2(PM,97VCVS_$?^K*&Y[+[7/\ H_VTI[IN
M>P>S>U'[QL>9U^_U:I+O0EB>[5V15[54^N]DUF"YVT)-5^M\W;;V108FK3-@
MOG08EAE[%&4O<^IPBC;*) 0 HIA3<R0IJNN-?()#2<$WG JU?8V-MU+>SL9:
ML;EW!!8L[FP^,R$UN"OCMN/6AK2WL)EW2.J]BP[HI@4-9!X<D]-3S#";=5^O
M9K;GOUX<+AY8(,#DK]..O+-;S"SR3QU,KC49IUAA5682MQ 1R@'O%/K[#(T#
M"##L2HHX\1&L,#3IA4C-CLM!LMM,3$@<;)''2K*$I;D##)$\HDM+SY!I3RUO
MN:HL,S6)V9HG9II69JZ)' S%V):&.-(HXXB>\:)'&B(55410%&Q80%AB4"10
M(T 69V>50% E=WD=Y .SNSNS-R6=B236+G*P3TSMGMN/EYN7E0:QTI7X6MA
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MYK& IS6)I9Y6FR0:6:1Y9&"92[&@9W+,0B*J*"3THJJ. !Q7J_4<%,[_P"4
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MNE8$U_#F4Y2AU',O/8.$LX2A.4M_9":5G"\N*^XIS.%X3E*$<[ED:3$;&4@
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MWALF&#,"R4QNXLQ-6-6?R&ZKM#"),)"4D#*!3BZ I4E^2W4 ND][[ER>V=U
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M[<D9,)OI 1-MVBC<\\@+NK;TH*\$<'JC4'D$<$CCG@CS,VH;*[2)YY3-6V'
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%A%1%_]D!
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g166948g08s10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g166948g08s10.jpg
M_]C_X 02D9)1@ ! 0(!>0%Y #_[2@24&AO=&]S:&]P(#,N, X0DE-! 0
M )_:^$",#A"24T$! 61P!6@ #&R5'' ( )P6QP"4 (<G(R.3
M,W-#D< @4 .$UI8W)O<V]F="!7;W)D("T@06QI9V]S("T@1%)3($UA>2 R,#
M(Q(#$R,S@P.34Y,RXQ,2YD;V-X #A"24T$)0 $"@*5+S4>(1C+KYL$0
MWY)NLX0DE-!#H .4 0 0 "W!R:6YT3W5T<'5T !0
M !0<W138F]O; $ 26YT965N=6T 26YT90 !#;')M #W
M!R:6YT4VEX=&5E;D)I=&)O;VP "W!R:6YT97).86UE5$585 $
M ]P<FEN=%!R;V]F4V5T=7!/8FIC # !0 '( ;P!O &8 ( !3 &4 =
M!U ' IP<F]O9E-E='5P 0 !";'1N96YU;0 QB=6EL=&
MEN4')O;V8 )<')O;V9#35E+ #A"24T$.P "+0 ! !
M 2<')I;G1/=71P=71/<'1I;VYS %P !#<'1N8F]O; 0VQB<F
M)O;VP %)G<TUB;V]L !#<FY#8F]O; 0VYT0V)O;VP
M $QB;'-B;V]L !.9W1V8F]O; 16UL1&)O;VP $EN='
M)B;V]L !"8VMG3V)J8P $ !21T)# P !29" @9&
M]U8D!OX $=R;B!D;W5B0&_@ 0FP@(&1O=6) ;^
M !"<F1456YT1B-2;'0 !";&0@56YT1B-2;'
M0 !2<VQT56YT1B-0>&Q <L IV96-T;W)$87
M1A8F]O; $ 4&=0<V5N=6T 4&=0<P !09U!# $QE9G15;G
M1&(U)L= %1O<"!5;G1&(U)L= %-C;"
M!5;G1&(U!R8T!9 $&-R;W!7:&5N4')I;G1I;F=B;V]L
MYC<F]P4F5C=$)O='1O;6QO;F< #&-R;W!296-T3&5F=&QO;F<
M #6-R;W!296-T4FEG:'1L;VYG MC<F]P4F5C=%1O<&QO;F
M< #A"24T#[0 $ $L 0 " 2P ! (X0DE-!"8
MX /X #A"24T$#0 ! '@X0DE-!!D 0
M >.$))30/S ) ! #A"24TG$ "@ !
M(X0DE- _4 $@ +V9F $ ;&9F 8 $ +V9F $ H9F: 8
M $ ,@ $ 6@ 8 $ -0 $ +0 8 $X0DE- _
M@ ' /____________________________\#Z #___________
M__________________ ^@ _____________________________P/H
M /____________________________\#Z .$))300( 0 0
M D ) #A"24T$'@ ! X0DE-!!H S4 &
M ,E '9 ! $
M !V0 ,E $
M $ $ !N=6QL @ 9B;W5N9'-/8FIC 0
M %)C=#$ $ %1O<"!L;VYG !,969T;&]N9P
M 0G1O;6QO;F< ,E %)G:'1L;VYG '9 9S;&EC97-6;$QS
M 4]B:F, ! %<VQI8V4 2 !W-L:6-E241L;VYG
M =G<F]U<$E$;&]N9P &;W)I9VEN96YU;0 Q%4VQI8V5/<F
MEG:6X -875T;T=E;F5R871E9 !4>7!E96YU;0 I%4VQI8V54>7
M!E $EM9R &8F]U;F1S3V)J8P $ !28W0Q !
M!4;W @;&]N9P 3&5F=&QO;F< $)T;VUL;VYG #)0
M !29VAT;&]N9P !V0 #=7)L5$585 $ !N=6QL5$585
M $ !-<V=E5$585 $ 9A;'1486=415A4 0
M #F-E;&Q497AT27-(5$U,8F]O; $ (8V5L;%1E>'1415A4 0
M "6AO<GI!;&EG;F5N=6T /15-L:6-E2&]R>D%L:6=N !V1E9F%U;'
M0 )=F5R=$%L:6=N96YU;0 ]%4VQI8V5697)T06QI9VX '9&5F87
M5L= MB9T-O;&]R5'EP965N=6T 115-L:6-E0D=#;VQO<E1Y<&4
M 3F]N90 ET;W!/=71S971L;VYG IL969T3W5T<V5T;&]N9P
M ,8F]T=&]M3W5T<V5T;&]N9P +<FEG:'1/=71S971L;V
MYG X0DE-!"@ P "/_ X0DE-!!$ $! #
MA"24T$% ! 4X0DE-! P '7T ! H $0 '@
M!_@ '6$ & !_]C_X@Q824-#7U!23T9)3$4 0$ Q(3&EN;P(0 !M;G
M1R4D="(%A96B 'S@ " D !@ Q !A8W-P35-&5 !)14,@<U)'0@
M 0 ]M8 0 #3+4A0("
M !%C<')T !4 #-D97-C
M !A &QW='!T !\ !1B:W!T "! !1R6%E: "& !1G6%
ME: "+ !1B6%E: "0 !1D;6YD "5 '!D;61D "Q (
MAV=65D #3 (9V:65W #U "1L=6UI #^ !1M96%S $#
M "1T96-H $, QR5%)# $/ " QG5%)# $/ " QB5%)#
M $/ " QT97AT $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A8V
MMA<F0@0V]M<&%N>0 9&5S8P 2<U)'0B!)14,V,3DV-BTR+C$
M !)S4D="($E%0S8Q.38V+3(N,0
M 6%E:( /-1
M$ !%LQ865H@ %A96B !OH@ ./4
M.06%E:( &*9 "WA0 &-I865H@ )* ^$ "VSV1E<V
M, %DE%0R!H='1P.B\O=W=W+FEE8RYC: %DE%0R
M!H='1P.B\O=W=W+FEE8RYC:
M !D97-C "Y)14,@-C$Y-C8M,BXQ($
M1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T( "Y)14
M,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M 9&5S8P L4F5F97)E;F-E(%9I97
M=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0 +%)E9F
M5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M '9I97< !.D_@ 47RX $,\4 /MS
M $$PL UR> 5A96B $P)5@!0 5Q_G;65A<P !
M H\ "<VEG( !#4E0@8W5R=@
M0 !0 * \ % 9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &
M@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$ Q@#+ - U0
M#; . Y0#K / ]@#[ 0$!!P$- 1,!&0$? 24!*P$R 3@!/@%% 4P!4@%9 6
M !9P%N 74!? &# 8L!D@&: :$!J0&Q ;D!P0') =$!V0'A >D!\@'Z @,"#
M(4 AT")@(O C@"00)+ E0"70)G G$">@*$ HX"F *B JP"M@+! LL"U0+@ N
ML"]0, PL#%@,A RT#. -# T\#6@-F W(#?@.* Y8#H@.N [H#QP/3 ^ #[
M/Y! 8$$P0@!"T$.P1(!%4$8P1Q!'X$C 2:!*@$M@3$!-,$X03P!/X%#04<!2
ML%.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%]@8&!A8&)P8W!D@&609J!GL&C
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MH<JH^K JMUJ^FL7*S0K42MN*XMKJ&O%J^+L "P=;#JL6"QT
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M #_X4 5:'1T<#HO+VYS+F%D;V)E+F-O;2]X
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M/S[_VP!# $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0'_P 1" $" ET# 1$ A$! Q$!_\0 '@ ! $$ P$!
M 4$!@<( 0,) @K_Q !R$ !@$" 00*"@D-# 8'!0D! @,$!08' @1"1(6
M&1,5%R%55UB6E]44,5%6DY73U-;7&$%4<9*4L;/2(B8R-#5A<W1UD:&TT1HC
M)#,V.%)R@;*U\ HE)W:VP2A&8G=XA;="1%-DI45'A(:'HJ/#QO_$ !T! 0 "
M @,! 0 ! @,$!08'" G_Q !I$0 ! P(" @L+"00$!PP(!04!
M @,$ 4&$1(A!Q,6%S%155:4E=,4%4%487&AT=+4\!@B@9&2D['!U3)24^$C
M)#;Q""4T-T)UM#,U0T1%5V-E<G2%LB9&9'-V@K.U8H.$I,26HJ/#Q?_: P#
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MLV/>:ML^R_VU-W6+^7[A]XGV*=:7R@?E1Y#_ *YZBTWK-CWFK;/LO\ ;4W=
M8OY?N'WB?8IUI?*!^5'D/\"N>HM-ZS8]YJVS[+_;4W=8OY?N'WB?8IUI?*!^
M5'D/\"N>HM-ZS8]YJVS[+_;4W=8OY?N'WB?8IUI?*!^5'D/\"N>HM-ZS8]YJ
MVS[+_;4W=8OY?N'WB?8IUI?*!^5'D/\ KGJ+3>LV/>:ML^R_P!M3=UB_E^X
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M=8OY?N'WB?8IUI?*!^5'D/\ KGJ+3>LV/>:ML^R_P!M3=UB_E^X?>)]BG6E
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M=8OY?N'WB?8IUI?*!^5'D/\ KGJ+3>LV/>:ML^R_P!M3=UB_E^X?>)]BG6E
M\H'Y4>0_P*YZBTWK-CWFK;/LO]M3=UB_E^X?>)]BG6E\H'Y4>0_P*YZBTWK-
MCWFK;/LO]M3=UB_E^X?>)]BG6E\H'Y4>0_P*YZBTWK-CWFK;/LO]M3=UB_E^
MX?>)]BG6E\H'Y4>0_P "N>HM-ZS8]YJVS[+_ &U-W6+^7[A]XGV*=:7R@?E1
M9#[_ /[%<]1:;UFQ[S5MGV7^VINZQ?K_ /2"X?>)]G\,J=:7R@?E1Y#_ *Y
MZBTWK-CWFK;/LO\ ;4W=8OY?N'WB?8IUI?*!^5'D/\"N>HM-ZS8]YJVS[+_;
M4W=8OY?N'WB?8IUI?*!^5'D/\"N>HM-ZS8]YJVS[+_;4W=8OY?N'WB?8IUI?
M*!^5'D/\"N>HM-ZS8]YJVS[+_;4W=8OY?N'WB?8IUI?*!^5'D/\ KGJ+3>L
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MJ+3>LV/>:ML^R_VU-W6+^7[A]XGV*=:7R@?E1Y#_ *YZBTWK-CWFK;/LO\
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M19#_ *YZB_>TWK-CWFK;/LO]M3=UB_/^T%P^\3[.7HIUI?*!^5'D/\ KGJ
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M9JV03.LNNJFDF0QS XW76F&G7WW$,LL-N//.NJ2AMIII!6XXXM1"4(0A*E+
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M]=3<E6[!#-4GLO!RT6U7D9"(17D8YVQ34E(EM%O)2.*9TDD(O8]I-PSEXVX
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MR9S \+-O-/:>TNMNAIQ;+I;6E8;>:5HN-+T2=%QM7S5H.M)U$9U4I4G1TT*
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M""1U#\!YI1X#K!)DQH4=Z7,?9BQ8Z%./R)#B6F66TC-2W75D(0@#A4H@#A)
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M"6BW<[:[.>MC5Q@N7*.V'7[>B4RN:RV0@Z;L9*R\VG)QLE2D .-DD::<\ZH
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MAGF1B6=U"R;&0F[B=K"6HCEB1UN2K-=^Y+[9&;;%?:OLQV2F]JF--IB)DH8
M<FQRGNQR;:]JVNVF*B0TXW&@!<B'HN%&"//@B3;+D])D(<M<=MHVT1E+VY32
MG241G@H1T1IH7I3@\MIU"Y$S:V906D+A,C9NP5:L*2F"(F-M#)/'U+QJ\QC>
M%IEP[KECR#59&2<7ELVHAJ5'R]/C[TME3*LPI*RECD3NWL!16\@TCFZ2*<?E
MMUCOL6]MWUUZ&YWPFW-%S@!E*),:WRVFDP%JG]W.,S'(";3:6 TW%:"$2+@M
MM:UJ47:R[C;'K>NVML24=RQH2H4I3Q<:>E1W'5RD"(8J'(S<M5PN#Y6M]9*V
M8:5)0 -KT$'VQ_\ /V_]NN]UUZFE*:4II2N!#B A[H"'N>WIP5!U@CC!KU#5
MS%MYKF0<H7T^2D\CQ&<7N'(B2QZUH-Q0CJS!UC*6)L@6J;O0VR%BHN:<1D30
M9: AHJLH68\FM8'9U'+5@55*1\S[SXADP+5 %N-M=L2+P\U<%W"&IR4_*M-W
MMT1B#W(\\ZPEUZX-2'G92HP:1&1HI6X06^VB?:F)4^49/=B+J8#;L5,1\(8:
M9GV^8^Y*#[33;JVVHCK+2& _IE]>:@@9.6U$Y9VPFK./4YUE6492NNB(MX^'
MQ9&N$&\H>#O<<C:LBQDS1G;B>8PMDF:U97*4%E*QL;TRC6C&:Q/!JL&C-CM/
M6K$W=5P+#DHMR$9EQZ[.)*F@] <7$MKK$Y"8[C\9F5&2I^U1EP7'5.1[N^'%
MN+UV9UHVB(EYIK-E1 2W!0K)1:EI2],;<C*4\VT\XP\H-W!Y,E"$H=MK*D!
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M(!6HJ(0A("4)3GHI2D )2 !E41K+5:V?VV9P3P8TS5,(*H*SMJQO U6#@Y!
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M>Y4Z@K8QX3SMZ08'Z#Z?*#QWXOA[JZ3^H4WG,+>-7KI<;W*G4%;&/">=O2#
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MG<+>,7SIL3W*G4;;#/NW/WG_ %[Z&:?*#QW_ <.]6RO?Z;SN%O&+YTV)[E3
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MR@\=_P '#O5LKW^F\[A;QB^=-B>Y5]DY#+8:<JA@?9] $B <W&_UX.("H1,
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M>._X&'>KI7O]-YW"OC%\Z;$]QKXZC788'_WW/WG_ %WZ&:?*#QW_ ,.]6RO
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MS/\ WO;_ %_5[O=_AQ']9G>#B/#B.GR@\=_P,.]72M7_ .__ IO.X5\8OG3
M(GY0:=1KL,^[,_\ ?]K]?U>[_'VO_4S[>GR@\=_P,.]72O?Z;SN%O&+YTV)[
MC0>0UV& (@+S/P"'>$!OU>^AFGR@\=_P,.]6RO?Z;SN%O&+YTV)[E7'4;;#/
MNW/WG_7OH9I\H/'?\'#O5LKW^F\[A;QB^=-B>Y4ZC;89]VY^\_Z]]#-/E!X[
M_@X=ZME>_P!-YW"WC%\Z;$]RKU!VF[:L8[5,1M\38C4M*M/;V&<L"1K?*,YB
M8[8S2B"CX#/&;"+1%L!D$P02!J!DPYW.4.(\=>88LQ3<\97=5YNR8J9:H[$7
M*$TXPQM3&EH9-K==5I?/5I$KU^ "N]X=P]!PS;^]MO5)7'V]R1G*<0Z[INA
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M(@4I2E 3&,80*4 $3" .E0?5Y/#\?EKK2G%^\:0ROW.[C7-NV8%,!9>=226
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M@'A\HR\/&#X#Y/#F/#EGD19"]$. $.(T"25#_A&UY@)4 K6V!DL*3D<PG2"
M5)^U)CE"X2\XTBJ73\D&Q^YRY'R5RDI.'V^1C*TXTMNX"0B;B^R-!Q]#1LC2
MW0>&%6-O4DJ;:<>O%;#)%<HP=T,QL,?"Q5",^#A (&L\.7G\O#Y>&O1W:U7;
M74-L>W*IWQF^C[S5\#XAKMS82CHCZ38VR$Q]7HRQ,Y%ZDX=I/'S:8:O$7;I-
MVY3<+D45(X6*<%#*L/+Y?QU>BL[Z4II2LCUC]RR_PZWY2Z4J;<=F[ O['!,S
MCL*G8"K&,1(RW,-V(JIR$4.1,3\T%#$3.<I1$2D,8 9&CF-+2T<QI:(!5EF
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M<4NV=%JEI#<$OB:!OC>_PV#UI$]@/0B-FZC)C1'F4"1YI=YCQ!1H2F-;@O
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M1$!()7+E XF 1$"B7@8.!N/$ 4JG[82/@%]^-Q/S_2E.V$CX!??C<3\_TI
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M2F,(CQ\^]WFZI;1=+M<KDAE2E,HGSI,M+2E@!2FTR'7 A2@ %*2 2 3J%;D
M.U6FWJ6N!;K?"6XE*7%1(L>,IQ*5:24K++:"H)42I(5F 22,B:O[I_4_"#GX
MN=_H:XRN0S'&/K%.G]3\(.?BYW^AI3,<8^L57/;S5T2L14?+@"S%-9/FL'1N
M*9EG! $>!/U(\Y,P<![_ #C[0AI3,>;SZOQJAZ?U/P@Y^+G?Z&E,QQCZQ3I
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M"P= (**H/CIE O,XCQ*BH(F#O!S> \!$.*F8XQE_?\?0:H37ZHF*8IGS@Q3
M)3%-&NA*8HAP$I@$@@(" B @(<!#O#I3,<8^L5\#>::()E%VJ)41XHE&*<""
M0]B.AQ2 4^"8]A541_4</[TH=/\ 8&, JC-/&-7E'D]0JEZ64'^^]Y'^_I @
MO_U$?^_( A[%!%7^\?WQ(&W^#@F?B0$ !$ [& %TI\TY:QJ.?#X?KKN)=*0F
MHBLFL)%F[86:"I(=8JB+01(86J2A4@,FW$4TQ["003XID'F_J"\%3FGC''PB
MNWIW3A$YA>*B94H$5$8MR(J$+S@*1013_5E*!S@!3<0 #& _5#Q4S'&/K%4
M2-IQZW:F8H)MT&1E2N#,TH R;4RY#IJD7%N1 J0K$4124*J).>4Z29@,!B%$
M%,T\8^L5R>UX_4$HG*B<2%*0@G@3&$I2)+(%*410$2E*@X<(% . BNLD' B
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MV,8P[U=C#NDK6^/#J\.K@\VOP>"LH.6EJ!TAD"<\TY%)S3D0,\@4D*TD@*)
MTLB.5>4&L<#=*#1C0U8N*MSRC'5)Y)L;(BFX6KUTSD]P[!W&D%4B8>,FJC#B
M@2S)IPB]_G1B3MFUK/78Y[$W2:57+(<(\)X-7FRRX/36_P!MLM-DO.W3 5VN
M+Y23M]QPKBRTVJ25:-(]60LEAHL%+3CY1@P;,F#)1W)NW2YVC)FT:-C*"BV;
M((D(D16)0R)'QP5FK2HII4IX1YQ^-;?X5_R'1_E62_WTM*SUEEXL9NT<N"H+
MN3(-UEBMFP)BY<"DF8X(-P5422%=42]C2!15),5#% ZA"\3 I7Y_L?[1=\F/
M[1@;>))GI\]DV^Y>RA8]R. :_16,+D2MXRWD]JF-TJ<WF%YF.8JE_2VT+U7!
M3AFQB:I$F=UK#+EG6Y&5=*@A8E*J\88]W.9#Y-#"^RJ0VDY?Q;E_;_AS:G-A
M)9CEL*M<+9/O6U6_8;O,AB5*QT'+F0[.V9906H<A 1TU-49E$,XYRM)38M^P
M%CG:H^C@/AS'Q]'#P9UG.!<[Y,X;IV=YI$9N-VU8S;XZO<?:(/=7C_:%;L<T
M*[R,/3HNIQN&XG$-B?9ON9G4S#RUEO#R=S.SHKTJK0D5+. ;,(-C'Q_?_/\
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MX/H/XIK!^E8J:4KI<H^R6SAOV51#V0@JCV9$0!9'LJ9B=E2$>\"B?.YY!'O
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MY+BY<]Q$EZ"'-.);U%!&UM9$I7)6%92WD*VI:D-MM!2&0\[OMKRRN^5-3/\
MBX3^0VW]<D-*RKX!Y_R-0NE8J:4II2FE*:4J5@OW9B_X^U_/$TJZ.'Z1^"JB
M2^T'W@_)I4+_ &C]'X"N=*K32E-*4TI32E2R7[@OOY8B?ZC.:5D3^R?^S^:J
ML6Y3QZK4+59TVQ7IZY6YR>(S.J*!'9X>,=2!6QURIJBB5<6X)&5!)04P.)P3
M.)>:*J)&9 ^."O/2M[][(Y+CQY)XG+<X"\GJ J6'#[VQ3K:/=V'$F<,GS54:
MIW.M4R.EK744,212TJBRGSLRU^W%DWQXEVUAV%ENO:P4[6I9&B-(K2E!"]>8
M2$K7FG@R)()UYI'AWI;4%*FQ!=ENH+#9>,MEF.M,D@[:AI+,B2E;"3EM;JU-
MN+S5I,HR&>3I?E"-ND1(3,>I*6-X:+QXQR<S6:1<:4)VK/E<?)$?-&3^;93$
M$R0+E"G.W-CO494*8C&NY67Z3FBJS9GL12M70X. 'PZSK_#+/PZC5UU7>S@.
MXY,I6)82PK.+A>86'E(MLFM7WB#)[.TMSD*+@)#M9/OWJCYS3FJTP$W#L9>C
MI\]E&J6TDO+P\?(*C0'#P9'AS\&?XY:O!K]-ZM,SS:MCW!0<C0EH)#"];@K'
M!.GT]&NU[RPF8JX/RR M8CV<G7H]9U4548Y%V[<RZS-=-[)QL2Y'M:FHI(&7
M#K('#J\/G\PX<AQUA1CO$D*7 LYG.=.@H1*=Q=0LJUAQCRUHRS1U&7%RG&OX
M*?<Y ;8]AJI(04@X8F;R\Q84:_/-'HMVSUG--DXE_96@#\PJ(R3K4D).ED-(
M9!2AD%9A)SS(R) .JMB2W$#N41R0ZSM;1*Y+3;+H=+:2^G0:>?06TNE:6UEP
M*6VE*UMMJ4I"8;K'\),ZK-Y$GX>X0F,VTI50K-W<)5Y-C::I9\08ZS%TN0CY
M&P1<FU&-@LC1:)Z:DVD+[, D9>LUJ;71EX^%K6#0'GU>'/R^$? ^FO080X"(
M>X/#2L8_:'G'XUM]A7_(='^59+_?2TK/647<HS9* DX%R!Q*!P["P?.B<T1$
M XJ-6RR8#Q ?U(F P!WQ+P$!%2J7I!&?Z3[XHE_F.E*=((S_ $GWQ1+_ #'2
ME.D$9_I/OBB7^8Z4IT@C/])]\42_S'2E.D$9_I/OBB7^8Z4IT@C/])]\42_S
M'2E.D$9_I/OBB7^8Z4IT@C/])]\42_S'2E.D$9_I/OBB7^8Z4K7O+D-*V6>C
MGT+'NGC9.((V.<R?L0Q5B/'BAB]B?"V6$.8JF;G@F)!YPE PF*8 550S'#EJ
MR](]58JZ"6[P&Y^%9_.=*IHC]\>CUTZ"6[P&Y^%9_.=*:(_?'H]=.@EN\!N?
MA6?SG2FB/WQZ/73H);O ;GX5G\YTIHC]\>CUTZ"6[P&Y^%9_.=*:(_?'H]=.
M@EN\!N?A6?SG2FB/WQZ/73H);O ;GX5G\YTIHC]\>CUTZ"6[P&Y^%9_.=*:(
M_?'H]=.@EN\!N?A6?SG2FB/WQZ/74DYI-J/&QB9(9P91)1^*A06:<2@=1 2<
M1]D<!YP /M"/#AW^'>U&7#Y3GZ /RJRD@@9G++5Y_3Y*C>@EN\!N?A6?SG4U
M71'[X]'KIT$MW@-S\*S^<Z4T1^^/1ZZ=!+=X#<_"L_G.E-$?OCT>NG02W> W
M/PK/YSI31'[X]'KIT$MW@-S\*S^<Z4T1^^/1ZZ=!+=X#<_"L_G.E-$?OCT>N
MG02W> W/PK/YSI31'[X]'KIT$MW@-S\*S^<Z4T1^^/1ZZ=!+=X#<_"L_G.E-
M$?OCT>NL>98VP1&>L=6?&N4:G)2M7E4X=^9@SFEH9PM(0]BAY!F)'T5(-G1
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MOCP-QXM_/9'Y6AY_ZGMN7^S_ )TWJ\W!(U\=SG9#5X#MWDS\^=4G4T[6?
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MX55M8+ SCW2JR<+*PS\5D4CB=N*;],@* J$4)Q*/>]CC"D+&>*(]CN$F7%C
M/1)KZG8192^%QV=L0$E]E]O1)&2LVR<CJ(-=1QMB"7AFQKND)F.^^F3'9#<I
M+BFBEY12HD-.-+TDY IR7EP@C@(\"NOWW.^)[ 'Q9DGZR-?1/R<L*<N8D^]M
M7Z77C>_-B+DVR_=3O?J=?ON=\3V /BS)/UD:?)RPIRYB3[VU?I=-^;$7)ME^
MZG>_4Z_?<[XGL ?%F2?K(T^3EA3ES$GWMJ_2Z;\V(N3;+]U.]^IU^^YWQ/8
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MDB"=110X]XI"$*)C&'@ B(AJ4I4I02E)4I1"4I2,U*43D$@>$DD #PFH4I
M*$J4HA*4@J4HG()2!F23X "2>*O%?'DUE:O99J^[^P8Y&(QYNDM]DIEIL9[
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MVJ<P?=#^G^S2FD/@I]JG,-[H?T_V:4TA\%/KKZX*" )Q$ 'B <XW !]T ]K
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M% A"@!2@4H ?/:E*6I2UDJ6HE2E*)4I2E'-2E*)))4=9).9.NO8DZ*4A*$A
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M2'P4^U3F#[H?T_V:4TA\%/M4Y@^Z']/]FE-(?!3[55!2C[$5#W7+?O\ VO\
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M]5;CES<.*MV*1,?9T(HV1536-[+JH J<[I=<IP$+ASC<U-4B?ZL $.9P#]2
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MDC;&7$A12I#B"MM857>,,8PM>+([SMN4XS(C*RE0)(0)3*#_ +F]D@K2XPX
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M^/[E:FE2RQEG+-=GMV64<5V:1FGCNFA'0%8M\+'W/(T[C['1YZ4J\<:5,G&
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M8[1B.T3+5?&$/6]]LJ<6M0;5%6V%*1+9>/\ N#S&M:7> *"PILK0KD+5=+A
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MO@'G_(U"Z5BII2FE*:4II2I6"_=F+_C[7\\32KHX?I'X*J)+[0?>#\FE0O\
M:/T?@*YTJM-*4TI32E-*5+)?N"^_EB)_J,YI61/[)_[/YJK$\WEK%U:N,+CR
MQ9$I<'>[&FS5@:?*V6(86.63DG3IC&&8P[EVF^7[:OF+UC% 1$1DWC-VU8 X
M<-ETTU5"21^'E\WQ]-7K&R4=,Q[.6AW[*5BI%NB[CY*-=(/H]\U<$!1!TS>-
M3JMW3==,Q5$5T%#I*D,!R&,40'2H*2.$>D>"M77.W/;\G4\WPQBP:#S*]CR3
M%Y"OR#>G=/8>9S>^(:7K*-H)!G>,3D-:8EI 0\T5^JBS<0:;Q-^D9 REBM92
M$%2BA))""HZ()X2$YY GPD#,UMF5*5':B*>D*B,K6XW&4ZX6&W5@!QUM@J+:
M%K"0%+2E*EZ@HG*K-O.P[&MYOK>_2N0,KL3(9,ALMJ59I+4U:HJ6ZO9!@LDQ
MCQ!C-TB6?PHEFZZQ8R+^NRL/-3%?3)"RTJ\:-696\9G++P$@_2,\OQ-8M-6B
M4Y'1*DJRRX2E*@DGPZ@M0U:M>L9@5A%ELHVC/ZGV5'-"\[7Z_7;=D9Q*K*[?
M9BJ1V',AQL-$6P6M84Q2YQG7:'8AQ$F_=WJN5:'L[F5@K"\Z:&(YED5)2M2-
M+14I.DDH5HDC22K]I)RX4GPC@/AK*S)D1RZ8[S[!>:7&>VEU;1=8=3DZP[M:
MDAQEU.27&EDH6!DM) K=J\R>'&.5\,.+?D6OUF_LB6ECC.HOK- Q;FV],VD
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MDG-<;/:[N&4W*"Q,#"EJ9+R,U-[8D)=2E0(5M;J0$O-DEMU("7$J $=,X P
MO8+? 7R8QG3G]KJ[:%9P4PM"M>SL&U:<*NZTB5),I&BQ:R[77=5OV4W7&ON5
ME5X<62JASFR,8AOD:')M[%UFMPY:WW)#"7UZ+BY20B4HJ)*TF4A*42M!2>Z$
MI"7M-( K&]8K._+8G/6V(N7&2RAAXM)!;3&4I48:(R0H1U*4J/II5M"CI-:!
MUUF X!W@#7#5RU:GYY_RIB_Y!1_XA(:51?!]!_%-8/TK%32E-* Y:Q6'H
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MM5VL6\L4VJ"1J / H?B>#S?A]%>LN%?\AT?Y5DO]]+2KUE!TP4<J H22D&@
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M(53P S^'DOGVE-!/%Z3ZZJU:E5S-&A30;02)F<]C**\CP)V0Q!/P$'O$><)
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M!!)0A2]*7P F!W"RHE ?9 <>(GYXB(B/ZOAQ ;V./^:EWX?%Q[=-V^$.#
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MEQ^Q;?Q8GYQ72E4VE*:4II2FE*:4JI9_MIO_ I/RZ4JG-[8_?'\NE*XTI32
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M)$K=+PEIB6J$'%,Y%M'J&6BXR7"1DEXUV^:,VZT@LZ9HJN%52ZK\?'H^.'"
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M-\;Y$=VNI3;ZZ,K;)LE'$6S:0+>&4JJ4Y.:$C(2L.J#N"S/CG,,=W<TKOGF
M9XJD+YE%KN3M<7>,QHVF'L6.)>@QRTK;*_6IJHNZK4X%>@GK4/&U\2099*+D
MU*DK/R=&.K OCFKM,CY'@<"8^I^(*.7;RU)296E2E=P>XCEZ;#M+58JA+Y-I
M\),$@ZXTR/"TJYP+#(3.NQ[>;)S7MB&=?'KI7H;I2K MG[>0_BP?G#Z4JUM*
M4TI6,;=B6KW7(>*\E3*TKV\Q#T\"MLFRS,L,^+D.N)5>=3G6CABX7>)IQJ0&
M8E;.V0)N!,9R#I(W82SQ<.K^_P#,_&H1EP\&LY^$\/#J_NX?)KU Q#R8&U##
M<DF,-5I"VTN-M>8+I5\39*+6KWC"F3N938V;2Z]9KLW6E7#9*H5S%T#2\<(O
MY*1Z'4Y].P;$RB,B0[:*>3P<>>1] _,5(,^3ZI]+6!W@K.N?]NKLDQD95JGB
MV2Q6[@(ZF9/OC[)\WC**I62<49 H\93X.^35EL%'<L:XWN%0"SS,'%VDM8.R
M@V2FOR>OU>FLN88VAXAP&G,-,<)V6/C)?"^)L$FC)&9)*H,Z9APN1 K+QLY=
M,ADE;'(J9.L;BQ2<@]?(R#DK!5LR8=B<%=J:_)P>GU5ES#^,:]A/$V,,-U)Q
M*.JKB;'M,QK6G4XX;.YIS 4:NQU8AUY=VS9Q[1S)K1\8W4?N&K!DW6=&541:
M-DS%1(^/JH!EZ?3KK(NE332E52G[5;?ZRW^\&I\!\X_!51X1YC^*:Q7+XKKD
MUERAYH=N)8MKQY0<GXY@VJ#EL2$6@LL3N*[#9%Y)H=FH[7DFSW$-93B%T'[5
MNV;.I@CEJ]4<M5&,4U^3X^/+GY*Q8MM,QFOBE_AX\C;PJTEN$7W*.')9*,"9
M+?7&YXN[([!)V,,+4M9#)10C2L#,3R 5'_JT949/_KD7QY?R^.*FOR<'IX^
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M\-1L>MG@Y)AU)]@(KFQ;8:]9XC+\K;2&CD$@','2S5F,DD$ :6CDK]I68)S
MT2E.:3G4XT62V(K27"MI1D!;^V --J04(3MQ:"'U*#SI6VXX'6T!A<=DK9<W
M$B8;<56:)N$AY2S92RO;VN[?"Z])D[C5H5F5QB)Y9-N0VA[3DZA6:M7G58CH
M4F1)&3)$IN4H!^QFS/R(.4W22L$YDD $DY#/(>09DG(< S)/&2:Q+(4M:@A
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M&[%0]CV5B1=%4Z)0H>;P$I2.ET3 ?CD $143,8!#B'-,'$>/'4]T;%')VR!
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M1[H )2$;*@8./'B<G ![_!M^Q1R=L@CR=\\.Y?7WM)]&6O/, 4+6R3EJG8)
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MY>0A8U-!TS5,V56EGT8[:QR('*J\?-W3!J1=TT73)S<;%5E=5#8?N-OC39Q
MCP^[H[RW"Y(?C1TH<;5H+7)=CN(80,E.NH<9;"W&E@<)*PK>V4S7V+;<9,*
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M:M5AD)N NTNXR'YC]YFQW;M"S3=)*)4.,AQ,HI"FI<);[JT0MNPK*-JCMDQ
MR!XI-0E5B\99&F82!EEJR^Q&WJL6ADZ/=V 6S>/B LLK5J\W@TGK@DRY<O>>
MVC3-QE'+/6NF%9";=@'#;&W=TQ(,>P7R3%B256][#*;='1?F'INUH8C]W2;=
M";BH=4)+CC@T&%(V]:-JVXJCKN>/\3O;2F+,N,G$%BBRYD9-Q:Q,JXR%X??:
MA[8X_(,"/<9KLM;2516TM9.2 LL(<WQ*4I"E*0I2%* 4I2@4I2@ 4
M X:]> &0&0&H < '%7D.9.LYYG6<]9S/'Y:^M*4TI6I^>?\J8O
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M2L]90=/':"H$0C'3PHD PJH*L2% 1$0$@@Y>-U!$. "(@02\! ,(@( I5-V
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MAR^QXM%N83J2 8Q'+M3G$ (\1Y@@J' 3<T>(#^I . BJ2-+42>/@R^O/\-7
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MJ9E35QHJ$<().43=D;KID515 I@*HFH4#IF#G ASB"!@ 0 0#VP 0'2GX_'
MKK[TI32E: <IMG+*&W?:-<<FX?LH5*[1UGHD8TF1AX*<[$QE[,R:2*':^QQD
MO%G]D-C&3[(HR.JEQYZ"B9P P>E[$U@M.)<91;5>X@FP'(4]U;!?D1\W&6"M
MI6VQ76'AHJUY!P)/ H*&JNB[(EWN-DPV[.M<DQ98EQ6TO!IA[)MQ9#B="0T\
MV=(9#,HS'@(-?F2ZWSE"/'T7T98A^@.OJS>7V->;8ZVOGZE7@.^1C;EQ75]I
M]PIUOG*$>/HOHRQ#] =-Y?8UYMCK:^?J5-\C&W+BNK[3[A3K?.4(\?1?1EB'
MZ Z;R^QKS;'6U\_4J;Y&-N7%=7VGW"O5ODW.5UD\FV-OA+=I8(PEPL$F*>/L
ML'80M:BIAZ].((4RVLXAG%PD5(J+"5"M3;9HU:21U4X>3(E(@S>2?C^REL+L
MVR*J_P"#(KO<<5D&Y64./RG66VQ\Z?"<?6](>;"<U2XZW%K:2DO,E3>FVUZ+
M@39-=E2$VG$\A!>D.D0KJI#$=LK7J3$EH90RRWI'4P^E"4J6K:G0"4.*_0B(
M<-?-%>Y_'\OHII2FE*J5O\0U_@C?UAQJ? ?./P54>$>8_BFJ;45--*4TI32E
M-*4TI32E5*7[7=?>1_.:4JFTI32E-*4TI32E-*54N/V+;^+$_.*Z4JFTI32E
M-*4TI32E5+/]M-_X4GY=*53F]L?OC^72E<:4II2FE*:4II2JDO[36_C+?\TZ
MTI5-I2FE*:4II2FE*:4II2FE*R/6/W++_#K?E+I2K@-QYH\ XCP'O:@ZP1Q@
MTK06LUO),WC*AX7=8IN%;=0>2*W8I^\3SNHMZU&PM1RXCD91Y"'C+3)S\C*R
MK.,;Q<0@6$:%2<2)G,@NT;-E.R^.6Z#?I-@L^%',.W* Y$OD*=,NTU=L1;V8
MMNQ(F]J=B*CW!^:_(D-L-QXR.Y&P%O*<><0AHA7L,Z=8H=_N^*F\16V>W+L$
MV!#M,-JYKGOR[GAA5C#4M,BW,0F(T9V0X_)69;I4A@-LMN+=&C9,-BC*459,
M<2R]%GI>PQ;RL%4-/%BY"#C(YIDZPRDL^BKE%6^#M%!DF<!)=L9:.]B6VOW=
MD6/AGD*][(_:(<9'P[B"-<+))5:9DJ9'<MH/=@CO1([+=^FO2GH]SCW.'/LT
MAJ&_MTIDLW*'=6MIC.17M)UM/+2L18=DP+[%3=H<:&^U<"D0S)9ER'W,/P8T
M9F3:I%LEVZ\QW9L<,1Y =M<ZU.%^4W+:R:<7/]RZ_=&K9%L,;VE'*[EG;R7C
M)R5O;0;;(L4^R!%3)X6$>-)P7$H^M=.;O(JL+RZ$"GC=(YHYH]ARJBFKN]X;
MSW#<8S-BN*<0N-707:_IN;<-N]L/7B/*[DB.HE%R2]<K:AR/!7)1"38PI3*'
M(P.@K2W067N^VR'K[;U8=:=M:K3A\VMR:Y8Y#-ED1!,EM.PPB.S;KHIN5/;C
M+FF^J2'W&9)2%I^G&.\J0[BP7G!U"DZ(@210KE0Q].N8N-319VZJKUVW6LD(
MUF7\5"1,7;TZ#;58])=)V^0I-F?-& O+)SY,NRXBCNS;QA2TR;0VE]N!;++,
M<88 9N-N<AW*X]RHE/L1HS%R%FN2F$K0Z\FTSG&VBY/S>-WO#LI,&TXMO$>\
M+4PN?=;W#;D/E;MLN29MMMAEKBLR)<F3;#>;:F0ILMLKN\!EU\-0"&(M7!F1
M*_DDK*.8V9ZPB++CM/'MO9LXIX,1C:KUBLQ<K R%ODK@TE8=!\YC+.E9*VC5
MI,+6M8.V17+AZ^5?0>NO"5\AWTLL-3WF8\^RBRW1EJ,YW-8K?!@LR83]SD7)
M$B,EY<>>B=#3;I'?!R:E\.+<=4[$V$XNL<RP[:^[!9?E0+X;W:W'9+0E7VXW
M"X/QYC-L8MCD:4II$BWK@S57*.;<W"VC:T-LAJ91J8PG<98\V_5RKD4K.2\K
M4R-P]E%DI-"M8>V5OJ$1*W+(AS'?.S2EAH)Z?-F2>-E5DD49)R"2P-TT=8W;
M#,L-FP9"MJ3"OF([:SAC$+*YA5-VZYVV,_<KX<W'#(F68VR6I+K94$IDNZ*B
MWE61.((=^OF-)]Q(GV'#EUD8HPZ\F)H0MHMESE1[79 -I;$>%>A<X@4TZA"W
M%L-Z:=L4JO29BS;QS-JP:)@BU9-T6K9$HB()-VZ1$44@$PF$033(4@"(B/
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M^H%ZKKNO8.88UG2*Y<K,]<<EY1N^38,]JBVSQ[:T:?%9S+E*-L1<86&Z.8:
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M+;+0(*UJU9E* %.+0A?[UL$8ZL&),/8]QM:;_.91L%-K3&$E+W8BI%E9]PU
MW!54$P,J+5FF8D=&G?.'\L>-9M#R\I*29G<@Y_.W$=TC7N^W2[0[<Q:8T^6Y
M(9M\8DM1TKRS S^;IN*!>>#:6V0ZXL,,LLA#:?LFQV]^U6B!;I,UVX/Q(Z&7
M);X 6Z4YY#+6K0;!#;>V*<=VM"=L<6O24<M:X2N6II2JE;_$-?X(W]8<:GP'
MSC\%5'A'F/XIJFU%332E-*4TI32E-*4TI52E^UW7WD?SFE*IM*4TI32E-*4T
MI32E5+C]BV_BQ/SBNE*IM*4TI32E-*4TI52S_;3?^%)^72E4YO;'[X_ETI7&
ME*:4II2FE*:4JI+^TUOXRW_-.M*53:4II2FE*Q1D7'MRNKN,<5?.V3\0HL6R
MZ#MA0(/"DLUF5552J)O)%3*F(LDOD7#8A101)$O(QH9(YC.&JZP%6!3X^/C\
MJK<<T:U4I&63M&9<B9?4D5&9V;C($1B2)5@B-BN"KHQ9<4XPQH@NG("ND=V,
MVC,*IF9MP8*LB'=D<J5DK2E-*4TI61ZQ^Y9?X=;\I=*5@_+&\#;#@NT)4K,&
M<,?X[M:\2TGD8"T3:4=)*PSYP]:,Y(B!R&$6KAS'/D$E./ RC58H?L-=EM&#
ML4WZ*J;9K#<KE$2\N.9$2.IUH/MI;6XT5#_30EUM2AQ+3Y<N#N.)K!:) B7.
M[0H4DMI>#,AT(<+2RM*'-$C]E2D+ /A*3Q5C/K)=A@>UNKPV'_\ -*'R>N4W
ML\?\TKWT-=:&[G"'.&V=('JIUDNPSCQ^RKPWQ]WI2AQ_-Z;V>/\ FE>^AKIN
MYPASAMG2!ZJ=9+L,\JO#?G2A\GIO9X_YI7OH:Z;N<(<X;9T@>JG62[#/*KPW
MWO:_72AWO_\ 'IO9X_YI7OH:Z;N<(<X;9T@>JN.LEV&>55AOSH0^3TWL\?\
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M-[/'W-.]]!>]FF[G"'.&V=('JKO;<H-LC3<(G/NAPT4I5"F,8;E&\ !XB/[
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M?'V2-18X9Q.T2-")*&3;8YIR)3'%\^*)Q*G#% 3<TI2\>''@ />#4;I,19Y
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MJ12'53Z!U'LB9%!.!#J$[4\XA3BFH!#& ,*9^ CS3<&Z7$/+]]ZXG]O4=YK
M1J_Q-:1F<M=MB=C7*>&L,+)D52Q/BU5)0A5$U$Z%43IJ$. &(<ARQ(E.0Q1
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M( 4I0 1$1$ $1'AINEQ#R_?>N)_;U/>:T<C6KJV)V/TUR7#&&C%*8N)<7F
M*8 ,4Q:#4A*8HAQ Q1"($! 0$! 0'@(=\--TN(>7[[UQ/[>AL]G!R-FM/5T/
ML:UPW;3>+=L6!+EEF)V^X?MSZ,=5:)2B)2FUF.;"6<M4.P5<@[;5]TNFJ@B=
M3F 1+^^ <R9C%*81UW;8^CWS&N)8]B?Q9B* T]&ER%2&;E-?6#&:VQ*0A<IL
M$*(R)TM0SU'@KJ^+Y%KPU97+JSAZRRW&Y$=D,NPHS2"'BI)5IHCK5F,M0T<M
M>OR>-_6EUOR+-OWXE'?0_7OV\G-_YR,6_>O_ *C7DN^>QS)PY]AKW&G6EUOR
M+-OWXE'?0_3>3F_\Y&+?O7_U&F^>QS)PY]AKW&G6EUOR+-OWXE'?0_3>3F_\
MY&+?O7_U&F^>QS)PY]AKW&O0K93NAVS[K%']/L&$,1X\RPQ%P[:57HK5'T;:
M85(IEA?5E\Z@6;AR_CT2G-,0JB)G3=NF$HU4=,A>A&^4;(^"L:8&2U<8F)L0
MW>PNA#;DT7"X-/P9)(3M<UI$IU*&7E%(CR K04XK:'$MN;5M_?\ !>*,-8I4
MY"D6&S6Z[MZ2VXO<D-QF6P!I%45Q<=M:GVAF7HY!5M:=O;*D!U+/HMW%L-^*
M3&'F!4_5&O(MTN(>7[[UQ/[>O0N]%GY'M/5L/L:=Q;#?BDQAY@5/U1INEQ#R
M_?>N)_;T[T6?D>T]70^QIW%L-^*3&'F!4_5&FZ7$/+]]ZXG]O3O19^1[3U=#
M[&I1[A3#)6,,8N(L7 )VCH3B&/JB G,$D\* F$(<!,(% "@(B/ZDH!]H-1ND
MQ%G_ &@OO7%P]XR^G*I-GLVK_$]IUCDZ'QD?P?)47W%L-^*3&'F!4_5&IW2X
MAY?OO7$_MZCO19^1[3U=#[&L#9TM^S7;?'0DEEVI8LKA+&[7:0C-#&$),2<B
M9F"!G[A".BJ^[=@SCRNFQGCM1,B"1G""0',NNBD?>A7/%MP4M,6]WU>U@*6I
M5ZG(0G//1!4J0!I*R.BD9DY'573L88FV/<",0W\3,VB#WP<6W#819VY4E_:M
M#;G$,1HKCFTL!UO;7E (27&T EQ:$'+-4H.WF\UN$N%2QWB2>K-CC6LO"3+"
MAU-1G(Q[Q,%4'")C0Y3EYQ1YJB2I$UD%2J(+IIK)G(75=Q!B5AQ;3M]OZ'&U
M%*DJN\_,$:CP2"/I!(/""1D:[);6,,W>WP[I;(%DFV^?';E0Y;-NBEI]AT9H
M6G282H<2D+2E;:P6W$I6E21<'<6PYXI,8>8%3]4:Q[I<0G@O]]ZXG]O6[WGL
M_(UIZMB=C3N+8<\4F,/1_4_5&FZ3$7+]]ZXN';T[SV?D:T\?^]L3@X_]QIW%
ML.>*3&'F!4_5&FZ7$/+]]ZXG]O4]Y[1R-:N+_>V)PG@'^XT[BV&_%)C#S J?
MJC3=+B'E^^]<3^WJ.\]GY&M/5L/L:E&F%<-#&RIAQ%BX3%!ES##CVHB8O.<"
M!N:88?B'.#O#P'OAWAU!Q)B(_P#K!??+_CBX>#B_K RJPLUF()-GM.H9C_%T
M/B/_ $-1?<6PWXI,8>8%3]4:G=+B'E^^]<3^WJO>BS\CVGJZ'V-.XMAOQ28P
M\P*GZHTW2XAY?OO7$_MZ=Z+/R/:>KH?8T[BV&_%)C#S J?JC3=+B'E^^]<3^
MWIWHL_(]IZNA]C3N+8;\4F,/,"I^J--TN(>7[[UQ/[>G>BS\CVGJZ'V-.XMA
MOQ28P\P*GZHTW2XAY?OO7$_MZ=Z+/R/:>KH?8T[BV&_%)C#S J?JC3=+B'E^
M^]<3^WIWHL_(]IZNA]C4S+X4PR5.&YN(L6EY\,W4.)<>U HF.+M\43&$L. F
M,)2E#G&XCP* <> !J!B3$7."^_1=[@/_ .01Z,ZNJRV9(S%GM6L\G0^+_P!S
MY*ANXMAOQ28P\P*GZHU.Z7$/+]]ZXG]O5.]%GY'M/5T/L:=Q;#?BDQAY@5/U
M1INEQ#R_?>N)_;T[T6?D>T]70^QIW%L-^*3&'F!4_5&FZ7$/+]]ZXG]O3O19
M^1[3U=#[&G<6PWXI,8>8%3]4:;I<0\OWWKB?V].]%GY'M/5T/L:=Q;#?BDQA
MY@5/U1INEQ#R_?>N)_;T[T6?D>T]70^QJ4A<*89/+QI#XBQ<<AWS8IBGQ]43
M%,452@("!H<0$! > @/>'[>H.),1'(C$%]!&?_*]P/#_ /J!Z<ZLFSV8ZC9[
M3D3D1WNAZ]1/\'R5%!A?#@@ CB3&'$0#_P#=_4@_)$ &I&),1#_U@OO7%P_-
M\_C4*L]F!([SVGJZ'Q?^YKGN+8;\4F,/,"I^J--TN(>7[[UQ/[>H[T6?D>T]
M70^QIW%L-^*3&'F!4_5&FZ7$/+]]ZXG]O3O19^1[3U=#[&G<6PWXI,8>8%3]
M4:;I<0\OWWKB?V].]%GY'M/5T/L:=Q;#?BDQAY@5/U1INEQ#R_?>N)_;T[T6
M?D>T]70^QIW%L-^*3&'F!4_5&FZ7$/+]]ZXG]O3O19^1[3U=#[&I5+"N&NTC
MT_<BQ:)PEHLA3CCVH"<"'9S)CE PP_. IC$()@ > B0@B'ZD-0<28B)_M!?>
MN+C^/=&KZOKJPLUF()[SVG,))_WNA\9_Z'R"HKN+8;\4F,/,"I^J-3NEQ#R_
M?>N)_;U7O19^1[3U=#[&G<6PWXI,8>8%3]4:;I<0\OWWKB?V].]%GY'M/5T/
ML:=Q;#?BDQAY@5/U1INEQ#R_?>N)_;T[T6?D>T]70^QIW%L-^*3&'F!4_5&F
MZ7$/+]]ZXG]O3O19^1[3U=#[&G<6PWXI,8>8%3]4:;I<0\OWWKB?V].]%GY'
MM/5T/L:=Q;#?BDQAY@5/U1INEQ#R_?>N)_;T[T6?D>T]70^QIW%L-^*3&'F!
M4_5&FZ7$/+]]ZXG]O3O19^1[3U=#[&G<7PWXI,8>C^I>J-#B3$)!'?\ ONO_
M *XN';U(L]GS'^)[3PC_ ).A]C6]FW:JUBIX]%C5:W 5ABYG9-VX95V&C81F
MN[$K9 SM9K&-FJ"KDR""")ESD,J9%!%,3\Q(@!QDR9,N#B7I\R7-=0@-I=ER
M7I3B6P2H(#CZW%A 4I2@D$)"E*5EFHD\A'BQ8B"W$C1XJ%*TU(C,-,(4O()T
MU):2A)5HI2G2(ST4I&>0%9]/^Q-_JB/^T XAK7K,?)QC\1GZ*\*L:N<)V##F
M!*GBZ-J+_=O ;AJO)D<4^OM%,CTZ-8[B'+W)TU>)>*8A)Q-05P_TKC;*:QO$
MXR982C2$YCJ0D8MN?WV[(OL:^8BF7=V:U@R3AJ6PM$V0L6R:XYAI"+6Q;V'7
M=I=G)O7<;L0QFRZPXTM_-+3;RAXU;S:7K18XUM9C+Q0Q?8KJ51&$]WQ6DWU;
MEP=F/-MZ;<0VGNE$@/KVMUMQ#616IO*6IF?LKUZSX7:O\B+-H24E*9'CBNF-
M*%4[9(GL.=;G6YQ^UQ7-XL0[JM7E8<\>6RSV,LBUZ<QNSAY"P.Z\[>D>.YG!
M.PY9Y,2^K;M:5OM,SW!=YJ[C-AM=S8?@RHZ%W=B[GO/+9>2Z8L>[VR4Q=%O-
MQD26VRA#.5B]W2-+M*3<' PM^&V;7$1 C27!(O,N,\M%N=MH-TC.-EH2'[;<
M([MO2VX^MM:@LO7P?/V6FU&OEBC\WV]_G;M;D0,@8-;8]JMHC\ 0\?ER"KA[
M>SBXNJM;+".<<XZ=R,[5FUX?VEGF(J9YQJRDV2 "303ARSJN%OBN6"$WAX.6
MP6[$"[E,B.8D>=LLF4(:G7I:XDA-UN;;4>6J U#79BKN=;C;B]>RN^75$&;)
M;O,Q=Z+<[NZRIM\64BPM)NL>.9:6FHZ'V%6ZWK=?CIFKE(NNB74I<0@Y=TAN
M0RGC1Y<;SC_(-FW28+J<LTHT)-A'4^9<6:^9)H#MU5(9E::)5H"+LJ-9R[7Z
M12S2<4D1M&CG&3CK$NZ6J+8T55K"]HNK<&!<K;$PGB"8RY<)$<.SF$Q+=:[F
MA$MY<6XRY+T54NS2I\[:GE:3HL#3L9*$2U[=D<O]TMRIDR#.E8ELT1U$-A[:
MXCRI,VX0%*CM)D0HT9J0F-=&(D8K; ".^ZVW5*,= :MQ7,&ZNHYD#'=GRW#J
MV2G77#E&C:[.2T'$O\OTIW2*2ODG)$?BR$P-/V2R&G9N5ODDA=:UD2K4J@2-
M89QE@8Q$-7K.,_M)LN#YMD-SC65Y,6=!O=P>EQV9#S=EFMSIPMEL<N[^(HL6
M(8\=BWMJ@2K9+GW%N4MV,X\])C=SZO?7%,2["WR;LVN3$E6F$B.\ZPRJZQ50
MXW=]P1;F;&])D!]]V6YW;'GQHD%<<-OMM-,O%^<ALH[F<=8&VW9$?Y.N.5K9
MNJQ' U5DUL]7H[9A0-R67*C39_&4JS95.FUY:/H,(*5Z3G6<\>75(9./.[?*
M&4X):S]IPK<\08FMC=I@6B'A"\2)CBHDNX*<N6%[-+FQKJRXN7-DI=GOYP#'
M6P&00IQ+:!E\[98N&([?9;!/=N<VZ2L2VQJ(E,J-"2F%?[G&BOV]]"(T2.41
M&M&8'4/%T:FRXO+,CU[BFBS"-8,G+YQ)N&C-LW7DG94".Y!9!!-)5ZZ(V20;
M$<.CD,NL5NBB@50Y@2233 I"^..K2XXXXAM+2''%K2T@J*&DJ42EM!6I2RA
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MX <BB9RF(<AP Q3 )3 @(:5B5^T?CS>BM+N57_S*<B_]X<=?^-X77L>P1_G
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M61()'<4K+,:QJVO+AJ.^5L\-P@'+/+.7'.6?#PN>&@9-Q8 B8,@T/G& ,;I
M9 <XP![0&'MAQ$ XCPXB/#[6G>B[G4;7<<M>KN*5EKX=6U9:Z=\[8-8N$'P#
M_*X_@X/^$\%"Y-Q84H%+D&AE* B(%+;( 1'G"( $@ !Q'OC[HZ&SW8DDVN
MY$GA)A2L^#+AVOBH+E; !<(( X!W7'RX_XG'X:#DW%@B!AR%0^< " &Z60'
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MS;H;BY,=\.N/-.IR9*B4Z"'D',A68.9UC6,CF/'3JAFWE;8P\WD_IQKWW?\
M%_\ -_?.E+_3:\GWIASOL_W:?>J=4,V\K;&'F\G].--_Q?\ S?WSI2_TVF],
M.=]G^[3[U3JAFWE;8P\WD_IQIO\ B_\ F_OG2E_IM-Z8<[[/]VGWJO0C97LU
MP;M0/(VR8R32LC94D1<,VUN5=Q$6RK4&KP(:.K<6O,R2C1Z_* C+S2CH7CE
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M0 E*4@ 5*]/:+[]*GYQP_SS5.]-UY,N'0I/9UL]\('C\+I<?M*=/:+[]*GY
MQP_SS3O3=>3+AT*3V=.^$#Q^%TN/VE.GM%]^E3\XX?YYIWINO)EPZ%)[.I-Q
M@GAGPNEQ^TIT]HOOTJ?G'#_/-.]-UY,N'0I/9U'?"!X_"Z7'[2I1I?J($;+
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MU(I0?-1$QK)#@ "Q.(B(O> !^^.G>BZ\F7#H4GLJLFX6\<,^%P^-Q^)7_2>
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M29.-9 !,<YBE+Q$ XB'?UWY<+9]0E2U+QB$H2I2B;@=02"5'_*? :ZBF3L0
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M":)A1Q56\),+124V1JX3NE1KKA0G:M=-V=TW16:))F$%%R'*8I6^/CWG=?\
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M B.T_ W XC_ -FM9]H/_E^HWQ\>\[K_ -92/;JNXG"7-VT]#:]FHJ$V(\G_
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M.R,#N/9$,W =&8NP3Y@G$10/Q .]QQX?V>+MBI4I&'MDBYW94)+*I0BW26H
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M %:1U)(4=(:.B<R$G2)3HY)"E;W:5%-*4TI32E-*4TI32E-*4TI32E-*4TI
M32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-
M*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI
M32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-
M*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI
932E-*4TI32E-*4TI32E-*4TI32E-*5__V0$!
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g166948g09t20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g166948g09t20.jpg
M_]C_X 02D9)1@ ! 0(!>0%Y #_[1S44&AO=&]S:&]P(#,N, X0DE-! 0
M '+B^<U(X0DE-! 0 %D< 5H QLE1QP" "<%L< E "')R,CDS
M-S0Y' (% #A-:6-R;W-O9G0@5V]R9" M($%L:6=O<R M($124R!-87D@,C R
M,2 Q,C,X,#DU.3,N,3$N9&]C> X0DE-!"4 ! H"E2\U'B$8RZ^;!$-
M^2;K.$))300Z #E $ $ MP<FEN=$]U='!U= 4
M 4'-T4V)O;VP! $EN=&5E;G5M $EN=&4 0VQR;0 ]P
M<FEN=%-I>'1E96Y":71B;V]L MP<FEN=&5R3F%M951%6%0 !
M /<')I;G10<F]O9E-E='5P3V)J8P P 4 !R &\ ;P!F " 4P!E '0
M=0!P *<')O;V93971U< $ 0FQT;F5N=6T ,8G5I;'1I
M;E!R;V]F "7!R;V]F0TU92P X0DE-!#L BT 0 0
M$G!R:6YT3W5T<'5T3W!T:6]N<P !< 0W!T;F)O;VP $-L8G)B
M;V]L !29W--8F]O; 0W)N0V)O;VP $-N=$-B;V]L
M !,8FQS8F]O; 3F=T=F)O;VP $5M;$1B;V]L !);G1R
M8F]O; 0F-K9T]B:F, ! 4D="0P , 4F0@(&1O
M=6) ;^ !'<FX@9&]U8D!OX $)L("!D;W5B0&_@
M 0G)D5%5N=$8C4FQT 0FQD(%5N=$8C4FQT
M 4G-L=%5N=$8C4'AL0%? *=F5C=&]R1&%T
M86)O;VP! %!G4'-E;G5M %!G4', 4&=00P !,969T56YT
M1B-2;'0 !4;W @56YT1B-2;'0 !38VP@
M56YT1B-0<F- 60 !!C<F]P5VAE;E!R:6YT:6YG8F]O; .
M8W)O<%)E8W1";W1T;VUL;VYG QC<F]P4F5C=$QE9G1L;VYG
M UC<F]P4F5C=%)I9VAT;&]N9P +8W)O<%)E8W14;W!L;VYG
M X0DE- ^T ! #O_XU ( @.__C4 @ ".$))300F .
M #^ X0DE-! T 0 !X.$))3009 $
M'CA"24T#\P "0 0 X0DE-)Q H 0 "
M.$))30/U !( "]F9@ ! &QF9@ & ! "]F9@ ! *&9F@ &
M ! #( ! %H & ! #4 ! "T & !.$))30/X
M !P #_____________________________ ^@ ____________
M_________________P/H /____________________________\#Z
M #_____________________________ ^@ #A"24T$" $ $
M ) "0 X0DE-!!X 0 .$))300: ,U !@
M !(@ CP 0 !
M (\ !(@ !
M ! ! ;G5L; ( &8F]U;F1S3V)J8P $
M !28W0Q ! !4;W @;&]N9P 3&5F=&QO;F<
M $)T;VUL;VYG !(@ !29VAT;&]N9P CP &<VQI8V5S5FQ,<P
M %/8FIC 0 !7-L:6-E $@ =S;&EC94E$;&]N9P
M '9W)O=7!)1&QO;F< !F]R:6=I;F5N=6T ,15-L:6-E3W)I
M9VEN #6%U=&]'96YE<F%T960 5'EP965N=6T *15-L:6-E5'EP
M90 !);6<@ !F)O=6YD<T]B:F, ! 4F-T,0 0
M5&]P(&QO;F< $QE9G1L;VYG !"=&]M;&]N9P 2(
M 4F=H=&QO;F< (\ W5R;%1%6%0 ! ;G5L;%1%6%0
M ! 37-G951%6%0 ! &86QT5&%G5$585 $
M YC96QL5&5X=$ES2%1-3&)O;VP! "&-E;&Q497AT5$585 $
M EH;W)Z06QI9VYE;G5M #T53;&EC94AO<GI!;&EG;@ =D969A=6QT
M "79E<G1!;&EG;F5N=6T /15-L:6-E5F5R=$%L:6=N !V1E9F%U
M;'0 +8F=#;VQO<E1Y<&5E;G5M $453;&EC94)'0V]L;W)4>7!E
M $YO;F4 )=&]P3W5T<V5T;&]N9P *;&5F=$]U='-E=&QO;F<
M #&)O='1O;4]U='-E=&QO;F< "W)I9VAT3W5T<V5T;&]N
M9P .$))300H , C_P .$))3001 ! 0 X
M0DE-!!0 0 %.$))300, !) 0 * !1 !X
ME^ !(D !@ ?_8_^T #$%D;V)E7T-- +_[@ .061O8F4 9( !_]L
MA ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,
M# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P 1
M" !1 * # 2( A$! Q$!_]T ! *_\0!/P 04! 0$! 0$ P !
M @0%!@<("0H+ 0 !!0$! 0$! 0 ! (#! 4&!P@)"@L0 $$ 0,"
M! (%!P8(!0,,,P$ A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+1
M0P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25
MQ-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$ @(! @0$ P0%
M!@<'!@4U 0 "$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C
M<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2E
MM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,! (1 Q$ /P#U5)))
M)2DDEE=7Z[1TP2\@P8#1)+B&N<]GYK6;?T.ZW<_^<_FT8Q,C0U02 +.CJI+#
MZ1]9,;J#BQKC+ "X/ #MHW-];=3OJLW.]'?LV,K?8MQ*43$T0J,@184DDD@E
M22&[(H9]*QC?BX!#.=AC_"M^1E)384+;/387Q,?#0?O>XM^C])"&=AG_ K?
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MU:=U/)&=4TV4W[G^DYXI>TN&UK]QW;JMS?7K_/\ 31Q"%GCV
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M /_A0!5H='1P.B\O;G,N861O8F4N8V]M
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M=R(_/O_; $, 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! ?_ !$( 24"0@,!$0 "$0$#$0'_Q > !! ,! 0$
M ! 4'" ,&"0(!"O_$ &(0 $$ 0($ P0&!P4#! H."P$" P0%!@<1 !(A
M,0@3010B46$)%7&!D:$6(S*QP='P%R1"4N$E,_$856+5&31#1522DY2BT@HF
M-39$4U9C9'*"A++4)S='976#A8:EQ=;_Q = 0 !!0$! 0$
M 0(#! 4&!P@)_\0 3Q$ 0,"!0$%!08$! 0$! ,) 0(#$00A 42,4%1!A,B
M87$'@9&A\!0C,K'!T15"4N$(,V+Q%E-RTB1#@I(T8Z+3%U1S@[(UL\+B=*/#
M_]H # ,! (1 Q$ /P#]_'!@P<&#!P8,'!@P<&#!P8,'!@P<&#!P8,'!@P<&
M#!P8,'!@P<&#!P8,'!@P<&#!P8,'!@P<&#!P8,'!@P<&#!P8,'!@P<&#!P8,
M'!@P<&#!P8,'!@P<&#!P8,'!@P<&#!P8,'!@P<&#!P8,'!@P<&#!P8,'!@P$
M[ GX#?@P8@9?B.TS&MT3P]1YEU-U-?H'<FE5\'&KN32T]2VR^^V[<Y*B&*6
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MC0IA;KE2A*"TV'5TX#JJE@ *>"0"417:1XDJJBD2F+2>[D%DB2\M,FIHZ
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M?]7	HOPTXIH_2S)FNVMMCKCK!2XA,R/4'*;3*I>)NY#2V<SZRC/RHSL>!B
M=6NE#":Z#%K8:DR7+ .@I4'?DH9,<\<S=U#V59:C),F>KU-4Z= J?LSK0+8^
M\"UOO%\@.+6I1*4H4" ,?:E=VI0R<D/\(JDC.,S9RR&PLIIUK8=6*ETK"UE
M[@E1*4 A2E@B3B6_%#XS-&O"'1UE]J_)REF)<.*9KDXWBEE?!]Y+J60P[*9#
M-?$?=<4$QX\N<R_(',MEMT#CE:>E>JB0RD*(XF#$3,&^.A<=2T 5 P=R!,?7
M[><2SI7K7ISK+C\#(,"RV@O$R8$:9,K(%O F6U,M] 4N'<5S+AFU\IE:O*<;
MDL,GG0KE!VZL=9=944.(*5#?D?$6XPY+B%@%*@9CU^!O];XE4J4-B#N-AUZ;
M?'<]NG< @].(L/Q3/$_&U@6=ZX9MHMB6$ZEW3&F^46N"YWJA&HJQO3;%<RI
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M'E5M;*E )9<*1W2$>'NP[44KE9 TMAM"?\ *4#^L70FFPG2>;7:++U&U%SG
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M#$..U(Y7TM[.3Y/59GWE2FEK':!C6A]RF0C7WQ0KN$([R 2MW2% G02;$":
M5>^NG8"FELAXNTR1WNM2 AVH;;5J2WXPHMJ44*C0% %1TSCGOXX_#_J5XQ_'
ME]'&VWA1SOP::>56<ZT9KF<"1%GX2]FSU2Z[@ZY[0D%%L&IM5BDJA06WHTF)
M>6JU*\HOI5N9%F%)E&1]I-;H;S>H6S1,4[B5(>#(7I?TP("@E3B5[$ 2+@0]
MY#KI:#:M,0LN I!$6(5$@D]/ECL[BD'(J^ND1\GLZVTF(N+IRO=JZ\UT>+C
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M0/1!/%C_ /$+L\J4Y=E6<UM EI[-*')Z@49[N%N*IX"#4MA@^(M"&TPLS,#
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MCBME]129]FJ6<SKJ7)*-S+4,U#[I<4E3E%30AU/(JZ@I $ J) Q9[2NOT-%
M]ORK*',PK&':8M4E&AIM3B5(2T^BVF&U)!*A!O$F08LBK3G$=2-*X>(:DZ;4
M$:HR:/49%ENGKS<2341LG790\OFL2C6AB+92(F5,F7(F("F[*:PJ4_YWG.<^
M&U7U>59HY5Y7F#_>4ZW*>DKP=#RZ<M*I=2=6HH[RG.B)D))"=,"+]12,YUEJ
M*?.:%IQ-0RRNLH'5=\VVXC0I+1(@.):6D!$[A D$$C$OQ($2 Q'BPX[4:+$8
M:C18S#;;,>.PPA#3++#+24-M-M-MH;;0A*4(0D(2D) SU%2U%:U*6M1*EK6
M2I:UJNI:U&2I:KRHF3)G%]*4H2E"$I0A "4(2 E"$)_"A"$@)2E/ M C;"O
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M:3JB1BM1/.LI<14NK="7G2V^N$=XAQ:B$:0+!((2B0HF!>!B'OIL_
-%]
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M T &$Z0 $B2 ((YD"^.P;I%/*=<><=6Z^LO/O*45+<62"M2CNJ0GQ _BDW!
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M24= 5$)"E]3RC<]SL4[=]Q[N_H>@GR&"0-R .IVQHM]JE@N-(<5;9-5-.(8
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M?8E-!;DA]YQ,Z',4II V2E#?GL )"E-/ D)6@$GAW_BB(T$;<1/KQ%_='.%
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M(,A_F#[-;]6NMA?JHL?K(;JMRPC]2X7N_ :5&W>M_ #]0<,-4K^A?EXIOO\
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M":2D"@9[II(3/3Q$; =<(RE ;3ITDN0I12J0%$$D),WB //?TZ*Y;EM;AM'
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M9S^I:KD4:*5VI;#_ '5!#-2FL=:9"N]+JJ5E+Q2T720LI^M/9S[!*WM=D?\
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ME&8XE3B4K)+;I'E/#E4E)4-SS$\2)ID".[:*Q.X4%;< 7)X$;BPG$*JIU=U
M$-&+RL)Z\6!B.8VXN,(WK:W?=6I<E:5N+<>46]DD+6.4N) /)S^6/+4I*4[H
M)0H*!V,A3 (#"VR!,K0N+;?RB#,\F.N(PLKD)?U*&Z4J;N(VC6=_J=\(2I]S
M]M]Q0]4E9 4-E!*4D=#VY1LGJ0-M^C2\"!&I1,24F ?.()'F=P?(74()&I3
M6@3:>=HD@CWQ;W8QEC<E2OD/UBR24C_#ML5*(&W3H$C8#ANM4[N%/!W\O?\
M"_KA-"?Z1 VL(L0+>A_V'"-ZPJ(Q5[38P(Q3[Q#TF.TL '8C9UUL;$[_ +7*
M?3L=N$\9_P"89B_=J$]?+SGW>> 7M:+P!\_*_U.-0LM4=-*@J3:YYB<$M!0
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MD$:DR>3MQM%NN \D1Y@WZWO\/=CZ ^D\R5NI(5S@\V^R^7EYNNYW">F^X(]
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MR'9+?EAKF6V%GV594E*"' H@:P0 ),29( &Q), ^1Q(*M$$J"FU 2$*'B/^
MD#J8@>9'48C7 O%;,SG0S4S6/)='LQQ^IQ!&43X>"K1#GYSE6"U,8R$WC6/E
MYA<>39U:9<N/3K=7(DM-);C*?>?8;<W\TR!K+,UR_+Z+.*/,'*A%*7*UDJ11
M4U6^I$-)J%2E:6E* 6[ 5(( !C&[.YVOM!25+]7EE1E*$U+K#=/6Z2^Y2@E
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M-N\J)]7$G_6+8C'S(J&Y+[D1#4E*%N>29+04PXVL^45C#%.IMMFI%2LMJ^T
M-J;#+J5E/=^(G6-("BH6O'&+=(]5/=\7Z8TJ4/E+!+B5J?9T AX@ %N5$ITG
MQ"/?BD.+?1OZ5:=ZPZO>)?'KC)L^\0&H[\Y['\EUAR"9EV/X!#FS_;$4>,4Q
M:#=71QR3RPXH2GRVVV&$QD[K&XGM-4+9I,N>;;I\L9"0\S0(^SNU @E;I*_
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M74"L3[HY9#H#A4YN4;- EW902H@\G*0-^;AZ6UK_ @GSC_?]L,6XA&Y]PN?
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M15N-,("UF$ J&D\Z2L$H!6%3CY?5[6>VG:):W<L[-9]5,J;<?ISE])65+*V
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M)M#.('^%=S06MFA1/8K^HFP!UY3MPH=IG?QM.H(G\) $[D%)^1OY## AV!)
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MY!V(WW)WZ@[=3V'NC8; >K=(F18R"2+3'!\CSUP8\AA 3NH@ CJ01U[[ C8
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M_P"XIO#C[CYV 0VTH/B1+5.@_>N:MB$H(!5>X$@W)L+$<['#%%P?A .Y!(,
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M92D)XZ'-?9_V6S-#93E--E]:T%BES'*T?PZLIUK\(+;U(62I $-N:D$<3X@
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M]$O#C-T+T&AQJ7!8^=NS,(TEQ*HB18-6PC%*9$]=;#BH4A$6.Q 2T4A25ND
MHW+B_>X!0JJU=56+*G724K?>7)<7)NI1@S DQ: -AQ=*D)T)D)U Z0( M?CK
MZ7C>XB>K"MKK6#,J[6%%L:N>P[$G5\Z,S+A38LA!:D19<:0EQJ0R\A90ZTZE
M3:T$A22"08D+4VM*T*4A:%!25),*2I)!2H$7!!$@@V.!:$N)4A:0M"TE*DJ
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M2+6'%TH><%.I8 6IH*T%0@PJ-0*E&;VA^S4_?IJBPR:E"%(14%EKOTH4 "D
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MUK GZQ>_PXY13=CZVM7GF9.]IZ2@<KNY;8'\)=[JF^U.LI:51(J0A" IH/\
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M96\=2BH$ Q)L/4R1?C'U]E]$UE](W0M!*6VDP-.QB..3ZG:^V'/V-?\ 6_\
MZO%?4.H^(Q>U#Z*?WQY]B5\/_0'\^"1U'Q&&]YY?/^V#V)7P_P#0'\^$\/\
M5_\ 4?WPFKR)_P#4?TC![$KX?^@/Y\+(ZCXC!J\C_P"XX\+C;=A]R@/Y;?\
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M&"NRG2,7QEF):I:D!N1'B-V=:IQ*E,6KR!L728'GU'PY&_PZ<376 #:!>-@
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MUBZFZ<R5=E&>BMI#=BC(:2C::?4&(STQQ#O(8,;_ ]8M*+#]'Q7ZH:>SCED
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MLBS5PHM. @A=,V"4F1]VD( C@I2F#U-[F3BNP-.MN_A=6H [RXKO#Z@J)(^
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M$V@&=M@!8[1.*[M4 AD!*"8L$](-QN;_0QJ+BWY+G,XK974!*$I0A"2>H0E
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MZ[?9TWX/$8O$W.Q(_*Q]"9WPH.GU-S($[]5 _"=[X7L1-MB/3L>OV#N>P_U
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MWK-O.TU4IZF<6THD*"DJ*=)!E-Q_*#^+@S'%FN,,U#*J>H0EQI8@I*01)Y
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MI $!*B+K' "B8L<.H9&X(/7L._V=M]OZW]3Q75<0=MX _(>7%\6Y,1-OKG?
M'KRC\_\ Q3_/ANA/3YG]\$'R^(_?'GRU_P"4\)H'4_+]L.TC^L?+]\?.19[
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M97#=8BX=HHLZL4H*5[!56$J3!,R.M+<4F3#;4%>8SPJRD1$#T%]P!$;G?R^
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MI9F D Q_P!0@D#U/QOB,E+()6=;I)U+WDCRV$$&_P [1C1)MM(F<J6RIME#
M+# 5[B7G6F6W&VTNN-MM+?6A!"%/.\[JTA(4H[ <3MA#8($201>3!.UR#$<]
M/RJN.+=/B)(Z;>I@0)CZ-Y;VFE;[DD;GTW"B3N-R1W)!ZGU))/J.$*CY$WVF
M ((_>Y\O*&0!L!Z;WVGY2(L+86(9)VV&VY[D@'K\]N@Z$'??UW![%H!_W]_7
M?8X<-0!*>G.WSW]U\1AJ+J4K$WX6)8K5_I7J7D+:S08PPOE:BM$%*KK)9#9_
MV910U K<=66WYG*J/$"W5%35A#2E)UK(2F-C )'K (F2-P>G.%$:0/YKR(!O
MZP(YV $X]:;Z.BBGNYOG-DK-=4+..E-CD4U(]CIV73SFCQ*M5^IHZ=CW6PS
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M4MMH62$*2LI<#:PE0(0L(0YRN=205)(Z <VRP0@)+:U+L/*^Q M:]MS?;GR
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M-^O$Y?=<2AM;CBFFH[IHJ);0=I0V3H21N% C<1.*Z6&$.+=;992Z[J[Q?=-
MA:]1DRO3)!-H)\HOCTXV=]@ 220?4]AS#;J4CH"=R!T!VXA4--A(DDD@PHD
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M[R)'7;K\=SOTWVZ_('8?+8>G!@PE>>:C-N/2'$-M,A3CCBU (;2D*5S ; D
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M GDP>G,F=K= = )W%X'D;;&.A,P>F%@CI6A2%)W2I)2H#H2% @C?T!&_3O\
M?W4\[;'K L(&Y.WBB -L)YGYD\;;7)\[@#KL.55\K4=,K4#$)$"]MZO0&QR
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M)'D8M^P(B%W08* (@7/&^Y%NAB#L,6T:8V0 >A'Q]=_CZ]/C]WIPX7!/6_$
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M:!;&XK;&Q !5T6=]AL?4)!.P (!6H[>I/%8E4^&9%P+B3XNAY@1O)C:3BS^
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M1I32TP?2E%.E)6"22EZ ZK1<+=U3$Z03.,]FG-$Y6+6\\.]5?[QQ>@W\+.H
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MT_F.\C""^\ "XXC]3/3<Q,CE<VUL1TWZCIU/?X\. CW#<\\^X?,\[76" 8D
M W.YB8'D)O>YG$)Y[J%F</4*DTMTUQ^BM\FFXM/SBWL,GG2X=-68_ M8E.&6
MD00F7*LID^:PRR X&HS85(>\P)\I3%J*9(WD? 1;I>9MMSAP!N3$[$=1'P\S
M!B]QT09'XD=.L'R"PQ3.(%M3W\'&YU_+4W$K;&NLQ14WUW<P:A;-E]9SG(4)
M,E^.Y.JZ^.^EAX-/E9#9=J'Y3;?];=#N/(SA4-JW'02.AM?TO;?]VY/BLTI<
M-?"DXYFC%Y-O:BLK\6L<=J8=TH9)16>34UZRF9=M5:*JVJZ>W=@239"PDR8<
MJ((!D$,*+*%XF8]U[&>(DG:=M\&A0V)L+S<6$6]]C'7<#&IYUXNZO",!U0M*
MJD>RS/,7@ZQ6U938Y1O_ %?"J=*$18DBWS-R7;LNQZR'86536V$V"^[(DID)
M%;6J3'<#,?> &Y'00-HZQ)B^V]HVPJ&2HS!BQY^ G?X3^MH-4M3*S2C2^XU(
MO(SLIJLKX3S-?&/*N=96BXL2!"0M15Y+;L^<P%.KW\J*E3RN<^[QM9%E3^>Y
MHQEM.L(6\/&3![E F7=O$-K&1SCBNW_;3+_9[V2SGM7F+:JA&5LL*9I$2%5U
M36/-,4M*%"Z-2WD%2TD1^+\)"3P.UAU]U!UKN7[')[9UJJ2^R[5XW!<=9IJL
MQCSL.,1B5%R4"HK7/>)?<=(//NE.WTQD?9?*,B9;:I*=IQ] )>K'$]Y4*7>/
MOE@K\-H$B(!CE7Y8=OO:QVQ]HF9OUN;YD]241E--E%"^MK+:5HB A#22D/+<
M4HAQYT*6HF"3Q"FY4OF.ZU$]2=R5==]E'NKKL>IW)"=]]AQTH!@)!)FT3 .U
MC V.Q\B<>9DDF=1F\F3>=P>LXL%X>=&:S5VYS&5E60S,6P+3G"[#.\SM:R*B
M;<_5<.1&AQJZHB/GR564^;*0PS[0E3#7DK4Z.4\<_GN<N98U1HI*9-165]:U
ME](VM2D-%\MJ6XZXH&0VD7('$Z1)&/0?9]V,I.U]9G#V:YBYEF0=GLFJL]SB
MKIVD.U?V5EUMIJEI&EPA52^ZX@-%<H _&9(&)RT/\,&EFONH.;1<+S/-H.F^
M-T=.BKO+ZGK6,@D9KDSAAT=',CQ6GX!@JG,RTRY++;3R8[3;@#97NK%SCM-F
M61T-$JLI*-S,JE]\/,-/.?9TT=,$K>?2M12H*2V4E*5$@J,09QW/8?V7=ENW
MG:#/6<FS[.V.S65T.7_9<PK*2E;S%><YFI3%'0O--H<84PJH0XEUQL!26TI4
M").%N*^!VTS#2FHSBNN9J<G<U@F:=Y'CKL>.EFKH(-F]"GY,SS-B0KZMCQGY
M4]#BRVVDM ) 4"657;.GI<T<H76$(IUY4FOHZD+45O.J;[QME8,('?%24(($
MF 1OB7*_8?59UV6I,\IJRI3F7_&+O9S-,O4EL"DH:>J6Q49D@E 6O[.VTMY]
M*B4)!1M.*Z>)32.OT,UARW32FN9=_6XV[$;8MYC;#3\[SXS3RE^7'0VRD*+F
M[20-_*V*NO&_V<S)W.LFI<U<:^SA\*E$D0I*U(4(F=A!\^NV/.O:3V2I>PO;
M#-NS5'6NY@QEJF^[JG4-H4ZE:4K"BEL!(D*E(B"+^6((.Q!3L DG<I Z;_';
M\_\ @.-V!_?GIOZ?4XX7>?.9]^^-VQ#4?.L"GLV.(93<T,EDIY?89S[3*PD[
MA+L<K+#B=^Z5H*2.A&W&=7Y1EN9M]U7T;%2F\=ZVDE,\@P""-P9D&X..D[/=
MK^T_96J:J^S^=9AECS<!(IZAQ+1$@Z5-$EM23$*!3<$@[G':/P<>*FRUP%CA
M>:Q8S>8T=<B>U:0V_)CWE>TZW'><>82 B-/CJ<2IP-#R7FSSH0%)/-X)V\['
M-=GRU74,KH'E%I2"I2E-.=-2O&H3>\Q B1C]$/\ #_[<*OVC(J^S7:-AEKM!
ME;'VQ%53)2EG-*4.)0X5(0-+#[4IUI;TM]WXA"@K%\?*^2?P_P!./.-*NJOE
M_P!V/IS $$=DC\N%(2=]7_U?KANE/3\\9/+!Z =?C_/<\5U6$B?B?G)_+"!)
MF^DCT'[#'CR4@].GVC<]-^$! @ &YYMO;"^*#,3%HZ^_ZZXQ*97N2-CZ].GW
M <6 L1!!Z=;>?^V&$G90].#ZS<<^F$ZV^;<$;*Z@';U[??Z<*.J2(Y!.WITY
MW_V$FX (BUCZ\>?YSMT3EE8('?\ $?S_ #X=(B>F_P!"1[L2<'C?ZMC&4*[%
M)Z^A'38_'TX(2;VMS/3KQ;SP&#&UB+XKYJ&M-9D0#K,F6Y8MH7$APF%29+P;
M2$/%+((V;03L5K4E)/3?;B[2#O)3.@@'Q<$0;CCK?>_&,NL< 5HT@D$;;1TC
M<3\YQJ,<8\B:E7F7.%6ZRD,S5,2*I2W"=P7%M\\!].^X*7E*!W/W74H-Y6D@
M<&/$.0#(WFW]HQ14JXTI6F>4D@ ^83>.?AP+R+(M[%FJ>K,Y@,Y+C$QI;0R.
MH:2XMI"D[!RQ@M%7(6_VA+B%1)',4#B'NO&5,C20=B9!(O&\;1;??:!BP'@$
M%-00J9%K1( )D"_G)\O(QQ-H!5"(ARQ3,HI+Z5XIF49?,N#)< $>%:J1OR)<
M'ZHO*"4/-DM/A*CUD0I)6M4$..0I=.3 !)))!BQ DB(VN.L+C:DH0F06D6#P
MO(CD7F8W/J,-#-A)2S;Z;WJ! ER'53:%X?\ :;,M:C)2B,H^ZJOG/(,FN*%%
MMMP+B+V"4;JMH)7]H3,GC>)CB?/W6(&V')>"F12+()29*K\3%Q\S;@W28Q/T
M74&O<P^'<2XKTNP=DQ:"72LH;$A=^MY,1=?R.D,M(=DJ2MIQS9LL^^"KKM3+
M2P\?Q! V'K/( )@@@Q.UL6P\E;1C3WEAMR1R-KB3M:W,X;,.J)]?$ME38;=8
MU9W<^S@U#;Z9*:N),1&28ZG$A+?,Y+#LDLM)Y$E/N@;<5JA86Z0B\\7('7?K
MZ>73%BG2MMJ#!'I'7:#S/^V*_P#B S>SN'4:+Z>VB6<DR%,-O.;: ^1-P_#K
M9],-IB,^@>7#RG+%&1"I"^M)@1(]G=%M'LL$/S4C?B[YPD)1XDIC4H*!U))3
M'B C;8GPQ!.$J7BA*DIN5+2@3L-9@C<F+Q.X$]3B6Z#&<KP3&*BDI\2QT8]C
MU;&KH=316#J)4>!"C(;;:CB0T69+C:4I4I0* ]L23S@'ASC;"U&''BM2INB/
M$=@#8@$V(M8G# Z^$P4-!*9)\<D)%S')5$QN9._3:JNPBW5?'L816IB1SC9T
M!#S*VU*0XR\C8<K[3B5(=3^RE0V3WXIJ26U*"K;V M8;]>#Z_E.A>I (Y@W%
MMIFYWB8M\8&%:F@>OX?RW_T_GPA)! ZGX^[]CZCC#PJ+3'7GWQY>O[83J;WW
MV&Y.^W3?;\]S]WXCAQMU^$_D,.U'TB)M,GS@6^.VV$BVCOT!Z_'[QUV VV/3
M?<C8;GIPU2B?PI( Z_L;F?CQQ@*P+'T/'PO\.O483+;'O;G;;U&XW]1V^SK^
M'7B1.H@QQ,CDD2+?#>V%T) ,F/,\>=OG\L:;*LX]R+BDJ/*FR453I]L?9<D4
M"W9(=CIA2)<=Y)==W#@D16%(<;0E06M"^AOIHG6/L]55(4FG4^$J;1*:O2AI
M+JRII7^6DDPVYLK<).YS36-5;SM)0.!=2W3..%PI I0HG0D]Y'WA;(\3:+@F
M%*&V.6M_]$OI9E7B)H->K3*;"FA4WU%,;TYP^MK:"B18U)2ZJ.FTA,-VDF&_
M,+SKDF2^Y8OM*2S(D.)0!QV"^V]9]@?H*=@$*"VVWWG%.K2A7A2DH5".]#8\
M1*0W,E*18XGIFEML,MOJ[RH6-3ZU>))(%R ?PW%@+"PQ:CQ7^*3&?#SAEE%J
M(<K-M7+:NEQ\#TSQB.]<9!:6CC2TQYLZ%7I=?JZ& M0DS[64VPPU&;<*5*4$
M@<YDV3U.:5">\!IZ1HS5U:S#;1D2E*U?C!$"),[22;N40H:E$I2!^&8383(!
MYCG?<8BSP0Z!93X<O#SE-GJAYMAK'J7=91K'JDU&=Y[!F[O6#+AT*7&UE0<@
MPHS0\II2DMV$N:(SA90WS7>T&8,UN<TZ*4=S04**>BR];K:DMJ;81"WRB (+
MAE03NW8B3B+6Q5)[M*V@K5W1"5D%3A7J,Z8"/NH$*B=^,<GM!?I7]:-7O$WH
M;IUB]-BN(:>WS:<7S##LKELIKE*JQ=3?:J#(?8'[R)<.8["B5U97S%2W+K,7
M68KFT:>TRSW>;=C,O3E^85[IFM*#4)JFSH:+P@'O*=)[I#*5SWA"1I:\2=1&
M(:=D4%(&=16W2_Y2%$K<$ 'Q+,J4;#<D[D0,=ZX6G"+_ #6;G&7V=]<?5%]:
MQ</QJS,9G&\=9K93]4W<UM;&2&K&1:LL_64&VLTN63$:<6-F5$\>5O@4BV:=
MNII*D.4=+5*72E:K5C:G0/&#I+2=*3L003N!A*9;M0R7G*5RFBIJZ8)>4VI1
M-(L-%7@-DN+E0.VDXL-47)\QN)9+?0VEL1$2XYVEQHBA9NRXT92UCR$32\A#
MQ3^WS$*&QXSG&@[=/XNH-Y,1>>!T.+[3Q00%$E,ID$ B ;[V$CZG$L87G5[@
M-ZB^J'FVFDIB)N*R.4&KEPI3E6IBIK$NA]<JT,51]I?2WSQW'.?WBE9<A2M"
MYIW$^) .E=@20#>>9B_PVMBRI):BH:,I5!*)D:21( V!WCI(Y..D6GFHM%J+
M3)LZM?ERD)2BQJUE2I%:^05>0^I3;7F ;='$)Y5;[=""!7<;4WN)!B".9]?U
M_?%MMU+HE-CR#N./SMC@EJA0ZM9/K*Z-.;)VEU::^D\F(D9+:8_8Y-58YAL/
M <D8P*?D=9$4TI>.)QDL,0A)D,0]WV' L*V"F8E^O3;Z^K5#U=P[52JS M:X
M7,9Y;7CQUY>RK4&RT:SG+M.Y$69IY[/ O6L!Q^':3G*27,4ENL+*G80E@%#V
M^^Q@Q(FE?B+UR\.]-X;/K*QUAL,'QG&UUK>B6,4F?5>274=617DJ!J+/@2<:
MM*B]PS(HA84O$K:WJ;[$JU+;$<)<"$ P8T6JU,\7WA$PK5G-,KQG(=*9OBQT
MZJ=88.3U]_/S&6K,FLQE2K"#(4G&X_\ 9EDUEIWDD2HK:]3-U.CV-.VZRW)D
M->3P8/KZ_OB\/AKSC(,XR_P@Y'.UCL-6]1W_ !/:RU;T>PR"TR#(,&TF?TAR
MF8K#<GFW%-C]BZ[&J41+68_(JHT:3:BO6P79+0<68,?H"Y4_#?J"-^NVVVVV
M_8 C<#X\&#'K@P8.#!@X,&#@P8.#!@X,&#@P8.#!@X,&#[.#!AOFV,6NBOS)
MTAF)%CH4Z](D.(::0E ).ZEE*>H!Y>O7<#OP038;G;R\\(2$B2;#ZMCG=K+K
M%)S^6]35;[D#%8<KV7S0D*5.G.(<;;39-H=2I%=))"4.[*91N%*)/%M(# $W
M<-M[>L#U'0?I1<67HB WOM<V]8XYWXQ76TMQ7EMIEKR9;:G'&&FUE9JUNAL3
M&(<MMQQ#T&64D\J@=@#L-U*W>VV-6M=R!-YB=MN?3@^[%=YXZ2AHB"+2!,7Y
ML.($7]VVD;..K!7NH[I"E$#]D #8;#8;A*1L/\H&_0;3+)(&P\HC8?[]-]L5
MDIGDD@&^\[6\N/3XX6(8)Z[;#8C<]>^Q[?<-A]XX8 3Z#<\8< 3L.MSM]?KB
MBOC1UUO<1:I-&]/ICL+,<YAN3[ZYB)6Z_B^')>7$?F-!K]8AV:M$TE]LAUB%
M!D+W!D,K3[Q[(NQR,P5_&ZQL/LM.!M#:TV<>0L:0.-(/=E4V5WP%P ,>!^V3
MMR.SU+4LZTPPW&E)A3M0IL'N4%)4H%;A<1J \"&%.2-6./&<:B1\<878QLCL
M*G'8;,NCQ^EJ9'M!S!'M+365W2YDHJ?@,6LAQM;96DN..M2^10##F_K&:]I<
MYJ<X=[+]CJ.F=J<N2RC.LPK6UIR_*%5B2JC2CN2E-15LMZW%T^P0&2X9>D<#
M[-O8MD=7DC':OVIAY:L[#N8TF6(<5_%*^F"E-EELJ)#5'5U5,H/.%04E"SI2
M2UB*W_%9(D/1XRF+R"Q&5(=$Z'<)5:ORU0Q7PY\AR0A49UUJ.5!;!;#"4N^6
MV-D$\0C)O:2@JJ6>U^75%6XS3ZJ:LR= RU3C3H4ZTTAI8<IFS 0%-**UA1<<
M\8 /?)]G/L2>8<0_V JT!:U!!9SA]3U)KAM-2DJ'W[J6R4GOAI*);$@G$[X=
MF\^VKH>1X!E5C)S#"GFIV.7JWU+R"RA,M-2)]!]7PPW'7'KRX5R%%!1(:7[P
MWWXV,MK7^T= _E7:7+6J',D(J>_I4+"Z=YE+[C#592.N>,AY.D]V3K;*A(N9
M\B[8]C4^R7M31]HNSU<U5]BL\>8H@IMY:%Y;7-L(*&JMD =TIH(>6V(4VX M
M.HI3./T&^%36^/KYI5496I*&;V.!69)$1U$>UB(2B2=CLM+;Y_7,E8YBA6X'
M0\?*GM [,K[.9TIL)*6:C4I@JDA*)L#.ZM.WF<?5'8/M"K/,I"'4A52TE*A!
MV;@#42-Q_/'10' BT33).PV.W0==QO\ ==]N_\ 7IPVP-K[P+[\\3] 8[R0
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MYG'Q3>X.WJ"-N_7;Y_T.$ .YBUI-NL?WP7]?.8/R%_ET]4BDE(.X[';MW[]
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MJK+)[MMIU^PERI<A]Q4B4X@R'"-E+\A@--%0" !P-8X]F#U=F8ID(2I:5/\
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M6$@(:-B+DW,'<VYZ=1/)OI04MYPN$[[]2H@>YMOT '<].NW3??KQ,J][0?
M3XG>2)BVWQQ7*0D;F;&_P/6_D-AUPO91OO\ #;IMN2=OY?#U/#?Q23:),\W
MV'[?#"HF^WK%_3?;"Y".;T/P '];>O!*E0/*P&W2>GOVP\E0@ 3:YB!^8^&.
M$WCBNI]/JIKID=4I<Z_KAAF+LNQC*9F85CSN%T$QVP#Z/U!B7<F?8H6RK]H.
MK61S'?C[1]ES::?L!D[S027*FG<=7I4$E;P?J$W)DI@(:E7!"3;3(^&O:6C^
M->V=&29L&Z?*FJEPL,N]Z6:Y^*-P-!28;6I7>KID(6I*R._ D*!5R)U\N_:,
MWL8[+"(L&"W"CU\:,A]N,W:PEA+VRW$)4IQ ?\M ?Y5O+!+Q4:OLMIVO^
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M678B4A+BQ[I))[$<>1>W9EE+66OV+RU*2;ZB!J4)!1( )^'GCSS_ X9CF-9
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MJB::<*CN2NG#*U3 G4HX@VY\ _AON"KDQ>RIPK<!-+<R(:6P0 D.)D=$@=
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M3MMTZFW,7VC>T0 09D7'3& (2!MM^/]=/NXF*9,C>9XCWP)^N)PTB0?0CXX
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M46$3=)Y6W&C)0G??;KP\(0J#I(,2 0-IG:T\G?UYA4M:9"5!0O)5<WMU!]?
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M"D+)2>8;[H/QXJJ04*TD3')W^8GWV'2-L7&U=XD$FXZFPC>08)O8Q;TVPJ*
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M9B+0MM+ZN7?VEM#G-_A5TZ<6F4!"0ZL2#9(D3/$[BYX\OA3><+BNZ;/B_F/
M$=?3]>)FDUA,9A,J5^J6MYHAH(4EV#*9"0IJP+"I/G1+9!'ZT].HY2G8$<2-
MM]XLN. D;B.3OM>=_P N3B!]T,(T(@JB-0%Y%]^HOZS)'&-'<<=E/./.*4XI
M2E%)45*Y/>YD[%1)WZGJ3UW._$Y41$1'%C_;X>AYM2!5 *IGSO\ V]V,[+/0
M)&VW^(GU/\3_ ,=N(Q,B\1R3 YM/G?SPX J/S)Z?EAS8:! !WV&^^Q]3UZ_?
MMM]_IPY(D7V$V\^NW3:>1[L2I3P.38?0_/8>EW-ID>NY_?\ (#;U_=Z?- 2)
M YY_;ZGTQ($@]8Z]3Y6VQQJ\?&!R\&UCK]394,3M-]5Z*%B^;>T^?]4PKNIC
MIJH=C:,Q$J4H1ZKV*56I<_WLF%/: V925?5?L9[0L5.1-9,LA#V6Z]"5*2"I
ML.J>4$ZI22J2-KI.V\_(WMU[(5-1F:\VR]&C, IROH*I*72ZFH2PKNDH#9!6
MI<]^DJ2X ZPAM "S?D_J3I4WFF>55%D&1PJ.\KY>,U,BVNG6ZO\ 3/%;.WCU
MM5D=+&?4D*FQ:E158,K<09+C:'D(&Z@JGVES/.?9!0]LJ_+<GS#/>SHRG.^T
MF3TM!2KJ?X)F.7Y>7592^EE)TT%=7,I+"D3]GEY1*PB3] >R'M%V9]L>2]DD
M+KE93VC:>H<BS%JI6VFG?2:VG2I2%NJ0\*I%'5_:RFH2C42VBRE)U= /%%X.
M?#SC?ARMI6(4=/4Y-14=4_CES'4L7MA;B0P)QL)3K_D2V[!A3[JVT,MEA2?.
M "$['\V/89_B2]KO:#VU]FSF?:C-,\RKM'6NHSOL]W"G:1G+UTV8*#C%.AO7
M0_8UHITTR5*45"6B2IQ!'WMVY]D_8JD["UU)19)295F.6A":#-WWTMK?=74-
M(27"I<O-J:4X7R4H/=DN)'@4,4&T%QFOT[Q?(\SGO-7,>-*;B4;NTQ--D=WY
M#:68\!Y#0=:L:"2IUQ3BMVU+1L"I.Q'ZY9<V]F69,]HLQI4Y:RQ0/,4=+4H<
M37TY74**WG@I0:#3R&T!(3K5 )(&F<?E%[;.TU)4HI/93D%2_7OYAF:,R[1Y
M@TI35!3T-.P4"F;2G[U84I;507GRR##?<SWBL?HS^C>T<O\ -)Y689@U(1D
MVI5DO))B9OO3&(C[*!!8DE0"^<L<KA0KJ%E05L=AQ\W^U_M$SFV=HHF5!Q%(
M5RI!A )))VMN20)_+'HOLG[.)R?*=8:2AI2=%*!J"2G2D$IDZBD!((U%4*))
M)-L=*$-)3UVZ_#T'R_C_ *<>/B3(3MU.Y/\ M\AP<>N!'6=OK?X#IO8V&=MO
ML$IV'3Y#I^77;K\^'0 (49G<=;S:!-L*4I$R3?K<S[KF_&%R4;[!(WY1N/N^
M)[G?8#;?8CIMPD #Q;D\<3T&TCKOZ\M'A(DW)O?8>?$WF\_NL;: Z>\>O3I
MMT ^X#8$?#H.PVXC4I(V@ P+[W]=K_E;"@3L(21ZGDV!GD_*0<*D-GJ-AVV^
M0'7OZ=>G3X ?/B*5&PB1)G@;@7N#O^_.' 1$[;?"_EL)XXCC"E+:CUV&VZ@
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M 7\IFI6#L?\ W6*W_T^_C/<_P 0%2/P=G:3F9S!7E_\@@\_KC41_A@H3&KM
M74B3_P#D&=O<_P#/@=<98_TM-P2@S]'JU"#T(C9/(6OY^ZY7( Z=?GVX<GV\
MOK@K[.-@Q%JXCK&[9/NB0=YVPUW_ OTR#X.UKY$&_\ #D$DCT?3]<\XDG'_
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M6P:W'H">AK/-)=5K0\G:#Y[6 WO WF;\XG:>4R@AQE< $&.EB3,;1S%L2!6
MV%?>0FIU=):EQG KWFR0MM23U;=0H!3;C?9QM0"T*W20.O%52"@FT3P-K=-K
MD<[;'%Q#B5)[Q,Z# @S()B)Z28$_*UO:D*"B-M]NOW?\/3OPGU?K/[_VQ-((
MN.>1S]6];83*1MOT&VX/3?;<>I&_?OU^?7X<-(5! )N?$)%_?''2!\AAI)]#
M)L;@]()$$;6MYQOAKG0(\Z,_$EMAV/*:<8?;*E .,N)*'&R4*0H<R5%)4DI4
M.X4#U#D.N-+2M"B%!2% D1XD1I)ZBTP=^?.)U"5H4VM(4A:5H@\)<D&/Z9O
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M;=!MW]._?KQ"+F\P!UZ;;_",/ !-Q( ]]NFT] #>".F')IH$; =!V]/MW/\
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M2U*(67$:3JDG2G8"X ,<WN>LXA_A2/\ PH; 932OI>80SI;0E:4*1I4E +:
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MZ<T;L:!&;9=<>M*KV-P-MA)5'9C)6H;MI2RA:=^JN&EH=Y"'IF2)B_,?+
MD2;"V']^"V IB/00H6WV)C;DQ\<5TL;%S,:9RXQ-N5$=IPJ?]23G/;'H$$+0
MAZ966#K:7I=4CWF9L%Y"PT!YR0XC8&SJ4BRR)%SI'K:P\X^46Q4 "S+=IZ_0
MO))@B?7;"]2:ZNKV(MG5OS*UMP5E\^E3?L]DF6PW8LNQ6RKFB283$AU^EF.A
M*9C4.3%/,W^J*J YD; CJ9_V'YW PU(@[S%QJ$@=;VW D[P=MQC2LKP^?@TJ
M,MF2;+&K=M$N@N64GV>1'<;4]T W\N4VE3;<J,I1_6-*:5S)+2^%"PHQ(*H
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M*EV64[@7@BY]YOL>EIQ9(218&3Z<>H]03OA.I/=(!][O\!W_ /]#AWIAMQ,
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M3ZP3]3O$^DB4QS_O]6^?EAS8:3N03OL.W0$[?#Y_'^MP*TS'/._7R'7IAZ0
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M00# M?:Q'NC?U5)&A*H!,001*509(5,R-Y!-Q(GIM:6DI(('78#I\COT [G
MOTW/3AGXYU;2(&VWI^^X.'@6@@ 00$@ )$G< "QXW/,=<+&F^G,H=^P^7QX6
M23 XW/Z#SZ],(5&8'&YZ?&V%J&BH;GH/3[/LV_#MPTJ";#SDGK\K\8;(N()&
MYZD^<<>HWPL;;V [#U^/^O$)69),1.UYWBTP/V&'!(!F_7J!_MY_P"RQ"-O
M3[!MV^?V_P!>O#= B3//E/2Q%I]^'3)W'[^GE^Q%HQG2G8[[@@?U_7];/3J.
MX@\ "_ZX>$ZIDP.?/]A]=<*4(ZC?N=MAZCY^NWX;C\>)4I"!)Z&.8/QW^ WO
MAX$6 F+W,6L)XN.D$B1YC"M#9VZ=!OW/J.GYC\.(UJ(Z6L!Q'EY?VXPX "(F
M^\];]!M\/WR<FY))&WH$C;]^_#180-]P#8^_\[1MZX;K,[0 ;FY'RCZ.(HU;
MTTEZ@,X!,I[%FGR+3S4G%<^J;!]#CK7D0%R*?)ZUU322\CZ]Q"YR&G;*08_M
MTIA;ZPU&"N)F7PTAQ"A*G6PV8%A A)&_.YZ3[HG!JTP+)4#.TQ%C Y]U@#YF
M8DC9)Z$J'+S;#=/78;A?0$;_ W_ !('$,!()'F?H_[[X=)/,[#IUB1UY' B
M^/:4D]0/Q]?E\^'"X'F,* N=]CR3!@_''U2"#ML>O8;'?[/Z^?#5F(_ZA,>7
MRP[21(FQ!@=#QUZG'I*%@[\O3?KW W^T=/MX"KR5;RCXW_/")$'=$$WO,#R
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MI*WEI65\H5I?=+UI %S(N1M< BQXX]0,7G1WJ="I@\@01?PF2#OYCKUQ8D4
MC5-,G3E/*><"$MM*<2$\A3N5<@W/*DJV*B3N#TZ]^-5E?>I"A(3N"3$DGSOL
M;^7QQA/M%API))C:-]_+;;<3?U&*9:RY)-S#)(>&5)<>9;<2[8&,AQX=#O\
MK"A*@@(W )4-CL=]@01;;2@2=()YMQQ-AT//3TQ6=6Y )(O8G<&)OYSN?/>
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M))3*52E0,#'JWBTR@ +)&X,;#B!R9-P1L<<J\IS[-,W?8?RW)[K(%Q1RQ$6
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M\W"M1T+1WBTDBVM,E)C^:QO +T$<J224\H2-U="C;=2@=U@;%70D H3N22
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M< QB==,M%[3'<>O9^2.L#-K^0N87(S@D)@M);<4Q"5)0?+<2HKV<,8N!9"2
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M.!YC8'K[S\/+ 4@$V,#D[$Q(''I\K3A$ZWR@]#OMW[]NVWVG??\ #IPJT?S
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MP^?[OAW]>$Q( 22!'4QMZ3ZVZ$QY8=H[6Y V.P^'KZ'_ $^S;B,SS!(&]Y!
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MQ>8[-=H:I$,Y)F:A$@JI'F@/]1*T ;WD#DD#;D*_P!I_LXRQ6BM[;]E*9:1
M="^T66+?V)(-*VZI\S>V@$_A$2,::]XQ/#5$6&W-5J%U8[F*S:34[#N0J)7O
M [?YAOOZ?.VCL'VM<NG)JJ)L2MH;VW[RQ.WZ8YQWV_>R"G.E7;3+'>2:5-2^
M -B3W-.X2!O:;<R1C+'\9?AG>7R)U4J$>G,[6WK()]#S/5;8V^W;;UVXD_X!
M[8)'_P# JF!O][3$[FQ"79)Z "38 28Q&C_$!['UFW;C+Y,0#1YH/FJB Y)
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M^STU.7%O=RM;JV=(2533/UST PBMQZBG:KZ:UR;"@B.8G2/YMCB)^14C<$"
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MS'EQ)+"T/1Y4:0VEQB0T\@J:+3S2T*:<"O>002$!22(0=K G_P!6_E!%P?\
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M8J$PU-6%+;:3.F*AKCQ5@*<\D<S" M-/4XTRH_>(6HZM0A)U0($!.D#?828
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MM^ZMN+P6H^%2ONSNB!I)'!M),'=1)\Y@XG"U V.@;'2 /E!!\['XX;5I(W[
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M@X,&#@P8.#!C&ZI*&W%K4A"$(4I:W%<J$(2"5K4H]$I2D$DD@ DD <&^V$)
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M5( @];;$S;IZ@D>6_D\,,@;?$G]WY_=VW'#E) Z_+SW]V'[?"/KY_'#FTV=
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MN+8:4;53=02=#2T@1I$7)$F)-L?;OL-]O#'M1%7D^;43&6=JJ"E75+;HRO\
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M]::R/!KJ;ANI$<[+<[3>.]IR]!GY->PGZXO8I43JVVO<LK*MFBNEY/"-G/
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M!>=XE%A5T3F"KG'*=D&6MO<M5 '=E0?3)4RI) &\*4)48M[Q<X%%0(U:5#:
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ML[;]^I/$Y4JPG;R%CSQZ;6'S- W,>I('NWYV\_(;87LIZ@^B>F_KOMT[?QZ
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MN-B=PB=\/LL>($1_,F1',R.9,S^4#'U"0@= >I) &^Y^??U^/" !.P M&TG
MWDW)\]\(HD@ DJ ZR;^^_3X3C(E))[=-^O"X$I).UIOC*$@=MQ]A/[AOO^!^
MS@.QG$A2D [BUX)_?\\>9#C++3KK[C+##*%+>>>6E##3:4E2EO.*V;;2E(YE
M%XIY0"HD#?B-(02 D*49 @1Q ,38R/3WC#!$$E82-[GF^W3@;WG?%3=3/&O
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M UAW.XY=B0 D_L[#8\I"B H;@@GF*]MT].$64J(.LR38SN=Q(Y](\KVPV#P
M%F#<ZEV\P9.W]QUP_P!%EF;XHE36,Y;DE$TZEU#K5-=VE=%?9< 0ZVZU#?99
MD,.<RFWF'CY;B7%A:' 2#'W;*E)4IM&NQE*0@V-@2F"01P9$7-L2!;B!(6NU
MQ*B18>=O(\XW;2SQ?:Y^&%OV*@LH.2:7RK!R7+Q?)8*IL?%I,QS=Z;3/Q7HL
MZNIW7%?WB%&DLQ6%K,AMA""OBM4993U*M6G2H29"EQOS"@#?@\R; 6M4]8XD
M?B@S),"\B8F!$\Q'Q.+;>&_Z0+#HFH.M&4:DXQ:U\O/\JH7E6F->5;U\.+2T
MB:V(U[++D,S_ &1#7OI+3LE:4[<J5]#Q0J<H<+32$+"@R%!">A)!,F2223N=
M1 '&V+C=<@**U#Q*]+;R(%HGR'J2<=8]/]:]*=4X[;N#9S1W;[C?F&L3)1#N
M6Q_C#M-.,:S2&SNE13%Y#MS)>4GOA.TK].2'FR@W)2D%6_$WWVM$8T6WFGR"
ME82;1-XZ<CGDDB_PDPH2C<A/IZ]^4]]TD]"?\!V6A0^?%4 D_A*(F9GCUXX^
M.)E>$QK"Q_I%KQN0#UVZV\L85)[E(V'PW[?C_P >'F#&JYWWVO-[B0-CUPW2
M1.D\7ZR.F\?'G&%0WZCN.WY].O3[^%+B229W\B>(Z86X3>1$F;&8F!]#C"7E
M21[O\?Z'#@1S<>1P!(@6OSN/7TZ[?G.,9 /0\.6 (@=?TQ&"1M];_N<)^W#5
MI(M-C\QR/[_0GQC4#OS ?,_=\OY<1Z0#86MSL9\S]1MAJI D';>>?KW8PJ3O
M\/G\>W<;?#X=CP\*F%;WGWX9'!@'TW$0"(Z=.?7&-0'P^'0D?;U'?\_Y<.)Y
ML209-YVB^P^'SY"$B3!MP2+_ *^=\)G6BH\R>I/0@G]VY_+\.%2J+';K'YQ^
M>_Z-B8C<^F$YYDD@C;J#V'0_=Z>H/;OV]1>HC4@V ((MMSO_ +X12;W'Z<SZ
M<<8PJ ZGUYOX;_OX<@ZD F\B_P!#"HN8/4_(G]L)0.AV[>O;?J?Q[_#ABAH@
M)L# BYW,'?U]V&%*2;[GUZ?#"9:>7?8;;]NVQ&_X=OCU_'A"H]?KUW_N,1%1
M-B?D,)5@$'F[>HV']?9MM^'#U64"(O%R=H]_3>9)XP#?@7L3Q]><X:GD$<Q]
M 0?GUZ?QW_KH\7 ^?KSB1*I@'>_U\/RPC6.F_KO^77[N_ =XF)!^-L..\;2#
M\;1ZX1.H^'VC^(_K^'"21O<C<_Z3,&/(^L7ZXC(@WOR=XY@F/.T>1ZX;G@=_
MM(_=L/LZ]/OX+#?_ %7VC8QZQ?K8X<F +\:@;[7DCX7MTPC<'7?[OO'Q_KTX
M6WZCZYZD^8PBATXO[OUO))\\(7!TW]=]OW_=P\$[3 N;>0G?W88=SZG\\-[H
M(/7KZ[[>N^_]#MN#PW>_U?"&)M]?77"9U/,"20#Z=/M)_'^NYX< "#< CZ^?
MRCSPQ29'I^73"!Q 4#ON"!T_/X_?_'?AN(L(]MP-^H3OO\"#\>PV/7N1]H'$
MB)ZVGGRC;W6]-IX10DDF9 C<R/+G]<;;2S6W8#]?)4PXU''M*&;6=)CU 2E/
M5<UJ-LY+:4QS,-,1GD.*6KE"7D\1U""I(4D>(&018^5MYMTD8LTKI"M*B"F.
M!:(N)-S8Q8FW3%U_"SF88LKC#WW^>#:-(O*!T(-96N/-[-6C%7#EH;D2&MW6
MVVG&7'"INO3SQV$DN&%^%MH<$:@(=(-IW%OY8O(@1BVPK0XMLF$J@M"UO*=S
MZDWMUQ>/BKB[@X,&#@P8.#!@_K^N_!@QSU\3>6&US:'C@7"=@XQ";68EFER'
M&F7-BEESE:L83B9/O(-<A/GR&&6'67O,3NDDVTPAA1L'7 0DWDH-B(,IB#OI
M]X&*+A*ZA,W:;@F\>*1%P1R 8F#$7VQ4_))6P;@!V4MMA):2B5+9L A6_,ZE
M$J*&VEMI.Q93S**6U_K%.'?B9E.AKB8F1R8Z'SQ4JEEQPID%(.PWWF?AN?+K
MC664\PZ@$#HD;;#[MMATZ_9P&9,[\R.N(1T%A$'F!]>^=KX<VD$';[M_MV)W
MZ^@_H;<*#$SR(^/[=/<8Q(D1<V)@?E\R?VP[,M[#M]G7UW_A^&Y^7#%2-N#?
MT&_'['$D1MS^T3Z1MY7@8=64'H?AMM_P^?#2HS O8R>!\OY?GZXD22.+;Q:U
M[R=[<W,V&X,/<=L';IZ_/T/[_P!Y/7@_F.UI-SY7ZQ,CW QR,(;G80+W,B2/
MRV/HDQA[CHV/O [$]1Z_#Y$>G3?O\^G"DV@&+;_[#I)MM$[8%< <<^0%MM^2
M+;28B^'="2=MAZ@ _#IUW^[_ (\"=IY-SYW/U_OA$B=^9)\Q(CTO/PZ87-()
MV"E=0#UZ<JB0@(Y=OV4A:]R5\O,V#L1R+<X"3Q>?D-YVZ;<VV-\.@6*=_6VW
M,R;Q%HW/3"]A! 3NK?WCLD\Q0%; J)0>;EYM^_NA1.RBX.Z&#JN1)OOP-A<
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M.I*%((*'$I6E84"GW3N8S[7,RU>#*<M0L W"ZD'Q74?\V3(Z[Q.QQ(C_ 9]
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ML4C#<?T-,MH0DVW QL20/=&P[G?Y[#?8^A!WZC;8@)W_ &1M %) !/B M
MJL#XX_&+[*D>6- 20!)\6J2#!B]@=P#)D"QD]3@*B1L=N'883(B !,\_J3@"
M2>H'YC@P08!X.V,VP'8;<&"3$6CT'[8R);*NIZ =_0[>OH=O7T)^1X+FPW.T
M[3YX4(,2;>7)_;ZMC#.L*ZHARK*TFPZVMAM%^7-G2F842,R/VGGY,A99893L
M=W'7-AL0H[D$" M:@A""M<@6!N"8&QM,CTOA9"0=2DI2 20>8W'D2+6(VMUQ
MSGUR^D8T]P<S:'2V&C4#)&2XP;AWSV,2A/()2I?F-EJ=;!*^@;BF,VK;G1(<
M1[IUJ;*W5D*J/NTS9(L57_#-^+2"=^M\4'\Q0@E*/$=H D WW!B!;<G;@WQR
M UK\7&JNILU4/.LUN;,RR%PL#QEM46 VWS%3:33P%,Q-F^G+.MU*4A(YE/J7
MN>-ZGHZ=@0EI .\P5'8Q,SR+&;=!C+=J'GY/>!"=C 2D$SY0=7F/7%?D-ZA6
MBO,BUM%CD9X; VRY5Q9!)]X>9'A28,5"E'8E'GR$\W<*'%DE/7;H5;^Z ?CB
M (F+%0WDV$^049CH=HDD$XSR,8U)3$D+CY75OR?*=+488ZRRVITH(2 Y[8J0
MUL2#Y@4HI_;Y5$;%FI!)L+'C<?/]O?%I G_2/35>V^_EYC:Q)B-DTZIL^B5A
MC9X[439;7*(<NN6^X\XWU_5S4NM,)=4V-@EU*4K<ZJ<4LG?A5*&XZ7G]]QYD
M;;CG#DM),RDA,2;]1?D3UN8%A<;375U]9%@39-I63)CSH8BU80^W'C-N.K67
MIKQ0[YZT,LMN(9;5'2RM\ +4M""#Q&;9AF&9YHG(LDJ7J-ZC8779IF2*>G=0
ME'>-):I&S5MOM)*BX)4:5*@A*PEX+"EH[3+LAH,MIJ+-NT%0E-!7MN.T5&U3
MU+U4^E*EH05I0[2M#4MM0)%4L@E"BRH%+;B>)[?'BM1FY#L9:4!I^3"/L<E]
M@*;<,5R3%\EYR*IUEMU<92RPMQM+BD%0XE8[(Y5]L.:5K8S#,U2DU+CC@@E)
M2I26VU);"E(*T%8;"RVMQ!5H<4#:K.W>:J?4UEW<T>44SY;HLK72TU30M-!@
M4P2_2U+3S*WNZ$$!$!8[TCO#KQG:9<8+Z_(9FNN2VY^UD7Y+ DM.%P(<8,A'
M*R]U:?#92D, 1@ S^KX94=CJ,]T[EE16Y,ZRH*;&7/NI;2J=PUJ4V%6NK23Q
MYX=3]N\RJ54U%G::>JR-2OL-7EZ*.DIW&\O@GNJ-%.PTT*H.??MNK!*Z@_:2
M2^2O&:S:C6$J1/@U*JB&[+0TVP/.]G,A;+CJA%6^_)4VVXB/*=$=<I]X)2EU
M8:2XVSQ+DN8UC-:]DV<O YAWRJK+U%MMHUN6K* TAPMI2SJ;6BJ*G6FF":1M
MEU02I:EFKFW9RC1E:\]R7,Z*MRY+,/M(=>%52.AYFG[WN*BF;*@E>896A2>_
M>2NIJ'>X2XRP\EIL77=?V=^A._*K;;?WMQU*>3]@;'E\WW2=NG'5"-P8\K7C
MCJ2=A!YQQMA *2J2!JZ D#@Q%Y@F8,@81KKMNH!YNX.Q^/<@$;]NV_V?'A9$
M0;6N-O<)^%A\#A\ 7%HD\^^W2VWPQ<B@IM![#%,?=G/T%9<9=0P8^1(7%AOR
M\:D8Q^B^/REQG)T&:BNEY9,=O\A+D)+4IIAF*6'V6$.,*HD/AQ1"I1ND6DD@
MD"U[*\/78D1!$Y2P4I@:5DPH@DP.3!,&-Y ,6Y&%-!IYX<8M<[DB;J )WUQD
MM34T=];1+=F5 5CN9UD.9<1WHK*&YIM(E!8US[45#$=V>VM#Y5NU$.]JRXE)
M;\)4 22(@$#8"T7WZ8:&:;0J%G4!*;&Y@\WDS;TD'>!0:?4-/HD,/LM/L/%U
MIQL[+96A14AQ&RBI"BL%24*YE)/O;=P.- *'\TVV,QM(D7 \X/)!]:"V5$@I
MBUX!WZ\].GI%\1EA>!NX@<@CAY,BOL+3VNK2I2B\S#6@[QY!5N26E]$=3NE(
M'4 #B4*) $R)DBX/%@;2?4[;F).&JDDDQ8<1UCB8-]IQN[(EUTEN9"D/Q);"
MPXS*C/.L2&EH.Z5M/M*2XA8/5*DJ'+L"-N_ H-N3K2E1BX6D$QOS\<-!4G\*
ME)/D2;^_>/=BY&DOCIUGTW,2NR28C47&6E-H5&R1;CMY$CA0YC!O@4R]PC<(
M38BP:&PY$)'3C-J<J9?1+:0@SOJ,$^=R3^?GBZQF*V++\<6D@'KM;TVL)MUQ
MU;T9\5.DVM;342AN$U&3K0 [B=XMF'9AT)'F)A.*48]D.;<MB,X)! W7!3U
MYZJH'Z54J 6F=_+D$@6@'TYG&PS5M.[$">#//Y]+@1Q;%BRD[[ <O?N%*40!
MZ#W=E<GZP$[MN=0WTZ<4 $F804 =28WN+^<]/*V)RJ;#GT^'T9^4IB@(W(&R
M?QVZ?/K_ %TXD VP)((,DS%_03M;S]<82D;[CJGN?CT[CJ=^W7^NL@4%749
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M 5Q;:/V.(MG.F1*62.H*@H!(2.;TV0 &THW(V2A( '8#BP5186 \K]!UM,
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M05;EY"VV5I5LGR4$;<6$; FY/*KW$&^Y\/!X_*->E1A B9M>WGM!VW\\3-;
M5%9D%7-H[J!%M:FSC/0Y]?/9;DQ)460@MNLOLO)6VMI2%%)21ML1\.) "@A8
M44J%][:@.DZ=^""-^,(L:D]W%E<I@&#O,"8O8S&V^*FIKM0?"\Z%TL>[U*T
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M W@7]?AA^@08K,F,Y8<R8(=;,Q32"M88YDI44)2A96L).P3W]!WXHYD\6<N
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MA\^O7?\ #B3\._,F?T'S,>N!9-QP;_7O!Z[X2K;2LJ*@3[H/?;X_#[.& D0
M;:BGCJ+^M_3RPP6@C>3^0_?#8\ -MO4[_?UXD%L2I)()/7]!A$X 3]P_>>&&
MQM_6/F+_ )G";;?UCYBX^9PC< 5M\?X@?PX0C\/FE7Y3^9.&$7'FDGWP=NE
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M-A0!AJ X2-E?F+'RC:,6*52BA:%?B;41M$@[<<0;D;?#%CN(,6L'!@Q\5OL
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M* H\Q'8;]]MNAZ DD @]?>)^\<&H$FQ2 ;^OGU_?IA3XC((M(%[^46%S/'R
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M"=R.1_A 'IVZ#W?MY=R1VVW/7J>'$F3)(*BDFW]$1Z=!,8B3'!)VY/7SVN/
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M""\V4N*:&P/(24%6Y(.YXNM=D<J-0:NN:>JZZ"4NU52\^VVH@@K9:<4II"U
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M9Z<)WJ+C2;[WWYPTTRST]Y'[3S)OY=(3*\*FI9._M&-'J3UL9'_Y(?@>')J
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M/>/,=[3%FQU@? B?KUZ3BE5JU/R#M(\HV/OC^^&",A!/O? $G?;Y@?<> %1
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M'G;IS)F3Q?B_%L!, CWBW&USSQTVVPA>C!).XWV'<?Z=3TZD#\.$2D"XF 0
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M3EV8N%]Q3*G6G$(2 DCPJ(Y@P9%N (O6R/.JBJJ3251[Q:FRXA02!IB\*(]
MXO>8XMCIUEGT@&A.('+:ZVG6S63XM<9;2?HY]6R5.V4S$[!VL<0S/;8>A1_K
M64RZW6)?6''E-E)2#MOZCCKAYVQI:OI+-"4V&&I;9MWZ7*6VTS[1AJ2Y/Q.9
M]7MSY4>]H/J_VU"87FH;?DLO*92D^>H);X,&V'>M^D8T0GRY++K[L"#72Z0V
M>0R'73C+=3D%G;5U;/K[=,#ELY+J:A^2NJ;CL/H0H(2^L@K)@Q*&(>-?P\9Q
ME5#A>/YNX]D>0(=]FK)=-:P7(;S,6RF+A6SDF*ANLG+C54IYB))4AUU 0M(*
M'4JX,&&&O\<FD.3ZGX1I=@CEAEUIE-KE,:WL66)%77XO2XK1WUR]DDA<Z(/K
M*LM%X[90*=<-2&Y[L2<\T_Y<3]:8,:WA/TC7ALS2MJYS6138$F]S?),&I:[Z
MO=M7K"?17VG]# G!^I$N-&K\D>U;TO-,N4ZRMQ[-JJ(\EIY$KRC!A/C'TCOA
MUO*W%+BTOI6,PL^:P63AL:UB/BZGQ,\I\-L:Z59U26$&G98D9]B45WGDS%+1
M=QYZ>6"W*=BF#$E8#XU= ]5[2JQ_33+AEN19!3R;BBJ8M?/8$]E$3()E>VN>
M]'$*&JZC8S;2JOVAU*WXS"G2A*T/,MF#$>X_](1HX[C%SDFH$6ZTU515MCD%
MA66S(M'8V+P<ROL!1>R9T%M$&.W-RK%,GKZ^&X[[9+;II,AEIQ)"4F"?U^6-
MUC^.OPT2[214Q<_3(E,Y#2XNE:*JP1#D6][<9#10F(LYYEJ&\R+/%KN))E>>
M&&7X?LX6J2_&8=,'U\X^O+"2M\?'AAM5UK474'=VVLXE;":<I;=MQUJ<:-N/
M<$&* BA>?R6ACMVY(B%ZUBH"CNXILP8^8YXX]&<T8S1_##DMY&P_ V,_38.4
M,RJJKVLGSI%94LU,^>D!Q5I8,HCQGULAO9Y+HYD)4 8,:)+\?=,S/N*V-I/F
M,BPI<ZH,$G5<J= JK1F9D)2S!M_89[#;K]$],\R/&M(OM$24AOS4/ K2UP8,
M:]=_25:=X]71["QT\S>+]=*@2\28?-:@Y10R\FEX<]<Q'&W'1&5&R*!+@(KY
M"#)E*0TMH[/!*3!B1,'\<N%YQDK5 QA.78^E[*\%Q)"\GCHI;A$K4*/7*Q^P
M7CLMI$Y54]/M(U:[/8<>BM2A(0XZEQHLDP8O)P8,<BM<7E1]<\S6E1&UI!1N
MDK2=U4]8=D*00I"CU*5 [I_(Z;!E@"T01;?G8]=QY>4XQ*@D51N1!F-C<^OS
MV^!.%."6S6.YMBMU'6PABNR2,IWZNARG=X5CY/M27+"7[KY6%R(;9/*DRE%:
M2D@JXKMIE#K7*9(O!L3[IXCKO>,6W3XJ9TW L#UGRMY"=KR+XZSI4HI!W'7J
M"!T VYMSU.^XVVY3U!W';BIC0QEX,&/BOV5?8?W<&#'+G6BW-SJKF+K3S:EL
MSXE%&3'M/8'2FN0VS*Y&Y']W>;0B XJ0AXH8!9?6 KFW-I0'<-H@P5)4>.0=
MQ-CM%SO;?&>E154ND[I0H"(M;:/*^Y&T7.*]7K[KT]9<+BM^8I+Q:4XHI)2K
MF4TE*%J1L$**0$+Y?,3N3OQ: T(2$]!,WW%OA\-O?0<4"X?/KN-O,[V@?[81
ML[CE[;D=2/Q'PX9-R>3/NGI@3N/,@?,'],.K W(/R'V=M_X<.0 9WMT]^)C_
M "^OZ'#XV!NGIZ;_ '[=^&R;^>^W.)D 1/7]#]3UP[L)'3[/OZ'8<)@!)(GR
M]TI)/S&'E@;D;=-MR?Z^SAH(BT["!,;DC\YOOZV& F 3Q"8]./?,WXW%Q&'I
M!(;!^&W\/Y\,CQ#S)/P)_;# 2!U!_7]L+V^FW4=MOM^S\OMXD$\^[K'GZ?M
M<[X)/BC8[^^?ASZ;3A8@JWWV'0; ?;L>V_V?EMZ\)X0>A-]^G/UO??$@ @'H
M-_S]PX^6'!*0D#;J1TW_ ,PW5N#M\=^NW4[#<].(U$DF1'D>/KY28O?"))),
MF+;1UY^NN)OP32:7DE>Q<64HU]=(&\1#:?,D2$ E1<Y%@(0TI23RJ4>8A&X[
MCB-;D$P) -QR0-@"/*T\V-\3MLZ]*B=(%@"9Z@WZ#RX](Q*:=%<8 2!(L"=@
M-_.2"-]DJ.VVVW4KV[[@>F_# ^H R(.J0HS)!X*9,F!$SY@8G[E'F;7 )D22
M)G:/GA1_8SC(W2)%@!U/,'4J">J=@"0 1RGU[[_+JO>KB+;1MQ]?WPO=)N+W
MN;_VQ[&CF,[C:1/2!W <2-QNK<$[?'9( Z; *WZ<,D]3@[M/G\OVQE1I!CG,
M 9$\D;@DK2#OOT].VQV'7< =3PNLD1:XC!W2=[]=_P"W''3C"@:08Z"2),[_
M ,HG@"B/.! ^7[83ND7WN9-^;_OCVG23'DG<29WP/OI['OPNLG@?/]\*&D#:
M?CCTG2K'$ A,B=L=M]W-^WW<&L^7U[\)W2+B]][],>SI;CQ_^$3=MP=N<#?;
MT.P[=-MOAP:ST%][;^M^EO3"EI)WGXQ^6(WSC'(F.2X3$)UY;4AAUQ7FJ"B"
MA:$[)([) )&Q'7X^O"I4J0).YM[MY]Y^CB-:$IVD6G?ZZ7WG$0YEF%-@F+WV
M7Y'-17T>.5TFTGRG2 E,>,V5K2C?;S'W"E+,9"3S.R5M-#JK8R-H<>7W;9)/
M2W2_OWVVQ&MP(3J6HZ;[J(.Y@SR#.WI!YQ^9;6W5[(M==1;O/+];J&)+CD3'
MJQ2N9FEH&7'EU\%EL'E0M312Y*= YY,A:G7"3RA/:TU,BDI U$JO*@?'<P)(
MO-_3F<<P^Z:A04DB9F]QS>#^HOC6Z>LFKJ[>?$BL+8C"L9LYCS@;,:+)D+Y&
MVD*W!,B<TRDJ(!3Y:&PL&0D<<AV@6VUVI[*J<:?<6VC-G6BVE/<L+#=-1%))
M,)<J6LP4H $DMTA0D!<$=YV6+&8]G>TN3FSSJ6ZZAJ/"'*E=,W5U*DNB.\^Y
MH\M=0U"ON2^0I*B1AXAQ^4;\I 4$C8CJE*>O;?8\W4@_#N>FW'7 3L5%Q0U:
M%IT%*09F>2 -M[&TVQQ1\*U;>$Z5#SD"!:QG@W_388K(44].Q'0^OV_(=OE]
MI/"@;\7-SRK@\VG8<>9V628XW !ZVN;<&P\_6VQQH@4D$C8=/P^0Z';[Q^/#
M=1 BQX@_ "WY$3^09I4>2(V(_$+6(\Q%MK\3.%L5J8]+4XEAANM:*V?/Y@J3
M)EI "V@E)V;8B@\JBYU+I4C;=/7':6BKS26W=1HD*0\T1<ZQH3!-AH(XV5)Y
MQV-0',I[-4]$_IJ'<]6QF:6A$9:TSWB6%K-_OZME:5*TB A(!),Q)&(Y-98?
M.E3J]J%)]MKI=3.AV<42X$VNG! DQ),<J:*VUEM"O=6@A21UZ <:CS27$=VN
M=((*8(!@3S<^4VM.QQQZ%K:42FQ(,R-YM^4XDI>L^526)3,FMQ9]$^) B30[
M2!9E"I?#]5(>/M0YI5<H)1%= 0VA*5(7L#Q *5H?U?^[ZZ?4XLBH=(GPB_"
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M1(H&'W-HT;*8+:BIEH*(2TJZ@.+2L#I(DU\- !+B"K$S>FULH>;![Q)\?0)
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MD.RB "M:CL0 !Z)BYADL_!+X7[9Q3TS2>C4\9?MZGF'[.,ZN26F&%J4N/-:
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M^[9,ZDK7G0USJ;1),5M$IM"E^\0F5YJ$J)(+8Y@=@.*:AI41T.+Z%A:$*_J
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M?[25CC![.(715E0\@)>JZEM-,A"V&YET5AJ&E4[;94%?:&T$S)QURNQ"L_K
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M[D].^XW4 -B0G;?U!/3KQ(/ET._ODG],.(VW/%^";P3M-[[?&3A"\VTZ%MO
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M.HF4/LMB.^*% )#>X3^%1B,>@99GF49AE=/DG:&B2G[.6VZ/-*-\-K;:0DM
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M>E-_629D1;G,RA,(1U GHIP.K4X.4)(YDH(V!&V_#:2E>?6Q7UBU-OLZRFD
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MKB_4BY ]F%@752$Q!MYI1Y@_9V'&%[$U9C_ ,2OI9#BZ#[*^NJ4"M3(<*TA
MI(42$%8!)40 223/&.B_Q#-Y7_P73FL4A.:MYBPG+M00*@M*"E/WC7W:DE)
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M3FC5%5.PC+\M@9%0XO5PD,T;5=8XWFDGPQ8!6V]A=B:XTE.,JUNS";<.S%A
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MT"2D#_/_ XF) $^<;><'Z_/#@8@V_#S/]1Z?'"Y &Q^\?=TX")^O?/U;RPY
M!N1QO^6'6L.\Z*#MM[1'_P#1<!'YCK\>$58$]-OR_7ZO,@%_<3'%I/SY\K8Z
M.R7FHL=^7+?:8CQFG'I#S[B6FVV6D\[KCSBB$-MH;_6*65 )3U)Z=*&D22"K
MK$VVO87WN+XNK<2VA3BUH0VV%*<6L@)2E()E2B0 /Q3 @>6(ZKM7M++:FO\
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M)JH"D,A,HQTA2G_+)+8;62@#<\1AQH)2G^1!4 )D:W)%S8BY\-[<80H4 "@
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MMWEI0$7,;1UX @6CT@G&4Z99I[/*?FT-K5J:@-V$-B=63VG;5#DIF$VU 84
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M\7Z]0#BUO@0O%TWB/QV$VLI1D=)D=$^$@)\Q#=<J\"5 =Y%(%!(Z ) ">91
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M0E " 2(,^<1)'0[[7B=C?&&Z2I:UG=9&H; $7WZ7L8$ C"O&WBU&LE NI+;
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MV*"H$=!RD;GKQHY>I(J6+<6M>XC;F.HF^V*E5/V9]4R9$CK>]N-IM( G'YM
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MRW*["9&G4IH9C(8BS,8^JT4\!"�OBONF8C3?MUB%/-V4CGD"&R7E(+?LPT
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M!G\(%HC@]-IOQQ[_ -&%9;SJ:>S8U\@QIK/,>H;6M*7$K0L +0M&RDN*!)
M23\#TXY%323U)@B)L<="F1 !/ GF/KG>V-K.J6=\^WUZX=]D[F'7]B03VB@'
MTZ$$#;<#?<F,MH2?"(!!MN-R)O)!MU^4#$JW5#A,I&]P56V5! (YV%]HDR.:
MI9VGWTWSH5OT_NE>0"?7K%(.W8<VX [ =>&E"3! @\Q_,>JIF_I&(0^Z29(
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M1"5<"J?CRD1S+3:K6I]H5ZGB$-HILC4 3XE%4^8VCIT,W&QY&)$U:$K0 4=
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M?SV_*-_=SAX&J0=B(,1(\[CW6]]HPN;()W[;;[;_ &?NV/Q'RXKK2 1,DW]
M]X ]W7?"1$@ ^$<]!SM^F%J%<W;8$;;$GW3TW!^.W#@9!D7BX&_Z?#IAHM _
M3@1^AWZ_#&9MXA0(V.Q&_P!F^_0D@>G3KP! $[W$?5L+T\OV(_7"Q"@K8@_N
M!_/IU'\N'?7U];;VPL0;[>7(\L94J))&_3O]W^G3\^'* $'B]Y%H^'.)$JD
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M]T[$'T^/8]">&18CUV\^G2??TQ<"IM /3S/K;>(\YVMAZCN$$;$)]T)'3NG
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M1WQV,?=Q'VCNN&K'22?,Q PA-.3^-L1,Q,W _%*KB=^0#OQC2Z7^PM;^H=%
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M#Y01/3W1[ DBY(WVZ^O%Q,S'.$3@'7??H2!]OS_CPX'8R!82+ ;^O,#U&%!
MOZA/H! ]_-HY.$3FVYW[#<_B"3^\\-(@"-]4? P/_P!T?/"J-@=C)'EOO_\
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MXI!<#293$F,%*2GD"U1UJ;"BMHH="7$N0HH4% D&8.V&.(#B%()("@1(B18
MB02#$3/YXKXYX5,4>;\A[,\Z<CI;:;;83(QUAMM$<+$8#V;'65*]G*DN-%:E
M%+Z%2B3*D27WI$O%*U+TI)5N+Q[KR/G:PC$2Z=*T);*E:4^E_EMY?WPR#P8Z
M<@$'(\T)/<^TT0ZE7,2 FB &YWZ #<;#W4<KC4+,V1?R/E_J\N9\L1"A:"2
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M8?\ S]7^/_N5P=\9F+^O'3Z]V TR20=1M$6''&,J?#CB".@NLD[[G]?5]?\
M_%_NX7OS_2/B?KG :9)W4KY?MC./#OB _P"^^2'_ .\5@] /^:S\.&]\J9A.
MYX/,\SYX=W"0 I5A''[?5]^,J/#[B:#N+;(CTVZOUOR^%8/4?UWX"\HV(3[
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M@]-SO^B?<D;_ ![ #IP?QFH_P"4QSPYS_\ M,+_ MB9[Q^W^IN/_Y<_/&9
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M^&W_ #-PO?*M9-C.QWDGKYX#3)(C4K>>-Y/EYXPGPDX$3N<@R_\ \YIO^I>
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H8::7NHL4X5(0@@> $ @F2/,$Q\!B1#24*4H$^/<&-^N)4XCQ+C__V0$!
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>